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Abstract 
The sharp rise in antimicrobial resistance has been matched by a decline in the 
identification and clinical introduction of new classes of drugs to treat microbial 
infections. Thus new approaches are being sought to target pathogenic 
microorganisms. In that context, the use of non-biocidal small molecules, that target 
quorum sensing signalling networks in pathogens, has emerged as a solution with real 
clinical potential. Previous work has shown that two alkyl quinolone signal molecules 
(HHQ and PQS) from the nosocomial pathogen Pseudomonas aeruginosa have 
modulatory activity towards other microorganisms. Chapter 1 of this thesis outlines 
the synthesis of analogues of HHQ with the aim of learning more about the 
structure-activity relationship of alkyl quinolone quorum sensing molecules. 
Chapter 2 of this thesis describes work carried out during a six-month work placement 
at Syngenta Crop Protection in Stein, Switzerland. The project involved efforts 
towards a new total synthesis of pyridohomotropane (PHT), a synthetic alkaloid which 
has shown agonistic activity towards nicotinic acetylcholine receptors (nAChRs). 
Since they are found in the central nervous system of insects, nAChRs are a key target 
of insecticidal crop protection products. This chapter outlines the retrosynthetic 
analysis and synthesis of key intermediates towards the total synthesis of PHT. 
The formation of aryl-aryl bonds is an important transformation in organic synthesis 
due to the abundance of aryl-aryl moieties in natural products and pharmaceuticals. 
Direct arylation strategies aim to avoid the installation of one or both of the activating 
groups typically required for traditional cross-coupling methods. The application of 
direct arylation protocols towards the synthesis of polycyclic benzofuroquinoline 
compounds is described in Chapter 3. Expansion of the methodology to facilitate a 
one-pot tandem reaction combining Suzuki-Miyaura and direct arylation 
transformations is also discussed. Finally, the retention of specific carbon-bromide 
bonds of the quinoline substrates is achieved via a reversible oxidative addition 
protocol. 
  
v 
 
Abbreviations and Acronyms 
Å ångström 
ABSA acetamidobenzene sulfonyl azide 
Ac acetyl 
AcOH acetic acid 
Add. additive 
aq. aqueous 
Ar aryl 
BINAP 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl 
Bn benzyl 
Boc tert-butyloxycarbonyl 
Bu butyl 
c centi (10-2) 
°C Celsius 
13C-NMR carbon nuclear magnetic resonance 
ca. circa 
calcd calculated 
cataCXiumA di(1-adamantyl)-n-butylphosphine 
CDI N,N'-carbonyldiimidazole 
conc. concentrated 
COSY correlation spectroscopy 
Cy cyclohexyl 
δ NMR chemical shift 
D, d deuterium 
DABCO 1,4-diazabicyclo[2.2.2]octane 
DavePhos 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl 
dba dibenzylideneacetone 
DCC N,N'-dicyclohexylcarbodiimide 
DCE dichloroethane 
DCM dichloromethane 
DEPT distortionless enhancement by polarisation transfer 
DIBAL diisobutyl aluminium hydride 
DIPEA N,N-diisopropyl ethyl amine 
DMA dimethylacetamide 
DMAP 4-dimethylaminopyridine 
DME dimethoxyethane 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
DPEphos bis[(2-diphenylphosphino)phenyl] ether 
dppf 1,1'-bis(diphenylphosphino)ferrocene 
e.g. for example 
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
equiv. equivalent(s) 
ESI electrospray ionisation 
esp α,α,α′,α′-tetramethyl-1,3-benzenedipropionic acid 
Et ethyl 
et al. and others 
19F-NMR fluorine nuclear magnetic resonance 
FDA Food and Drug Administration 
vi 
 
FT-IR Fourier-transform infrared spectroscopy 
g gram(s) 
h hour(s) 
1H-NMR proton nuclear magnetic resonance 
HMBC heteronuclear multiple-bond correlation spectroscopy 
HMDS hexamethyldisilazane 
HRMS high-resolution mass spectrometry 
HSQC heteronuclear single-quantum correlation spectroscopy 
Hz Hertz 
i iso 
i.e. that is 
IR infrared 
J coupling constant 
John Phos (2-biphenyl)di-tert-butylphosphine 
L ligand 
litre 
LCMS liquid chromatography mass spectrometry 
LDA lithium diisopropylamide 
LED light-emitting diode 
lit. literature 
μ micro (10-6) 
m metre 
milli (10-3) 
m meta 
M metal 
molar 
m/z mass-to-charge ratio 
max maximum 
Me methyl 
MIC methylisocyanide 
mg milligram 
MHz megahertz 
min minute(s) 
minimum 
mL millilitre 
mmol millimole 
mol mole 
molecular 
mol% mole percent 
m.p. melting point 
MS mass spectrometry 
molecular sieves 
ν frequency of absorption 
n nano (10-9) 
n normal 
n-BuLi n-butyllithium 
NMP N-methyl-2-pyrrolidone 
NMR nuclear magnetic resonance 
o ortho 
OAc acetate 
vii 
 
OTBS tert-butyldimethylsilyl ether 
OTf triflate 
trifluoromethanesulfonate 
p para 
Ph phenyl 
PivOH pivalic acid 
PMP 1,2,2,6,6-pentamethylpiperidine 
ppm parts per million 
Pr propyl 
p-TsOH p-toluenesulfonic acid 
q quaternary 
QPhos 1,2,3,4,5-pentaphenyl-1′-(di-tert-butylphosphino)ferrocene 
R.T. room temperature 
RuPhos 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl 
s second(s) 
sat. saturated 
SPhos 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl 
t time 
t, tert tertiary 
T temperature 
TEA triethylamine 
TFA trifluoroacetic acid 
trifluoroacetate 
TFE 2,2,2-trifluoroethanol  
THF tetrahydrofuran 
TLC thin-layer chromatography 
TMS tetramethylsilane 
trimethylsilyl 
TOF LC-MS time-of-flight liquid chromatography-mass spectrometry 
Tol tolyl 
Ts 4-toluenesulfonyl, tosyl 
USD United States Dollars 
UV ultraviolet 
W Watt 
Xantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene 
XPhos 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl 
 
  
 
 
 
 
Nothing in life is to be feared, it is only to be understood. Now is the time to understand 
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1.1. Antibiotic Resistance 
The discovery, isolation and development of antibiotics revolutionised medicine in the 
20th century.[1] Antibiotics have successfully prevented or treated previously fatal 
infections, greatly contributing to longevity and quality of life. In developing 
countries, antibiotics decrease morbidity and mortality caused by poverty-related 
infections.[2] Unsurprisingly, antibiotics can be considered one of the most successful 
forms of chemotherapy in the history of medicine.  
Nowadays however, there is evidence to suggest that the widespread use of 
broad-spectrum antibiotics has contributed to the emergence of resistance among both 
targeted and non-targeted microbes, since current antibiotic therapies tend to be 
non-pathogen specific.[3] Consequently, there is an urgent need to create innovative 
new medicines for the prevention of microbial infections, while avoiding the 
development of resistance.[3-4] In contrast to classical antibiotic drug targets, which are 
involved in vital processes of the bacterial cell, ‘antivirulence’ strategies aim to abolish 
pathogenic behaviours without affecting cell viability, circumventing the problem of 
acquired resistance.[5-6]  
1.2. Quorum Sensing 
One way in which microorganisms coordinate their behaviour is by utilising a system 
of chemical regulation of gene expression in response to population density, known as 
quorum sensing (QS).[7] QS involves the production, release and detection of small 
molecules, known as autoinducers (AIs), which accumulate in the extracellular 
environment as the population increases. Once the concentration of AIs rises to a 
minimal threshold, population-wide alterations of gene expression are triggered, 
leading to a coordinated response.[7] In this manner, QS regulates the expression of 
genes that underpin various biological processes.[8]  
Importantly, among the behaviours controlled by QS in pathogenic microorganisms 
are those that promote infection or circumvent the host immune system.[9] Using QS, 
pathogenic bacteria can coordinate critical pathogenicity traits, like the production of 
virulence factors or biofilm formation. A biofilm can be defined as a structure 
consisting of surface-attached microbial cells that is enclosed in an extracellular 
Synthesis of Biologically Active HHQ Analogues Introduction 
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polysaccharide matrix (Figure 1).[10] They can grow on living or inert surfaces, such 
as lung tissue or medical implants. Bacterial biofilms can cause chronic infections 
because they display increased tolerance to antibiotics and resist phagocytosis by the 
host immune system.  
 
  
Figure 1 Biofilm formation in pathogenic bacteria. 
Targeting the QS networks that are responsible for virulence factors and biofilm 
formation in pathogens constitutes an attractive alternative to antibiotics for the 
control of microbial diseases. The term ‘antivirulence therapy’ has emerged to 
describe this strategy.[11] This intervention does not directly lead to bacterial death or 
growth inhibition, but instead it supresses pathogenic behaviour.[12] As the viability of 
the target population is not directly affected, it is proposed that development of 
resistance to drug candidates would be stunted.[6] Thus, interference with the QS 
network responsible for virulence behaviour in pathogens represents an excellent 
therapeutic strategy. ‘Quorum quenching’ as an antivirulence target is a 
rapidly-growing area of research.[13-14] Synthetic molecules capable of interfering with 
bacterial QS networks are known as quorum sensing inhibitors (QSIs).[15] In order to 
design effective QSIs, it is important to understand the native AIs that operate in the 
QS networks of the target pathogen.  
Synthesis of Biologically Active HHQ Analogues Introduction 
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1.3. Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a Gram-negative pathogenic bacteria often associated 
with hospital acquired infections, particularly in immunocompromised patients. For 
example, it is a common cause of morbidity and death in people with cystic fibrosis 
(CF).[16] P. aeruginosa is one of the so-called ESKAPE pathogens (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, P. 
aeruginosa, and Enterobacter species) which are responsible for the majority of 
nosocomial infections.[17-18] In 2017, the World Health Organization (WHO) 
published a priority list of pathogens with an urgent need for new treatment options.[19] 
P. aeruginosa ranked in the highest ‘critical’ category. 
The persistence of chronic P. aeruginosa lung infections in CF patients, for example, 
can be largely attributed to the establishment of a biofilm mode of growth. Prevention 
of chronic biofilm lung infections is only possible by early, aggressive antibiotic 
intervention. However, once chronic biofilm infections are established, permanent 
eradication is almost impossible to achieve.[20]  
1.3.1. Quorum Sensing in Pseudomonas aeruginosa  
A complex QS network controls virulent behaviour and the development of biofilms 
in P. aeruginosa (Figure 2).[21] Typically, the QS system of Gram-negative bacteria 
consists of a transcription regulator, the AI molecules and one or several enzymes 
involved in the synthesis of the latter. The transcription regulator controls the 
transcription of the biosynthetic enzymes and also functions as a receptor for the signal 
molecules themselves. In P. aeruginosa, there are three different chemotypes of AIs: 
alkyl homoserine lactones (AHLs) used by both the las and rhl QS systems,[5, 18] alkyl 
quinolones (AHQs) used by the pqs system,[22] and the integrating quorum sensing 
signal (IQS) 2-(2-hydroxyphenyl)thiazole-4-carbaldehyde used by the iqs system.[23] 
The focus of this thesis chapter is the pqs network and the AHQ signalling molecules. 
Synthesis of Biologically Active HHQ Analogues Introduction 
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Figure 2 The four QS networks of P. aeruginosa. 
The primary AIs of the P. aeruginosa AHQ QS pathway are 2-heptyl-4-quinolone 
(HHQ, 1) and 2-heptyl-3-hydroxy-4-quinolone, known as the Pseudomonas quinolone 
signal (PQS, 2).[24] HHQ is converted to PQS in P. aeruginosa by the monooxygenase 
PqsH (Figure 3). Both PQS and HHQ are agonists of the transcription regulator called 
‘multiple virulence factor regulator’ (MvfR), more commonly referred to as PqsR. 
Through interaction with this receptor, HHQ and PQS induce the transcription of a 
variety of genes, including their own biosynthetic enzyme cascade (PqsABCDE), as 
well as genes responsible for the production of virulence factors and biofilm 
formation.[14]  
 
 
 
1  2 
   
Figure 3 P. aeruginosa QS molecules HHQ 1 and PQS 2. 
Thus, AHQ-derived QSIs capable of interrupting the QS network responsible for 
virulence behaviour in P. aeruginosa potentially represent a new generation of 
antimicrobial agents.[14, 25-26] Encouragingly, it has been shown that PqsR-targeting 
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QSIs are able to increase the susceptibility of P. aeruginosa biofilms against 
antibiotics.[27] Therefore, integrated treatment approaches where a conventional 
antibiotic therapy is potentiated by quorum quenching agents could also be an 
effective treatment option. 
The P. aeruginosa signalling molecules HHQ and PQS have also been shown to 
possess interspecies and even interkingdom activity, influencing the phenotypic and 
transcriptional behaviour of other pathogenic microorganisms, such as fungi and 
yeasts.[28-30] This may be a consequence of the proximity in which these organisms 
co-exist in clinical and environmental niches, including the lungs of 
immunocompromised patients and plant ecosystems. Interactions between co-existing 
organisms have been widely reported, and many signalling molecules display activity 
ranging from interspecies to interkingdom.[31-32] Exploiting interspecies and 
interkingdom communication networks, and the mode of action of the chemical 
signals employed therein, offers a powerful platform from which to combat a range of 
microbial diseases.[33] 
1.4. Previous Structure-Activity Relationship Studies of HHQ 
In light of the important roles played by PQS and HHQ in virulence, both molecular 
structures have been the subject of a number of structure–activity relationship (SAR) 
studies in recent years (Figure 4). The Welch group was among the first to undertake 
a SAR approach to the PQS framework.[34] Around the same time, Spring and co-
workers developed an excellent high throughput method for the preparation of PQS 
analogues using flow techniques.[35] Overall, these studies indicated that almost every 
part of the PQS molecule appears to contribute in some way towards its function as a 
signalling molecule. Most of the alterations to the quinolone backbone and the alkyl 
chain resulted in reduced agonistic activity towards PqsR. For example, shortening or 
lengthening the C-2 alkyl chain resulted in diminished activation of the receptor. In 
addition, substitution of the quinolone ring with electron-withdrawing groups 
appeared to increase agonistic activity, while a decrease was observed with 
electron-donating substituents.  
The McGlacken group is engaged in a long-standing collaboration with Dr Jerry Reen 
and Prof Fergal O’Gara from the BIOMERIT Research Centre at UCC. Their research 
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focuses on contributing to further understanding of the SAR of P. aeruginosa QS 
molecules and the development of quorum quenching antivirulence treatments.  
In 2011, they demonstrated that PQS and HHQ modulate interspecies and 
interkingdom behaviour in a variety bacterial and yeast strains.[28] McGlacken and 
co-workers also published the synthesis of C-3 halogenated and other analogues of 
HHQ, and reported the first crystal structure of PQS.[36] An investigation carried out 
in 2012 focused on the implications of substitution at the C-3 position of AHQs on 
biofilm formation in bacterial and yeast species that coexist with P. aeruginosa.[37] 
HHQ was shown to inhibit biofilm formation in species that inhabit the same 
environment as P. aeruginosa, whereas PQS and 3-halo analogues did not (Figure 4).  
 
  
Figure 4 Structure-activity relationship analysis of the HHQ/PQS framework. 
The influence of PQS and HHQ on the pathogenic capabilities of P. aeruginosa is 
complex,[38] but is known to be dependent on the PqsABCDE biosynthetic operon 
which is positively regulated by the transcriptional regulator PqsR.[39-40] As already 
mentioned, PQS and HHQ are PqsR agonists, and thus enhance the expression of this 
operon and the production of virulence factors. Therefore PqsR is a key target in the 
search for a P. aeruginosa QS inhibitor. Hartmann and co-workers showed that 
analogues of HHQ which possess strong electron-withdrawing groups at the C-6 
position were antagonistic towards PqsR in E. coli reporter gene assays.[41-42] With 
reference to structural data related to the binding pocket of PqsR,[43] it was suggested 
that interaction of the strong electron-withdrawing group at the C-6 position with an 
isoleucine residue (Ile-149) decreases activation of the receptor. However, when tested 
in vivo on P. aeruginosa, the lead compound 6-NO2 HHQ (3) seemed to display 
agonistic behaviour, reminiscent of PQS (Scheme 1). 
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Scheme 1 Hartmann's antagonists 3 and 5 and their interaction with PqsH. 
Further investigation led to the discovery that the supposed antagonist was being 
hydroxylated by PqsH in P. aeruginosa into the corresponding PQS-like analogue (4), 
which was a strong PqsR agonist. In order to suppress this functional inversion, the 
authors ‘blocked’ the C-3 position, thus preventing hydroxylation by PqsH. Of the 
derivatives tested, the C-3 carboxamide (5) proved to be a highly active antagonist, 
and was even shown to reduce mortality caused by P. aeruginosa in an animal 
model.[41]  
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1.5. Aims of this Chapter 
Given the continuing development of antibiotic resistance, there is an urgent need for 
innovative strategies to tackle infection. This is particularly prevalent in species such 
as P. aeruginosa, and co-habiting pathogens such as Bacillus species, Candida 
albicans and Aspergillus fumigatus. The established roles of HHQ and PQS as key 
virulence factor determinants provides the opportunity to interrupt the P. aeruginosa 
QS network by designing structurally modified analogues. In addition, by taking 
advantage of the cross-species and cross-kingdom influences of HHQ and PQS, 
treatments for tackling infections caused by mixed-microbial communities can be 
investigated. This non-biocidal approach should dramatically reduce the evolutionary 
pressure on microbes to develop resistance.  
This thesis chapter outlines the synthesis of functionalised analogues of HHQ, with 
alterations to the aryl ring, the alkyl chain, and the C-3 position. The compounds 
described herein were synthesised as part of a larger substrate scope of AHQ 
derivatives. McGlacken group member Dr Rafael Cano also worked on this project 
and synthesised a selection of substrates. Any compounds made by Dr Cano are 
labelled RC, and are only included to provide context when summarising the results 
of the SAR analysis. All of the AHQ analogues prepared during this project were sent 
to Dr Reen at the BIOMERIT Research Centre at UCC for inclusion in various 
biological studies, the results of which are summarised at the end of the Results & 
Discussion section. The aim of these SAR studies was to further delineate the 
interspecies and interkingdom influence of these molecules, and to further define the 
role of the C-3 position in the development of PqsR antagonists. 
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1.6. Objectives 
The aim of this project was to synthesise a variety of analogues of HHQ, substituted 
at the C-5, C-6, C-7 and C-8 positions of the quinolone ring. In addition, C-3 
substituted derivatives of HHQ were also prepared to see if these would display 
activity similar to either PQS or HHQ in species that coexist with P. aeruginosa. 
Functionalising the C-3 position of the quinolone also prevents hydroxylation of this 
position by PqsH to PQS-type compounds in P. aeruginosa. All of the compounds 
were sent to Dr Reen to be included in biological studies to learn more about the SAR 
of AHQs within the QS system of P. aeruginosa, and to determine their influence on 
pathogenic species of bacteria, fungi and yeast. As stated in the introduction, several 
compounds were synthesised by Dr Cano, and these are labelled RC. Experimental 
data for those compounds are not included in this thesis.  
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1.7. β-Ketoester Synthesis 
The synthesis of quinolones like HHQ began with the preparation of β-ketoesters 
which determine the length of the alkyl chain at the C-2 position of the quinolone 
product. For example, a β-ketoester bearing a heptyl chain (7) is required for the 
synthesis of HHQ. The β-ketoesters used in this project were synthesised using 
methodology developed by Oikawa et al.[44] Deprotonation of the highly acidic proton 
(pKa = 4.97)
[45] of Meldrum’s acid by pyridine and subsequent reaction with octanoyl 
chloride led to formation of acylated Meldrum’s acid 6 (Scheme 2). Thermal 
decomposition of this intermediate, releasing carbon dioxide and acetone, resulted in 
the formation of β-ketoester 7. 
 
 
 
  
    6 
 
 
 
 
 7,[46] 64% 
  
Scheme 2 Synthesis of β-ketoester 7 from Meldrum's acid. 
The amenability of acyl Meldrum’s acid adducts such as 6 to react with various 
nucleophiles allows quick access to a variety of functionalised compounds.[47] The 
mechanism for the fragmentation process was studied in detail by Xu et al. in 2004.[48] 
Based on rate law calculations and reaction monitoring by IR spectroscopy, the authors 
concluded that heat initiates the decomposition of acyl Meldrum’s acid adducts like 6 
into an α-oxoketene species 8, which then undergoes methanolysis to yield the 
β-ketoester product 7 (Scheme 3).  
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Scheme 3 Mechanism for decomposition of acyl Meldrum's acid 6 to form β-ketoester 
product 7. 
1.8. Synthesis of HHQ  
The next step in the synthesis of HHQ involved reaction of the β-ketoester 7 with 
aniline in the presence of a catalytic amount of an organic acid, forming the enamine 
intermediate 9 in near quantitative yield (Scheme 4). The enamine then underwent a 
Conrad-Limpach cyclisation in refluxing diphenyl ether to give the HHQ product 1.[36] 
A very high temperature (>250 °C) was required for the Conrad-Limpach cyclisation 
step. Once cyclisation occurred, methanol was expelled and aromaticity restored to 
form the quinolone framework. Due to the harsh conditions required, yields for this 
step were low to moderate. 
 
  
 
7   9 
   
 
 
 
   
1,[37] 41%    
    
Scheme 4 Synthesis of HHQ 1. 
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1.8.1. Synthesis of Aryl-Substituted HHQ Analogues 
In order to carry out further SAR studies on the quinolone framework, a range of novel 
aryl-substituted analogues was prepared. Aryl-substituted HHQ derivatives were 
prepared by reacting β-ketoester 7 with a variety of substituted anilines under the same 
conditions as for the synthesis of HHQ 1 (Scheme 5).  
 
 
 
 
7  10–18 
   
   10, 31%    11, 45%         12, 35% 
   
   
       13, 33% 14, 12%          15, 13% 
   
  
 
 
      16, 14% 17  18 
  
 20% 
  
Scheme 5 Synthesis of aryl-substituted HHQ analogues. 
As previously mentioned, owing to the harsh reaction conditions, the products were 
obtained in low to moderate yields. Overall, anilines bearing electron-donating 
substituents gave rise to higher yields of the quinolone products (10–13) compared to 
those with electron-withdrawing groups (15–18). Quinolone product 14 was an 
exception to this trend, having a very low yield of 12%. This may be due to steric 
interference of the ortho-methoxy group of the enamine intermediate during the 
cyclisation step.   In the case of meta-substituted anilines, two different isomers of the 
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quinolone product are possible due to free rotation about the Ar-N bond in the enamine 
intermediate (like 9 in Scheme 4), resulting in a mixture of C-5 and C-7 substituted 
products. Interestingly, in the case of meta-anisidine, only the C-7 isomer 13 of the 
product was isolated, possibly due to unfavourable steric interactions between the 
methoxy and carbonyl groups of the C-5 isomer. In the case of meta-chloroaniline, a 
mixture of both products was obtained, in a ratio of 1:0.7 in favour of the C-7 
substituted product 18. Attempts to separate these two isomers by column 
chromatography or crystallisation methods were unsuccessful. 
1.8.2. Synthesis of C-2 Nonyl Chain Analogues 
In addition to these aryl-substituted HHQ analogues, two compounds were synthesised 
with a nonyl chain at the C-2 position in order to expand the scope of the SAR 
investigation. Once again, these compounds were prepared from the appropriate 
β-ketoester and substituted aniline. The β-ketoester bearing a nonyl chain was 
prepared as described in Scheme 2 from decanoyl chloride. 
 
  
 
19[49]   20–21 
  
20,[50] 10%    21, 19% 
   
Scheme 6 Synthesis of aryl-substituted quinolones bearing a nonyl chain at the C-2 
position. 
Compounds 10–21 (Scheme 5 and Scheme 6) were synthesised as part of a larger 
substrate scope contributing to the McGlacken group and BIOMERIT collaborative 
projects. Also working on the synthesis of AHQs was Dr Rafael Cano. The structures 
of Dr Cano’s compounds are shown in Figure 5, and were prepared using the same 
methods outlined above. All of the HHQ analogues prepared during this project were 
sent to Dr Reen in the BIOMERIT Research Centre at UCC for inclusion in various 
biological studies, the results of which are summarised at the end of this Results & 
Discussion section. 
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RC1 RC2 RC3 
   
  
RC4 RC5 
  
   
RC6 RC7 RC8 
   
  
RC9 RC10 
  
Figure 5 Compounds synthesised by Dr Rafael Cano (McGlacken group) as part of 
this project.  
Synthesis of Biologically Active HHQ Analogues Results & Discussion 
17 
 
1.8.3. Methylation of HHQ Analogues 
4-Quinolones like HHQ exist as two tautomeric forms – a 4-quinolone (1) and a 
4-hydroxyquinoline (1ʹ) (Scheme 7). Equilibrium tends towards the quinolone form 
under physiological conditions.[51] Since proton transfer from the nitrogen atom to the 
oxygen atom drives tautomerisation, substitution of this proton forces the molecule to 
stay ‘locked’ in one of the isomeric forms. Hence, further insight can be gained into 
the biological activity of the quinolone or the quinoline framework specifically.  
 
 
 
1  1ʹ 
   
Scheme 7 Quinolone/quinoline tautomerisation. 
Two of the aryl-substituted quinolones were chosen to undergo methylation based on 
results obtained from a study on the influence of the HHQ analogues on swarming 
motility in Bacillus atrophaeus, which will be discussed later. To prepare the N- and 
O-methylated isomers, compound 12 was reacted with methyl iodide in acetone and 
K2CO3. The resulting isomeric mixture was purified by column chromatography to 
afford the desired products 22 (quinolone) and 23 (quinoline) in 10% and 37% yield, 
respectively (Scheme 8). A C-2 nonyl analogue previously synthesised by Dr Cano 
(RC6) was subjected to the same methylation conditions to yield compounds 24 and 
25, in 14% and 42% yield, respectively. 
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R1 = C6H13, R
2 = C7H15: 12 
R1 = OMe, R2 = C9H19: RC6 
22 
24 
23 
25 
  
22, 10% 23, 37% 
  
  
24, 14% 25, 42% 
  
Scheme 8 Methylation of quinolones. 
When the methylated compounds 22–25 were subjected to the same biological tests 
as N-H quinolones 12 and RC6, there was a detectable difference in activity. This will 
be discussed further in the Biological Results Section 1.13.  
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1.9. Quinazolinone Synthesis 
As discussed in the introduction, HHQ and PQS differ by the presence of a hydrogen 
atom (HHQ) or hydroxyl group (PQS) at the C-3 position. Modification of this site is 
known to play an important role in dictating the biological activity of the molecule.[37] 
The 3-aminoquinazolinone compound 28 was synthesised for inclusion in biological 
studies to determine whether it displayed activity similar to PQS (Scheme 9). 
   
 
 26 
 
 
 
 
 
27 28, 3%  
   
Scheme 9 Synthesis of quinazolinone compound 28. 
The synthesis of the quinazolinone compound began with acylation of commercially 
available anthranillic acid with octanoyl chloride to give the amide intermediate 26. 
Cyclisation of this compound to form intermediate compound 27 and subsequent 
reaction with hydrazine hydrate led to formation of the desired product 28. Problems 
with the purification process resulted in a very low isolated yield of 3% pure product 
over three steps, although there was still enough material to obtain full characterisation 
and submit for biological analysis.  
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1.10. Synthesis of HHQ Analogue with a C-2 Terminal Alkene  
As discussed in the introduction, the alkyl chain at the C-2 position of HHQ and PQS 
seems to play an important role in the biological activity of the molecule. Having 
already extended the chain length by two carbon atoms (compounds 20 and 21), the 
effect of a terminal alkene was also of interest, and thus HHQ analogue 31 was 
synthesised (Scheme 10). 
 
 
 
  29, 63% 
 
 
 
 
 
 
30 31, 16%  
   
Scheme 10 Synthesis of HHQ analogue 31 with a terminal alkene. 
In order to incorporate the terminal alkene into the alkyl chain, a novel β-ketoester 
was prepared. This was achieved by deprotonation of methyl acetoacetate at the 
less-acidic C-4 position and subsequent reaction with 6-bromohex-1-ene to yield 
β-ketoester 29 in 63% isolated yield. This β-ketoester was then subjected to the same 
reaction conditions used for the synthesis of HHQ to form the desired product 31 in 
16% isolated yield. This novel HHQ analogue was also sent to Dr Reen for biological 
analysis, and a publication describing those results is in preparation.  
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1.11. Synthesis of Potential PqsR Antagonists  
Hartmann and co-workers developed potent HHQ-derived antagonists of the PqsR 
regulator of P. aeruginosa.[41-42, 52] As outlined in the introduction, antagonistic 
activity is dependent on two key features of the molecule. Firstly, the presence of the 
NO2 group at C-6 greatly improves the antagonistic effects towards PqsR. Secondly, 
insertion of a C-3 blocking group prevents hydroxylation by PqsH in P. aeruginosa, 
and thus the in vivo formation of agonistic molecules (Scheme 1). Thus, understanding 
the mode of action of the blocking group is of interest. For example, does the installed 
C-3 group merely block the hydroxylation site? Or does it infer additional biological 
activity? The addition of the amide group in compound 5 (Scheme 1) likely 
contributes additional properties to the molecule, such as H-donor/acceptor 
capabilities. Therefore, it is unlikely that the C-3 group only acts to prevent 
hydroxylation.  
To gain further understanding of the role of the C-3 group in Hartmann’s PqsR 
antagonist, the McGlacken group prepared a number of analogues of 6-NO2 HHQ (3) 
with different groups at C-3. This project began by developing a new route to 3. 
Hartmann found that when using the same conditions as for the synthesis of HHQ 
(Scheme 4) to access 3, the Conrad-Limpach cyclisation step was very low yielding 
(1%).[42] This result is probably due to the lower nucleophilicity of the nitroaniline 
group in the Conrad-Limpach cyclisation step. Instead, HHQ 1 itself was selectively 
nitrated in one step via electrophilic aromatic substitution in 67% yield (Scheme 11).  
 
 
 
1         3,[42] 67% 
   
Scheme 11 Nitration of HHQ. 
Importantly, this improvement allowed access to greater quantities of 3. Next, a 
number of blocking groups were then installed at the C-3 position, 
namely -F, -Cl, -Br, -I, -D and -Me. These compounds were prepared by McGlacken 
group member Dr Rafael Cano.[53]  
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1.11.1. Synthesis of Substituted Analogues of Hartmann’s Antagonist 
In addition to testing analogues with non-amide functional groups at the C-3 position, 
understanding the H-donor/acceptor properties of the amide group in Hartmann’s 
antagonist 5 was also of interest. Therefore, it was necessary to prepare compound 5 
to act as a comparator in the biological tests. In addition, the corresponding secondary 
and tertiary amides were also synthesised. All three amide compounds were prepared 
by initially following Hartmann’s synthesis of the carboxylic acid precursor (Scheme 
12).[41] 
 
   
7          32,[41] 58% 
    
Scheme 12 Synthesis of carboxylic acid compound 32. 
Compound 32 was then reacted with the coupling reagent 1,1'-carbonyldiimidazole 
(CDI), and treatment of the resulting imidazoyl intermediate with an excess of the 
appropriately substituted amine afforded the corresponding primary (5), secondary 
(33) or tertiary (34) amide. 
   
                  32 
 
        5, 33–34 
   
       5,[41] 65%                    33, 53%        34, 59% 
   
Scheme 13 Synthesis of Hartmann's amide (5) and secondary (33) and tertiary (34) 
derivatives. 
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1.12. Conclusions 
Analogues of HHQ were synthesised with substitutions at the C-5 to C-8 positions 
(10–21). Two of the quinolone compounds were methylated to give the N-Me 
quinolone and O-Me quinoline isomeric products (Scheme 8). A C-3 substituted 
quinazolinone analogue (28) was prepared, and a HHQ analogue with a terminal 
alkene on the heptyl chain at C-2 was also synthesised (31). An improved route to 
access 6-NO2 HHQ 3 via regioselective nitration of HHQ 1 was developed, and the 
secondary (33) and tertiary (34) methylated analogues of Hartmann’s antagonist 5 
were prepared. 
All of the HHQ analogues prepared were sent to Dr Reen at the BIOMERIT Research 
Centre at UCC to be tested in various biological studies. The experimental details of 
these tests are outside the scope of this thesis. However, due to the fact that the results 
of the biological analysis often guide the design of structural analogues of lead 
compounds, the results of the studies are summarised in the next section. Full details 
of the biological experiments can be found in the various publications, and are 
included in Appendix I.  
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1.13. Biological Results 
A Structure Activity-Relationship Study of Bacterial Signal Molecule HHQ 
Reveals Swarming Motility Inhibition in Bacillus atrophaeus 
(Organic & Biomolecular Chemistry, 2015, 13, 5537–5541) 
Bacillus atrophaeus is a Gram-positive species of bacteria that co-inhabits with P. 
aeruginosa in soil. P. aeruginosa QS molecules have been shown to influence 
behaviour in B. atrophaeus.[28, 54] B. atrophaeus also exhibits strong swarming and 
biofilm phenotypes that are characteristic of the multicellular behaviour underpinning 
virulence in many pathogens.[9] Swarming motility is considered a key virulence 
phenotype in many organisms controlled by QS.[55] 
The aim of the SAR in this study was to learn more about the influence of AHQs on 
Gram-positive bacteria and provide a platform for therapeutic developments. To 
achieve this, a diverse range of novel aryl-substituted HHQ analogues were tested on 
B. atrophaeus. A previous report from Reen et al. showed that swarming motility of 
B. atrophaeus was abolished in the presence of PQS, while use of HHQ showed little 
reduction.[28] Interestingly, some of the aryl-substituted HHQ analogues showed 
significant alteration in activity relative to the parent HHQ, with some compounds 
exhibiting inhibition comparable to PQS. In particular, RC5 and RC6 completely 
inhibited swarming, despite differing in the alkyl chain length at C-2. It appears that 
for compounds with a C-2 heptyl chain, an electron-withdrawing substituent at C-6 is 
required for anti-swarming activity, while for compounds with a C-2 nonyl chain, an 
electron-donating substituent at C-6 is required.  
As mentioned, 4-quinolones such as HHQ exist as two interconverting tautomeric 
forms: 4-quinolone and 4-hydroxyquinoline. It would be interesting to determine if 
either structure maintained anti-swarming activity if ‘locked’ in these tautomeric 
forms by methylation at the oxygen or nitrogen atom. Indeed, when anti-swarming 
molecule RC6 was methylated, both the quinolone form 24 and the quinoline form 25 
lost this activity (Figure 6). Compound 12 was also methylated and both isomers 
tested for their impact on swarming motility in B. atrophaeus. Again, both methylated 
derivatives 22 and 23 exhibited reduced activity relative to the parent molecule. In 
fact, the quinoline analogue 23 appeared to promote swarming.  
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Figure 6 Impact of HHQ analogues on swarming motility of B. atrophaeus. The 
smaller the swarming diameter, the greater the anti-swarming activity of the 
compound.[56] 
Modification of the quinolone at C-6 resulted in compounds possessing anti-swarming 
activity similar to that of PQS. These results suggest that the C-3 hydroxyl group of 
PQS is not essential for anti-swarming activity of AHQs towards B. atrophaeus.  
Synthesis of Biologically Active HHQ Analogues Results & Discussion 
26 
 
Exploiting Interkingdom Interactions for Development of Small Molecule 
Inhibitors of Candida albicans Biofilm Formation (Antimicrobial Agents and 
Chemotherapy, 2016, 60, 5894–5905) 
Candida albicans causes a variety of complications ranging from mucosal disease to 
deep-seated mycoses, particularly in immunocompromised individuals.[57-58] Along 
with other bacterial, fungal and yeast pathogens, C. albicans is known to form biofilms 
on medical devices, leading to recurring infections and in some cases death.[59-60] Once 
established in the biofilm phase, C. albicans presents a significant clinical problem, as 
biofilms themselves are considered a breeding ground for the emergence of antibiotic-
resistant strains.[61] 
C. albicans is known to coexist with P. aeruginosa in the cystic fibrosis lung, and 
interkingdom communication between the two organisms has previously been 
reported.[62-63] Previously, Reen et al. have shown that HHQ, but not PQS, suppresses 
biofilm formation in C. albicans (Figure 7).[28] In order to visualize the biofilm 
structures, attached cells were treated with specific intracellular stains to assess impact 
on key cellular components. These included cellulose and chitin with Calcofluor; 
lectin (carbohydrate) structures with Concanavalin A; and live cellular vacuolar stain 
FUN-1 which functions as a live/dead stain. As both PQS and HHQ promote virulence 
and pathogenicity in P. aeruginosa,[24, 64] these compounds fall short of being a viable 
antifungal treatment. However, chemical modification of these molecules provides an 
opportunity to develop compounds with greater specificity of function. 
 
Figure 7 C. albicans biofilms grown in the presence of PQS and HHQ.[65] 
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Analysis of the suite of analogues based on the core HHQ quinolone framework led 
to the identification of compounds that retain anti-biofilm activity toward C. albicans. 
Several analogues displayed anti-biofilm activity similar to HHQ, including the C-3 
substituted quinazolinone analogue 28. Overall, electron-withdrawing substituents 
(e.g. compounds RC4, RC5) promoted anti-biofilm activity in a similar manner to the 
HHQ parent, while electron-donating substituents (e.g. compounds 12, 13, RC3) 
resulted in some loss of activity. Extension of C-2 chain (20) did not seem to alter 
activity. Microscopic staining revealed that, like HHQ, the active compounds caused 
structural changes in the biofilm, causing atypical morphologies.   
Importantly, the new compounds exhibited significantly reduced cytotoxicity toward 
IB3-1 airway epithelial cells compared with the parent HHQ molecule. Evaluating the 
cytotoxicity of synthetic compounds is crucial in the context of developing targeted 
therapeutics that are benign to human cellular physiology and ideal for use in a clinical 
environment. Furthermore, unlike HHQ, the lead compounds were inactive toward the 
P. aeruginosa PqsR receptor system, a critical requirement for their potential future 
development as anti-biofilm therapeutics.  
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Harnessing Bacterial Signals for Suppression of Biofilm Formation in the 
Nosocomial Fungal Pathogen Aspergillus fumigatus (Frontiers in Microbiology, 
2016, 7, 2074) 
Aspergillus fumigatus is a pathogenic fungus associated with hospital-acquired 
infections. A. fumigatus infections contribute to morbidity and mortality in people with 
respiratory diseases such as cystic fibrosis, as well as infecting open skin wounds in 
burn patients and areas surrounding medical implants.[66-67] However, as with its 
bacterial counterparts, the defensive biofilm of A. fumigatus has led to conventional 
antifungal therapies rapidly becoming redundant.[68] Additionally, the co-existence 
and mutual interaction of bacteria and fungi at the site of infection contributes to the 
pathogenesis of disease. In the case of CF, A. fumigatus has been isolated in up to 60% 
of patients with P. aeruginosa infection, suggesting a close relationship between 
colonisation by P. aeruginosa and chronic infection by A. fumigatus.[69-70] 
In this study, the anti-biofilm activity of P. aeruginosa AHQs against A. fumigatus 
was investigated. Biofilm biomass and structure was significantly altered in the 
presence of both HHQ and PQS. Confocal microscopic analysis revealed that cells 
treated with either HHQ or PQS appeared locked in a spore form, with minimal 
evidence for formation of hyphal structures, characteristic of A. fumigatus biofilms. 
Next, the suite of analogues was tested and lead compounds were identified that 
retained activity against A. fumigatus (11, 12, 13, 20, 28). Of these, compound 12 
(n-hexyl group at C-6) and compound 13 (methoxy group at C-7) gave the greatest 
reduction in biofilm formation. Compound 20, in which the alkyl chain length was 
extended relative to the parent molecule HHQ, retained its anti-biofilm activity. 
Quinazolinone compound 28 also displayed good anti-biofilm activity. 
Importantly, anti-biofilm activity was retained against clinical isolates from paediatric 
samples. It has been shown that the genomes of clinical isolates can vary markedly 
from typed environmental strains, with niche-specific selective pressures manifesting 
with considerable specificity, even within species.[71] Both HHQ and PQS were 
capable of suppressing biofilm formation in each of the clinical isolates. Lead 
compounds 11 and 28 were also found to be effective against biofilm formation in 
clinical strains, underpinning their suitability for further therapeutic development 
(Figure 8). As expected, anti-biofilm compounds disrupted the formation of hyphal 
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structures, and appeared to lock the fungal cells in the spore state. Notably, however, 
the suppression of biofilm formation was not to the same extent as that seen against 
the lab strain Af293, suggesting some degree of tolerance or adaptation in the clinical 
isolates. 
 
  
28 11 
  
Figure 8 Confocal laser scanning microscopy analysis of biofilm formation in model 
strain (Af293) and clinical isolates (CFBRC1, CFBRC2, CFBRC3) in the presence of 
HHQ, PQS and lead compounds 28 and 11.[72] 
This study identified compounds with anti-biofilm activity comparable to the parent 
HHQ molecule, providing important insights into the SAR underpinning the 
suppression of fungal biofilms.  
28 11 
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The Requirements at the C-3 Position of Alkylquinolones for Signalling in 
Pseudomonas aeruginosa (Organic & Biomolecular Chemistry, 2017, 15, 306–310) 
As described in the introduction, Hartmann and co-workers reported a potent PqsR 
antagonist could be accessed by placing a nitro group at the C-6 position of HHQ 
(Scheme 1).[41-42, 52] In order to suppress functional inversion by in vivo hydroxylation 
of the C-3 position, the C-3 position was ‘blocked’ with a primary amide, leading to 
the development of a highly active antagonist 5. Previous work form the McGlacken 
group and collaborators showed that altering the C-3 position of HHQ prevented 
restoration of phenazine production in P. aeruginosa mutants, and also resulted in loss 
of anti-biofilm activity displayed by HHQ towards B. subtilis.[37] However, since then, 
the observations made by Hartmann compel further investigation of the role played by 
the C-3 position of AHQs.  
As previously stated, the P. aeruginosa QS system is known to be dependent on the 
PqsABCDE biosynthetic operon, which is positively regulated by PqsR. As PqsR 
controls the expression of PqsA, the monitoring of PqsA promoter activity can be used 
to determine PqsR agonism and antagonism. Thus all of the C-3 substituted 6-NO2 
HHQ analogues were tested using promotor fusion analysis of the PqsR-regulated 
PqsABCDE operon. Two genotypes of P. aeruginosa were chosen to be tested with 
the prepared molecules: a wild-type P. aeruginosa (PAO1) which would appropriately 
reflect the natural biochemistry of the species, and an isogenic PqsA mutant 
(PAO1pqs−) in which the ability to produce HHQ and PQS has been abolished 
(Figure 9). Overall, while all of the compounds showed some decrease in PqsR 
activity, none proved to be as potent as Hartmann’s amide 5, particularly when tested 
on the wild-type strain PAO1. 
Substituted amide compounds 33 and 34 showed minimal inhibition and were less 
potent than compound 5 (Figure 9). Inhibitory effects decreased with increasing 
substitution of the amide, indicating that the amide group is not acting solely as a 
blocking group. Furthermore, this result suggests that the H-bond donor capability of 
the amide N-H is important. This is in agreement with an extensive study on AHQ 
receptor interactions by Williams and co-workers,[43] which highlighted the 
requirement for an -NH2 group at the C-3 position of HHQ derivatives for competitive 
antagonism of PqsR. They suggested that strengthened electrostatic interactions 
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between the -NH2 group and carbonyl groups in the Leu207 backbone within the 
receptor pocket results in stronger binding than with native ligands such as PQS.  
 
  
3 5 
  
33 34 
  
Figure 9  PqsR activation in the presence of 6-NO2 HHQ analogues.
[53] 
From this study, it is clear that the substituent at C-3 has a more complex role beyond 
acting as a blocking group to prevent hydroxylation by PqsH. Overall, it appears that 
antagonistic behaviour seems to be strongly dependent on the ability of the molecule 
to engage in hydrogen-bonding interactions at the C-3 position. 
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1.14. General Considerations 
Solvents and reagents were used as obtained from commercial sources, without 
purification. Unless otherwise indicated, starting materials were also obtained from 
commercial sources. Column chromatography was carried out using 60 Å (35-70 µm) 
silica. TLC was carried out on pre-coated silica gel plates (Merck 60 PF254). The 
developed plates were visualised under UV light.  
Melting points were measured in a Thomas Hoover Capillary Melting Point apparatus. 
Infrared spectra were measured on a Perkin-Elmer FT-IR spectrometer. High 
resolution precise mass spectra (HRMS) were recorded on a Waters LCT Premier TOF 
LC-MS instrument in electrospray ionisation (ESI) mode using 50% acetonitrile-water 
containing 0.1% formic acid as eluent; samples were made up in acetonitrile at a 
concentration of ca. 1 mg/mL. Reported results are all within the range of ± 5ppm of 
the calculated mass. For brominated compounds, Br80 was used for the calculated and 
reported molecular ion mass. 
Nuclear Magnetic Resonance (NMR) samples were run in deuterated chloroform 
(CDCl3) or deuterated dimethylsulfoxide (DMSO-d6), as specified. 
1H-NMR (600 
MHz), 1H-NMR (500 MHz),1H-NMR (400 MHz), and 1H-NMR (300 MHz) spectra 
were recorded on Bruker Avance 600, Bruker Avance 500, Bruker Avance 400 and 
Bruker Avance 300 NMR spectrometers, respectively, in proton coupled mode using 
tetramethylsilane (TMS) as the internal standard. 13C-NMR (150 MHz), 13C-NMR 
(125 MHz), 13C-NMR (100 MHz) and 13C-NMR (75 MHz) spectra were recorded on 
Bruker Avance 600, Bruker Avance 500, Bruker Avance 400 and Bruker Avance 300 
NMR spectrometers, respectively, in proton decoupled mode at 20 C using 
tetramethylsilane (TMS) as the internal standard. All spectra were run at University 
College Cork. Chemical shifts (δ) are expressed as parts per million (ppm), positive 
shift being downfield from TMS; coupling constants (J) are expressed in hertz (Hz). 
Splitting patterns in 1H-NMR spectra are designated as: s (singlet), br s (broad singlet), 
d (doublet), dd (doublet of doublets), ddd (doublet of doublets of doublets), t (triplet), 
td (triplet of doublets), q (quartet), quin (quintet) and m (multiplet). Please note that 
the numbering system displayed on the structures is to assign the NMR data, and 
differs from the IUPAC system used for naming.  
Synthesis of Biologically Active HHQ Analogues Experimental 
39 
 
1.15. Synthesis of β-Ketoesters  
Methyl 3-oxodecanoate[46] (7)  
2,2-Dimethyl-1,3-dioxane-4,6-dione (Meldrum’s acid) (1 equiv.) was dissolved in dry 
DCM (1.5 mL/mmol). The solution was cooled to 0 °C under a nitrogen atmosphere. 
To the cooled solution were added pyridine (2 equiv.) and octanoyl chloride 
(1.1 equiv.), dropwise. The solution was stirred at 0 °C for 1 h and then at room 
temperature for 1 h. The mixture was washed with 5% HCl (3 × 0.5 mL/mmol) and 
water (0.5 mL/mmol). The organic layer was dried with MgSO4, filtered and 
concentrated in vacuo to yield acyl Meldrum’s acid 6 as a brown oil, which was used 
in the next step without purification. 
Acyl Meldrum’s acid 6 was dissolved in MeOH (1.4 mL/mmol) and heated at reflux 
for 5 h with constant stirring. After cooling to room temperature, the reaction mixture 
was concentrated in vacuo to yield the crude product as an orange oil. Purification by 
fractional distillation afforded the β-keto ester 7 as a colourless oil (16.7 g, 64 % yield). 
Colourless oil; yield: 16.7 g (64%); 1H-NMR (300 MHz, 
CDCl3, only signals of the predominant keto tautomer 
are given) δ: 0.88 (t, J = 6.7 Hz, 3H, CH3-11), 1.19–1.40 (m, 8H, CH2-7, CH2-8, 
CH2-9, CH2-10), 1.52–1.68 (m, 2H, CH2-6), 2.53 (t, J = 7.4 Hz, 2H, CH2-5), 3.45 (s, 
2H, CH2-3), 3.73 (s, 3H, CH3-1); 
13C-NMR (75 MHz, CDCl3, only signals of the 
predominant keto tautomer are given) δ: 13.8 (CH3-11), 22.4 (CH2-10), 23.3 (CH2-6), 
28.8 (CH2-8), 28.9 (CH2-7), 31.5 (CH2-9), 42.8 (CH2-5), 48.8 (CH2-3), 52.0 (CH3-1), 
167.6 (qC-2), 202.7 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C11H21O3: 
201.1491; found: 201.1482. 
Spectral data were consistent with those reported in the literature. 
Methyl 3-oxododecanoate[49] (19)  
Synthesised according to the same procedure as for 7 using decanoyl chloride. 
Colourless oil; yield: 8.08 g (59%); 1H-NMR (300 
MHz, CDCl3, only signals of the predominant keto 
tautomer are given) δ: 0.88 (t, J = 6.7 Hz, 3H, CH3-13), 1.15–1.41 (m, 12H, CH2-7, 
CH2-8, CH2-9, CH2-10, CH2-11, CH2-12), 1.49–1.71 (m, 2H, CH2-6), 2.53 (t, J = 7.4 
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Hz, 2H, CH2-5), 3.45 (s, 2H, CH2-3), 3.73 (s, 3H, CH3-1); 
13C-NMR (100 MHz, 
CDCl3, only signals of the predominant keto tautomer are given) δ: 14.1 (CH3-13), 
22.7 (CH2-12), 23.5 (CH2-6), 29.0 (CH2-7), 29.3 (CH2-10), 29.35 (CH2-8), 29.39 
(CH2-9), 31.9 (CH2-11), 43.1 (CH2-5), 49.0 (CH2-3), 52.4 (CH3-1), 167.8 (qC-2), 
203.0 (qC-4); HRMS (ESI-TOF) m/z: [M-H]- calcd. for C13H23O3: 227.16527; found: 
227.16487. 
Spectral data were consistent with those reported in the literature. 
Methyl 3-oxodec-9-enoate (29)  
A mixture of NaH (1.05 equiv.) in dry THF (2.5 mL/mmol) was cooled to 0 °C under 
a nitrogen atmosphere. Methyl acetoacetate (1 equiv.) was added dropwise, and the 
resulting white suspension was stirred at this 0 °C for 15 mins. Next, n-BuLi (1 equiv.) 
was added dropwise and the resulting bright yellow mixture was stirred at 0 °C for a 
further 20 mins. To this dianion mixture was added 6-bromohex-1-ene (1 equiv.) 
dropwise, and the resulting orange mixture was allowed to warm to room temperature 
and stirred until complete consumption of the starting materials was observed by TLC 
analysis (hexane/EtOAc 8:2), 3 h in total. The reaction was quenched with saturated 
aq. NH4Cl (3 mL/mmol) and extracted with EtOAc (3 × 1.5 mL/mmol). The combined 
organic layers were washed with brine (2 mL/mmol), dried over MgSO4, filtered and 
concentrated in vacuo to yield the crude product as an orange oil. Purification by 
column chromatography (hexane/EtOAc 9:1) yielded the product as yellow oil (1.25 
g, 63%). 
Pale yellow oil; yield: 1.25 g (63%); IR (NaCl): ν 3081 
(C-H stretch), 2932 (C-H stretch), 1740 (ester C=O 
stretch), 1701 (ketone C=O stretch), 1506 (alkene C=C stretch), 1477 (alkyl C-H 
bend), 1264 (C-O stretch) cm-1; 1H-NMR (300 MHz, CDCl3, signals of the 
predominant keto tautomer are given) δ: 1.21–1.47 (m, 4H, CH2-7, CH2-8), 1.52–1.69 
(m, 2H, CH2-6), 1.99–2.12 (m, 2H, CH2-9), 2.53 (t, J = 7.3 Hz, 2H, CH2-5), 3.44 (s, 
2H, CH2-3), 3.74 (s, 3H, CH3-1), 4.86–5.09 (m, 2H, CH2-11), 5.68-5.92 (m, 1H, 
CH-10); 13C-NMR (75 MHz, CDCl3, signals of the predominant keto tautomer are 
given) δ: 23.3 (CH2-6), 28.4 (CH2-8), 28.6 (CH2-7), 33.5 (CH2-9), 43.0 (CH2-5), 49.0 
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(CH2-3), 52.3 (CH3-1), 114.5 (CH2-11), 138.7 (CH-10), 167.7 (qC-2), 202.7 (qC-4); 
HRMS (ESI-TOF) m/z: [M+2H]+ calcd. for C11H20O3: 199.1339; found: 199.1338. 
1.16. General Procedure for the Synthesis of HHQ and HHQ Analogues 
To a solution of methyl 3-oxodecanoate 7 (or, for C-2 nonyl analogues, methyl 
3-oxododecanoate 19) (1 equiv.) in hexane (1.5 mL/mmol) were added the appropriate 
substituted aniline (1 equiv.) and p-TsOH (2 mol%). The reaction mixture was heated 
at reflux overnight under a Dean-Stark system. The reaction mixture was concentrated 
in vacuo to afford the crude β-enamino ester as an orange oil. This enamine 
intermediate was added dropwise (max. 10 mins for addition) via syringe to refluxing 
(>260 °C) diphenyl ether (0.5 mL/mmol) and left to cyclise at this temperature for 1.5 
h. After cooling to room temperature, diethyl ether (approx. 400 mL) was added to the 
reaction residue and left overnight at 5 °C, allowing the quinolone product to 
precipitate. The product was collected by vacuum filtration and washed with diethyl 
ether. If necessary, the quinolone was recrystallised from methanol.  
2-Heptylquinolin-4(1H)-one (HHQ)[37] (1)  
Pale yellow solid; yield: 10.01 g (41%); m.p. = 143–
146 °C (lit. 146–147 °C); IR (KBr): ν 3253 (N-H stretch), 
2956 (C-H stretch), 1636 (C=O stretch), 1596 (aromatic 
C-C stretch), 1465 (alkyl C-H bend), 1196 (C-N stretch) 
cm-1; 1H-NMR (300 MHz, CDCl3) δ: 0.81 (t, J = 6.8 Hz, 3H, CH3-17), 1.09–1.37 (m, 
8H, CH2-13, CH2-14, CH2-15, CH2-16), 1.64–1.79 (m, 2H, CH2-12), 2.39 (t, J = 7.7 
Hz, 2H, CH2-11), 6.24 (s, 1H, CH-3), 7.28–7.37 (m, 1H, CH-7), 7.53–7.63 (m, 1H, 
CH-8), 7.75 (d, J = 8.3 Hz, 1H, CH-9), 8.36 (dd, J = 8.2, 1.1 Hz, 1H, CH-6), 12.04 (br 
s, 1H, NH-1); 13C-NMR (75 MHz, CDCl3) δ: 14.0 (CH3-17), 22.6 (CH2-16), 28.96 
(CH2-14), 29.05 (CH2-12), 29.2 (CH2-13), 31.6 (CH2-15), 34.4 (CH2-11), 108.2 
(CH-3), 118.5 (CH-9), 123.5 (CH-7), 125.0 (qC-5), 125.3 (CH-6), 131.8 (CH-8), 140.6 
(qC-10), 155.1 (qC-2), 178.9 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C16H22NO: 244.1701; found: 244.1692. 
Spectral data were consistent with those reported in the literature.  
Synthesis of Biologically Active HHQ Analogues Experimental 
42 
 
2-Heptyl-6-methylquinolin-4(1H)-one (10) 
Pale yellow solid; yield: 398 mg (31%); m.p. = 177–179 
°C; IR (KBr): ν 3259 (N-H stretch), 2956 (C-H stretch), 
1644 (C=O stretch), 1593 (aromatic C-C stretch), 1490 
(alkyl C-H bend), 1203 (C-N stretch) cm-1; 1H-NMR 
(300 MHz, DMSO-d6) δ: 0.85 (t, J = 6.8 Hz, 3H, CH3-17), 1.17–1.40 (m, 8H, CH2-13, 
CH2-14, CH2-15, CH2-16), 1.59–1.74 (m, 2H, CH2-12), 2.38 (s, 3H, CH3-18), 2.56 (t, 
J = 7.7 Hz, 2H, CH2-11), 5.87 (s, 1H, CH-3), 7.40–7.46 (m, 2H, CH-8, CH-9), 7.82 
(s, 1H, CH-6), 11.37 (br s, 1H, NH-1); 13C-NMR (75 MHz, DMSO-d6) δ: 13.9 
(CH3-17), 20.7 (CH3-18), 22.0 (CH2-16), 28.4 (CH2-12, CH2-14), 28.5 (CH2-13), 31.1 
(CH2-15), 33.2 (CH2-11), 107.3 (CH-3), 117.8 (CH-9), 124.0 (CH-6), 124.6 (qC-5), 
131.8 (qC-7), 132.7 (CH-8), 138.2 (qC-10), 153.1 (qC-2), 176.6 (qC-4); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C17H24NO: 258.1858; found: 258.1848. 
2-Heptyl-6-hexylquinolin-4(1H)-one (12)  
Pale pink solid; yield: 580 mg (35%); m.p. 
= 112–113 °C; IR (KBr): ν 3245 (N-H 
stretch), 3051 (C-H stretch), 2926 (C-H 
stretch), 2741 (C-H stretch), 1643 (C=O 
stretch), 1590 (aromatic C-C stretch), 1486 (alkyl C-H bend), 1362 (alkyl C-H bend), 
1112 (C-N stretch) cm-1; 1H-NMR (300 MHz, DMSO-d6) δ: 0.80–0.95 (m, 6H, 
CH3-17, CH3-23), 1.19–1.40 (m, 14H, CH2-13, CH2-14, CH2-15, CH2-16, CH2-20, 
CH2-21, CH2-22), 1.52–1.75 (m, 4H, CH2-12, CH2-19), 2.53–2.71 (m, 4H, CH2-11, 
CH2-18), 5.88 (s, 1H, CH-3), 7.45 (s, 2H, CH-8, CH-9), 7.82 (s, 1H, CH-6), 11.37 (br 
s, 1H, NH-1); 13C-NMR (150 MHz, DMSO-d6) δ: 13.9 (CH3-17, CH3-23), 22.0 
(CH2-16, CH2-22), 28.2 (CH2-20), 28.35 (CH2-12), 28.37 (CH2-14), 28.4 (CH2-13), 
30.9 (CH2-19), 31.1 (CH2-15, CH2-21), 33.2 (CH2-11), 34.7 (CH2-18), 107.3 (CH-3), 
117.8 (CH-9), 123.3 (CH-6), 124.5 (qC-5), 132.2 (CH-8), 136.9 (qC-7), 138.4 
(qC-10), 153.2 (qC-2), 176.8 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C22H34NO: 328.2640; found: 328.2628. 
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2-Heptyl-5,7-dimethylquinolin-4(1H)-one (11)  
Pale yellow solid; yield: 612 mg (45%); m.p. = 158–
160 °C; IR (KBr): ν 3329 (N-H stretch), 3091 (C-H 
stretch), 2959 (C-H stretch), 1641 (C=O stretch), 1551 
(aromatic C-C stretch), 1462 (alkyl C-H bend), 1227 
(C-N stretch) cm-1; 1H-NMR (300 MHz, DMSO-d6) δ: 0.88 (t, J = 7.0 Hz, 3H, 
CH3-17), 1.20–1.36 (m, 8H, CH2-13, CH2-14, CH2-15, CH2-16), 1.56–1.70 (m, 2H, 
CH2-12), 2.32 (s, 3H, CH3-19), 2.44–2.56 (m, 2H, CH2-11), 2.74 (s, 3H, CH3-18), 5.76 
(s, 1H, CH-3), 6.77 (s, 1H, CH-7), 7.10 (s, 1H, CH-9), 11.05 (br s, 1H, NH-1); 
13C-NMR (75 MHz, DMSO-d6) δ: 14.4 (CH3-17), 21.5 (CH3-19), 22.5 (CH2-16), 23.5 
(CH3-18), 28.6 (CH2-14), 28.88 (CH2-13), 28.90 (CH2-12), 31.7 (CH2-15), 33.1 
(CH2-11), 109.7 (CH-3), 115.9 (CH-9), 121.4 (qC-5), 127.2 (CH-7), 139.3 (qC-6), 
140.7 (qC-8), 142.5 (qC-10), 152.0 (qC-2), 179.9 (qC-4); HRMS (ESI-TOF) m/z: 
[M+H]+ calcd. for C18H26NO: 272.2014; found: 272.2009. 
2-Heptyl-7-methoxyquinolin-4(1H)-one (13)  
Recrystallised from hot methanol. Pale yellow solid; 
yield: 450 mg (33%); m.p. = 135–138 °C; IR (KBr): 
ν 3199 (N-H stretch), 2929 (C-H stretch), 1638 
(C=O stretch), 1508 (aromatic C-C stretch), 1466 
(alkyl C-H bend), 1257 (C-O stretch), 1168 (C-N stretch) cm-1; 1H-NMR (300 MHz, 
DMSO-d6) δ: 0.85 (t, J = 6.9 Hz, 3H, CH3-17), 1.16–1.39 (m, 8H, CH2-13, CH2-14, 
CH2-15, CH2-16), 1.55–1.73 (m, 2H, CH2-12), 2.54 (t, J = 5.9 Hz, 2H, CH2-11), 3.83 
(s, 3H, CH3-18), 5.82 (s, 1H, CH-3), 6.74–6.99 (m, 2H, CH-7, CH-9), 7.92 (d, J = 8.9 
Hz, 1H, CH-6), 11.32 (br s, 1H, NH-1); 13C-NMR (75 MHz, DMSO-d6) δ: 14.4 
(CH3-17), 22.5 (CH2-16), 28.7 (CH2-12), 28.8 (CH2-14), 28.9 (CH2-13), 31.6 
(CH2-15), 33.7 (CH2-11), 55.8 (CH3-18), 99.4 (CH-9), 107.9 (CH-3), 113.1 (CH-7), 
119.4 (qC-5), 127.0 (CH-6), 142.4 (qC-10), 153.5 (qC-2), 162.1 (qC-8), 176.9 (qC-4); 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C17H24NO2: 274.1807; found: 274.1805. 
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2-Heptyl-8-methoxyquinolin-4(1H)-one (14)  
Recrystallised from hot methanol. Pale yellow solid; 
yield: 167 mg (12%); m.p. = 111–113 °C; IR (KBr): ν 
3372 (N-H stretch), 2923 (C-H stretch), 1634 (C=O 
stretch), 1592 (aromatic C-C stretch), 1435 (alkyl C-H 
bend), 1263 (C-O stretch) 1198 (C-N stretch) cm-1; 1H-NMR (300 MHz, DMSO-d6) 
δ: 0.86 (t, J = 6.8 Hz, 3H, CH3-17), 1.15–1.42 (m, 8H, CH2-13, CH2-14, CH2-15, 
CH2-16), 1.52–1.73 (m, 2H, CH2-12), 2.67 (t, J = 7.6 Hz, 2H, CH2-11), 3.99 (s, 3H, 
CH3-18), 5.92 (s, 1H, CH-3), 7.17–7.23 (m, 2H, CH-7, CH-8), 7.56–7.65 (m, 1H, 
CH-6), 10.88 (br s, 1H, NH-1); 13C-NMR (75 MHz, DMSO-d6) δ: 14.4 (CH3-17), 22.6 
(CH2-16), 28.9 (CH2-14), 29.0 (CH2-13), 29.5 (CH2-12), 31.7 (CH2-15), 33.2 
(CH2-11), 56.6 (CH3-18), 108.7 (CH-3), 111.4 (CH-8), 116.5 (CH-6), 123.0 (CH-7), 
126.1 (qC-5), 131.3 (qC-10), 148.8 (qC-9), 154.2 (qC-2), 177.0 (qC-4); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C17H24NO2: 274.1807; found: 274.1801. 
Ethyl 2-heptyl-4-oxo-1,4-dihydroquinoline-6-carboxylate (15)  
Pale yellow solid; yield: 202 mg (13%); m.p. = 
197–198 °C; IR (KBr): ν 3258 (N-H stretch), 
3057 (C-H stretch), 2926 (C-H stretch), 1719 
(ester C=O stretch), 1645 (C=O stretch), 1593 
(aromatic C-C stretch), 1495 (alkyl C-H bend), 1278 (C-O stretch), 1172 (C-N stretch) 
cm-1; 1H-NMR (300 MHz, DMSO-d6) δ: 0.86 (t, J = 6.8 Hz, 3H, CH3-17), 1.21–1.41 
(m, 11H, CH2-13, CH2-14, CH2-15, CH2-16, CH3-20), 1.60–1.75 (m, 2H, CH2-12), 
2.60 (t, J = 7.6 Hz, 2H, CH2-11), 4.34 (q, J = 7.1 Hz, 2H, CH2-19), 6.01 (s, 1H, CH-3), 
7.61 (d, J = 8.7 Hz, 1H, CH-9), 8.12 (dd, J = 8.7, 2.1 Hz, 1H, CH-8), 8.66 (d, J = 1.9 
Hz, 1H, CH-6), 11.75 (br s, 1H, NH-1); 13C-NMR (150 MHz, DMSO-d6) δ: 13.9 
(CH3-20), 14.2 (CH3-17), 22.0 (CH2-16), 28.2 (CH2-12), 28.3 (CH2-14), 28.5 
(CH2-13), 31.1 (CH2-15), 33.2 (CH2-11), 60.8 (CH2-19), 108.7 (CH-3), 118.5 (CH-9), 
123.8 (qC-7), 123.9 (qC-5), 127.1 (CH-6), 131.3 (CH-8), 143.0 (qC-10), 154.5 (qC-2), 
165.3 (qC-18), 176.7 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C19H26NO3: 
316.1913; found: 316.1913. 
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6-Bromo-2-heptylquinolin-4(1H)-one (16)  
Recrystallised from hot methanol. Light brown solid; 
yield: 355 mg (14%); m.p. = 186–188 °C; IR (KBr): ν 
3319 (N-H stretch), 2926 (C-H stretch), 1632 (C=O 
stretch), 1595 (aromatic C-C stretch), 1467 (alkyl C-H 
bend), 1129 (C-N stretch), 842 (C-Br stretch) cm-1; 1H-NMR (300 MHz, DMSO-d6) 
δ: 0.86 (t, J = 6.8 Hz, 3H, CH3-17), 1.15–1.42 (m, 8H, CH2-13, CH2-14, CH2-15, 
CH2-16), 1.57–1.76 (m, 2H, CH2-12), 2.61 (t, J = 6.9 Hz, 2H, CH2-11), 6.04 (s, 1H, 
CH-3), 7.53 (d, J = 8.7 Hz, 1H, CH-9), 7.79 (dd, J = 8.8, 2.4 Hz, 1H, CH-8), 8.13 (d, 
J = 2.3 Hz, 1H, CH-6), 11.81 (br s, 1H, NH-1); 13C-NMR (75 MHz, DMSO-d6) δ: 14.4 
(CH3-17), 22.5 (CH2-16), 28.8 (CH2-12, CH2-14), 28.9 (CH2-13), 31.6 (CH2-15), 33.8 
(CH2-11), 108.1 (CH-3), 116.6 (qC-7), 121.3 (CH-9), 125.6 (qC-5), 127.2 (CH-6), 
135.1 (CH-8), 139.3 (qC-10), 155.8 (qC-2), 174.8 (qC-4); HRMS (ESI-TOF) m/z: 
[M+H]+ calcd. for C16H21BrNO: 322.0807; found: 322.0798. 
2-Nonylquinolin-4(1H)-one[50] (20)  
Synthesised according to the same procedure as for HHQ using β-ketoester 19. 
Off-white solid; yield: 312 mg (23%); m.p. = 133–
134 °C (lit. 138–139 °C); IR (KBr): ν 3256 (N-H 
stretch), 2923 (C-H stretch), 1641 (C=O stretch), 
1503 (aromatic C-C stretch), 1472 (alkyl C-H bend), 
1137 (C-N stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 0.84 (t, J = 6.8 Hz, 3H, 
CH3-19), 1.05–1.43 (m, 12H, CH2-13, CH2-14, CH2-15, CH2-16, CH2-17, CH2-18), 
1.62–1.82 (m, 2H, CH2-12), 2.69 (t, J = 7.6 Hz, 2H, CH2-11), 6.24 (s, 1H, CH-3), 
7.27–7.38 (m, 1H, CH-7), 7.50–7.66 (m, 1H, CH-8), 7.77 (d, J = 8.3 Hz, 1H, CH-9), 
8.36 (dd, J = 8.1, 1.2 Hz, 1H, CH-6), 12.16 (br s, 1H, NH-1); 13C-NMR (75 MHz, 
CDCl3) δ: 14.1 (CH3-19), 22.6 (CH2-18), 29.1 (CH2-12), 29.25 (CH2-15, CH2-16), 
29.32 (CH2-14), 29.4 (CH2-13), 31.8 (CH2-17), 34.4 (CH2-11), 108.2 (CH-3), 118.5 
(CH-9), 123.5 (CH-7), 125.0 (qC-5), 125.3 (CH-6), 131.7 (CH-8), 140.7 (qC-10), 
155.2 (qC-2), 178.9 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C18H26NO: 
272.2014; found: 272.2012. 
Spectral data were consistent with those reported in the literature.  
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6-Methyl-2-nonylquinolin-4(1H)-one (21)  
Synthesised according to the same procedure as for HHQ using β-ketoester 19. 
Pale yellow solid; yield: 109 mg (19%); m.p. = 
172–174 °C; IR (KBr): ν 3261 (N-H stretch), 2954 
(C-H stretch), 1647 (C=O stretch), 1589 (aromatic 
C-C stretch), 1495 (alkyl C-H bend), 1198 (C-N 
stretch) cm-1; 1H-NMR (300 MHz, DMSO-d6) δ: 0.85 (t, J = 6.7 Hz, 3H, CH3-19), 
1.17–1.40 (m, 12H, CH2-13, CH2-14, CH2-15, CH2-16, CH2-17, CH2-18), 1.57–1.75 
(m, 2H, CH2-12), 2.39 (s, 3H, CH3-20), 2.53–2.60 (m, 2H, CH2-11), 5.88 (s, 1H, 
CH-3), 7.41–7.46 (m, 2H, CH-8, CH-9), 7.83 (d, J = 0.9 Hz, 1H, CH-6), 11.35 (br s, 
1H, NH-1); 13C-NMR (75 MHz, DMSO-d6) δ: 14.4 (CH3-19), 21.2 (CH3-20), 22.5 
(CH2-18), 28.8 (CH2-12), 29.0 (CH2-16), 29.1 (CH2-15), 29.2 (CH2-14), 29.3 
(CH2-13), 31.7 (CH2-17), 33.7 (CH2-11), 107.8 (CH-3), 118.3 (CH-9), 124.5 (CH-6), 
125.0 (qC-5), 132.3 (qC-7), 133.2 (CH-8), 138.7 (qC-10), 153.6 (qC-2), 177.1 (qC-4); 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C19H28NO: 286.2171; found: 286.2167. 
2-(Hept-6-en-1-yl)quinolin-4(1H)-one (31)  
Synthesised according to the same procedure as for HHQ using β-ketoester 29. 
Pale yellow solid; yield: 109 mg (16%); m.p. = 122–124 
°C; IR (NaCl): ν 3426 (N-H stretch), 2929 (C-H stretch), 
1638 (C=O stretch), 1595 (aromatic C-C stretch), 1505 
(alkene C=C stretch), 1472 (alkyl C-H bend), 1137 (C-N 
stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 1.26–1.44 (m, 4H, CH2-13, CH2-14), 
1.67–1.82 (m, 2H, CH2-12), 1.93–2.08 (m, 2H, CH2-15), 2.66 (t, J = 7.7 Hz, 2H, 
CH2-11), 4.86–5.01 (m, 2H, CH2-17), 5.73 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H, CH-16), 
6.20 (s, 1H, CH-3), 7.32 (ddd, J = 8.1, 5.9, 2.2 Hz, 1H, CH-7), 7.51–7.64 (m, 2H, 
CH-8, CH-9), 8.35 (d, J = 7.9 Hz, 1H, CH-6), 10.43 (br s, 1H, NH-1); 13C-NMR (75 
MHz, CDCl3) δ: 28.4 (CH2-12, CH2-14), 28.6 (CH2-13), 33.5 (CH2-15), 33.6 
(CH2-11), 108.1 (CH-3), 115.2 (CH2-17), 118.3 (CH-9), 123.2 (CH-7), 125.1 (qC-5), 
125.2 (CH-6), 131.9 (CH-8), 139.1 (CH-16), 140.6 (qC-10), 153.9 (qC-2), 177.3 
(qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C16H20NO: 242.1545; found: 
242.1535.  
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1.17. General Procedure for the Methylation of HHQ Analogues 
To a solution of the quinolone substrate 12 or RC6 (compound synthesised by Dr 
Rafael Cano, refer to Figure 5 for structure) (1 equiv.) in acetone (6 mL/mmol) were 
added K2CO3 (3 equiv.) and MeI (3 equiv.). The resulting mixture was stirred at 79 °C 
for 4 h. The cooled reaction mixture was poured into deionised water (25 mL/mmol) 
and extracted with EtOAc (3 × 10 mL/mmol). The combined organic extracts were 
dried over MgSO4, filtered and concentrated in vacuo to yield the crude isomeric 
mixture of the N- and O-methylated products. Separation of the mixture by column 
chromatography (hexane/EtOAc 8:2) afforded the pure products. 
2-Heptyl-6-hexyl-1-methylquinolin-4(1H)-one (22)  
Yellow oil; yield: 13 mg (10%); [not enough 
material was obtained for IR analysis]; 
1H-NMR (300 MHz, CDCl3) δ: 0.75–1.00 
(m, 6H, CH3-17, CH3-23), 1.13–1.53 (m, 
14H, CH2-13, CH2-14, CH2-15, CH2-16, CH2-20, CH2-21, CH2-22), 1.57–1.79 (m, 
4H, CH2-12, CH2-19), 2.62–2.81 (m, 4H, CH2-11, CH2-18), 3.72 (s, 3H, CH3-1), 6.22 
(s, 1H, CH-3), 7.38–7.53 (m, 2H, CH-8, CH-9), 8.25 (d, J = 1.7 Hz, 1H, CH-6); 
13C-NMR (75 MHz, CDCl3) δ: 14.1 (CH3-17, CH3-23), 22.6 (CH2-16, CH2-22), 28.6 
(CH2-20), 28.9 (CH2-12), 29.0 (CH2-14), 29.2 (CH2-13), 31.4 (CH2-19), 31.7 (CH2-15, 
CH2-21), 34.1 (CH2-11), 34.7 (CH2-18), 35.2 (CH3-1), 110.9 (CH-3), 115.3 (CH-9), 
125.5 (CH-6), 126.5 (qC-5), 132.7 (CH-8), 138.3 (qC-7), 140.2 (qC-10), 154.3 (qC-2), 
177.8 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C23H36NO: 342.2797; found: 
342.2788. 
2-Heptyl-6-hexyl-4-methoxyquinoline (23)  
Orange oil; yield: 46 mg (37%); IR (NaCl): 
ν 3583 (C-H stretch), 2926 (C-H stretch), 
2854 (C-H stretch), 1596 (aromatic C-C 
stretch), 1462 (alkyl C-H bend), 1362 (C-N 
stretch), 1112 (C-O stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 0.81–0.96 (m, 6H, 
CH3-17, CH3-23), 1.18–1.50 (m, 14H, CH2-13, CH2-14, CH2-15, CH2-16, CH2-20, 
CH2-21, CH2-22), 1.60–1.87 (m, 4H, CH2-12, CH2-19), 2.70–2.97 (m, 4H, CH2-11, 
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CH2-18), 4.02 (s, 3H, CH3-24), 6.60 (s, 1H, CH-3), 7.49 (dd, J = 8.6, 2.0 Hz, 1H, 
CH-8), 7.83–7.94 (m, 2H, CH-6, CH-9); 13C-NMR (75 MHz, CDCl3) δ: 14.1 (CH3-17, 
CH3-23), 22.0 (CH2-16, CH2-22), 29.0 (CH2-20), 29.2 (CH2-14), 29.6 (CH2-13), 30.3 
(CH2-12), 31.5 (CH2-19), 31.7 (CH2-15), 31.8 (CH2-21), 36.1 (CH2-18), 40.0 
(CH2-11), 55.4 (CH3-24), 99.7 (CH-3), 119.8 (qC-5, CH-9), 128.1 (CH-6), 131.1 
(CH-8), 139.6 (qC-7), 147.5 (qC-10), 162.0 (qC-4), 163.3 (qC-2); HRMS (ESI-TOF) 
m/z: [M+H]+ calcd. for C23H36NO: 342.2797; found: 342.2784. 
6-Methoxy-1-methyl-2-nonylquinolin-4(1H)-one (24)  
Pale yellow oil; yield: 22 mg (14%); IR (KBr): 
ν 3369 (C-H stretch), 2929 (C-H stretch), 1599 
(C=O stretch), 1566 (aromatic C-C stretch), 
1493 (alkyl C-H bend), 1318 (C-N stretch), 
1069 (C-O stretch) cm-1; 1H-NMR (500 MHz, CDCl3) δ: 0.88 (t, J = 6.6 Hz, 3H, 
CH3-19), 1.20–1.50 (m, 12H, CH2-13, CH2-14, CH2-15, CH2-16, CH2-17, CH2-18), 
1.65–1.75 (m, 2H, CH2-12), 2.72 (t, J = 7.5 Hz, 2H, CH2-11), 3.75 (s, 3H, CH3-1), 
3.93 (s, 3H, CH3-20), 6.23 (s, 1H, CH-3), 7.25–7.30 (m, 1H, CH-8), 7.46 (d, J = 9.3 
Hz, 1H, CH-9), 7.86 (s, 1H, CH-6); 13C-NMR (125 MHz, CDCl3) δ: 14.1 (CH3-19), 
22.7 (CH2-18), 28.7 (CH2-12), 29.25 (CH2-16), 29.29 (CH2-15), 29.32 (CH2-14), 29.4 
(CH2-13), 31.8 (CH2-17), 34.3 (CH3-1), 34.7 (CH2-11), 55.8 (CH3-20), 105.7 (CH-6), 
110.4 (CH-3), 117.0 (CH-9), 122.6 (CH-8), 127.8 (qC-5), 136.7 (qC-10), 153.8 
(qC-2), 156.0 (qC-7), 177.2 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C20H30NO2: 316.2277; found: 316.2282. 
4,6-Dimethoxy-2-nonylquinoline (25)  
Orange oil; yield: 66 mg (42%); IR (NaCl): ν 
3583 (C-H stretch), 2925 (C-H stretch), 1599 
(aromatic C-C stretch), 1489 (alkyl C-H bend), 
1223 (C-N stretch), 1089 (C-O stretch) cm-1; 
1H-NMR (300 MHz, CDCl3) δ: 0.87 (t, J = 6.6 Hz, 3H, CH3-19), 1.20–1.50 (m, 12H, 
CH2-13, CH2-14, CH2-15, CH2-16, CH2-17, CH2-18), 1.75–1.85 (m, 2H, CH2-12), 
2.88 (t, J = 7.6 Hz, 2H, CH2-11), 3.92 (s, 3H, CH3-20), 4.03 (s, 3H, CH3-21), 6.61 (s, 
1H, CH-3), 7.30 (dd, J = 9.1, 2.9 Hz, 1H, CH-8), 7.40 (d, J = 2.8 Hz, 1H, CH-6), 7.87 
(d, J = 9.2 Hz, 1H, CH-9); 13C-NMR (75 MHz, CDCl3) δ: 14.1 (CH3-19), 22.7 
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(CH2-18), 29.3 (CH2-12), 29.54 (CH2-16), 29.56 (CH2-15), 29.6 (CH2-14), 30.3 
(CH2-13), 31.9 (CH2-17), 39.7 (CH2-11), 55.5 (CH3-20, CH3-21), 99.7 (CH-3), 100.0 
(CH-9), 120.5 (qC-5), 121.8 (CH-6), 129.8 (CH-8), 144.7 (qC-10), 156.8 (qC-7), 
161.4 (qC-4), 161.7 (qC-2); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C20H30NO2: 
316.2277; found: 316.2270. 
1.18. Synthesis of Quinazolinone Compound 28 
3-Amino-2-heptylquinazolin-4(3H)-one (28)  
Triethylamine (2 equiv.) was added to a suspension of anthranilic acid (1 equiv.) in 
DCM (3.5 mL/mmol). The mixture was cooled to 0 °C and octanoyl chloride (1 equiv.) 
was added dropwise, and the reaction mixture was stirred at room temperature for 
2.5 h. After this time the reaction mixture was again cooled to 0 °C, and more 
triethylamine (1.1 equiv.) and ethyl chloroformate (1.1 equiv.) were added dropwise 
to the mixture, successively. The reaction mixture was then stirred at 0 ºC for 1 h and 
at room temperature for 1.5 h, and then concentrated in vacuo to yield intermediate 27 
as a pale yellow solid, which was carried through to the next step without further 
purification. Compound 27 was dissolved in pyridine (2.5 mL/mmol). Hydrazine 
hydrate (2 equiv.) was added and the reaction mixture was stirred at 115 °C for 1 h. 
After cooling to room temperature, conc. HCl (2 mL/mmol) and ice (2 g/mmol) were 
added to the mixture which was left to stand at room temperature overnight. A small 
amount of solid precipitated and was collected by vacuum filtration and washed with 
water. The solid was then recrystallised from ethanol to yield the pure product 28 as 
an off-white solid (52 mg, 3%). 
Off-white solid; yield: 52 mg (3%); m.p. = 73–75 °C; IR 
(KBr): ν 3300 (N-H stretch), 3202 (C-H stretch), 2927 
(C-H stretch), 1665 (C=O stretch), 1591 (aromatic C-C 
stretch), 1474 (alkyl C-H bend), 1230 (C-N stretch), 1108 (N-N stretch) cm-1; 
1H-NMR (300 MHz, CDCl3) δ: 0.89 (t, J = 6.8 Hz, 3H, CH3-18), 1.23–1.54 (m, 8H, 
CH2-14, CH2-15, CH2-16, CH2-17), 1.76–1.90 (m, 2H, CH2-13), 2.94–3.10 (m, 2H, 
CH2-12), 4.86 (s, 2H, NH2-4), 7.44 (ddd, J = 8.1, 6.8, 1.5 Hz, 1H, CH-8), 7.63–7.78 
(m, 2H, CH-9, CH-10), 8.24 (dd, J = 8.0, 0.9 Hz, 1H, CH-7); 13C-NMR (75 MHz, 
CDCl3) δ: 14.1 (CH3-18), 22.6 (CH2-17), 27.2 (CH2-13), 29.1 (CH2-15), 29.4 
(CH2-14), 31.7 (CH2-16), 34.6 (CH2-12), 120.0 (qC-6), 126.2 (CH-7), 126.5 (CH-10), 
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127.2 (CH-8), 134.2 (CH-9), 147.1 (qC-11), 158.4 (qC-2), 161.9 (qC-5); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C15H22N3O: 260.1763; found: 260.1752. 
1.19. Synthesis of 6-Nitro HHQ 3 
2-Heptyl-6-nitroquinolin-4(1H)-one[42] (3) 
HHQ 1 (1 equiv.) was dissolved in conc. H2SO4 (1.2 mL/mmol) and the solution was 
cooled to 0 ºC on an ice bath. In a separate vessel, conc. H2SO4 (0.12 mL/mmol) and 
conc. HNO3 (0.12 mL/mmol) were combined and also cooled to 0 °C on ice. The 
HNO3/H2SO4 solution was added dropwise over approx. 5 min to the HHQ solution 
whilst maintaining the temperature between 0–5 ºC (this proved to be important for 
selective nitration at the C-6 position and minimising the formation of other nitrated 
isomers). The resulting yellow solution was allowed to warm to room temperature 
with stirring for a further 2 h. Ice-water (2.5 mL/mmol) was added to the solution and 
a bright yellow solid precipitated, which was collected by vacuum filtration and 
recrystallised from hot methanol and diethyl ether. The yellow solid obtained was 
collected by vacuum filtration, washed with diethyl ether, yielding the pure product 3 
(388 mg, 67 %).   
Yellow solid; yield: 388 mg (67%); m.p. = 183–185 
°C (lit. 185–186 °C); IR (KBr): ν 3102 (C-H stretch), 
2921 (C-H stretch), 1658 (C=O stretch), 1616 (N-O 
stretch), 1494 (aromatic C-C stretch), 1468 (alkyl 
C-H bend), 1355 (N-O stretch), 1193 (C-N stretch) cm-1; 1H-NMR (300 MHz, 
DMSO-d6) δ: 0.86 (t, J = 6.8 Hz, 3H, CH3-17), 1.16–1.44 (m, 8H, CH2-13, CH2-14, 
CH2-15, CH2-16), 1.59–1.81 (m, 2H, CH2-12), 2.68 (t, J = 7.7 Hz, 2H, CH2-11), 6.22 
(s, 1H, CH-3), 7.78 (d, J = 9.2 Hz, 1H, CH-9), 8.44 (dd, J = 9.2, 2.7 Hz, 1H, CH-8), 
8.82 (d, J = 2.6 Hz, 1H, CH-6), 12.37 (br s, 1H, NH-1); 13C-NMR (75 MHz, 
DMSO-d6) δ: 14.4 (CH3-17), 22.5 (CH2-16), 28.6 (CH2-12), 28.8 (CH2-14), 28.9 
(CH2-13), 31.6 (CH2-15), 33.8 (CH2-11), 109.2 (CH-3), 120.5 (CH-9), 121.8 (CH-6), 
123.5 (qC-5), 126.5 (CH-8), 143.2 (qC-7), 144.1 (qC-10), 156.8 (qC-2), 176.0 (qC-4); 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C16H21N2O3: 289.1552; found: 289.1538. 
Spectral data were consistent with those reported in the literature. 
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1.20. Synthesis of Carboxylic Acid Precursor 32 
Methyl 2-heptyl-6-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
To a suspension of NaH (1.1 equiv.) in dry DMF (3 mL/mmol) was added a solution 
of methyl 3-oxodecanoate 7 (1.1 equiv.) in dry DMF (2 mL/mmol) via a dropping 
funnel under a nitrogen atmosphere, and the reaction mixture stirred at room 
temperature. Once the evolution of H2 had ceased, a solution of 5-nitroisotoic 
anhydride (1 equiv.) in dry DMF (2 mL/mmol) was added dropwise via a dropping 
funnel. The resulting orange reaction mixture was then stirred at room temperature 
overnight. The reaction mixture was concentrated in vacuo (Kugelrohr) to 
approximately 25% the original volume. HCl (1 M aq.) was then added to precipitate 
the crude product as a yellow solid, which was collected by vacuum filtration and dried 
in vacuo. The crude product was recrystallised from hot methanol, collected by 
vacuum filtration and dried in vacuo to yield the pure product as a pale yellow solid 
(0.859 g, 31%). 
Pale yellow solid; yield: 859 mg (31%); m.p. = 235–
239 °C; IR (KBr): ν 3101 (C-H stretch), 2927 (C-H 
stretch), 1727 (ester C=O stretch), 1661 (C=O 
stretch), 1615 (N-O stretch), 1504 (aromatic C-C 
stretch), 1469 (alkyl C-H bend), 1343 (N-O stretch), 1200 (C-N stretch), 1065 (C-O 
stretch) cm-1; 1H-NMR (300 MHz, DMSO-d6) δ: 0.86 (t, J = 6.8 Hz, 3H, CH3-17), 
1.18–1.45 (m, 8H, CH2-13, CH2-14, CH2-15, CH2-16), 1.61–1.74 (m, 2H, CH2-12), 
2.65 (t, J = 7.8 Hz, 2H, CH2-11), 3.80 (s, 3H, CH3-19), 7.77 (d, J = 9.1 Hz, 1H, CH-9), 
8.45 (dd, J = 9.1, 2.6 Hz, 1H, CH-8), 8.81 (d, J = 2.6 Hz, 1H, CH-6), 12.30 (br s, 1H, 
NH-1); 13C-NMR (75 MHz, DMSO-d6) δ: 14.4 (CH3-17), 22.5 (CH2-16), 28.7 
(CH2-12), 29.1 (CH2-14), 29.2 (CH2-13), 31.5 (CH2-15), 32.5 (CH2-11), 52.5 
(CH3-19), 116.2 (qC-3), 120.6 (CH-9), 122.0 (CH-6), 124.1 (qC-5), 127.0 (CH-8), 
143.5 (qC-7), 143.6 (qC-10), 154.7 (qC-2), 167.1 (qC-18), 173.6 (qC-4); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C18H23N2O5: 347.1607; found: 347.1594. 
2-Heptyl-6-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid[41] (32) 
A suspension of methyl 2-heptyl-6-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(1 equiv.) in 10% aq. NaOH (70 mL/mmol) was heated at 97 ⁰C with stirring for 4 h. 
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The reaction mixture was then cooled to room temperature and extracted with EtOAc 
(3 × 5 mL/mmol). The aqueous layer was then acidified to pH 4.5 with conc. HCl on 
ice, causing a white solid to precipitate. The crude product was collected by vacuum 
filtration, and recrystallised from hot methanol to yield the pure product 32 as a white 
solid (0.209 g, 58%). 
White solid; yield: 209 mg (58%); m.p. = 194–197 °C 
(lit. 192–194 °C); IR (KBr): ν 3439 (N-H stretch), 
3099 (C-H stretch), 2932 (C-H stretch), 2852 (O-H 
stretch), 1737 (acid C=O stretch), 1681 (C=O 
stretch), 1619 (N-O stretch), 1515 (aromatic C-C stretch), 1418 (alkyl C-H bend), 
1344 (N-O stretch), 1251 (C-O stretch), 1225 (C-N stretch) cm-1; 1H-NMR (300 MHz, 
DMSO-d6) δ: 0.87 (t, J = 6.7 Hz, 3H, CH3-17), 1.20–1.52 (m, 8H, CH2-13, CH2-14, 
CH2-15, CH2-16), 1.61–1.79 (m, 2H, CH2-12), 3.18–3.45 (m, 2H, CH2-11), 7.93 (d, J 
= 9.2 Hz, 1H, CH-9), 8.59 (dd, J = 9.1, 2.6 Hz, 1H, CH-8), 8.94 (d, J = 2.6 Hz, 1H, 
CH-6), 13.23 (br s, 1H, NH-1), 15.67 (br s, 1H, OH-19); 13C-NMR (75 MHz, 
DMSO-d6) δ: 14.4 (CH3-17), 22.5 (CH2-16), 28.8 (CH2-12), 29.6 (CH2-13, CH2-14), 
31.6 (CH2-15), 33.9 (CH2-11), 108.2 (qC-3), 121.4 (CH-9), 122.0 (CH-6), 123.2 
(qC-5), 128.1 (CH-8), 142.3 (qC-7), 144.7 (qC-10), 164.5 (qC-2), 166.0 (qC-18), 
179.0 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C17H21N2O5: 333.1450; 
found: 333.1451. 
Spectral data were consistent with those reported in the literature. 
1.21. General Procedure for the Synthesis of Hartmann’s Amide and 
Methylated Analogues 
N,N'-Carbonyldiimidazole (CDI) (2 equiv.) was added to a solution of 32 (1 equiv.) in 
dry DMF (5 mL/mmol), and the resulting yellow mixture was stirred for 4 h at 65 ⁰C. 
The cooled reaction mixture was then added to a solution of the appropriate amine, 
30 wt% NH4OH for 5, 40 wt% NH2Me in H2O for 33, or 30 wt% NHMe2 in Et2O for 
34 (25 mL/mmol) on an ice bath and the resulting mixture was stirred at room 
temperature overnight. The reaction mixture was then concentrated by approx. 50% in 
vacuo (Kugelrohr) and iced water (15 mL/mmol) was added, causing the product to 
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precipitate as a pale yellow solid which was collected by vacuum filtration and dried 
in vacuo. 
2-Heptyl-6-nitro-4-oxo-1,4-dihydroquinoline-3-carboxamide[41] (5) 
Pale yellow solid; yield: 129 mg (65%); m.p. = 238–
241 °C (lit. 237–239 °C); IR (KBr): ν 3392 (N-H 
stretch), 3222 (N-H stretch), 3091 (C-H stretch), 2927 
(C-H stretch), 1684 (C=O stretch), 1651 (amide C=O 
stretch), 1595 (N-O stretch), 1501 (aromatic C-C stretch), 1409 (alkyl C-H bend), 
1342 (N-O stretch), 1223 (C-N stretch) cm-1; 1H-NMR (300 MHz, DMSO-d6) δ: 0.87 
(t, J = 6.7 Hz, 3H, CH3-17), 1.19–1.47 (m, 8H, CH2-13, CH2-14, CH2-15, CH2-16), 
1.62–1.79 (m, 2H, CH2-12), 3.02 (t, J = 7.8 Hz, 2H, CH2-11), 7.36 (br s, 1H, one of 
NH2-19), 7.77 (d, J = 9.1 Hz, 1H, CH-9), 8.46 (dd, J = 9.1, 2.7 Hz, 1H, CH-8), 8.55 
(br s, 1H, one of NH2-19), 8.88 (d, J = 2.6 Hz, 1H, CH-6), 12.30 (br s, 1H, NH-1); 
13C-NMR (75 MHz, DMSO-d6) δ: 14.4 (CH3-17), 22.5 (CH2-16), 28.8 (CH2-12), 29.5 
(CH2-14), 29.7 (CH2-13), 31.6 (CH2-15), 33.2 (CH2-11), 115.8 (qC-3), 120.4 (CH-9), 
122.4 (CH-6), 124.4 (qC-5), 126.8 (CH-8), 142.9 (qC-7), 143.6 (qC-10), 158.2 (qC-2), 
167.2 (qC-18), 175.5 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C17H22N3O4: 
332.1610; found: 332.1597. 
Spectral data were consistent with those reported in the literature. 
2-Heptyl-N-methyl-6-nitro-4-oxo-1,4-dihydroquinoline-3-carboxamide (33)  
Pale yellow solid; yield: 11 mg (53%); m.p. = 243–
245 °C; IR (KBr): ν 3302 (N-H stretch), 3100 (C-H 
stretch), 2928 (C-H stretch), 1677 (C=O stretch), 
1634 (amide C=O stretch), 1568 (N-O stretch), 1501 
(aromatic C-C stretch), 1410 (alkyl C-H bend), 1337 (N-O stretch), 1216 (C-N stretch) 
cm-1; 1H-NMR (300 MHz, DMSO-d6) δ: 0.79–0.96 (m, 3H, CH3-17), 1.17–1.48 (m, 
8H, CH2-13, CH2-14, CH2-15, CH2-16), 1.58–1.79 (m, 2H, CH2-12), 2.77 (d, J = 
4.5 Hz, 3H, CH3-20), 2.94 (t, J = 7.6 Hz, 2H, CH2-11), 7.76 (d, J = 9.1 Hz, 1H, CH-9), 
8.45 (dd, J = 9.1, 2.2 Hz, 1H, CH-8), 8.86 (d, J = 2.2 Hz, 1H, CH-6), 9.01 (m, 1H, 
NH-19), 12.28 (br s, 1H, NH-1); 13C-NMR (75 MHz, DMSO-d6) δ: 14.4 (CH3-17), 
22.5 (CH2-16), 26.2 (CH3-20), 28.8 (CH2-12), 29.5 (CH2-14), 29.7 (CH2-13), 31.6 
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(CH2-15), 33.1 (CH2-11), 116.0 (qC-3), 120.6 (CH-9), 122.3 (CH-6), 124.3 (qC-5), 
126.7 (CH-8), 143.1 (qC-7), 143.4 (qC-10), 157.8 (qC-2), 165.9 (qC-18), 175.3 
(qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C18H24N3O4: 346.1767; found: 
346.1773. 
2-Heptyl-N,N-dimethyl-6-nitro-4-oxo-1,4-dihydroquinoline-3-carboxamide (34)  
Pale yellow solid; yield: 59 mg (59%); m.p. = 236–
238 °C; IR (KBr): ν 3229 (N-H stretch), 3096 (C-H 
stretch), 2922 (C-H stretch), 1667 (C=O stretch), 
1621 (amide C=O stretch), 1556 (N-O stretch), 1504 
(aromatic C-C stretch), 1394 (alkyl C-H bend), 1334 (N-O stretch), 1062 (C-N stretch) 
cm-1; 1H-NMR (300 MHz, DMSO-d6) δ: 0.86 (t, J = 6.5 Hz, 3H, CH3-17), 1.17–1.42 
(m, 8H, CH2-13, CH2-14, CH2-15, CH2-16), 1.53–1.79 (m, 2H, CH2-12), 2.84 (s, 3H, 
CH3-19/20), 2.99 (s, 3H, CH3-20/19), 2.40–2.57 (m, 2H, CH2-11), 7.76 (d, J = 9.1 Hz, 
1H, CH-9), 8.44 (dd, J = 9.1, 2.6 Hz, 1H, CH-8), 8.82 (d, J = 2.6 Hz, 1H, CH-6), 12.25 
(br s, 1H, NH-1); 13C-NMR (75 MHz, DMSO-d6) δ: 14.4 (CH3-17), 22.5 (CH2-16), 
28.7 (CH2-12, CH2-14), 29.2 (CH2-13), 31.5 (CH2-15), 32.1 (CH2-11), 34.6 
(CH3-19/20), 37.7 (CH3-19/20), 119.5 (qC-3), 120.4 (CH-9), 122.1 (CH-6), 123.6 
(qC-5), 126.6 (CH-8), 143.2 (qC-7), 143.7 (qC-10), 153.0 (qC-2), 166.6 (qC-18), 
173.3 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C19H26N3O4: 360.1923; 
found: 360.1919.
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2.1. Crop Protection 
The science of crop protection involves managing plant diseases, weeds and other pests (both 
vertebrate and invertebrate) that damage or inhibit the growth of agricultural crops.[1] As the 
world’s population continues to grow, the agricultural industry is under increasing pressure to 
provide not only food, but also crops for conversion into renewable fuels and other raw 
materials. The demand for higher crop yields per unit area requires chemicals used in crop 
protection to become ever more sophisticated. In order to contribute to programmes of 
sustainable crop management, new treatment and prevention products need to display high 
target specificity, demonstrate benign environmental and toxicological profiles, and be 
biodegradable.[2-3] Improved manufacturing processes are also required, because waste 
generated by the production process mitigates the overall benefit.  
2.2. Syngenta  
Syngenta is a global agribusiness company that produces agrochemicals and seeds. 
Headquartered in Basel, Switzerland, Syngenta was formed in 2000 by the merger of the Swiss 
company Novartis Agribusiness and the British company Zeneca Agrochemicals. In 2017, the 
company was acquired by ChemChina, a Chinese state-owned chemical enterprise. As a 
leading agriculture company Syngenta is committed to helping improve global food security 
by enabling farmers to meet the challenge of feeding a fast-growing population in a sustainable 
manner.[4] 
2.3. Nicotinic Acetylcholine Receptor (nAChR) Agonists as Insecticides 
Nicotinic acetylcholine receptors (nAChRs) are found in the central and peripheral nervous 
system and muscle tissue of many organisms, including humans.[5] At the neuromuscular 
junction, nAChRs are the primary receptor controlling the nerve-muscle communication that 
controls muscle contraction. Pharmacophores of nAChRs (such as nicotine analogues) 
continue to be of interest in pharmacological studies on central nervous system (CNS) diseases 
in humans. In particular, synthetic nAChR ligands have emerged as potential treatments for 
Parkinson’s disease, Alzheimer’s disease, Tourette’s syndrome, epilepsy, schizophrenia, 
attention-deficit hyperactivity disorder (ADHD), and depression.[5-6] In insects, nAChRs are 
limited to the CNS, and have been a molecular target site in crop protection research for many 
years.[7]  
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The global market for insecticides in 2015 was valued at $2.6 billion USD, and is estimated to 
reach almost $3.5 billion USD by 2021.[8] The most widely-used class of insecticides are 
neonicotinoids, which accounted for more than 25% of the global insecticide market in 2014, 
and are beginning to replace many conventional insecticide classes, such as chlorinated 
hydrocarbons and organophosphates.[9] The insecticidal activity of neonicotinoids, which are 
designed to be chemically similar to nicotine, is attributed to their agonistic action on the 
nAChRs found in the CNS of insects. Since they selectively target insects, neonicotinoids have 
been considered to be of low toxicity risk to mammals and humans in comparison to more 
conventional insecticides.[10] The first neonicotinoid released to market was imidacloprid in 
1991 by Bayer Crop Science AG.[11-12] Today, imidacloprid and thiamethoxam (Syngenta AG 
1998) occupy the leading market share of commercial neonicotinoid insecticides (Figure 
10).[13] 
 
Figure 10 Nicotine and structurally related commercial neonicotinoid insecticides. 
As part of the vast research that has gone into developing novel nAChR agonists, the design of 
nicotine analogues that are more rigid in their structure has been helpful in evaluating the SAR 
of the receptors.[14-15] The first highly potent bridged nicotinoid, exhibiting bioactivity 
surpassing that of the conformationally free parent, was designed and synthesised by Kanne in 
1986.[16] The new derivative, pyrido[3,4-b]homotropane (PHT), exhibited three times the 
toxological activity and 16 times the receptor binding affinity of nornicotine.[16]  
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2.4. Pyridohomotropane (PHT) - Design 
PHT is a synthetic bridged hybrid of anatoxin-a and nornicotine (Figure 11). Anatoxin-a is a 
semi-rigid alkaloid toxin which has an affinity for nAChRs that is about 20 times that of 
acetylcholine.[17] This highly potent agonist binds irreversibly to the receptor, preventing 
neuromuscular transmissions and resulting in convulsions, respiratory failure, and eventually 
death. Due to its superior binding affinity, anatoxin-a has been used in medical studies to 
evaluate newly-developed agonists or antagonists of nAChRs.[18-19] Nornicotine is also a potent 
nAChR agonist in its own right, although its toxicity is significantly less than that of 
anatoxin-a.[20] The design of PHT was based on the observation that one of the conformers of 
nornicotine would position the pyrrolidine N-hydrogen (a hydrogen-bond donor) and the 
pyridine nitrogen lone pair (a hydrogen-bond acceptor) in the same spatial orientation as those 
found in the s-cis conformation of anatoxin-a (Figure 11). Insertion of a two-carbon bridge in 
nornicotine between the C-4 of the pyridine and C-5ʹ of the pyrrolidine would ‘freeze’ the 
structure in this conformation.[16] 
 
Figure 11 Design of PHT - a hybrid of anatoxin-a and nornicotine. 
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2.4.1. PHT - Previous Synthetic Routes 
Kanne and co-workers first described the synthesis of PHT in 1986[16] and again in 1988[20] 
along with some new PHT analogues. This method used 1,2-oxido-5-cyclooctene as the 
starting material, with eight steps required to reach PHT (Scheme 14). 
 
Scheme 14 First synthesis of PHT by Kanne and co-workers (1986). 
The first asymmetric synthesis of PHT was described by Carroll and co-workers in 2006, and 
was carried out using a procedure similar to that reported by Kanne (Scheme 15).[21] 
(R)-(+)-Methylbenzylamine was used instead of benzylamine in the first step to produce 
diastereomers that could be separated and then converted to (+)-PHT and (-)-PHT using 
Kanne’s method.  
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Scheme 15 First asymmetric synthesis of PHT by Carroll and co-workers (2006). 
This was an important development in the synthesis of PHT as now, for the first time, further 
insight into the receptor pharmacophore could be established. Indeed, the (+) and (-) 
enantiomers of PHT exhibit different binding selectivities for different nAChR subtypes, 
meaning both are highly useful pharmacological probes for studying nAChRs.[21-22] For 
example, (+)-PHT exhibits 260 times higher binding affinity than (-)-PHT for the α4β2 nAChR, 
a major subtype present in the human brain.[21-22] In 2008, Zhai and co-workers reported a new 
asymmetric total synthesis of (+)-PHT over 12 steps (Scheme 16).[23] 
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Scheme 16 Asymmetric synthesis of (+)-PHT by Zhai and co-workers (2008). 
2.5. Aims of this Chapter 
Despite the interesting bioactivities displayed by PHT in pharmacological studies, there is 
virtually no data on the insecticidal activity of the compound. The project undertaken at 
Syngenta Crop Protection in Stein, Switzerland during this PhD was aimed at developing a 
new total synthesis of PHT that would allow for derivatisation and scale-up to provide material 
for in-house biological studies. This chapter describes the retrosynthetic analysis and synthetic 
steps carried out towards a new total synthesis of PHT. 
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2.6. Retrosynthetic Analysis of PHT – Strategy 1 
The retrosynthetic strategy for the synthesis of PHT designed during this project is outlined 
(Figure 12). The key step would involve an intramolecular [3+2] cycloaddition of a 
cyclopropane 1,1-diester with a protected imine. The imine would be derived from an aldehyde 
on the pyridine ring, therefore compound 47 was a key target in the retrosynthetic plan. 
Cyclopropanation of a terminal alkene such as 46 with a diazodiester would give access to the 
cyclopropane diester of 47. Compound 46 could be formed by alkylation of commercially 
available 4-methylnicotinaldehyde 36. 
 
 
 
35     
    
 
 
 
 
 
 
36  46  47 
     
Figure 12 Initial retrosynthetic analysis of PHT 35. 
2.7. Route 1 – Beginning from Aldehyde Starting Material 
The first challenge was accessing the key cyclopropanated intermediate 47 with the aldehyde 
at the C-3 position. Commercially available 4-methylnicotinaldehyde 36 was chosen as the 
starting material for the synthesis of 47. The idea was to protect the aldehyde as its 
corresponding acetal 37 while carrying out the alkylation and cyclopropanation steps (Scheme 
17). Acetal protection was achieved in a moderate 55% isolated yield despite optimisation 
efforts, while alkylation of 37 gave product 38 in a maximum isolated yield of 45% (formation 
of di-alkylated side-products proved difficult to completely eliminate). 
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36  37,[24] 55%  38, 45% 
     
Scheme 17 Acetal protection and alkylation of the aldehyde precursor. 
The next step was to cyclopropanate the terminal alkene of 38 using diazo intermediate 40. 
This was synthesised from dimethyl malonate 39 and 4-acetamidobenzene sulfonyl azide 
(p-ABSA) in 98% isolated yield (Scheme 18).[25] This diazo compound 40 was reacted with 
38 via rhodium catalysis resulting in cyclopropanation of the terminal alkene to give 41 in 47% 
isolated yield.[26] Boron trifluoride diethyl etherate (1 equiv.) was required as an additive to 
coordinate to the pyridine nitrogen in order to prevent unproductive coordination of the 
rhodium catalyst. Whilst addition of the diazo compound was carried out dropwise via syringe, 
it was important to add the diazo reagent over a period of no more than five minutes. 
 
 
 
 
39   40,[27] 98% 
    
    
 
 
 
38   41, 47% 
    
Scheme 18 Synthesis of diazo reagent and subsequent cyclopropanation of 38. 
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2.8. Retrosynthetic Analysis of PHT – Strategy 2 
Concurrently with the synthetic strategy outlined above, an alternative route to access the key 
intermediate 47 was investigated. This route was based on the idea of using a nitrile group on 
intermediate 44 as a ‘masked aldehyde’ rather than acetal protection (Figure 13). 
 
 
 
35     
    
 
 
 
 
 
 
42  44  47 
     
Figure 13 Alternative retrosynthetic plan for PHT synthesis. 
2.9. Route 2 – Utilising the Nitrile Group as a ‘Masked’ Aldehyde 
This route began with commercially available 3-bromo picoline 42, which underwent 
cyanation at the C-3 position (Scheme 19).[28] This gave access to the ‘masked aldehyde’ 
precursor 43 in 89% isolated yield, which then underwent alkylation at the methyl group to 
give compound 44 in 73% isolated yield (Scheme 19).[29]  
 
 
 
  
42 43,[30] 89% 44, 73% 
     
Scheme 19 Nitrile synthesis and subsequent alkylation. 
Towards the Synthesis of PHT  Results & Discussion 
70 
 
Gratifyingly, these yields were a significant improvement on the first two steps compared to 
the original aldehyde route which gave maximum isolated yields of 55% (37) and 45% (38), 
respectively (Scheme 17). This was an important factor to consider when choosing which 
synthetic route to progress with later, as it would be necessary to access large quantities of 
intermediate products. Clearly, using the nitrile-masked aldehyde rather than the acetal-
protected aldehyde was a better choice as it provided access to intermediate 44 with better 
yields in each step. 
2.10. Accessing Key Intermediate 47 
At this point the next goal was to reach the key aldehyde intermediate 47, which could be 
obtained via either of two approaches: 1) first reduce the nitrile to the aldehyde, followed by 
cyclopropanation of the terminal alkene, or 2) carry out cyclopropanation first and then reduce 
the nitrile (Scheme 20). The determining step turned out to be the cyclopropanation – while 
this proceeded well in the presence of the nitrile, furnishing the cyclopropanated product 45 in 
70% isolated yield, attempts to carry out the same reaction in the presence of the aldehyde 46 
failed to yield any product. Notwithstanding this, reducing the nitrile group on compound 45 
proved challenging due to the tendency of the aldehyde product to further reduce to the 
corresponding primary alcohol. Under optimum conditions,[31] the desired aldehyde 47 could 
be obtained in 50% isolated yield, with the remainder of the mixture comprising of starting 
material and the alcohol side-product.   
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46, max 30%  47,[32] 50% from 45 
   
Scheme 20 Options for synthesis of aldehyde intermediate 47 from 44. 
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2.11. Building the Bicyclic PHT Framework 
Next was the key step in this strategy, an intramolecular [3+2] cycloaddition of the 
cyclopropane 1,1-diester with a protected imine, forming the structural framework of the PHT 
molecule. First, the aldehyde was stirred with benzylamine in the presence of a drying agent 
(magnesium sulphate proved best) to give the imine intermediate 48 in quantitative yield 
(Scheme 21). Tin (IV) chloride was employed as a Lewis acid to promote the cycloaddition 
reaction; pleasingly, this reaction led to isolation of compound 49 in 78% isolated yield.[33] 
 
 
 
47  48 
   
  
 
   
  
 
  49,[32] 78% 
   
Scheme 21 Imine formation and intramolecular [3+2] cycloaddition.  
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2.12. Krapcho Decarboxylation – Removing the First Ester Group 
With the PHT framework now constructed, the following steps were to involve removing the 
extraneous functional groups (i.e. the diester at C-8 and the benzyl group on the amine) from 
the molecule. Krapcho decarboxylation conditions[34] were used to remove the first ester group, 
which gave the monoester 50 as a 1:1 mixture of diastereomers in 78% isolated yield (Scheme 
22). Separation of the diastereomers was not attempted as this was not deemed necessary at the 
time (Figure 14). 
 
  
49  50,[32] 78% 
   
 
 
Scheme 22 Krapcho decarboxylation of the diester 49 and associated mechanism. 
 
Figure 14 a) 1H-NMR (CDCl3) spectrum of diastereomeric mixture of 50. b) 
1H-NMR (CDCl3) 
spectrum of diester 49.  
49 
50 
a) 
b) 
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2.13. Barton Decarboxylation – Removing the Remaining Ester Group 
To remove the remaining ester group, a Barton decarboxylation was investigated. This involves 
a radical-mediated reaction in which a carboxylic acid or acid chloride is first converted to a 
thiohydroxamate ester (commonly referred to as a Barton ester) by coupling with pyrithione.[35-
36] This intermediate is then heated in the presence of a radical initiator and a suitable hydrogen 
donor to complete the reductive decarboxylation of the carbonyl compound (Figure 15). For 
carboxylic acids, the reaction with pyrithione requires the addition of a stoichiometric coupling 
reagent, such as DCC or EDC, as well as a non-nucleophilic base such as DMAP, to generate 
the thiohydroxamate ester.[37] In reactions where the carboxylic acid is first converted to the 
corresponding acid chloride, the sodium salt of pyrithione along with a catalytic amount of 
DMAP is used to form the Barton ester.[37] 
 
Figure 15 Barton decarboxylation of carboxylic acids and acid chlorides.[37] 
This method was chosen based on a literature precedent for the synthesis of epibatidine by 
Pandey and co-workers,[38] which also provided a precedent for the final debenzylation step. 
For the decarboxylation, Pandey and co-workers converted their ethyl ester to the acid chloride 
and then treated this with the sodium salt of pyrithione to produce the Barton ester. This highly 
reactive intermediate then underwent radical decarboxylation as per Barton’s conditions to give 
the desired product in 75% isolated yield. The subsequent debenzylation step furnished 
epibatidine in 90% isolated yield (Scheme 23). 
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Scheme 23 Barton decarboxylation and debenzylation steps in the synthesis of epibatidine. 
Under Barton’s original decarboxylation conditions, the hydrogen-donor reagents typically 
used are tributyltin hydride or tert-butyl thiol, which are not only highly toxic (organotin 
compounds) and pungent (thiols), but their by-products are often difficult to separate from the 
target compound. Whilst reviewing the literature in an effort to find conditions which avoid 
these complications, a report from Williams and co-workers in 2011 proved insightful.[37] 
Therein, the use of chloroform as both a suitable solvent and convenient H-donor for the Barton 
decarboxylation was demonstrated on a range of substrates, producing yields that were 
comparable to (and in some cases better than) those obtained from traditional H-donors such 
as organotin and thiol reagents. Given these apparent advantages, the Williams version of the 
Barton conditions was chosen as a starting point for carrying out the desired transformation. 
2.13.1. Barton Decarboxylation of Model Substrates 
To garner some experience on this type of chemistry, the Williams method was tried on a 
selection of model substrates (Figure 16). The models were chosen based on their structural 
similarity to PHT (compounds 51 and 52). A substrate similar to one used in the Williams paper 
(compound 53) was also included. 
 
 
 
 
 
 
 
51  52  53 
     
Figure 16 Model substrates for Barton decarboxylation. 
Model compound 51 was first hydrolysed to the corresponding acid 54 using lithium hydroxide 
in a mixture of methanol and THF (Scheme 24).  
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51  54 
   
Scheme 24 Hydrolysis of ester 51. 
The carboxylic acid was then subjected to Williams’ decarboxylation conditions in the absence 
of light and heat, in an effort to form the Barton ester 55 (Scheme 25). After 2 h only starting 
material and no product could be observed by LCMS analysis. The reaction was heated at 
reflux for a further 2 h but no improvement was observed. 
 
 
 
 
54   55 
    
Scheme 25 Attempted formation of the Barton ester of 54. 
At this point, after reviewing the literature, it became evident that the Barton ester itself would 
be very difficult to isolate. Instead, the formation of the Barton ester and the decarboxylation 
was tried in one pot. This time, the pyrithione was added to a pre-mixed suspension of 54, EDC 
and DMAP, and the reaction mixture was immediately irradiated with visible light from an 
LED lamp and heated at reflux (Scheme 26). The decision to use an LED lamp rather than a 
tungsten light bulb was made with the intention to eliminate an additional heat source from the 
reaction set-up, and allow for controlled monitoring and manipulation of the reaction 
temperature through use of an oil bath. As both light sources emit visible light, failure of the 
decarboxylation reaction merely due to the choice of lamp was not considered likely. 
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54   56 
    
Scheme 26 Attempted Barton decarboxylation of 54. 
Unfortunately, only starting material could be observed by LCMS analysis, even after 6 h. At 
this point, having consumed all of model compound 51, attention was turned to the remaining 
model compounds 52 and 53. 
Model compound 53 was chosen from an in-house library of compounds as it was very similar 
to one of Williams’ substrates which was decarboxylated in 77% isolated yield.[37] Following 
Williams’ method, compound 53 was first converted to the corresponding acid chloride 57 and 
used immediately in the Barton step without further purification (Scheme 27).[37] This time, 
the decarboxylated product 58 could be obtained in 40% yield by quantitative 1H-NMR 
analysis of the crude reaction mixture. This was a poorer yield than expected, however the fact 
that the reaction yielded some product was a positive outcome. 
 
 
 
53  57 
   
 
 
 
   
  
 
  58, 40% (NMR) 
Scheme 27 Chlorination and decarboxylation of 53.   
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A more substantial proof-of-principle for these conditions would be their successful application 
to a heterocyclic compound like the target PHT. Therefore, the acid chloride decarboxylation 
that proved successful for 53 was performed on nicotine analogue 52. In this case, thionyl 
chloride proved to be a better chlorinating agent than oxalyl chloride and gave the acid chloride 
59 in quantitative yield (Scheme 28). However, after 59 was added to the reaction mixture for 
the subsequent decarboxylation, no decarboxylated product 60 could be detected by analytical 
methods, even after stirring for 3 h at 60 °C. 
 
 
 
52  59 
   
  
 
   
  
 
  60 
   
Scheme 28 Chlorination and attempted decarboxylation of model compound 52. 
At this point it was clear that the acid chloride 59 was unsuitable for this reaction and so focus 
returned to decarboxylation conditions for carboxylic acid 52. An observation, made by Martin 
and co-workers,[39] regarding the inefficacy of chloroform as a H-atom donor in these types of 
reactions led to the decision to include t-butyl thiol in the reaction conditions. Pleasingly, using 
the original conditions for the decarboxylation of carboxylic acids reported by Williams and 
co-workers and by including t-butyl thiol as a more reactive H-atom donor, the decarboxylated 
nicotine analogue 60 was obtained in 31% isolated yield (Scheme 29).  
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52   60,[40] 31% 
    
Scheme 29 Decarboxylation of model compound 52. 
2.13.2. Attempts to Perform Barton Decarboxylation on PHT Substrate 
Having achieved a better understanding of the intricacies of this transformation, the 
decarboxylation of the PHT framework could now be pursued. Hydrolysis of the monoester 50 
proceeded well under the same conditions used for model substrate 51. Unfortunately, several 
attempts to isolate 61 from the reaction mixture with aqueous work-ups led to loss of product 
to the aqueous layer each time. However, the product could be isolated in an analytically pure 
form (as its TFA salt) by reverse phase chromatography, to give 62 in 77% isolated yield 
(Scheme 30). Isolation of 62 in this manner was performed by a dedicated purifications 
laboratory at Syngenta. 
 
 
 
50  61 
  
 
  
 
  62, 77% 
   
Scheme 30 Hydrolysis of monoester 50. 
Interestingly, despite starting with a mixture of diastereomers of 50, only the anti-isomer of the 
carboxylic acid was observed, probably due to epimerisation to the more stable configuration 
during the hydrolysis reaction. The anti-isomer was identified based on the coupling constant 
of the C-7 proton in the 1H-NMR spectrum (J = 2.3 Hz). Computational work carried out by a 
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previous member of the group predicted the 3J coupling constants of both the syn- and anti-
isomers of compound 50 (Figure 17).[41] On that occasion, the diastereomers of 50 had been 
separated by chiral chromatography, and their individual coupling constants were also 
measured experimentally. As mentioned earlier, the diastereomers of 50 were not separated 
during this PhD project. 
 
Figure 17 Computed 3J coupling constants for compound 50, calculated with Maestro software 
by Schrödinger on the optimized structures. Experimental 1H-NMR coupling constants are: 
Janti = 2.2 Hz and Jsyn = 9.2 Hz. This work was carried out prior to the project discussed in this 
PhD thesis.[41] 
The carboxylic acid salt 62 was subjected to the same decarboxylation conditions that proved 
effective on the model substrate 52. However, this did not yield any of the decarboxylated 
product 63 (Scheme 31). 
 
 
 
 
62   63 
    
Scheme 31 Attempted decarboxylation of 62. 
Next, a more careful, step-wise approach was tried whereby a chloroform solution of 62, EDC 
and DMAP was first cooled to -10 °C and shielded from any light by wrapping the reaction 
vessel in aluminium foil (Scheme 32). Next, pyrithione was added and the resulting mixture 
stirred in darkness at -10 °C for 1 h and then at room temperature for 1 h. This was done in an 
effort to allow the formation of the Barton ester 64 which is the key intermediate in the 
decarboxylation. Unsurprisingly however, efforts to observe this intermediate by LCMS, TLC 
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or 1H-NMR proved unsuccessful. Nevertheless, t-butyl thiol was added and the reaction 
mixture was immediately irradiated with visible light, this time from a tungsten lamp, and 
heated at reflux. Unfortunately, reaction monitoring by LCMS showed no trace of the 
decarboxylated product 63 after 3 h, and so the reaction was cooled and concentrated in vacuo. 
1H-NMR analysis of the crude reaction mixture revealed a complex mixture comprising mainly 
of an unknown compound retaining the carbonyl group at C-8. No signals consistent with the 
desired product could be detected. 
 
 
 
 
62   64 
    
   
 
    
   
 
   63 
    
Scheme 32 Step-wise approach to decarboxylation of 62. 
Given that decarboxylation of the acid chloride variant of model compound 53 proved to be 
effective (Scheme 27), the next approach was to apply these conditions to the PHT analogue. 
Hsung and Gerasyuto used a similar approach in their synthesis of the quinolizidine alkaloid 
2-deoxylasubine II.[42] On this occasion, the crude carboxylic acid product 61 was used, as 
there was not enough time left in the project to wait for purification (as mentioned previously, 
the isolation of the TFA salt 62 was carried out by a different lab and could take up to 2 weeks 
to complete). The crude acid was then chlorinated using oxalyl chloride as per Hsung’s 
procedure (Scheme 33). The crude acid chloride 65 was then added to a chilled solution of the 
pyrithione sodium salt and DMAP in DCM and stirred in darkness for 1.5 h in an attempt to 
form the Barton ester 64. However, in line with previous attempts, 64 could not be observed 
by analytical methods. Next, t-butyl thiol was added to the reaction mixture, which was 
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immediately irradiated with visible light from an LED lamp. After stirring at room temperature 
for 1 h and then heating at reflux for 3 h, no decarboxylated product 63 could be observed by 
LCMS analysis. 
   
61  65 
   
  
 
   
  
 
63  64 
   
Scheme 33 Chlorination and attempted decarboxylation of 61. 
At this point, with only a small amount of the TFA salt 62 left, one final attempt at the 
decarboxylation was made. This was once again based on Hsung’s work, and methodology 
used for the total synthesis of myrrhine.[43] Rather than an acid chloride, this method uses a 
mixed anhydride intermediate to activate the carbonyl group. Although complete consumption 
of the starting material 62 and formation of the mixed anhydride intermediate 66 was observed 
by LCMS analysis, once again the decarboxylated product 63 could not be detected (Scheme 
34).  
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63  64 
   
Scheme 34 Attempted decarboxylation of 62 via a mixed anhydride intermediate. 
2.14. Proof-of-Principle Debenzylation 
At this point it became clear that the second decarboxylation of compound 50 was not going to 
be achieved during the timeframe of this work placement. In an effort to support that the final 
product PHT could be reached once the decarboxylation step was accomplished, debenzylation 
of monoester 50 was carried out. Indeed, hydrogenolysis of 50 using Pearlman’s catalyst led 
to formation of the free amine 67 (Scheme 35).[20]  
 
 
 
50  67 
   
Scheme 35 Debenzylation of 50. 
Evidence for the disappearance of the benzyl group can be seen in the 1H-NMR spectra below 
(Figure 18). For clarity, the 1H-NMR spectrum of the diester 49 is shown, as the monoester 50 
was isolated as a 1:1 mixture of diastereomers. The two 1H doublets corresponding to the 
diastereotopic benzylic protons at 3.40 and 3.65 ppm, as well as the 5H multiplet of the phenyl 
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group at 7.21-7.36 ppm, are no longer present in the 1H-NMR spectrum of 67. This is a good 
indication that, providing that the Barton decarboxylation be optimised, this total synthesis of 
PHT could be completed. 
Figure 18 a) 1H-NMR (CDCl3) spectrum of diester compound 49. b) 
1H-NMR (DMSO-d6) 
spectrum of crude product 67 from debenzylation of monoester 50. 
Interestingly, the free amine product 67 was observed as a single, syn-isomer, as indicated by 
the large coupling constant (J = 9.1 Hz) of the CH-7 doublet at 4.55 ppm. The anti-isomer may 
have become trapped in the aqueous layer during work-up due to coordination with water 
molecules (Figure 19). Indeed, LCMS analysis of the aqueous layer indicated that some 
product was still present after several extractions with EtOAc. 
 
 
 
67   
Figure 19 Possible trapping of syn-isomer of 67 in aqueous layer due to H-bonding. 
Unfortunately, the contract under which the above work was carried out came to an end before 
any further attempts at completing the total synthesis could be made. In compliance with a 
b) 
49 
67 
a) 
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confidentiality agreement between the student and Syngenta, no further investigations could 
be carried out upon returning to University College Cork.  
2.15. Conclusions 
A new route towards the total synthesis of PHT was developed, which was envisaged to be 
completed in eight steps. After investigating two different retrosynthetic plans, the first six 
steps were optimised to produce good to excellent yields of compounds 43, 44, 45, 47, 49 and 
50. Pleasingly, the key [3+2] cycloaddition step, which was required to access the bridged 
bicyclic framework of PHT, worked efficiently (Scheme 21). The methodology of the 
photochemical Barton decarboxylation proved very difficult to apply consistently to model 
substrates, although some proof-of-principle results were achieved, such as the decarboxylation 
of models 52 (Scheme 29) and 53 (Scheme 27). However, ultimately, decarboxylation of the 
PHT substrate 61 could not be achieved despite several attempts using various different 
approaches. A proof-of-concept debenzylation of intermediate compound 50 indicated that if 
the challenges of the decarboxylation step could be overcome, the target compound 35 would 
indeed be accessible using this novel synthetic route (Scheme 35).   
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2.16. Publication of Completed Total Synthesis of PHT in 2018 
Interestingly, in 2018 Wang and co-workers published their total synthesis of PHT (Scheme 
36) using the same intramolecular [3+2] cycloaddition strategy we had planned (Scheme 
21).[32] Most importantly, they were able to perform the Barton decarboxylation of compound 
61, under conditions similar to those in Scheme 31, in 72% yield. Their success appears to be 
owed to the use of two 100 W tungsten lamps as the light source, as opposed to our use of an 
LED lamp or a single 60 W tungsten lamp. Additionally, Wang and co-workers managed to 
extract the neutral carboxylic acid compound 61 from the hydrolysis reaction mixture by using 
a sat. NH4Cl aqueous work-up. Our initial attempt at an aqueous work-up of this reaction 
mixture (Scheme 30) led to significant loss of material to the water layer. Not wanting to waste 
anymore of the monoester 50, on the next attempt, reverse-phase chromatography of the 
reaction mixture was used to isolate the carboxylic acid as its TFA salt (62), without pursuing 
any other work-up methods. Our use of the salt 62 and insufficient light power appear to be the 
reasons why our decarboxylation reactions failed.  
After obtaining the decarboxylated product 63, Wang and co-workers next carried out the 
debenzylation of this compound, which led to isolation of the target, PHT (Scheme 36). This 
report also included an asymmetric synthesis of (-)-PHT, using the same approach as shown in 
Scheme 36. 
This publication proves that the synthetic strategy outlined in the above work was viable and 
that, perhaps with more time, completion of this total synthesis of PHT would have been 
achieved.   
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Scheme 36 Total synthesis of PHT by Wang and co-workers (2018).[32] 
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2.17. General Considerations 
Solvents and reagents were used as obtained from commercial sources, without purification. 
Unless otherwise indicated, starting materials were also obtained from commercial sources. 
Flash chromatography was carried out on a Teledyne Isco Combiflash® Rf 200i automated 
chromatography machine. TLC was carried out on pre-coated silica gel glass plates (Merck 
60G F254). The developed plates were visualised under UV light.  
Melting points were obtained using SRS (Stanford Research Systems) Optimelt V.1.107. IR 
spectra were recorded on a Perkin Elmer UATR Two spectrometer. All samples were examined 
as neat oil or solid samples. LCMS analysis was obtained on a Waters SQD/SQDII single 
quadrupole mass spectrometer equipped with an electrospray source and a Waters Acquity 
UPLC; column: Waters UPLC HSS T3, 1.8 µm, 30 x 2.1 mm, Temp: 60 °C, DAD Wavelength 
range (nm): 210 to 500; solvent gradient: A = water + 5% MeOH + 0.05 % HCOOH, B= 
Acetonitrile + 0.05 % HCOOH, gradient: 10-100% B in 1.2 min; flow (ml/min) 0.85. HRMS 
were recorded on a Thermo Q Exactive in ESI+ mode. Reported results are all within the range 
of ± 5ppm of the calculated mass. For brominated compounds, Br80 was used for the calculated 
and reported molecular ion mass. 
NMR spectra were run in CDCl3 using TMS as the internal standard at 25 °C unless otherwise 
stated. 1H-NMR (400 MHz) spectra were recorded on a Bruker Avance 400 NMR 
spectrometer. 13C-NMR (100 MHz) spectra were recorded on a Bruker Avance 400 NMR 
spectrometer in proton decoupled mode. Chemical shifts (δ) are expressed as parts per million 
(ppm), positive shift being downfield from TMS; coupling constants (J) are expressed in hertz 
(Hz). Splitting patterns in 1H-NMR spectra are designated as s (singlet), br s (broad singlet), d 
(doublet), dd (doublet of doublets), dt (doublet of triplets), ddt (double of doublet of triplets), t 
(triplet), m (multiplet). For 13C-NMR spectra, the number of attached protons for each signal 
was determined using the DEPT pulse sequence run in the DEPT-90 and DEPT-135 modes. 
COSY, HSQC and HMBC experiments were routinely performed to aid the NMR assignment 
of novel chemical structures. Please note that the numbering system displayed on the structures 
is to assign the NMR data, and differs from the IUPAC system used for naming. 
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2.18. Aldehyde Route 
2.18.1. Synthesis of Compound 37 
3-(1,3-Dioxolan-2-yl)-4-methylpyridine[24] (37) 
The following procedure was carried out using Dean-Stark apparatus. 4-Methylpyridine-3-
carboxaldehyde 36 (1 equiv.) and p-TsOH monohydrate (1.25 equiv.) were dissolved in toluene 
(4 mL/mmol) and the resulting mixture was stirred at 90 °C under an argon atmosphere for 
15 min. Ethylene glycol (5 equiv.) was added and the reaction was stirred at 120 °C overnight. 
The cooled reaction mixture was quenched with sat. NaHCO3 (equal volume to reaction 
solvent). The aqueous layer was extracted with DCM (3 × 2.5 mL/mmol) and the combined 
organic layers were washed with brine (2 mL/mmol), dried over NaSO4, filtered and 
concentrated in vacuo to yield the crude product as a yellow oil. Purification by column 
chromatography (cyclohexane/EtOAc 6:4) afforded the pure product 37 as a pale yellow oil 
(0.865 g, 55% yield). 
Yellow oil; yield: 865 mg (55%); IR (neat): ν 3100 (C-H stretch), 2888 (C-H 
stretch), 1598 (aromatic C-C stretch), 1393 (pyridine C-N stretch), 1058 (ether 
C-O stretch) cm-1; 1H-NMR (400 MHz, CDCl3): δ 2.42 (s, 3H, CH3-10), 4.01–
4.10 (m, 4H, CH2-8, CH2-9), 5.98 (s, 1H, CH-7), 7.09 (d, J = 4.9 Hz, 1H, 
CH-5), 8.46 (d, J = 5.0 Hz, 1H, CH-6), 8.66 (s, 1H, CH-2); 13C-NMR (100 MHz, CDCl3): δ 
18.5 (CH3-10), 65.3 (CH2-8, CH2-9), 101.3 (CH-7), 125.6 (CH-5), 131.4 (qC-3), 146.5 (qC-4), 
147.5 (CH-2), 149.9 (CH-6); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C9H12NO2: 166.0868 
found: 166.0860.  
Spectral data were consistent with those reported in the literature. 
2.18.2. Synthesis of Compound 38 
4-(But-3-en-1-yl)-3-(1,3-dioxolan-2-yl)pyridine (38) 
3-(1,3-Dioxolan-2-yl)-4-methylpyridine 37 (1 equiv.) was dissolved in THF (4 mL/mmol) and 
the solution (yellow/brown) cooled to -78°C. LDA (2 equiv.) was added slowly, temperature 
maintained below -75 °C. The resulting orange solution was stirred at -78 °C for 2.5 h to 
complete deprotonation. Allyl bromide (1.1 equiv.) was added dropwise, maintaining 
temperature below -75 °C, and the reaction mixture stirred at this temperature for 1 h until 
alkylation was complete as determined by LCMS. The reaction mixture was quenched with 
Towards the Synthesis of PHT  Experimental 
91 
 
sat. NH4Cl solution (3.5 mL/mmol) at -78 °C and then allowed to warm to room temperature. 
The aqueous layer was extracted with EtOAc (3 × 2.5 mL/mmol) and the combined organic 
layers were washed with brine (2 mL/mmol), dried over NaSO4, filtered and concentrated in 
vacuo to yield the crude product as an orange oil. Purification by column chromatography 
(cyclohexane/EtOAc 1:1) afforded the pure product 38 as a pale yellow oil (0.114 g, 46% 
yield).  
Yellow oil; yield: 114 mg (46%); IR (neat): ν 3150 (C-H stretch), 2889 
(C-H stretch), 1640 (alkene C-C stretch), 1597 (aromatic C-C stretch), 1415 
(pyridine C-N stretch), 1054 (ether C-O stretch) cm-1; 1H-NMR (400 MHz, 
CDCl3): δ 2.40 (dt, J = 7.7, 6.6 Hz, 2H, CH2-11), 2.84 (dd, J = 9.0, 6.9 Hz, 
2H, CH2-10), 4.00–4.21 (m, 4H, CH2-8, CH2-9), 4.98–5.11 (m, 2H, 
CH2-13), 5.86 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H, CH-12), 6.01 (s, 1H, CH-7), 7.12 (d, J = 5.1 
Hz, 1H, CH-5), 8.50 (d, J = 5.1 Hz, 1H, CH-6), 8.71 (s, 1H, CH-2); 13C-NMR (100 MHz, 
CDCl3): δ 30.9 (CH2-11), 34.2 (CH2-10), 65.3 (CH2-8, CH2-9), 101.0 (CH-7), 115.6 (CH2-13), 
124.2 (CH-5), 130.9 (qC-3), 137.2 (CH-12), 148.1 (CH-2), 149.8 (qC-4), 150.1 (CH-6); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C12H16NO2: 206.1181 found: 206.1180.  
2.18.3. Synthesis of Diazo Compound 40 
Dimethyldiazomalonate[27] (40) 
To a solution of 4-acetamidobenzenesulfonyl azide (1.1 equiv.) in acetonitrile (4 mL/mmol) 
under argon were added dimethyl malonate 39 (1 equiv.) and triethyl amine (1.1 equiv.). The 
resulting pale yellow solution was stirred at room temperature. After 1 h a beige precipitate 
formed, and more solvent was added if necessary to improve stirring. The resulting beige 
suspension was stirred overnight at room temperature. The insoluble material (sulfonamide 
by-product) was removed by filtration and the filtrate concentrated in vacuo (water bath at 
20°C – diazo thermally unstable at 40°C). Chloroform was added to the residue and the 
mixture filtered to remove any remaining sulfonamide.  The filtrate was concentrated in vacuo 
to yield the crude product as a yellow oil. Purification by column chromatography 
(cyclohexane/EtOAc 3:7) afforded the pure product 40 as a yellow oil (2.97 g, 99% yield).  
Yellow oil; yield: 2.97 g (99%); IR (neat): ν 2958 (C-H stretch), 2132 
(diazo C=N stretch), 1734 (ester C=O stretch), 1083 (ester C-O stretch) 
cm-1; 1H-NMR (400 MHz, CDCl3): δ 3.81 (s, 6H, CH3-1, CH3-7); 
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13C-NMR* (100 MHz, CDCl3): δ 52.5 (CH3-1, CH3-7), 161.4 (qC-3, qC-5) *Diazo carbon 
cannot be detected[27]; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C5H7N2O4: 159.0406 found: 
159.0410.  
Spectral data were consistent with those reported in the literature. 
2.18.4. Synthesis of Compound 41 
Dimethyl 2-(2-(3-(1,3-dioxolan-2-yl)pyridin-4-yl)ethyl)cyclopropane-1,1-dicarboxylate 
(41) 
A solution of 4-but-3-enyl-3-(1,3-dioxolan-2-yl)pyridine 38 (1 equiv.) in DCM (2 mL/mmol) 
was cooled to 0 °C under argon. BF3·Et2O (1 equiv.) was added and the reaction mixture stirred 
at 0 °C for 30 min. Rh2(esp)2 (5 mol%) was added followed by a solution of 
dimethyldiazomalonate 40 (2 equiv.) in DCM (1 mL/mmol diazo) which was added dropwise 
over no more than 5 min. The reaction mixture was stirred at room temperature for 1 h. Once 
the reaction was completed, as determined by 1H-NMR, the reaction mixture was quenched 
with NaHCO3 (equal volume to reaction solvent) and extracted with DCM (3 × 50 mL/mmol). 
The combined organic layers were washed with brine (50 mL/mmol), dried over NaSO4, 
filtered and concentrated in vacuo to yield the crude product as a red oil. Purification by column 
chromatography (cyclohexane/EtOAc 6:4) afforded the pure product 41 as pale yellow oil 
(0.038 g, 47% yield).  
Yellow oil; yield: 38 mg (47%); IR (neat): ν 2954 (C-H stretch), 2892 
(C-H stretch), 1724 (ester C=O stretch), 1598 (aromatic C-C stretch), 
1437 (pyridine C-N stretch), 1213 (ester C-O stretch), 1065 (ether C-O 
stretch) cm-1; 1H-NMR (400 MHz, CDCl3): δ 1.36–1.48, (m, 2H, 
CH2-11), 1.57–1.82 (m, 2H, CH2-13), 1.90–2.01 (m, 1H, CH-12), 2.89 
(t, J = 7.9 Hz, 2H, CH2-10), 3.74 (s, 3H, CH3-16 or 18), 3.76 (s, 3H, 
CH3-16 or 18), 4.03–4.22 (m, 4H, CH2-8, CH2-9), 6.00 (s, 1H, CH-7), 7.16 (d, J = 5.1 Hz, 1H, 
CH-5), 8.53 (d, J = 5.1 Hz, 1H, CH-6), 8.73 (s, 1H, CH-2); 13C-NMR (100 MHz, CDCl3): δ 
21.0 (CH2-11), 28.0 (CH-12), 29.5 (CH2-13), 31.1 (CH2-10), 34.0 (qC-14), 52.6 (CH3-16 or 
18), 52.7 (CH3-16 or 18), 65.4 (CH2-8, CH2-9), 100.5 (CH-7), 124.8 (CH-5), 131.9 (qC-3), 
146.8 (CH-2), 148.7 (CH-6), 151.2 (qC-4),  168.5 (qC-15 or 17), 170.6 (qC-15 or 17); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C17H22NO6: 336.1447 found: 336.1440.   
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2.19. Nitrile Route 
2.19.1. Synthesis of Nitrile Compound 43  
4-Methylpyridine-3-carbonitrile[30] (43)  
3-Bromo-4-methylpyridine 42 (1 equiv.) was dissolved in DMA (3.7 mL/mmol) under an 
argon atmosphere. Zinc dust (0.12 equiv.) and zinc cyanide (0.6 equiv.) were added (grey 
suspension) and argon was bubbled through the reaction mixture for 20 min with stirring. 
Pd(dppf)Cl2 (20 mol%) was added (red/orange mixture) and the reaction mixture was stirred 
at reflux (130 °C) overnight under argon. After cooling, the reaction mixture was filtered 
through Celite and the filtrate poured onto 2 M NH4OH solution (4 mL/mmol) while cooling 
on an ice bath. The aqueous layer was extracted with EtOAc (3 × 2.5 mL/mmol) and the 
combined organic layers were washed with water (2 mL/mmol), brine (2 mL/mmol), dried over 
NaSO4, filtered through Celite and concentrated in vacuo to yield the crude product as a dark 
red/brown oil. Purification by column chromatography (cyclohexane/EtOAc 6:4) afforded the 
pure product 43 as a light brown crystalline solid (1.8 g, 89% yield). 
Beige crystalline solid; yield: 1.8 g (89%); m.p. = 45–47 °C (lit. 44–46 °C); IR 
(neat): ν 2942 (C-H stretch), 2227 (nitrile C≡N stretch), 1593 (aromatic C-C 
stretch), 1487 (pyridine C-N stretch) cm-1; 1H-NMR (400 MHz, CDCl3): δ 2.58 
(s, 3H, CH3-8), 7.30 (d, J = 5.1 Hz, 1H, CH-5), 8.65 (d, J = 5.1 Hz, 1H, CH-6), 8.79 (s, 1H, 
CH-2); 13C-NMR (100 MHz, CDCl3): δ 20.1 (CH3-8), 110.9 (qC-4), 115.9 (qC-3), 124.8 
(CH-5), 150.8 (qC-7), 152.5 (CH-6), 152.7 (CH-2); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C7H7N2: 119.0609 found: 119.0610.  
Spectral data were consistent with those reported in the literature. 
2.19.2. Synthesis of Compound 44 
4-But-3’-enylpyridine-3-carbonitrile (44) 
A solution of 4-methylpyridine-3-carbonitrile 43 (1 equiv.) was dissolved in THF (4 mL/mmol) 
and the solution (yellow/brown) cooled to -78 °C. LiHMDS (1.1 equiv.) was added slowly, 
temperature maintained below -75 °C. The resulting orange solution was stirred at -78 °C for 
3 h to complete deprotonation. Allyl bromide (1.1 equiv.) was added dropwise, maintaining 
temperature below -75 °C, and the reaction mixture stirred at this temperature for 15 min until 
alkylation was complete as determined by LCMS. The reaction mixture was quenched with 
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sat. NH4Cl solution (3.5 mL/mmol) at -78 °C and then allowed to warm to room temperature. 
The aqueous layer was extracted with EtOAc (3 × 2.5 mL/mmol) and the combined organic 
layers were washed with brine (2 mL/mmol), dried over NaSO4, filtered and concentrated in 
vacuo to yield the crude product as an orange oil. Purification by column chromatography 
(cyclohexane/EtOAc 6:4) afforded the pure product 44 as a yellow oil (1.65 g, 73% yield).  
Yellow oil; yield: 1.65 g (73%); IR (neat): ν 2934 (C-H stretch), 2228 (nitrile 
C≡N stretch), 1641 (alkene C=C stretch), 1589 (aromatic C-C stretch), 1405 
(pyridine C-N stretch) cm-1; 1H-NMR (400 MHz, CDCl3): δ 2.47 (m, 2H, 
CH2-9), 2.95 (t, J = 7.5 Hz, 2H, CH2-8), 5.03–5.08 (m, 2H, CH2-11), 5.75–
5.88 (m, 1H, CH-10), 7.28 (d, J = 5.1 Hz, 1H, CH-5), 8.68 (d, J = 5.1 Hz, 1H, 
CH-6), 8.81 (s, 1H, CH-2); 13C-NMR (100 MHz, CDCl3): δ 33.4 (CH2-9), 33.5 (CH2-8), 110.6 
(qC-4), 115.8 (qC-3), 116.8 (CH2-11), 124.0 (CH-5), 135.7 (CH-10), 152.5 (CH-6), 152.9 
(CH-2), 154.3 (qC-7); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C10H11N2: 159.0922 found: 
159.0920.  
2.19.3. Synthesis of Compound 45 
Dimethyl 2-[2-(3-cyano-4-pyridyl)ethyl]cyclopropane-1,1-dicarboxylate (45) 
A solution of 4-but-3’-enylpyridine-3-carbonitrile 44 (1 equiv.) in DCM (2 mL/mmol) was 
cooled to 0 °C under argon. BF3·Et2O (1 equiv.) was added and the reaction mixture stirred at 
0 °C for 30 min. Rh2(esp)2 (2 mol%) was added followed by a solution of 
dimethyldiazomalonate 40 (2 equiv.) in DCM (1 mL/mmol diazo). The reaction mixture was 
stirred at room temperature for 1 h. Once the reaction was completed, as determined by 
1H-NMR, the reaction mixture was quenched with NaHCO3 (equal volume to reaction solvent) 
and extracted with DCM (3 × 50 mL/mmol). Combined organic layers were washed with brine 
(50 mL/mmol), dried over NaSO4, filtered and concentrated in vacuo to yield the crude product 
as a red oil. Purification by column chromatography (cyclohexane/EtOAc 4:6) afforded the 
pure product 45 as a red oil (0.67 g, 70% yield). 
Towards the Synthesis of PHT  Experimental 
95 
 
Red oil; yield: 0.67 g (70%); IR (neat): ν 2954 (C-H stretch), 2229 (nitrile 
C≡N stretch), 1722 (ester C=O stretch), 1589 (aromatic C-C stretch), 1436 
(pyridine C-N stretch), 1213 (ester C-O stretch) cm-1; 1H-NMR (400 MHz, 
CDCl3): δ 1.35–1.51 (m, 2H, CH2-9), 1.67–1.98, (m, 3H, CH-10, CH2-11), 
2.93–3.00 (m, 2H, CH2-8), 3.74 (s, 3H, CH3-14/16), 3.77 (s, 3H, 
CH3-14/16), 7.28 (d, J = 4.8 Hz, 1H, CH-5), 8.69 (d, J = 5.2 Hz, 1H, CH-6), 
8.82 (s, 1H, CH-2); 13C-NMR (100 MHz, CDCl3): δ 20.8 (CH2-9), 27.3 (CH-10), 28.8 
(CH2-11), 33.3 (CH2-8), 33.9 (qC-12), 52.7 (CH3-14, CH3-16), 110.5 (qC-4), 115.7 (qC-3), 
124.0 (CH-5), 152.7 (CH-6), 153.1 (CH-2), 153.7 (qC-7), 168.8 (qC-13/15), 170.3 (qC-13/15); 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H17N2O4: 289.1188 found: 289.1180.  
2.19.4. Synthesis of Compound 47 
Dimethyl 2-[2-(3-formyl-4-pyridyl)ethyl]cyclopropane-1,1-dicarboxylate[32] (47) 
A solution of dimethyl 2-[2-(3-cyano-4-pyridyl)ethyl]cyclopropane-1,1-dicarboxylate 45 
(1 equiv.) in 1:1 acetic acid and water (1.5 mL/mmol) was added to a hydrogenation reaction 
vessel containing Raney nickel (7.6 equiv.) under an argon atmosphere. The reaction mixture 
was stirred at room temperature in the presence of hydrogen gas (1.5 bar) for 2 h. The nickel 
catalyst was removed by filtration through Celite and washed several times with water and 
EtOAc. The aqueous layer was adjusted to pH 9 and extracted with EtOAc (3 × 2.5 mL/mmol). 
Combined organic layers were washed with sat. NaHCO3 (2 mL/mmol), brine (2 mL/mmol), 
dried over NaSO4, filtered through Celite and concentrated in vacuo to yield the crude product 
as a red oil. Purification by column chromatography (DCM/MeOH 95:5) afforded the pure 
product 47 as a yellow oil (0.48 g, 50% yield).  
Yellow oil; yield: 0.48 g (50%); IR (neat): ν 2954 (C-H stretch), 2725 
(aldehyde C-H stretch), 1721 (ester C=O stretch), 1698 (aldehyde C=O 
stretch), 1590 (aromatic C-C stretch), 1436 (pyridine C-N stretch), 1210 
(ester C-O stretch) cm-1; 1H-NMR (400 MHz, CDCl3): δ 1.41–1.48, (m, 
2H, CH2-9), 1.57–1.66 (m, 1H, one of CH2-11), 1.75–1.84 (m, 1H, one 
of CH2-11), 1.93–2.01 (m, 1H, CH-10), 3.19 (t, J = 7.1 Hz, 2H, CH2-8), 
3.75 (s, 3H, CH3-14/16), 3.78 (s, 3H, CH3-14/16), 7.25 (d, J = 5.1 Hz, 1H, CH-5), 8.69 (d, J = 
5.1 Hz, 1H, CH-6), 8.97 (s, 1H, CH-2), 10.26 (s, 1H, CH-7); 13C-NMR (100 MHz, CDCl3): δ 
21.0 (CH2-9), 27.8 (CH-10), 29.5 (CH2-11), 31.6 (CH2-8), 33.9 (qC-12), 52.6 (CH3-14 or 16), 
52.7 (CH3-14 or 16), 125.8 (CH-5), 129.4 (qC-3), 152.3 (qC-4), 153.6 (CH-6), 154.8 (CH-2), 
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168.5 (qC-13 or 15), 170.5 (qC-13 or 15), 191.5 (qC-7); HRMS (ESI-TOF) m/z: [M+H]+ calcd. 
for C15H18NO5: 292.1185 found: 292.1170.  
Spectral data were consistent with those reported in the literature. 
2.19.5. Synthesis of Cyclised Diester Compound 49 
Dimethyl-11-benzyl-5,7,8,10-tetrahydro-7,10-epiminocycloocta[c]pyridine-9,9(6H)-
dicarboxylate[32] (49) 
A solution of dimethyl 2-[2-(3-formyl-4-pyridyl)ethyl]cyclopropane-1,1-dicarboxylate 47 
(1 equiv.) in DCM (14 mL/mmol) under an argon atmosphere containing MgSO4 (2 equiv.) 
was treated with benzylamine (1 equiv.). The resulting pale yellow mixture was stirred 
overnight at room temperature. The reaction mixture was filtered and the filtrate concentrated 
in vacuo to yield the crude imine 48 intermediate as a yellow oil which was used directly 
without purification. The imine intermediate was dissolved in DCM (14 mL/mmol) under 
argon and SnCl4 solution (1 M in DCM, 1.5 equiv.) was added dropwise at room temperature. 
The resulting bright yellow suspension was stirred for 15 min. The reaction mixture was 
quenched with sat. NaHCO3 solution (equivalent volume to solvent) and the resulting mixture 
stirred for 30 min at room temperature. The aqueous layer was extracted with EtOAc (3 × 
2.5 mL/mmol) and the combined organic layers were washed with sat. NaHCO3 (2 mL/mmol), 
brine (2 mL/mmol), dried over NaSO4, filtered and concentrated in vacuo to yield the crude 
product as a brown solid. Purification by column chromatography (cyclohexane/EtOAc 1:1) 
afforded the pure product 49 as a white solid (0.37 g, 78% yield). 
White solid; yield: 0.37 g (78%); m.p. = 115–117 °C (lit. 117–118 
°C); IR (neat): ν 2951 (C-H stretch), 1735 (ester C=O stretch), 1591 
(aromatic C-C stretch), 1434 (pyridine C-N stretch), 1266 (amine 
C-N stretch), 1227 (ester C-O stretch) cm-1; 1H-NMR (400 MHz, 
CDCl3): δ 1.52–1.62, (m, 1H, one of CH2-9), 2.08–2.20 (m, 1H, one 
of CH2-9), 2.60–2.77 (m, 2H, one of CH2-8, one of CH2-11), 2.97 (d, J = 14.5 Hz, 1H, one of 
CH2-11), 3.21 (s, 3H, CH3-14/16), 3.38–3.55 (m, 2H, one of CH2-8, one of CH2-17), 3.66 (d, 
J = 13.6 Hz, 1H, one of CH2-17), 3.74-3.83 (m, 1H, CH-10), 3.83 (s, 3H, CH3-14/16), 4.92 (s, 
1H, CH-7), 7.11 (d, J = 4.9 Hz, 1H, CH-5), 7.21–7.36 (m, 5H, CH-19, CH-20, CH-21, CH-22, 
CH-23), 8.08 (s, 1H, CH-2), 8.36 (d, J = 5.0 Hz, 1H, CH-6); 13C-NMR (100 MHz, CDCl3): δ 
24.2 (CH2-9), 31.9 (CH2-8), 35.7 (CH2-11), 51.4 (CH2-17), 52.4 (CH3-14 or 16), 53.1 (CH3-14 
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or 16), 60.1 (CH-10), 65.4 (qC-12), 68.6 (CH-7), 124.9 (CH-5), 127.1 (CH-21), 128.2 (CH-20, 
CH-22), 128.4 (CH-19, CH-23), 134.1 (qC-3), 138.0 (qC-18), 148.6 (CH-6), 150.5 (qC-4), 
151.8 (CH-2), 169.3 (qC-13 or 15), 171.9 (qC-13 or 15); HRMS (ESI-TOF) m/z: [M+H]+ calcd. 
for C22H25N2O4: 381.1814 found: 381.1810. 
Spectral data were consistent with those reported in the literature. 
2.19.6. Synthesis of Monoester Compound 50 
Methyl-11-benzyl-5,6,7,8,9,10-hexahydro-7,10-epiminocycloocta[c]pyridine-9-
carboxylate[32] (50) 
A solution of 49 (1 equiv.) in DMSO (14 mL/mmol) under an argon 
atmosphere containing LiCl (5 equiv.) and water (2 equiv.) was placed 
under a slight vacuum and heated at 160 °C for 1.5 h. The cooled reaction 
mixture was diluted with water and extracted with EtOAc (3 × 5 
mL/mmol). The combined organic layers were washed with water (3 × 5 mL/mmol), brine (5 
mL/mmol), dried over NaSO4, filtered and concentrated in vacuo to yield the crude product as 
a brown oil. Purification by column chromatography (cyclohexane/EtOAc 4:6) afforded the 
product 50 as a 1:1 mixture of diastereomers (yellow oil, 1.67 g, 78% yield). This mixture of 
diastereomers was used directly in the next step without further separation. 
2.19.7. Synthesis of Carboxylic Acid Compound 62 
11-Benzyl-5,6,7,8,9,10-hexahydro-7,10-epiminocycloocta[c]pyridine-9-carboxylic acid 
TFA salt (62) 
A solution of 50 (1 equiv.) in THF (7 mL/mmol) and methanol (1.6 mL/mmol) was cooled on 
an ice bath. LiOH (2 equiv.) was added followed by 0.5 mL water. The resulting pale yellow 
solution was stirred at room temperature overnight, then concentrated in vacuo to yield the 
crude product 61 as an orange oil. The TFA salt of the product (62) was isolated as a single 
(anti) isomer by reverse-phase chromatography (water/acetonitrile/1% aq. formic acid 3:6:1) 
in 77% yield (0.22 g). This purification step was carried out by analysts at a dedicated 
purifications laboratory at Syngenta. 
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White solid; yield: 0.22 g (77%); IR (neat): ν 2925 (C-H stretch), 2493 
(acid O-H stretch), 1667 (acid C=O stretch), 1601 (aromatic C-C 
stretch), 1455 (pyridine C-N stretch), 1195 (amine C-N stretch) cm-1; 
1H-NMR (400 MHz, CDCl3): δ 1.66–1.80 (m, 1H, one of CH2-9), 
2.14–2.37 (m, 2H, one of CH2-9, one of CH2-11), 2.74–2.94 (m, 2H, 
one of CH2-8, one of CH2-11), 3.07–3.29 (m, 2H, one of CH2-8,  
CH-12), 3.90 (apparent s, 3H, CH-10, CH2-14), 4.95 (d, J = 2.3 Hz, 1H, CH-7), 7.21–7.37 (m, 
6H, CH-5, CH-16, CH-17, CH-18, CH-19, CH-20), 8.34 (s, 1H, CH-2), 8.47 (d, J = 5.1 Hz, 
1H, CH-6), 10.03 (br s, 2H, qC-13OH, CH2-14N
+H); 13C-NMR (100 MHz, CDCl3): δ 26.0 
(CH2-9), 31.3 (CH2-8), 32.1 (CH2-11), 49.8 (CH-12), 53.4 (CH2-14), 61.9 (CH-10), 68.2 
(CH-7), 116.5 (q, 1JC-F = 290 Hz, TFA-CF3), 125.9 (CH-5), 128.4 (CH-18), 128.8 (CH-16, 
CH-20), 129.4 (CH-17, CH-19), 134.2 (qC-15), 136.1 (qC-3), 147.5 (CH-6), 147.8 (CH-2), 
151.6 (qC-4), 162.1 (q, 2JC-F = 35 Hz, TFA-qCO2), 176.4 (qC-13); HRMS (ESI-TOF) m/z: 
[M+H]+ calcd. for the free amine C19H21N2O2: 309.1603 found: 309.1600. 
Melting point and 19F-NMR for this compound were not obtained. 
2.19.8. Synthesis of Debenzylated Monoester Compound 67 
Methyl(7R,10R)-5,6,7,8,9,10-hexahydro-7,10-epiminocycloocta[c]pyridine-9-
carboxylate[20] (67) 
A solution of 50 (1 equiv.) in MeOH (8 mL/mmol) was degassed using argon in 
a hydrogenation reactor. Pearlmann’s catalyst (Pd(OH)2/C, 0.1 equiv.) was added 
to the reactor, followed by a 2.0 M solution of HCl in MeOH (2 equiv.). The 
reaction mixture was stirred at room temperature in the presence of hydrogen gas 
(10 bar) for 2 h. The catalyst was removed by filtration of the reaction mixture through Celite 
and washed several times with water and MeOH. The filtrate was concentrated in vacuo and 
the aqueous solution was adjusted to pH 10 and extracted with EtOAc (5 × 20 mL/mmol). 
Combined organic layers were washed with sat. NaHCO3 (10 mL/mmol), brine (10 mL/mmol), 
dried over NaSO4, filtered through Celite and concentrated in vacuo to yield the crude product 
as an orange oil (ca. 60% mass recovery). NMR and LCMS analysis of the crude product 
indicated that debenzylation of 50 to give the free amine 67 had occurred. Further purification 
of this mixture was not carried out. 
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2.20. Barton Model System 
1-Methyl-5-(pyridin-3-yl)pyrrolidin-2-one[40] (60) 
1-Methyl-5-oxo-2-(pyridin-3-yl)pyrrolidine-3-carboxylic acid 52 (1 equiv.), DMAP (1 equiv.), 
EDC hydrochloride (1.2 equiv.) and pyrithione (1.2 equiv.) were dissolved in chloroform 
(9 mL/mmol) resulting in a bright yellow solution. 2-Methyl-2-propanethiol (10 equiv.) was 
added and the mixture was immediately irradiated with an LED lamp, with CO2 evolution 
monitored via use of an oil bubbler. The reaction mixture was stirred at room temperature for 
2.5 h, and then at 60 °C for 2 h (monitored by LCMS). The cooled reaction was then 
concentrated in vacuo to yield the crude product as a brown oil. Purification by column 
chromatography (DCM/MeOH 9:1) afforded the pure product 60 as a pale yellow oil (0.013 g, 
31%). 
Pale yellow oil; yield: 0.013 g (31%); IR (neat): ν 2923 (C-H stretch), 1674 
(amide C=O stretch), 1421 (aromatic C-C stretch), 1393 (pyridine C-N 
stretch), 1115 (amine C-N stretch) cm-1; 1H-NMR (400 MHz, CDCl3): δ 
1.84–2.00 (m, 1H, one of CH2-8), 2.48–2.68 (m, 3H, one of CH2-8, CH2-9), 
2.72 (s, 3H, CH3-11), 4.62 (dd, J = 7.7, 6.0 Hz, 1H, CH-7), 7.45 (dd, J = 7.9, 4.9 Hz, 1H, CH-5), 
7.64 (dt, J = 7.9, 1.8 Hz, 1H, CH-4), 8.51 (d, J = 1.7 Hz, 1H, CH-2), 8.65 (dd, J = 4.8, 1.3 Hz, 
1H, CH-6); 13C-NMR (100 MHz, CDCl3): δ 28.28 (CH2-8), 28.30 (CH3-11), 30.0 (CH2-9), 62.2 
(CH-7), 124.1 (CH-5), 134.0 (CH-4), 136.7 (qC-3), 148.3 (CH-2), 149.6 (CH-6), 175.4 
(qC-10);  HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C10H13N2O: 177.1028 found: 177.1020.  
Spectral data were consistent with those reported in the literature. 
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3.1. Direct Arylation 
One of the most important transformations in organic synthesis is the linking of two 
(hetero)aryl groups via a new carbon-carbon bond.[1] The biaryl motif is an important 
substructure of many medicinally relevant compounds and is thus a critical synthetic 
target.[2] Traditionally, the most reliable class of aryl-aryl bond forming reactions 
involved the palladium-catalysed coupling of an ‘activated’ aryl halide with another 
‘activated’ organometallic reagent.[3-6] Examples include the Suzuki-Miyaura 
coupling,[7] Stille coupling,[8] and Negishi coupling[9] (Figure 20). 
 
Figure 20 Traditional aryl-aryl bond forming methods. 
While reliable and robust, the above named reactions have their drawbacks. Most 
notably, pre-activation of the coupling partners requires the use of stoichiometric 
amounts of expensive organometallic compounds, such as boron, tin or zinc reagents. 
The installation of the activating groups themselves is not trivial, often requiring 
several synthetic steps and suffering from regioselectivity problems, as well as the 
secondary issues of generating more waste from reagents, solvents and purification 
methods. Furthermore, subsequent disposal of the organometallic by-products of the 
coupling reaction renders these methods inherently wasteful. In addition, the 
organometallic waste is often toxic and therefore costly to dispose of. 
In recent years, there have been significant advances toward more cost effective and 
environmentally friendly cross-coupling methods. The aim is to eliminate the 
necessity for pre-activation, thus increasing atom economy and reducing waste output. 
This approach is termed direct arylation (DA), and utilises protocols which are less 
reliant on the installation of a reactive functionality to activate the coupling partners, 
prior to cross-coupling (Figure 21).[10-12] Modern methods to synthesise these 
compounds via direct arylation are among the ‘Wanted List’ of top pharmaceutical 
companies.[13] 
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Figure 21 Methods of aryl-aryl bond formation via direct arylation. 
Ideally, neither partner requires pre-activation. This methodology is termed double 
C-H activation or dehydrogenative coupling. Often, the only by-products are H2 or 
H2O (Figure 21 (i)).
[14] This type of reaction is usually performed in an intramolecular 
fashion to minimise chemoselectivity and regioselectivity issues. In 2008, Fagnou and 
co-workers published the synthesis of dibenzofurans and carbazoles via double C-H 
activation of diarylethers and diarylamines (Scheme 37 (i)).[15] In 2012, Shi and 
co-workers reported the synthesis of fluorenone derivatives via Pd-catalysed double 
C-H activation of benzophenones (Scheme 37 (ii)).[16] The McGlacken group 
developed a route to polycyclic pyrones and coumarins by intramolecular double C-H 
coupling of phenoxy-substituted substrates (Scheme 37 (iii)). 
 
 
Scheme 37 Literature examples of direct arylation via double C-H activation. 
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However, dehydrogenative coupling can be very difficult to achieve selectively, given 
that a number of C-H sites are usually available. Additionally, the reaction is 
thermodynamically disfavoured due to the strength of the aromatic C-H bond.[17]  
Alternatively, a chemical compromise can be reached whereby one of the coupling 
partners is pre-activated. This methodology is known as single C-H activation (Figure 
21 (ii)).[11] Once again, a transition metal catalyst is used to couple a pre-activated 
species (often a carbon-halogen bond) with a specific C-H site on another aryl ring. 
This can be performed in an intermolecular or intramolecular system, and 
regioselectivity can be controlled by use of a directing group, manipulation of steric 
effects or the latent electronics of the aryl ring.[18] In 2006, Fagnou and co-workers 
reported both intermolecular and intramolecular single C-H activation reactions of 
simple arenes (Scheme 38 (i)).[19] An intramolecular single C-H activation of 
privileged biological scaffolds was reported by the McGlacken group in 2015 
(Scheme 38 (ii)).[20] 
 
Scheme 38 Literature examples of direct arylation via single C-H activation. 
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Direct arylation of simple arenes has been used routinely in organic synthesis to access 
complex polycyclic ring systems.[20-24] By comparison, similar reactions involving 
heterocycles tend to require specialised catalyst/ligand systems and are therefore less 
prevalent in the literature.[25] One of the earliest examples of an intramolecular direct 
arylation of a heteroarene was reported in 1984 by Ames and Opalko.[26] More 
recently, Ha et al. reported a palladium-catalysed synthesis of benzofuropyridines in 
moderate to excellent yields.[27] As illustrated in Scheme 37 and Scheme 38, the 
McGlacken group have reported direct arylation methodologies involving pyrone, 
coumarin, pyridone and quinolone heterocycles.[20, 22-23, 28-29]  
Whether carrying out aryl-aryl bond formation by traditional or modern direct 
arylation methodologies, the mechanism of palladium-catalysed coupling reactions 
are expected to follow the same general steps (Figure 22). The catalytic cycle typically 
begins with oxidative addition of Pd(0) to the carbon-halide (or carbon-hydrogen) 
bond of the first coupling partner. Subsequently, the second partner undergoes 
transmetallation, which places both coupling partners on the metal centre. The final 
step is reductive elimination of the product to regenerate the catalyst.  
 
Figure 22 General catalytic cycle for palladium-catalysed cross-coupling reactions.  
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3.2. Quinolines 
The quinoline nucleus occurs in many natural and synthetic pharmacologically active 
compounds,[30] and is ranked 22nd in the top 100 most frequent ring systems present in 
FDA approved drugs (Figure 23).[31] Thus, the quinoline motif is considered a 
privileged biological scaffold, utilised by synthetic chemists to build molecular 
complexity, and ultimately improve biological activity. As a versatile heterocycle, it 
displays reactivity similar to that of other aromatic (pyridine/benzene) analogues, and 
thus can undergo a wide range of synthetic transformations.[32-33]  
 
Figure 23 Quinoline and the quinoline-containing drugs Chloroquine and Lenvatinib. 
This thesis chapter describes the development of a palladium-catalysed direct arylation 
of 4-phenoxyquinolines as a route to benzofuro[3,2-c]quinolines. Access to these 
products will aid exploration of their untapped biological potential, given that similar 
quinoline-based compounds exhibit anticancer,[34] antimalarial[35] and antibacterial[36] 
effects.  
Previous syntheses of some of similar benzofuroquinolines via direct arylation have 
relied upon positioning the activated carbon-halide bond on the C-3 position of the 
quinoline coupling partner,[37-38] which limits the accessibility and versatility of the 
products formed. The first example of a (non-directed) C-H activation selectively at 
the C-3 position of unprotected pyridines and quinolines was reported by Yu and co-
workers (Figure 24 (i)), using phosphine ligands and inert reaction conditions.[39] Yu’s 
method relies upon the use of a large excess of the quinoline or pyridine substrate, 
which is only applicable to an intermolecular system. The work in this chapter outlines 
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the development of an air-stable C-H activation of the C-3 position of the quinoline 
ring via intramolecular direct arylation with no added ligand required (Figure 24 (ii)). 
 
 
 
   
 
 
 
 
   
Figure 24 Palladium-catalysed C-H activation at the C-3 position of quinolines.  
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3.3. One-Pot Reactions 
Efficient and environmentally-friendly approaches to the construction of new 
chemical entities are highly desirable to synthetic chemists both in academic and 
industrial settings. Such methods aim to avoid or reduce the number of work-ups and 
purification steps and, when feasible, involve carrying out the entire synthesis in a 
single reaction vessel. Step-economic, telescoped procedures allow for a dramatic 
reduction of costs, mostly associated with operator time and chemical waste.[40-41] 
However, carrying out two or more reactions in a single step within a single pot places 
significant demands on the methodologies involved, specifically in terms of solvent, 
reagent and substrate compatibility. In addition, avoiding secondary manipulation of 
the system during the reaction (by the addition of a new reactant, reagent, or catalyst, 
for example) is preferable.  
Despite the associated challenges, one-pot synthetic strategies have been successfully 
employed to access valuable target molecules for over 100 years. In 1917, Sir Robert 
Robinson published his ground-breaking one-pot total synthesis of tropinone (Scheme 
39).[42] By comparison, the first total synthesis of tropinone, published in 1901 by 
Willstätter,[43] involved 21 steps with an overall yield of <1%. The step-economic and 
biomimetic approach displayed in Robinson’s tropinone synthesis serve as inspiration 
for the development of new, efficient strategies for complex molecule synthesis. 
 
Scheme 39 Robinson's one-pot synthesis of tropinone in 1917. 
One-pot strategies are frequently employed to streamline the synthesis of complex 
natural products and pharmaceutically active compounds.[44] In a more recent 
example, Hayashi and colleagues have developed a powerful one-pot reaction for the 
rapid construction of the polyfunctionalized cyclohexene core of Tamiflu.[45-46]  
Considering the variety of transformations that can be performed in a one-pot system, 
a complete summary of the topic is not possible within the scope of this thesis. Instead, 
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the focus of this introduction will be on reactions combining a Pd-catalysed 
Suzuki-Miyaura and direct arylation transformation in one pot. While there are several 
different terminologies used to describe multiple transformations taking place in one 
pot,[40] the term ‘tandem reaction’, whereby transformations occur one after the other, 
is the most applicable here.  
3.3.1. Literature Examples of One-Pot Suzuki-Miyaura/Direct Arylation 
Several tandem reactions combining a direct arylation step with a Suzuki-Miyaura 
reaction have been reported.[47-51] However, we are aware of a very limited number of 
protocols that do not require perturbation of the reaction set-up by the addition of 
secondary reactants, reagents or catalysts (Scheme 40).[52-55]  
 
Scheme 40 One-pot tandem Suzuki-Miyaura/direct arylation reactions in the 
literature. 
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As outlined above, tandem cross-coupling reactions can increase the efficiency and 
modularity of synthetic transformations. All of the examples shown in Scheme 40 fall 
under this category, as does the one-pot tandem Suzuki-Miyaura/direct arylation 
reaction shown in Scheme 41, which was discovered and optimised during this PhD 
project (see Section 3.10).  
 
Scheme 41 One-pot tandem Suzuki-Miyaura/direct arylation of dibrominated 
4-phenoxyquinolines. 
What separates this work from the examples in Scheme 40, however, is that neither 
phosphine ligands nor an inert atmosphere are required for this tandem reaction. This 
reduces the associated cost and simplifies the set-up of the one-pot reaction. The novel 
benzofuroquinoline products make for excellent molecular frameworks for further 
modification and structure-activity studies. 
3.4. Dihalogenated Substrates – Chemoselectivity and Regioselectivity 
In direct arylation reactions, chemoselectivity and regioselectivity are somewhat 
predictable in monohalogenated systems. Even when working with polyhalogenated 
starting materials, chemoselectivity can often be controlled by using two different 
halogens, since there is a marked difference in reactivity between the various 
carbon-halogen bonds of aromatic compounds.[56] The order of reactivity (Ar-I > 
Ar-Br > Ar-Cl >> Ar-F) is consistent with the strength of the C-X bond. The 
experimentally measured bond dissociation energies (BDEs) for phenyl C-X bonds 
are 126, 96, 81, and 65 kcal/mol at 298 K for X = F, Cl, Br, and I, respectively.[57]  
However, the outcome of cross-coupling reactions involving substrates bearing 
multiple identical halogens can be considerably more difficult to control, as rate-
differences in the oxidative addition step (I vs. Br or Br vs. Cl) can be difficult to 
harness. One potential problem that can arise when using dihalogenated substrates is 
irreversible oxidative addition of the catalyst to one of the C-X bonds, leading to a 
shutdown of the catalytic cycle. This type of catalyst deactivation can be avoided by 
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adding an intermolecular coupling partner, such as an alkene or boronic acid, to the 
reaction mixture. This strategy facilitates the conversion of the otherwise unproductive 
ArPd(II)X species through an intermolecular cross-coupling reaction, regenerating the 
active catalyst. Lautens[58-59] and Cramer[60] have reported employing tandem 
processes in this manner when working with dibrominated substrates (Scheme 42). In 
all three examples, the authors reported that the dibrominated substrates failed to 
undergo complete conversion to the ring-closed product in the absence of an 
intermolecular coupling partner. 
 
Scheme 42 Tandem reactions of dihalogenated substrates. 
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However, this tandem reaction strategy is not applicable when there is a desire to retain 
a particular halogen in the product. In the examples shown in Scheme 42, the authors 
noted in each case that the monobrominated product of their ring-closing reaction 
could not be obtained in high yield. Rather, the second bromide always had to undergo 
coupling for the overall catalytic cycle to remain productive. Lautens has speculated 
that the termination of the catalytic due to unproductive C-X oxidative addition is 
responsible for the notable absence of polyhalogenated substrates in the majority of 
scope evaluations.[61] 
3.5. Reversible Oxidative Addition 
While oxidative addition of Pd(0) to aryl halides is generally considered irreversible 
(Figure 22), Hartwig and Roy discovered that by using a large excess of a bulky 
phosphine ligand, it was possible to induce reductive elimination of ArPd(II)Br 
complexes to liberate Pd(0).[62-64] They found that the steric crowding and strongly 
electron-donating nature of ligands such as P(t-Bu)3 accelerated the rate of reductive 
elimination to such an extent that elimination became thermodynamically favoured. 
This work suggests that oxidative addition of specific Pd(0) complexes to 
carbon-halogen bonds can occur in a reversible manner. Inspired by these findings, 
Lautens hypothesised that a catalyst capable of both oxidative addition to and 
reductive elimination from C-X bonds could facilitate site-selective cross-coupling 
reactions of substrates bearing identical halides. In 2010, Lautens and Newman 
reported a modification of their tandem synthesis of 2-substituted indoles from 
gem-dibromoalkenes (Scheme 42 (ii)) that allowed for isolation of 2-bromoindole 
products (Scheme 43).[61] These brominated indoles had proved to be inaccessible 
under the previously reported conditions.[59]  
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Scheme 43 Importance of ligand choice in Lautens’ synthesis of 2-bromoindoles. 
Reversible oxidative addition occurs only when L = P(t-Bu)3. 
The key to their success was the choice of phosphine ligand, with bulky P(t-Bu)3 
proving capable of promoting the desired reaction. The reaction failed in the presence 
of all of the other phosphine ligands screened due to the irreversible oxidative addition 
of the palladium catalyst to the 2-bromoindole product after one turnover of the 
catalytic cycle. 
Since this seminal report, Lautens and co-workers have developed other 
Pd(0)-catalysed transformations whereby reversible oxidative addition is the key to 
catalysis.[65-70] As well as P(t-Bu)3, the ferrocene-derived QPhos ligand has also 
proved effective at promoting reversible oxidative addition in site-selective 
reactions.[67-69]  
 
Figure 25 QPhos = 1,2,3,4,5-pentaphenyl-1'-(di-tert-butylphosphino) ferrocene. 
3.6. Aims of this Chapter 
The three key concepts discussed in this introduction (Direct Arylation, One-Pot 
Synthesis and Reversible Oxidative Addition) will be applied to the synthesis of a 
range of quinoline-derived compounds containing the benzofuroquinoline scaffold. 
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3.7. Objectives 
As discussed in the introduction, direct arylation protocols aim to eliminate the 
requirement for pre-activation of the coupling partners prior to cross-coupling. Ideally, 
neither coupling partner requires the installation of a reactive functionality, and the 
direct arylation reaction proceeds by double C-H activation. Previous success in this 
area within the McGlacken group[22, 29] (Scheme 37 (iii)) inspired the following work 
on exploring conditions for the intramolecular double C-H activation of 
4-phenoxyquinolines as a route to benzofuroquinolines.  
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3.8. Attempts at Double C-H Activation 
To begin, 4-chloroquinoline 68 was synthesised by chlorination of commercially 
available 4-quinolinol using phosphorus oxychloride in near quantitative yield.[71] 
Multiple grams of 68 could be synthesised at a time to serve as a useful starting 
material for many of the substrates discussed in this chapter. 
   
  68,[72] 97% 
   
Scheme 44 Chlorination of 4-quinolinol to form 4-chloroquinoline 68. 
Next, 4-chloroquinoline 68 underwent substitution of the chlorine atom with a 
phenoxide group, formed in situ by deprotonation with sodium hydroxide.[73] A large 
excess of phenol was used to act as the solvent for the reaction. A lower excess can be 
used in the case of more expensive substituted phenols, and this will be discussed 
further later. This method allowed access to the 4-phenoxyquinoline substrate 69 in 
high yield. 
 
 
 
 
       68   69,[74] 91% 
    
Scheme 45 Synthesis of 4-phenoxyquinoline 69. 
Although there are examples of dehydrogenative coupling reactions involving 
heterocycles in the literature,[24] the transformation of 69 to 70 has yet to be reported. 
The investigation began with state-of-the-art conditions from reports by Shi[16] (Table 
1, entry 1) and Fagnou[15] (Table 1, entry 2). Unfortunately, neither of these reactions 
resulted in good conversion to product. Instead, a complex mixture of degradation 
products was observed. The literature example most similar to our substrate was found 
in a report by Miura and co-workers.[75] The substrate in Miura’s report was a 
2-phenoxyquinoline rather than a 4-phenoxyquinoline. Nevertheless, the new C-C 
bond formed was between the 3-position of the quinoline and the 2ʹ-position of the 
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phenoxy ring, as would be the case in our target product. However, Miura’s conditions 
(Table 1, entry 3) failed to promote the intramolecular cyclisation of 69. 
Table 1 Screen of conditions for double C-H activation of substrate 69. 
  
 
 
69  70 
        
Entry [Pd] Base Oxidant Solvent Add. 
T 
(°C) 
%Yield 
(NMR)[a] 
1[b] Pd(OAc)2 K2CO3 Ag2O TFA - 140 <10 
2[c] Pd(OAc)2 K2CO3 - PivOH - 120 13 
3[d] Pd(TFA)2 AgOAc Air PivOH - 150 6 
4 Pd(OAc)2 NaOt-Bu  Ag2O PivOH - 140 22 
5 Pd(OAc)2 NaOt-Bu  Ag2O PivOH - 155 16 
6 Pd(OAc)2 NaOt-Bu  Ag2O PivOH - 120 20 
7 Pd(OAc)2 NaOt-Bu  Ag2O DMF PivOH  140 <1 
8 Pd(OAc)2 NaOt-Bu  Ag2O NMP PivOH  140 <1 
9 Pd(OAc)2 NaOt-Bu  Ag2O DMSO PivOH  140 <1 
10 Pd(OAc)2 NaOt-Bu  Ag2O PivOH - 140 13 
11 Pd(OAc)2 NaOt-Bu  Air PivOH - 140 14 
[a]Yields were determined by 1H-NMR analysis of the C-2 proton of the product in the crude reaction 
mixture using 1,3,5-trimethoxybenzene as the internal standard. [b]Shi’s conditions (5 mol% Pd(OAc)2 
and 2.5 equiv. K2CO3). [c]Fagnou’s conditions (5 mol% Pd(OAc)2 and 10 mol% K2CO3). [d]Miura’s 
conditions (3 mol% Pd(OAc)2 and 2 equiv. AgOAc). 
Subsequent investigations were based on conditions previously optimised within the 
McGlacken group for the cyclisation of 4-phenoxy-2-coumarins and 
4-phenoxy-2-yrones via double C−H Activation (Table 1, entry 4).[22] Whilst these 
conditions gave the highest yield of 70, significant degradation of starting material 
was also observed. Increasing (Table 1, entry 5) or decreasing (Table 1, entry 6) the 
reaction temperature did not improve the outcome. Using a substoichiometric amount 
of pivalic acid in high boiling-point solvents (Table 1, entry 7–9) resulted in 
degradation of starting material, and no evidence of product formation was observed. 
Using a carbonate base instead of NaOt-Bu (Table 1, entry 10), or using air rather 
than Ag2O as the oxidant (Table 1, entry 11) did not result in greater product 
formation. Given the difficulties associated with trying to cleave two C-H bonds on 
the quinoline substrate, the decision was made to try a single C-H activation approach.  
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3.9. Single C-H Coupling 
As mentioned in the introduction, methods for accessing the framework of 70 via C-H 
bond activation of the C-3 position of the quinoline were lacking in the literature. The 
first example of a non-directed C-H activation of the C-3 position of pyridines and 
quinolines was reported by Yu and co-workers (Figure 26 (i)), using phosphine 
ligands.[39] The following section describes a ligand-free C-H activation of the C-3 
position of the quinoline via intramolecular direct arylation, in air (Figure 26 (ii)). 
 
 
 
   
 
 
 
 
   
Figure 26 Palladium-catalysed C-H activation at the C-3 position of quinolines. 
To begin, 4-(2-bromophenoxy)quinoline 71 was chosen as the substrate, synthesised 
by reaction of 4-chloroquinoline 68 with 2-bromophenol. This transformation 
proceeds via nucleophilic attack of the phenoxide anion (generated in situ) at the 
4-position of the quinoline (Scheme 46). 
 
 
 
 
68   71, 78% 
    
Scheme 46 Synthesis of 4-(2-bromophenoxy)quinoline substrate 71. 
To achieve the intramolecular cyclisation of 71, a relatively simple system of a 
palladium catalyst, inorganic base, and high-boiling polar solvent was first applied. 
Pleasingly, our initial coupling conditions allowed formation of the fused product 70 
in 57% isolated yield, in air (Scheme 47).  
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71  70,[37] 57% 
   
Scheme 47 Initial conditions for single C-H functionalisation of 71. 
Next, a variety of reaction parameters was assessed (Table 2). A solvent screen 
indicated that high-boiling point amide solvents were necessary for good conversion 
(Table 2, entry 1–3). Other solvents gave little or no conversion to product (Table 2, 
entry 4–8). Changing the base from Na2CO3 to K2CO3 or Cs2CO3 resulted in an 
increase in the isolated yield of the product (Table 2, entry 9–10), while use of a 
stronger butoxide base resulted in decomposition of the starting material (Table 2, 
entry 11). A further reduction in catalyst loading to 2 mol% was also achieved (Table 
2, entry 12), allowing the desired product 70 to be isolated in 95% yield. 
Table 2 Optimisation of direct arylation conditions for 4-(2-bromophenoxy)phenol. 
 
  
71  70 
Entry Pd(OAc)2 Base Solvent T (°C) 
%Yield NMR[a] 
(Isolated Yield) 
1 5 mol% Na2CO3 DMA 135 (57) 
2 5 mol% Na2CO3 DMF 135 67 
3 5 mol% Na2CO3 NMP 135 70 (72) 
4 5 mol% Na2CO3 DMSO 135 0 
5[b] 5 mol% Na2CO3 1,4-Dioxane 100 0 
6[b] 5 mol% Na2CO3 EtOH 78 0 
7[b] 5 mol% Na2CO3 1,2-DCE 55 0 
8[b] 5 mol% Na2CO3 MeCN 82 0 
9 5 mol% K2CO3 NMP 135 72 
10 5 mol% Cs2CO3 NMP 135 83 
11 5 mol% NaOt-Bu NMP 135 39[c] 
12 2 mol% Cs2CO3 NMP 135 99 (95) 
13 1 mol% Cs2CO3 NMP 135 33 
[a]Yields determined by 1H-NMR analysis of the C-2 proton of the product in the crude reaction mixture 
using 1,3,5-trimethoxybenzene as internal standard. [b]Reaction carried out at the boiling point of the 
solvent. [c] Decomposition of starting material observed. 
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3.9.1. Substrate Scope 
With optimised conditions in hand, an examination of the functional group tolerance 
under the optimised conditions was planned. For this investigation, a range of novel 
substituted analogues of 71 was synthesised. Compounds 72–83 were prepared using 
the same method as described for 71.  
 
 
 
 
   72–83 
   
72, 38% 73, 91% 74, 96% 
   
             75, 80% 76, 84%             77, 56% 
   
78, 93% 79, 90%        80, 70% 
   
     81, 74%     82, 80%   83, 65% 
  
Scheme 48 Synthesis of 4-phenoxyquinoline substrates. 
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However, in the case of a few of the substituted 2-bromophenols, this method proved 
unsuitable. The reactions did not proceed as desired in the presence of sodium 
hydroxide, resulting in unreacted starting materials or complex mixtures.  It was 
suspected that the nucleophilic nature of the hydroxide base was incompatible with 
these 2-bromophenols. As it was of interest to expand the variety of substrates bearing 
both electron-rich and electron-poor substituents, an alternative method was employed 
using the non-nucleophilic base DMAP. Gratifyingly, under these conditions the 
desired novel substrates could be obtained and included in the substrate scope. This 
method was also favourable as it required a lesser excess of the phenol, thus avoiding 
wasting large amounts of the more expensive phenol starting materials. 
  
 
 
   84–88 
   
84, 72% 85, 89% 86, 62% 
  
87, 56% 88, 61% 
  
Scheme 49 Synthesis of 4-phenoxyquinoline substrates using DMAP as base. 
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Next, each of these substrates were subjected to the optimised direct arylation 
conditions (Scheme 50). Overall, it was observed that the reaction allows for a variety 
of functional groups on both the phenoxy and quinoline coupling partners. Substrates 
with weakly electron-withdrawing substituents (72, 73, 74, 84, 85) on the phenoxy 
ring were well tolerated. Additionally, the chlorides in 74 and 85 were retained as a 
synthetic handle for further cross-coupling. Moderate yields of cyclised product were 
observed in the case of the nitro (75) and ester (86) containing analogues. Longer 
reaction times were required in the case of electron-rich phenoxy substrates (76, 77). 
In the case of the naphthyl analogue 88, the desired product could only be obtained in 
17% isolated yield, with the majority of the remaining product attributed to unreacted 
starting material. This may be due to the steric bulk of the naphthyl group hindering 
access to the coupling site. The scope of the reaction with respect to the quinoline was 
also examined. A methyl group at the C-2 position was well tolerated (78), as was the 
heptyl chain of the HHQ-derived substrate (79). As discussed in Chapter 1, 
quinolones/quinolines bearing a heptyl chain at the C-2 position display signalling 
activity in the QS network of P. aeruginosa and other microorganisms. On the aryl 
backbone, both electron donating -OMe substituents (80, 81) and electron 
withdrawing -CF3 (82) and -F (83) substituents also led to very good yields of product. 
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72–88  89–105 
 
  
89,[37] 91% (18 h) 90,[76] 87% (18 h) 91,[37] 93% (18 h) 
 
 
 
92,[37] 93% (18 h) 93, 79% (18 h) 94, 46% (18 h) 
 
  
95, 56% (18 h) 96,[37] 71% (48 h) 97,[37] 50% (48 h) 
   
98,[38] 42% (48 h) 99, 17% (48 h) 100,[37] 78% (30 h) 
   
101, 70% (30 h) 102,[37] 84% (18 h)[a] 103, 81% (18 h)[a] 
  
104, 63% (24 h) 105,[76] 67% (24 h) 
   
Scheme 50 Investigation of substrate scope. All yields are isolated yields. [a]5 mol% 
Pd(OAc)2 required. 
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In an effort to expand the substrate scope beyond 4-phenoxyquinolines, the ether linker 
was replaced with an amine, which would allow access to fused indoloquinolines. 
Compounds containing fused indoloquinoline rings are known to possess 
antimalarial[77] and anticancer activity.[78] 
It was envisaged that the amine-linked substrate could be accessed by performing a 
Hartwig-Buchwald coupling reaction between the 4-bromoquinoline starting material 
and an aniline. First, 4-bromoquinoline 106 was synthesised from 4-quinolinol 
(Scheme 51).[79] 
   
  106,[80] 82% 
   
Scheme 51 Bromination of 4-quinolinol. 
Next, the amine-linked substrate 107 was synthesised via Hartwig-Buchwald coupling 
of 4-bromoquinoline with 2-bromoaniline (Scheme 52).[77] 
  
  
106   107, 74% 
    
Scheme 52 Synthesis of amine-linked substrate 107. 
When 107 was subjected to the previously-optimised direct arylation conditions that 
worked for the 4-phenoxyquinolines, no cyclised product 108 was observed, even after 
prolonged reaction time (Scheme 53). 
 
  
107  108 
   
Scheme 53 Attempted cyclisation of 107 using previously optimised direct arylation 
conditions. 
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Given the possibility that the secondary amine was coordinating to the palladium and 
hindering catalysis of the desired reaction,[81] methylation of the amine was envisaged 
to hinder ligation of the linker to the catalyst by creating steric bulk around the nitrogen 
atom. However, this seemingly straightforward transformation proved difficult to 
achieve, and after several attempts using various approaches (outlined in Table 3), 
this strategy was abandoned. 
Table 3 Attempts at methylation of 107. 
 
 
 
107  109 
   
Entry Conditions Result 
1[82] NaH, MeI, DMF, N2, 0 °C Complex mixture 
2[83] n-BuLi, MeI, THF, N2, −40 °C Debromination 
3 KOH, MeI, Acetone, 65 °C Complex mixture 
4 KOH, MeI, DMF, 25 °C Complex mixture 
5[84] Paraformaldehyde, NaBH4, TFE Unreacted starting material 
6[85] 
Aq. formaldehyde, AcOH, Zn, 1,4-
Dioxane, 35 °C 
Unreacted starting material 
An alternative strategy for the synthesis of N-Me amine 109, whereby the methyl 
group was installed by using 2-bromo-N-methylaniline as the starting material in the 
Hartwig-Buchwald reaction, was also tried.[77] Unfortunately, multiple attempts using 
this approach also proved unsuccessful (Table 4). 
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Table 4 Attempts to synthesise 109 from 2-bromo-N-methylaniline. 
  
  
   109 
    
Entry [Pd] Ligand Result 
1 Pd2(dba)3 Xantphos Unreacted starting material 
2 Pd2(dba)3 dppf Unreacted starting material 
3 Pd2(dba)3 RuPhos Unreacted starting material 
4[a] Pd(OAc)2 RuPhos Unreacted starting material 
5[b] Pd2(dba)3 Xantphos Unreacted starting material 
[a]1 mol% Pd(OAc)2 and 2 mol% RuPhos, NaOt-Bu (1.2 equiv.) used as base.[86] [b]4-Iodoquinoline 
used as starting material. 
Given the difficulties associated with installing the methyl group on the amine linker, 
and since the methyl group itself would be difficult to remove or functionalise later, a 
removable protecting group strategy was pursued next. Gratifyingly, addition of a Boc 
group proved to be much more straightforward (Scheme 54). 
 
 
 
107  110, 45% 
   
Scheme 54 Boc protection of 107. 
Unfortunately, when 110 was subjected to the previously optimised direct arylation 
conditions, no cyclisation was observed and only deprotected starting material 107 
was present in the crude reaction mixture. 
 
 
 
110   
   
Scheme 55 Attempted direct arylation of 110. 
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At this point, it seemed that inhibitive N-ligation to palladium could only be avoided 
by the addition of competitive phosphine ligands.[87] Indeed, when a new catalytic 
system of 2 mol% Pd(OAc)2 and 4 mol% PCy3·HBF4 was employed, approximately 
20% conversion to the fused product was observed (Table 5, entry 1). Increasing the 
amount of catalyst and ligand led to 100% conversion, and now the product could be 
isolated in 83% yield after column chromatography (Table 5, entry 2). In contrast to 
the optimised conditions for the 4-phenoxyquinoline substrates, an inert atmosphere 
was required for efficient cyclisation of 107. Under aerobic conditions the reaction 
proceeded sluggishly, with concomitant decomposition of starting material (Table 5, 
entry 3). 
Table 5 Screen of modified conditions for direct arylation of 107. 
  
 
107  108[88] 
   
Entry 
Mol% 
Pd 
Mol% 
PCy3·HBF4 
Atmosphere t (h) 
Conversion 
(Isolated Yield) 
1 2 4 N2 24 20% 
2 5 10 N2 3 100% (83%) 
3 5 10 Air 3 ~50%[a] 
[a]Prolonging reaction time to 24 h did not improve conversion, instead resulting in a complex mixture 
of by-products. 
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3.9.2. Substrates that Failed to Cyclise 
As is to be expected when carrying out a substrate investigation, some functional 
groups were incompatible with the optimised direct arylation conditions. Four of the 
compounds that were synthesised for inclusion in the substrate scope failed to cyclise 
under the optimised direct arylation conditions (Figure 27). Reasons may be attributed 
to the electronics (111), steric effects (112), catalyst poisoning (113) or incompatible 
functionality (114). Compounds 111, 112 and 113 were prepared using the same 
conditions depicted in Scheme 48 (substrate 113 was synthesised under an inert 
atmosphere to prevent dimerisation of the thiol). Compound 114 was prepared using 
the same conditions as depicted in Scheme 49. 
    
    111 112 113 114 
    
Figure 27 Substrates that failed to cyclise under the optimised conditions. 
This work on the direct arylation of 4-phenoxyquinolines was published in a Special 
Issue of the European Journal of Organic Chemistry in 2018, and is included in 
Appendix II.  
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3.10. One-Pot Tandem Suzuki-Miyaura/Direct Arylation Reactions 
One other substrate (115) initially failed to cyclise under the optimised direct arylation 
conditions (Scheme 56). This result was reminiscent of observations made by 
Lautens[58-59] and Cramer[60] when working with polyhalogenated substrates. 
 
  
115  116 
   
Scheme 56 Substrate 115 failed to undergo cyclisation under the optimised reaction 
conditions. 
Due to the presence of a second site where oxidative addition of the palladium catalyst 
could occur, the catalyst was irreversibly inserting into the carbon-bromine bond at 
the C-6 position. In the absence of an obvious coupling partner, the catalytic cycle 
reached a dead-end. To test this hypothesis, the reaction was repeated under the same 
conditions with the addition of phenylboronic acid, which could potentially undergo a 
Suzuki-Miyaura coupling at the C-6 position of the substrate. Indeed, on this occasion 
a single novel product (117) was isolated (Scheme 57). 
 
   
115   117, 75% 
    
Scheme 57 Tandem Suzuki-Miyaura and direct arylation of 115. 
A range of different solvents was screened (Table 6, entry 1–7) in an effort to 
optimise the reaction, but ultimately, NMP proved to be superior in terms of 
conversion and isolated yield (Table 6, entry 1). It is worth noting, however, that 
1,4-dioxane was almost as effective as NMP at promoting the reaction (Table 6, entry 
2). Because dioxane is much easier to remove from the reaction mixture, this solvent 
was sometimes used in place of NMP for some investigative reactions. For substrate 
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scope reactions, where the final isolated yield was important, NMP was used. 
Replacing Cs2CO3 with K2CO3 (Table 6, entry 8–12) increased the isolated yield to 
83% (Table 6, entry 9). 
Table 6 Solvent and base screen for tandem Suzuki-Miyaura/direct arylation of 115. 
  
 
115  117 
   
Entry Base Solvent %Conversion[a] 
%Yield NMR[b] 
(Isolated Yield) 
1 Cs2CO3 NMP 100 73 (75) 
2[c] Cs2CO3 1,4-Dioxane 90 68 
3[d] Cs2CO3 Toluene 25 - 
4[d] Cs2CO3 Xylene 16 - 
5[d] Cs2CO3 Cyclohexanone 85 61 
6[d] Cs2CO3 i-PrOAc 25 - 
7[d] Cs2CO3 n-BuOAc 20 - 
8 Na2CO3 NMP 100 80 
9 K2CO3 NMP 100 86 (83) 
10 KOH NMP 30 20 
11 NaOH NMP 65 44 
12 NaOt-Bu NMP decomposition - 
[a]%Conversion determined as consumption of starting material by 1H-NMR analysis of the crude 
reaction mixture. [b]Yields determined by 1H-NMR analysis of the crude reaction mixture using 
1,3,5-trimethoxybenzene as internal standard. [c]Reaction carried out at 125 °C. [d]Reaction carried out 
at 110 °C. 
The use of heterogeneous palladium catalysts (i.e. Pd on charcoal, alumina or carbon) 
instead of Pd(OAc)2 resulted in degradation of the starting material, and no evidence 
for the formation of product was observed (Table 7, entry 1–3).  
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Table 7 Screen of heterogeneous palladium catalysts. 
  
 
115  117 
   
Entry Pd Source Result 
1 10% Pd on charcoal Decomposition 
2 10% Pd on alumina Decomposition 
3 10% Pd on carbon Decomposition 
The effect of adding phosphine ligands to the reaction was also evaluated (Table 8). 
Under aerobic conditions, the ligands inhibited the reaction (Table 8, entry 1–2), in 
comparison to the optimum ligand-free conditions (Table 6, entry 9). Under inert 
conditions, the reaction did proceed in the presence of PPh3 (Table 8, entry 3), 
although periodic 1H-NMR analysis of the reaction mixture indicated that the rate of 
reaction was slower than in the absence of added ligand (Table 6, entry 9). The bulky 
ligand P(t-Bu)3·HBF4 failed to promote the reaction under inert conditions (Table 8, 
entry 4). Like PPh3, QPhos also allowed the reaction to proceed under inert 
conditions, but once again, not to full conversion, even after prolonged reaction time 
(Table 8, entry 5).  
Table 8 Investigation of effect of adding phosphine ligands to the tandem reaction. 
  
 
115  117 
    
Entry Ligand Atmosphere %Yield (NMR)[a] 
1 PPh3 Air 0 
2 P(t-Bu)3·HBF4 Air 0 
3 PPh3 N2 57 
4[b] P(t-Bu)3·HBF4 N2 0 
5[b] QPhos N2 64 
[a]Yields determined by 1H-NMR analysis of the crude reaction mixture using 1,3,5-trimethoxybenzene 
as internal standard. [b]Reaction stirred for 48 h at 135 °C. 
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To further probe the hypothesis that the Suzuki-Miyaura reaction was occurring at the 
C-6 position before direct arylation at the C-3 position, substrate 118 was synthesised 
using the same methodology described in Scheme 48. This substrate could only 
undergo the Suzuki-Miyaura reaction, and therefore if this reaction did not work 
efficiently under the optimised conditions, a more complicated catalytic cycle may be 
at play in the tandem reaction. The reaction proceeded as anticipated and in a much 
shorter reaction time of just four hours (Scheme 58), compared to overnight (18 h) for 
the tandem Suzuki-Miyaura/direct arylation reaction. 
   
118  119, 84% 
   
Scheme 58 Suzuki-Miyaura coupling of substrate 118. 
Next, the tandem reaction was carried out at a lower temperature of 100 °C to see if 
only the Suzuki-Miyaura product could be isolated (Scheme 59). This would add 
further evidence that oxidative addition was occurring at the C-6 position initially. 
Indeed, at this temperature the major product was the uncyclised Suzuki-Miyaura 
product 120, although some of the tandem product 117 and starting material 115 were 
also isolated. 
 
 
 
115 
 
 
  
120, 49% 117, 13% 
  
  115, 14% 
   
Scheme 59 Tandem reaction carried out at 100 °C. Yields are isolated yields.  
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3.10.1. Substrate Scope 
Moving the second C-Br bond to the C-7 position of the quinoline (121) also facilitated 
the tandem reaction, with respect to the isolated yield of the product 122 (Scheme 60). 
  
 
121  122, 95% 
   
Scheme 60 One-pot reaction of the C-7 substrate 121. 
Both transformations of the tandem reaction could also be carried out on the phenoxy 
ring of substrate 123. However, the isolated yield of product 124 was lower than that 
of the quinoline-substituted compounds (Scheme 61).  
  
 
123  124, 65% 
   
Scheme 61 Tandem reaction involving a Suzuki-Miyaura reaction on the phenoxy ring 
of 123. 
Next, tri-brominated substrate 125 was synthesised to see if three transformations 
could be carried out in the one pot. Indeed, when two equivalents of phenylboronic 
acid were included in the reaction mixture using the optimised reaction conditions, 
compound 126 could be isolated in high yield (Scheme 62). 
  
 
125  126, 80% 
   
Scheme 62 Tandem reaction of 125 involving two Suzuki-Miyaura couplings and one 
direct arylation reaction on a single substrate. 
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However, when only one equivalent of phenylboronic acid was included, the reaction 
did not seem to show any overriding regioselectivity in the Suzuki-Miyaura reaction. 
The resulting complex mixture of products could not be separated (Scheme 63). 
  
 
125   
   
Scheme 63 Tandem reaction of 125 with only one equivalent of phenylboronic acid. 
To allow for differentiation between the two Suzuki-Miyaura coupling sites, one of 
the bromine atoms was replaced with a chlorine (127). The product 128 was isolated, 
with the C-Cl bond retained (Scheme 64).  
  
 
127  128, 60% 
   
Scheme 64 Tandem reaction of 127 with retention of the C-Cl bond. 
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Next, several substituted phenylboronic acids were screened to assess the performance 
of various functional groups under the optimised reaction conditions (Scheme 65). 
The products of successful reactions were isolated in moderate to good yields. 
 
   
115   129–138 
  
                         129, 72%              130, 65% 
  
                          131, 81%                  132, 77% 
  
                           133, 80%    134, 72% 
  
     135, 70%    136, 51% 
  
       137, 72%      138, 59% 
  
Scheme 65 Substrate scope of tandem reaction with various substituted phenyl 
boronic acids using the 6-bromo substrate 115. 
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A selection of four tandem products that were substituted at the C-7 position was 
synthesised from substrate 121. 
 
  
 
121   139–142 
  
139, 74% 140, 70% 
  
141, 79% 142, 67% 
  
Scheme 66 Substrate scope of the tandem reaction with various substituted phenyl 
boronic acids using substrate 121. 
Unfortunately, several of the substituted phenylboronic acids that were subjected to 
the optimised tandem reaction conditions failed to yield the desired products (Figure 
28). Additionally, the reaction conditions proved to be incompatible with both alkyl 
and heteroaryl boronic acids. Radically different, specialised conditions will be 
required to allow heteroaryl boronic acids to be included. 
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Figure 28 Boronic acids that were not compatible with the tandem reaction.  
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3.10.2. One-Pot Tandem Mizoroki-Heck/Direct Arylation Reactions 
Interestingly, the reaction conditions described here could also facilitate tandem 
Mizoroki-Heck/direct arylation transformations (Scheme 67 and Scheme 68) to yield 
products 143 and 144. 
 
 
  
115   143, 60% 
    
Scheme 67 One-pot Mizoroki-Heck/direct arylation of 115. 
 
 
 
 
121   144, 80% 
    
Scheme 68 One-pot Mizoroki-Heck/direct arylation of 121. 
This work, in combination with a larger substrate scope of the tandem Mizoroki-
Heck/direct arylation products which subsequently undertaken within the McGlacken 
group, was published post examination of this thesis in The Journal of Organic 
Chemistry in January 2020.[89]   
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3.10.3. Tandem Reaction on Pyridine Substrates 
Like quinoline, the pyridine nucleus is also present in many biologically active 
compounds, including vitamins such as niacin (a form of vitamin B3), coenzymes such 
as nicotinamide adenine dinucleotide (NAD), and alkaloids such as nicotine.[90] 
Pyridine is the 2nd most frequently occurring ring system in FDA approved drugs, after 
benzene (Figure 29).[31] Therefore, carrying out similar tandem reactions on a pyridine 
scaffold would allow access to novel polycyclic pyridines.  
 
Figure 29 Pyridine-containing drugs Imatinib and Pioglitazone. 
Firstly, the dibrominated 4-phenoxypyridine substrate 145 was synthesised from 
3-bromo-4-chloropyridine and 2-bromophenol (Scheme 69). 
 
 
 
 
   145, 88% 
    
Scheme 69 Synthesis of substrate 145. 
Next, the tandem reaction conditions optimised for the quinoline substrates were 
applied. However, clean conversion to the desired product was not achieved (Scheme 
70). Although complete consumption of 145 was observed after 3 h, a complex 
mixture of products was observed by 1H-NMR analysis of the crude reaction mixture. 
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145  146 
   
Scheme 70 Substrate 145 failed to undergo tandem Suzuki-Miyaura/direct arylation 
in a clean manner, under the previously optimised conditions. 
Nitrogen-containing heterocycles, such as pyridines and quinolines, are known to 
coordinate to transition metal catalysts such as palladium.[91] As such, they can be used 
as ligands to facilitate certain transformations.[92] On the other hand, the nitrogen atom 
may coordinate to the catalyst in an unproductive manner, occupying coordination 
sites needed for oxidative addition or transmetallation. Whilst this was not the case in 
the reactions carried out on the quinoline substrates, the pyridine substrate 145 may 
be susceptible to unproductive coordination to the catalyst. In an effort to improve the 
outcome of the reaction depicted in Scheme 70, phosphine ligands were included in 
the reaction mixture. (Table 9). Unfortunately, the addition of these ligands did not 
improve the one-pot reaction and no product formation could be detected. 
Table 9 Screen of ligands for one-pot reaction with 145. 
  
 
145  146 
   
Entry Ligand %Conversion[a] 
1 PPh3 0 
2 Pt-Bu3·HBF4 0 
3 QPhos 0 
[a]Some degradation of starting material was observed as indicated by the 1H-NMR spectra of the 
reaction mixtures. 
In order to gain better insight into the problem point of this transformation, a step-wise 
approach was taken whereby both the Suzuki-Miyaura and direct arylation reactions 
were performed individually before proceeding to the tandem transformation. First, 
the ring-closing direct arylation reaction was performed. This is a known 
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transformation carried out by Ha and co-workers,[27] using Pd(OAc)2, an imidazoyl 
carbene ligand (IPr·HCl) and K2CO3 in DME. However, it was important to confirm 
that the reaction would proceed under our optimised conditions. 
 
  
147[93]  148,[37] 78% 
   
Scheme 71 Direct arylation reaction of 147. 
Next, substrate 149 was subjected to the reaction conditions along with phenylboronic 
acid, to see if the Suzuki-Miyaura reaction would occur efficiently at the C-3 position 
(Scheme 72). 
   
 
 
   (1:2)  
149  150, 21%  148, 37% 
    
Scheme 72 Substrate 149 was subjected to the one-pot reaction conditions to see if the 
Suzuki-Miyaura reaction would occur efficiently at the C-3 position.  
However, rather than obtaining the Suzuki-Miyaura product 150 exclusively, a 
mixture of the Suzuki-Miyaura product 150 and the ring-closed product 148 was 
observed. There was no evidence of unreacted starting material post-reaction. 
Complete separation of these two products by column chromatography proved 
difficult. Nevertheless, there was sufficient pure material isolated for the structure of 
both products to be confirmed. Presumably, when the oxidative addition product of 
149 is formed, there is competition between intramolecular direct arylation of the 
phenoxy ring and the intermolecular Suzuki-Miyaura reaction, with the former being 
favoured. This, together with the result from Scheme 71 explains the complex mixture 
of products observed when the dibrominated substrate 145 was subjected to the 
tandem reaction conditions (Scheme 70). 
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To investigate if the Suzuki-Miyaura reaction could be forced to occur selectively over 
the competing direct arylation reaction, a variety of boron-based coupling partners that 
can undergo Suzuki-Miyaura coupling was screened. 
Table 10 Screen of coupling partners for the tandem Suzuki-Miyaura/direct arylation 
reaction of 145. 
  
 
145   
   
Entry Boron Coupling Partner Result 
1 
 
Complex mixture 
2 
 
Complex mixture 
3 
 
Complex mixture 
4 
 
Complex mixture 
5 
 
Unreacted starting material 
6 No added coupling partner Unreacted starting material 
Unfortunately, none of the boron reagents screened promoted any improvement in the 
outcome of the reaction. In addition, the control experiment, which had no added 
coupling partner, only yielded unreacted starting material. This may be due to 
oxidative addition occurring preferentially at the C-3 position of the pyridine, resulting 
in shutdown of the catalytic cycle. At this point it was clear that an alternative strategy 
would need to be considered. 
Looking at the various quinoline substrates that were tolerated under the optimised 
reaction conditions, substrate 123, with both bromides on the phenoxy ring, underwent 
both transformations of the tandem reaction (Scheme 61). Therefore, the same result 
might be achievable with the pyridine framework. Thus, substrates 151–153 bearing 
both C-Br sites on the phenoxy ring were synthesised (Scheme 73). 
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   151–153 
 
   
151, 65% 152, 65% 153, 66% 
    
Scheme 73 Synthesis of dibromophenoxy pyridine substrates. 
To begin, substrate 151 was subjected to the optimised tandem reaction conditions 
(Scheme 74).  
  
 
 side-product 
  (1:0.25) 
151  154   
    
Scheme 74 Tandem reaction of substrate 151. The ratio of the products is based on 
the ratio of the signals for the C-2 proton(s) of each product. 
Whilst 1H-NMR analysis of the crude reaction mixture indicated that all of the starting 
material had been consumed, peaks corresponding to an uncyclised side-product were 
also present in a ratio of approximately 1:0.25 (154:side-product). Attempts to 
cleanly separate the two products by column chromatography proved unsuccessful. To 
determine if the side-product was a brominated compound, the purified mixture of the 
two products was added to a new system containing Pd(OAc)2 (2 mol%), K2CO3 (2 
equiv.) and PhB(OH)2 (1.1 equiv.) in NMP, and heated at 135 °C overnight. 
1H-NMR 
and 13C-NMR analysis of this crude reaction mixture showed little change in the 
spectra, implying that the mixture of compounds obtained from the reaction depicted 
Direct Arylation of Phenoxyquinolines  Results & Discussion 
146 
 
in Scheme 74 most likely did not contain any reactive C-Br bonds. Elucidation of the 
correct structure of the side-product will be discussed later. 
Next, substrates 152 and 153 were subjected to the tandem conditions to see if varying 
the substitution pattern of the phenoxy ring would improve the outcome of the reaction 
in favour of the desired one-pot Suzuki-Miyaura/direct arylation product. Using 
regioisomer 152 with the bromide meta to the oxygen atom only slightly improved 
conversion to the tandem reaction product (Scheme 75). Once again, clean separation 
of the products by column chromatography proved unsuccessful. 
 
  
 side-product 
  (1:0.2) 
152  155   
    
Scheme 75 Tandem reaction of substrate 152. The ratio of the products is based on 
the ratio of the signals for the C-2 proton(s) of each product. 
In the case of substrate 153, which is symmetrically substituted on the phenoxy ring, 
less of the uncyclised side-product was formed, resulting in very good conversion to 
the desired product (Scheme 76). Quantitative 1H-NMR analysis of the crude mixture 
indicated yields of approximately 80% (156) and 10% (side-product). 
 
  
 side-product (~10%) 
153  156 (~80%)   
    
Scheme 76 Tandem reaction of substrate 153. 
Column chromatography of the crude mixture was carried out to see if it would be 
possible to isolate some clean fractions of the desired product. Gratifyingly, on this 
occasion it was possible to obtain a pure sample of 156 in 22% isolated yield. In 
addition, a sample of the side-product in 5% isolated yield was obtained. From careful 
consideration of the NMR spectra of the side-product, possible reaction pathways and 
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the stoichiometry of the reaction, the structure of the side-product was determined to 
be 157 as shown in Scheme 77. The side-product was also identified by HRMS 
analysis. 
 
  
 
 
153  156  157 
 Yield (NMR): 80%  10% 
 Isolated yield: 22%  5% 
     
Scheme 77 Overall outcome of the tandem reaction of 153 yielding the major desired 
product 156 and diarylated side-product 157. 
Having determined the side-product formed during the tandem reaction of 153, it is 
likely that side-products depicted in Scheme 74 and Scheme 75 were also formed as 
the result of a double Suzuki-Miyaura reaction on substrates 151 and 152, respectively. 
Indeed, subsequent HRMS analysis of the mixtures identified the presence of a double 
Suzuki-Miyaura side-product in both cases. 
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3.11. Reversible Oxidative Addition 
Returning to the ‘failed’ reaction (Scheme 56) that initiated the one-pot reactions 
project, it is most likely that oxidative addition of the palladium catalyst to the 
carbon-bromine bond at the C-6 position of the quinoline is more favourable than at 
the C-2ʹ position of the phenoxy ring. As a result, in the absence of an intermolecular 
coupling partner that will release the catalyst from the C-6 position, the intramolecular 
cyclisation reaction at the C-2’ position of this particular substrate cannot proceed 
(Scheme 78). 
 
  
115  116 
 
  
 
  
158   
   
Scheme 78 Irreversible oxidative addition of the catalyst into the C-6 C-Br bond of 
115 causes the catalytic cycle to reach a dead-end in the absence of an intermolecular 
coupling partner. 
However, if the oxidative addition of the catalyst to the C-6 position was reversible, 
this might allow the intramolecular reaction to proceed and allow formation of 
compound 116 (Scheme 79). As discussed in the introduction, the use of conditions 
which allow reversible oxidative addition to occur can provide access to products that 
retain certain carbon-halogen bonds, as reported by Lautens.[61] 
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115  116 
 
 
 
 
 
 
158   
   
Scheme 79 Promoting reversible oxidative addition of the palladium catalyst could 
allow formation of the cyclised product 116 with retention of the quinoline C-Br bond. 
Initially, several phosphine ligands were screened in an effort to observe any evidence 
for the formation of 116 (Table 11). The optimised conditions for the intramolecular 
cyclisation of compound 71 were chosen, as the desired reaction in this case was the 
cyclisation. However, 1,4-dioxane was used instead of NMP as the reaction solvent 
for ease of work-up. 
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Table 11 Screen of phosphine ligands to determine conditions for promoting 
reversible oxidative addition. 
  
 
115  116 
   
Entry Ligand Structure %Conversion 
1 PCy3·HBF4 
 
0 
2 cataCXium A 
 
0 
3 P(t-Bu)3·HBF4 
 
0 
4 DavePhos 
 
0 
5 SPhos 
 
0 
6 XPhos 
 
0 
7 
Tris(4-fluorophenyl) 
phosphine 
 
0 
8 
Triphenylphosphine-
3,3',3''-trisulfonic acid 
trisodium 
 
0 
9 Tri-o-tolylphosphine 
 
0 
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10 Xantphos 
 
0 
11 QPhos 
 
0 
12 dppf 
 
0 
Unfortunately, none of the ligands screened promoted the cyclisation reaction. Even 
the ligands that worked well in Lautens’ reactions, P(t-Bu)3·HBF4 (Table 11, entry 
3) and QPhos (Table 11, entry 11), failed to induce reversible oxidative addition.  
To further probe how to promote the cyclisation reaction in the presence of a second 
C-X bond, iodinated analogues of the substrates were synthesised. To achieve this, 
first an aromatic Finklestein reaction was performed on the commercially available 
brominated starting materials to give iodinated compounds 159 and 160.[94] 
 
 
 
 
 
159[95] (6-I, 75%) 
160[96] (7-I, 81%) 
Scheme 80 Aromatic Finklestein reaction of 6- and 7-bromo-4-chloroquinoline to 
form the 6-iodo (159) and 7-iodo (160) analogues. 
Next, both 159 and 160 were reacted with 2-bromophenol to give the iodinated 
quinolines 161 and 162 (Scheme 81). 
 
 
 
 
   
161 (6-I, 78%) 
162 (7-I, 91%) 
    
Scheme 81 Synthesis of 6-iodo and 7-iodo 4-phenoxyquinolines.  
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At this point, another screen of conditions was devised for the four dihalogenated 
compounds – the C-6 bromo (115), C-6 iodo (161), C-7 bromo (121) and C-7 iodo 
(162) substrates. It was thought that sticking with the ligands that worked for Lautens 
and varying other parameters would be the best place to start. Thus, three different sets 
of conditions were chosen varying the catalyst, ligand and base: 1) Pd(OAc)2, 
P(t-Bu)3·HBF4 and Cs2CO3 (already tried with the brominated substrates 115 and 121 
but not with 161 and 162); 2) Pd(OAc)2, QPhos and PMP (our catalyst, Lautens’ ligand 
and base) and 3) Pd(QPhos)2, QPhos and PMP (Lautens’ exact conditions).[68] The 
results of this investigation are outlined in Table 12. 
Table 12 Screen of conditions for reversible oxidative addition. 
  
 
Substrate Entry [Pd] Ligand Base %Yield (NMR)[a] 
161 
1 Pd(OAc)2 
P(t-Bu)3 
·HBF4 
Cs2CO3 0 
2 Pd(OAc)2 QPhos PMP 0 
3 Pd(QPhos)2 QPhos PMP 0 
162 
4 Pd(OAc)2 
P(t-Bu)3 
·HBF4 
Cs2CO3 0 
5 Pd(OAc)2 QPhos PMP 0 
6 Pd(QPhos)2 QPhos PMP 0 
115 
7 Pd(OAc)2 QPhos PMP 0 
8 Pd(QPhos)2 QPhos PMP 24%
 
121 
9 Pd(OAc)2 QPhos PMP 0 
10 Pd(QPhos)2 QPhos PMP 20%
 
[a]Yields determined by 1H-NMR analysis of the crude reaction mixture using 1,3,5-trimethoxybenzene 
as internal standard. 
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To our delight, on this occasion two of the reactions showed some formation of a 
cyclised product (Table 12, entry 8 and entry 10). Indeed, in addition to using QPhos 
as an added ligand, it was also necessary to include Pd(QPhos)2 as the pre-catalyst, as 
noted by Lautens.[68] 
In order to confirm the structure of the products that were observed, the reaction of 
dibromide 121 under Lautens’ conditions (Table 12, entry 10) was repeated on a 
larger scale in an effort to obtain enough product for isolation and characterisation 
(Scheme 82). The reaction was sampled periodically and analysed by 1H-NMR 
spectrometry to monitor the progress of product formation. Careful monitoring of the 
reaction progress revealed that catalytic turnover decreased dramatically after 
approximately 48 h. Thus, throughout the experiment, new batches of catalyst and 
ligand were added whenever the reaction halted. This was continued until the majority 
of the starting material had been consumed and the product constituted the majority of 
the reaction mixture. Under these forcing conditions, some material may have been 
lost to degradation pathways. Nevertheless, after careful column chromatography of 
the crude reaction mixture, a pure sample of the product 163 was isolated, albeit in 
13% yield. 
  
 
121  163, 13% 
   
Scheme 82 Scale up of reaction depicted in Table 12, entry 10. 
The structure of novel cyclised product 163 was confirmed by NMR and HRMS 
analysis. The 1H-NMR spectrum of 163 is shown in Figure 30 below. The singlet peak 
at 9.49 ppm is indicative of an intramolecular direct arylation having occurred at the 
C-3 position. The shift and splitting pattern of the peaks for protons at C-5, C-6 and 
C-8 are also consistent with other 7-substituted products synthesised in this project. 
Retention of the C-Br bond was indicated by the minimal shift of the quaternary C-7 
peak in the 13C-NMR spectra of the substrate 121 (δ = 124.6 ppm) and the product 163 
(δ = 123.4 ppm). By comparison, the quaternary C-14 peak for the phenoxy C-Br of 
substrate 121 occurs at 116.3 ppm. Upon cyclisation, this quaternary C-14 peak shifts 
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to 122.4 ppm. The HRMS data also confirmed the presence of 163 (ESI-TOF m/z: 
[M+H]+ calcd. for C15H9BrNO: 297.9862; found: 297.9865). 
Figure 30 1H-NMR (CDCl3) spectrum of product 163.  
This work proves that cyclised products such as 116 (C-6 Br) and 163 (C-7 Br), which 
retain the quinoline C-Br bonds, can be accessed under conditions that allow reversible 
oxidative addition of the palladium catalyst at the more favoured site. Optimisation of 
the reaction conditions for reversible oxidative addition and substrate scope 
investigations are currently ongoing within the McGlacken group. 
3.12. Conclusions 
The application of direct arylation methodology towards the synthesis of fused 
benzofuroquinoline products was demonstrated. Placement of the halide on the 
phenoxy component of the coupling precursor allowed for easy access to cyclised 
products. No added phosphine was required and the reactions were carried out in air. 
Modification of the methodology allowed for the inclusion of a 4-anilinoquinoline 
substrate, without the requirement for N-protection. Under virtually the same 
conditions, using dibrominated substrates, a new one-pot tandem reaction was 
discovered whereby a Suzuki-Miyaura coupling and direct arylation reaction occur on 
the same substrate, without requiring additional reagents or catalyst. Again, this 
tandem reaction occurs in the absence of added ligand and in air. Finally, reversible 
oxidative conditions allowed for the isolation of the C-7 brominated product of the 
direct arylation reaction. 
163 
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3.13. General Considerations 
Solvents, reagents and starting materials were used as obtained from commercial 
sources, without purification. Column chromatography was carried out using 60 Å 
(35-70 µm) silica. TLC was carried out on pre-coated silica gel plates (Merck 60 
PF254). The developed plates were visualised under UV light. 
Melting points were measured in a Thomas Hoover Capillary Melting Point apparatus. 
Infrared spectra were measured on a Perkin-Elmer FT-IR spectrometer. High 
resolution mass spectra (HRMS) were recorded on a Waters LCT Premier TOF LC-
MS instrument in electrospray ionisation (ESI) mode using 50% acetonitrile-water 
containing 0.1% formic acid as eluent; samples were prepared in acetonitrile at a 
concentration of ca. 1 mg/mL. Reported results are within the range of ± 5ppm of the 
calculated mass. For brominated compounds, Br80 was used for the calculated and 
reported molecular ion mass. 
Nuclear Magnetic Resonance (NMR) samples were run in deuterated chloroform 
(CDCl3) or deuterated dimethylsulfoxide (DMSO-d6), as specified. 
1H-NMR (600 
MHz), 1H-NMR (500 MHz),1H-NMR (400 MHz), and 1H-NMR (300 MHz) spectra 
were recorded on Bruker Avance 600, Bruker Avance 500, Bruker Avance 400 and 
Bruker Avance 300 NMR spectrometers, respectively, in proton coupled mode using 
tetramethylsilane (TMS) as the internal standard. 13C-NMR (150 MHz), 13C-NMR 
(125 MHz), 13C-NMR (100 MHz) and 13C-NMR (75 MHz) spectra were recorded on 
Bruker Avance 600, Bruker Avance 500, Bruker Avance 400 and Bruker Avance 300 
NMR spectrometers, respectively, in proton decoupled mode at 20 C using 
tetramethylsilane (TMS) as the internal standard. 19F-NMR (282 MHz) spectra were 
recorded on a Bruker Avance 300 NMR spectrometer in proton decoupled mode at 
20 C. All spectra were run at University College Cork. Chemical shifts (δ) are 
expressed as parts per million (ppm), positive shift being downfield from TMS; 
coupling constants (J) are expressed in hertz (Hz). Splitting patterns in 1H-NMR 
spectra are designated as: s (singlet), br s (broad singlet), d (doublet), dd (doublet of 
doublets), ddd (doublet of doublets of doublets), t (triplet), td (triplet of doublets), q 
(quartet), quin (quintet) and m (multiplet). Please note that the numbering system used 
on the structures is to assign the NMR data, and differs from the IUPAC system used 
for naming.  
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3.14. Synthesis of 4-Chloroquinolines 
4-Chloroquinoline[72] (68)  
A mixture of 4-quinolinol (1 equiv.) and POCl3 (5 equiv.) was stirred at 110 °C for 3 
h, until full consumption of the starting material was observed by TLC analysis of the 
reaction mixture (eluent DCM/MeOH 9:1). The cooled reaction mixture was slowly 
poured onto ice water (~4 mL/mmol) with stirring. Solid NaHCO3 was added 
portion-wise until the mixture reached pH 7–8. This aqueous mixture was transferred 
to a separating funnel and extracted with DCM (3 × 1.5 mL/mmol). The combined 
organic layers were washed with water (1.5 mL/mmol), brine (1.5 mL/mmol), dried 
over MgSO4, filtered and concentrated in vacuo to yield the crude product as a yellow 
oil. Purification by column chromatography (DCM/MeOH 95:5) afforded the pure 
product 68 as a yellow solid (2.17 g, 96% yield). 
Yellow solid; yield: 2.17 g (96%); m.p. = 29–30 °C (lit. 28–31 °C); IR 
(NaCl): ν 2462 (C-H stretch), 1617 (aromatic C-C stretch), 1381 (C-N 
stretch), 759 (C-Cl stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 7.50 
(d, J = 4.7 Hz, 1H, CH-3), 7.66 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H, CH-7), 7.79 (ddd, J = 
8.4, 6.9, 1.5 Hz, 1H, CH-8), 8.14 (d, J = 8.4 Hz, 1H, CH-9), 8.25 (dd, J = 8.4, 1.0 Hz, 
1H, CH-6), 8.79 (d, J = 4.7 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 121.2 
(CH-3), 124.1 (CH-6), 126.5 (qC-5), 127.6 (CH-7), 129.8 (CH-9), 130.3 (CH-8), 
142.6 (qC-4), 149.1 (qC-10), 149.8 (CH-2); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C9H7ClN: 164.0267; found: 164.0265.  
Spectral data were consistent with those reported in the literature. 
4-Chloro-2-heptylquinoline (precursor to compound 79) 
Prepared using the same procedure as for 4-chloroquinoline (68) using HHQ 1 as 
starting material. 
Orange sticky oil; yield: 0.461 mg, (86%); IR (NaCl): ν 
3410 (C-H stretch), 2926 (C-H stretch), 1585 (aromatic 
C-C stretch), 1493 (aromatic C-C stretch), 1378 (C-N 
stretch), 761 (C-Cl stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 0.88 (t, J = 6.8 Hz, 
3H, CH3-17), 1.19–1.49 (m, 8H, CH2-13, CH2-14, CH2-15, CH2-16), 1.73–1.87 (m, 
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2H, CH2-12), 2.93 (t, J = 7.9 Hz, 2H, CH2-11), 7.40 (s, 1H, CH-3), 7.57 (ddd, J = 8.2, 
6.9, 1.1 Hz, 1H, CH-7), 7.73 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H, CH-8), 8.05 (d, J = 8.4 
Hz, 1H, CH-9), 8.17 (dd, J = 8.4, 1.0 Hz, 1H, CH-6); 13C-NMR (75 MHz, CDCl3) δ: 
14.1 (CH3-17), 22.7 (CH2-16), 29.2 (CH2-14), 29.5 (CH2-13), 29.9 (CH2-12), 31.8 
(CH2-15), 39.2 (CH2-11), 121.4 (CH-3), 123.9 (CH-6), 124.9 (qC-5), 126.6 (CH-7), 
129.2 (CH-9), 130.3 (CH-8), 142.5 (qC-4), 148.7 (qC-10), 163.1 (qC-2); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C16H21ClN: 262.1363; found: 262.1352.  
3.15. General Procedure for Synthesis of 4-Phenoxy Quinoline Substrates – 
NaOH Method 
A mixture of the 4-chloroquinoline substrate (1 equiv.), the substituted 2-bromophenol 
(5 equiv.) and NaOH (crushed pellets) (1.5 equiv.) was stirred at 120 °C until reaction 
was completed (2–6 h) as evident by TLC (hexane/EtOAc 8:2). The cooled reaction 
mixture was diluted with 10% aq. NaOH (0.5 mL/mmol) and stirred at room 
temperature for 1 h. The aqueous phase was extracted with DCM (3 × 1.5 mL/mmol). 
The combined organic layers were washed with 6M NaOH (3 × 1 mL/mmol), water 
(1 mL/mmol) and brine (1 mL/mmol), dried over MgSO4, filtered and concentrated in 
vacuo. The crude mixture was purified by column chromatography over silica gel 
using hexane/EtOAc (8:2) as eluent. 
4-Phenoxyquinoline[74] (69) 
Yellow oil; yield: 2.45 g (91%); IR (NaCl): ν 3392 (C-H stretch), 
3063 (C-H stretch), 1595 (aromatic C-C stretch), 1487 (aromatic 
C-C stretch), 1393 (C-N stretch), 1207 (C-O stretch) cm-1; 
1H-NMR (300 MHz, CDCl3) δ: 6.55 (d, J = 5.2 Hz, 1H, CH-3), 
7.17–7.22 (m, 2H, CH-12, CH-16), 7.26–7.33 (m, 1H, CH-14), 
7.42–7.52 (m, 2H, CH-13, CH-15), 7.58 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H, CH-7), 7.76 
(ddd, J = 8.5, 6.9, 1.5 Hz, 1H, CH-8), 8.10 (d, J = 8.5 Hz, 1H, CH-9), 8.37 (dd, J = 
8.4, 0.9 Hz, 1H, CH-6), 8.67 (d, J = 5.2 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) 
δ: 104.4 (CH-3), 121.1 (CH-12, CH-16), 121.5 (qC-5), 121.8 (CH-6), 125.6 (CH-14), 
126.1 (CH-7), 129.1 (CH-9), 130.1 (CH-8), 130.3 (CH-13, CH-15), 149.8 (qC-10), 
151.1 (CH-2), 154.4 (qC-11), 161.9 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C15H12NO: 222.0919; found: 222.0915.  
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Spectral data were consistent with those reported in the literature. 
4-(2-Bromophenoxy)quinoline (71) 
White solid; yield: 2.89 g (78%); m.p. = 62–64 °C; IR (NaCl): ν 
3434 (C-H stretch), 1596 (aromatic C-C stretch), 1305 (C-N 
stretch), 1223 (C-O stretch), 659 (C-Br stretch) cm-1; 1H-NMR 
(300 MHz, CDCl3) δ: 6.41 (d, J = 5.1 Hz, 1H, CH-3), 7.18–7.27 
(m, 2H, CH-12, CH-14), 7.43 (ddd, J = 8.1, 7.3, 1.6 Hz, 1H, 
CH-13), 7.61 (ddd, J = 8.2, 6.9, 1.1 Hz, 1H, CH-7), 7.70–7.82 (m, 2H, CH-8, CH-15), 
8.12 (d, J = 8.2 Hz, 1H, CH-9), 8.42 (dd, J = 8.3, 0.9 Hz, 1H, CH-6), 8.68 (d, J = 5.1 
Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 103.7 (CH-3), 116.4 (qC-16), 121.1 
(qC-5), 121.9 (CH-6), 123.2 (CH-12), 126.3 (CH-7), 127.3 (CH-14), 129.1 (CH-9), 
129.2 (CH-13), 130.2 (CH-8), 134.3 (CH-15), 149.8 (qC-10), 151.0 (CH-2), 151.2 
(qC-11), 160.7 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H11BrNO: 
300.0024; found: 300.0016.  
4-(2-Bromo-4-fluorophenoxy)quinoline (72) 
Pale yellow solid; yield: 188 mg (38%); m.p. = 100–103 °C; IR 
(NaCl): ν 3065 (C-H stretch), 1480 (aromatic C-C stretch), 1305 
(C-N stretch), 1248 (C-O stretch), 1183 (C-F stretch), 765 (C-Br 
stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 6.39 (d, J = 5.1 Hz, 
1H, CH-3), 7.10–7.29 (m, 2H, CH-12, CH-13), 7.48 (dd, 3J(H,F)  = 
7.7, 4J(H,H) = 2.8 Hz, 1H, CH-15), 7.62 (ddd, J = 8.2, 5.5, 1.2 Hz, 1H, CH-7), 7.79 
(ddd, J = 8.5, 6.9, 1.5 Hz, 1H, CH-8), 8.12 (d, J = 8.5 Hz, 1H, CH-9), 8.40 (dd, J = 
8.3, 0.9 Hz, 1H, CH-6), 8.69 (d, J = 5.1 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) 
δ: 103.4 (CH-3), 116.1 (d, 2J(C,F) = 23 Hz, CH-13), 116.9 (d, 3J(C,F) = 10 Hz, qC-16), 
120.9 (qC-5), 121.3 (d, 2J(C,F) = 26 Hz, CH-15), 121.8 (CH-6), 124.3 (d, 
3J(C,F) = 9 Hz, 
CH-12), 126.4 (CH-7), 129.2 (CH-9), 130.3 (CH-8), 147.4 (qC-11), 149.8 (qC-10), 
151.0 (CH-2), 159.9 (d, 1J(C,F) = 250 Hz, qC-14), 160.7 (qC-4); 
19F-NMR (282 MHz, 
CDCl3) δ: -114 (CF-14); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H10BrFNO: 
317.9930; found: 317.9935.  
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4-(2-Bromo-5-fluorophenoxy)quinoline (73) 
Pale yellow solid; yield: 891 mg (91%); m.p. = 77–78 °C; IR 
(NaCl): ν 3066 (C-H stretch), 1476 (aromatic C-C stretch), 1305 
(C-N stretch), 1252 (C-O stretch), 1159 (C-F stretch), 601 (C-Br 
stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 6.49 (d, J = 5.1 Hz, 
1H, CH-3), 6.94–7.01 (m, 1H, CH-14), 6.99 (d, 3J(H,F) = 8.1 Hz, 
1H, CH-16), 7.57–7.74 (m, 2H, CH-7, CH-13), 7.80 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H, 
CH-8), 8.13 (d, J = 8.5 Hz, 1H, CH-9), 8.37 (dd, J = 8.4, 1.0 Hz, 1H, CH-6), 8.73 (d, 
J = 5.1 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 104.1 (CH-3), 110.7 (qC-12), 
110.9 (d, 2J(C,F) = 25 Hz, CH-16), 114.5 (d, 
2J(C,F) = 22 Hz, CH-14), 120.9 (qC-5), 
121.7 (CH-6), 126.5 (CH-7), 129.2 (CH-9), 130.4 (CH-8), 134.7 (d, 3J(C,F) = 9 Hz, 
CH-13), 149.9 (qC-10), 151.0 (CH-2), 152.0 (d, 3J(C,F) = 11 Hz, qC-11), 160.1 (qC-4), 
162.4 (d, 1J(C,F) = 250 Hz, qC-15); 
19F-NMR (282 MHz, CDCl3) δ: -111 (CF-15); 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H10BrFNO: 317.9930; found: 317.9936.  
4-(2-Bromo-4-chlorophenoxy)quinoline (74) 
Off-white solid; yield: 1.97 g (96%); m.p. = 112–115 °C; IR 
(NaCl): ν 3403 (C-H stretch), 1596 (aromatic C-C stretch), 1465 
(aromatic C-C stretch), 1392 (C-N stretch), 1257 (C-O stretch), 
824 (C-Cl stretch), 765 (C-Br stretch) cm-1; 1H-NMR (300 MHz, 
CDCl3) δ: 6.42 (d, J = 5.1 Hz, 1H, CH-3), 7.17 (d, J = 8.6 Hz, 1H, 
CH-12), 7.40 (dd, J = 8.7, 2.5 Hz, 1H, CH-13), 7.61 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H, 
CH-7), 7.70–7.84 (m, 2H, CH-8, CH-15), 8.12 (d, J = 8.5 Hz, 1H, CH-9), 8.38 (dd, J 
= 8.4, 0.9 Hz, 1H, CH-6), 8.70 (d, J = 5.1 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) 
δ: 103.7 (CH-3), 117.0 (qC-16), 120.9 (qC-5), 121.7 (CH-6), 123.8 (CH-12), 126.4 
(CH-7), 129.2 (CH-9), 129.3 (CH-13), 130.3 (CH-8), 132.0 (qC-14), 133.9 (CH-15), 
149.9 (qC-10), 150.0 (qC-11), 151.0 (CH-2), 160.4 (qC-4); HRMS (ESI-TOF) m/z: 
[M+H]+ calcd. for C15H10BrClNO: 333.9634; found: 333.9629.  
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4-(2-Bromo-4-nitrophenoxy)quinoline (75) 
Pale yellow solid; yield: 192 mg (80%); m.p. = 151–152 °C; IR 
(NaCl): ν 3376 (C-H stretch), 1523 (aromatic C-C stretch), 1346 
(N-O stretch), 1305 (C-N stretch), 1257 (C-O stretch), 665 
(C-Br stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 6.65 (d, J = 
5.0 Hz, 1H, CH-3), 7.23 (d, J = 8.9 Hz, 1H, CH-15), 7.64 (ddd, 
J = 8.1, 7.1, 0.7 Hz, 1H, CH-7), 7.83 (ddd, J = 8.4, 7.0, 1.3 Hz, 1H, CH-8), 8.17 (d, J 
= 8.5 Hz, 1H, CH-9), 8.25 (d, J = 8.8 Hz, 1H, CH-6), 8.27 (dd, J = 8.9, 2.7 Hz, 1H, 
CH-13), 8.65 (d, J = 2.6 Hz, 1H, CH-12), 8.80 (d, J = 5.0 Hz, 1H, CH-2); 13C-NMR 
(75 MHz, CDCl3) δ: 106.0 (CH-3), 115.9 (qC-16), 121.1 (qC-5), 121.2 (CH-12), 121.5 
(CH-6), 124.6 (CH-13), 127.1 (CH-7), 129.5 (CH-9), 129.9 (CH-15), 130.7 (CH-8), 
144.9 (qC-14), 150.2 (qC-10), 151.0 (CH-2), 157.2 (qC-11), 159.1 (qC-4); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C15H10BrN2O3: 344.9875; found: 344.9865. 
4-(2-Bromo-4-methylphenoxy)quinoline (76) 
Orange solid; yield: 242 mg (84%); m.p. = 122–125 °C; IR 
(NaCl): ν 3064 (C-H stretch), 1568 (aromatic C-C stretch), 1485 
(aromatic C-C stretch), 1392 (C-N stretch), 1255 (C-O stretch), 
765 (C-Br stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 2.41 (s, 
3H, CH3-17), 6.40 (d, J = 5.2 Hz, 1H, CH-3), 7.13 (d, J = 8.2 
Hz, 1H, CH-12), 7.22 (dd, J = 8.2, 1.5 Hz, 1H, CH-13), 7.54 (d, J = 1.4 Hz, 1H, 
CH-15), 7.61 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H, CH-7), 7.78 (ddd, J = 8.4, 6.9, 1.4 Hz, 
1H, CH-8), 8.11 (d, J = 8.5 Hz, 1H, CH-9), 8.43 (dd, J = 8.3, 1.0 Hz, 1H, CH-6), 8.67 
(d, J = 5.1 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 20.7 (CH3-17), 103.5 
(CH-3), 115.9 (qC-16), 121.1 (qC-5), 121.9 (CH-6), 122.9 (CH-12), 126.2 (CH-7), 
129.1 (CH-9), 129.8 (CH-13), 130.1 (CH-8), 134.5 (CH-15), 137.5 (qC-14), 148.8 
(qC-11), 149.8 (qC-10), 151.0 (CH-2), 161.0 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C16H13Br NO: 314.0181; found: 314.0169. 
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4-(2-Bromo-4-(tert-butyl)phenoxy)quinoline (77) 
Pale yellow solid; yield: 73 mg (56%); m.p. = 68–70 °C; IR 
(NaCl): ν 2963 (C-H stretch), 1568 (aromatic C-C stretch), 
1488 (aromatic C-C stretch), 1391 (C-H bend), 1306 (C-N 
stretch) 1263 (C-O stretch), 766 (C-Br stretch) cm-1; 1H-NMR 
(300 MHz, CDCl3) δ: 1.36 (s, 9H, CH3-18, CH3-19, CH3-20), 
6.43 (d, J = 5.1 Hz, 1H, CH-3), 7.16 (d, J = 8.5 Hz, 1H, CH-12), 7.41 (dd, J = 8.5, 2.2 
Hz, 1H, CH-13), 7.60 (t, J = 7.6 Hz, 1H, CH-7), 7.65–7.83 (m, 2H, CH-8, CH-15), 
8.11 (d, J = 8.5 Hz, 1H, CH-9), 8.42 (d, J = 8.3 Hz, 1H, CH-6), 8.67 (d, J = 5.0 Hz, 
1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 31.3 (CH3-18, CH3-19, CH3-20), 34.7 
(qC-17), 103.6 (CH-3), 115.8 (qC-16), 121.1 (qC-5), 121.9 (CH-6), 122.6 (CH-12), 
126.2 (CH-7), 126.3 (CH-13), 129.0 (CH-9), 130.2 (CH-8), 131.2 (CH-15), 148.5 
(qC-11), 149.7 (qC-10), 150.9 (qC-14), 151.1 (CH-2), 160.9 (qC-4); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C19H19BrNO: 356.0650; found: 356.0642.  
4-(2-Bromophenoxy)-2-methylquinoline (78) 
Pale pink solid; yield: 331 mg (93%); m.p. = 98–101 °C; IR 
(NaCl): ν 2923 (C-H stretch), 1599 (aromatic C-C stretch), 1470 
(aromatic C-C stretch), 1342 (C-N stretch), 1235 (C-O stretch), 
754 (C-Br stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 2.60 (s, 
3H, CH3-17), 6.29 (s, 1H, CH-3), 7.15–7.29 (m, 2H, CH-12, 
CH-14), 7.42 (ddd, J = 8.6, 7.3, 1.6 Hz, 1H, CH-13), 7.54 (ddd, J = 8.2, 6.9, 1.2 Hz, 
1H, CH-7), 7.68–7.79 (m, 2H, CH-8, CH-15), 8.02 (d, J = 8.4 Hz, 1H, CH-9), 8.35 
(dd, J = 8.4, 1.0 Hz, 1H, CH-6); 13C-NMR (75 MHz, CDCl3) δ: 25.8 (CH3-17), 104.2 
(CH-3), 116.3 (qC-16), 119.5 (qC-5), 121.7 (CH-6), 123.2 (CH-12), 125.4 (CH-7), 
127.1 (CH-14), 128.3 (CH-9), 129.1 (CH-13), 130.2 (CH-8), 134.3 (CH-15), 149.4 
(qC-10), 151.3 (qC-11), 159.9 (qC-2), 160.8 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C16H13BrNO: 314.0181; found: 314.0179. 
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4-(2-Bromophenoxy)-2-heptylquinoline (79)  
Off-white solid; yield: 205 mg (90%); m.p. = 75–77 °C; 
IR (NaCl): ν 2926 (C-H stretch), 2855 (C-H stretch), 1600 
(aromatic C-C stretch), 1470 (aromatic C-C stretch), 1359 
(C-N stretch), 1234 (C-O stretch), 763 (C-Br stretch) 
cm-1; 1H-NMR (300 MHz, CDCl3) δ: 0.85 (t, J = 6.7 Hz, 
3H, CH3-23), 1.14–1.42 (m, 8H, CH2-19, CH2-20, CH2-21, CH2-22), 1.60–1.73 (m, 
2H, CH2-18), 2.80 (t, J = 8.1 Hz, 2H, CH2-17), 6.30 (s, 1H, CH-3), 7.17–7.25 (m, 2H, 
CH-12, CH-14), 7.42 (ddd, J = 8.5, 7.2, 1.5 Hz, 1H, CH-13), 7.53 (ddd, J = 8.1, 7.0, 
1.1 Hz, 1H, CH-7), 7.63–7.81 (m, 2H, CH-8, CH-15), 8.05 (d, J = 8.4 Hz, 1H, CH-9), 
8.34 (dd, J = 8.3, 0.9 Hz, 1H, CH-6); 13C-NMR (75 MHz, CDCl3) δ: 14.1 (CH3-23), 
22.6 (CH2-22), 29.2 (CH2-18), 29.4 (CH2-20), 30.0 (CH2-19), 31.8 (CH2-21), 39.7 
(CH2-17), 103.8 (CH-3), 116.3 (qC-16), 119.7 (qC-5), 121.7 (CH-6), 123.1 (CH-12), 
125.4 (CH-7), 127.1 (CH-14), 128.5 (CH-9), 129.2 (CH-13), 130.1 (CH-8), 134.3 
(CH-15), 149.5 (qC-10), 151.4 (qC-11), 160.7 (qC-4), 164.2 (qC-2); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C22H25BrNO: 398.1120; found: 398.1135.  
4-(2-Bromophenoxy)-6-methoxyquinoline (80) 
Yellow sticky oil; yield: 599 mg (70%); IR (NaCl): ν 3392 
(C-H stretch), 1596 (aromatic C-C stretch), 1467 (aromatic C-C 
stretch), 1365 (C-N stretch), 1262 (C-O stretch), 1223 (C-O 
stretch), 778 (C-Br stretch) cm-1; 1H-NMR (300 MHz, CDCl3) 
δ: 3.98 (s, 3H, CH3-17), 6.40 (d, J = 5.1 Hz, 1H, CH-3), 7.16–
7.29 (m, 2H, CH-12, CH-14), 7.37–7.47 (m, 2H, CH-8, CH-13), 7.64 (d, J = 2.8 Hz, 
1H, CH-6), 7.73 (dd, J = 8.0, 1.5 Hz, 1H, CH-15), 8.01 (d, J = 9.2 Hz, 1H, CH-9), 8.54 
(d, J = 5.1 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 55.7 (CH3-17), 99.4 (CH-6), 
104.2 (CH-3), 116.4 (qC-16), 121.8 (qC-5), 122.9 (CH-8), 123.2 (CH-12), 127.2 
(CH-14), 129.2 (CH-13), 130.7 (CH-9), 134.3 (CH-15), 145.9 (qC-10), 148.4 (CH-2), 
151.3 (qC-11), 157.8 (qC-7), 159.7 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C16H13BrNO2: 330.0130; found: 330.0127.  
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4-(2-Bromophenoxy)-7-methoxyquinoline (81) 
Pale yellow solid; yield: 380 mg (74%); m.p. = 99–100 °C; IR 
(NaCl): ν 3388 (C-H stretch), 1622 (aromatic C-C stretch), 
1428 (aromatic C-C stretch), 1315 (C-N stretch), 1227 (C-O 
stretch), 665 (C-Br stretch) cm-1; 1H-NMR (300 MHz, CDCl3) 
δ: 3.98 (s, 3H, CH3-17), 6.30 (d, J = 5.2 Hz, 1H, CH-3), 7.15–
7.29 (m, 3H, CH-7, CH-12, CH-14), 7.36–7.47 (m, 2H, CH-9, CH-13), 7.72 (dd, J = 
7.9, 1.5 Hz, 1H, CH-15), 8.29 (d, J = 9.2 Hz, 1H, CH-6), 8.59 (d, J = 5.2 Hz, 1H, 
CH-2); 13C-NMR 75 MHz, CDCl3) δ: 55.5 (CH3-17), 102.4 (CH-3), 107.3 (CH-9), 
115.8 (qC-5), 116.3 (qC-16), 119.2 (CH-7), 123.1 (CH-6), 123.2 (CH-12), 127.1 
(CH-14), 129.1 (CH-13), 134.2 (CH-15), 151.2 (qC-11), 151.5 (CH-2), 151.8 (qC-10), 
160.7 (qC-4), 161.3 (qC-8); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C16H13BrNO2: 
330.0130; found: 330.0128.  
4-(2-Bromophenoxy)-6-(trifluoromethyl)quinoline (82) 
Off-white solid; yield: 254 mg (80%); m.p. = 67–69 °C; IR 
(NaCl): ν 3069 (C-H stretch), 1570 (aromatic C-C stretch), 
1467 (aromatic C-C stretch), 1316 (C-N stretch), 1224 (C-O 
stretch), 1126 (C-F stretch), 739 (C-Br stretch) cm-1; 1H-NMR 
(300 MHz, CDCl3) δ: 6.47 (d, J = 5.2 Hz, 1H, CH-3), 7.21–
7.32 (m, 2H, CH-12, CH-14), 7.46 (ddd, J = 8.1, 7.3, 1.6 Hz, 1H, CH-13), 7.75 (dd, J 
= 7.9, 1.3 Hz, 1H, CH-15), 7.95 (dd, J = 8.9, 2.1 Hz, 1H, CH-8), 8.22 (d, J = 8.9 Hz, 
1H, CH-9), 8.76 (s, 1H, CH-6), 8.77 (d, J = 5.2 Hz, 1H, CH-2); 13C-NMR (125 MHz, 
CDCl3) δ: 104.4 (CH-3), 116.4 (qC-16), 120.2 (qC-5), 120.3 (q, 3J(C,F) = 5 Hz, CH-6), 
123.4 (CH-12), 124.1 (q, 1J(C,F) = 272 Hz, qC-17), 126.0 (q, 
3J(C,F) = 3 Hz, CH-8), 
127.8 (CH-14), 128.2 (q, 2J(C,F) = 33 Hz, qC-7), 129.4 (CH-13), 130.3 (CH-9), 134.5 
(CH-15), 150.6 (qC-11), 150.7 (qC-10), 153.2 (CH-2), 161.3 (qC-4); 19F-NMR (282 
MHz, CDCl3) δ: -62 (CF3-17); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C16H10BrF3NO: 367.9898; found: 367.9894.  
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4-(2-Bromophenoxy)-6-fluoroquinoline (83) 
Pale yellow solid; yield: 344 mg (65%); m.p. = 75–79 °C; IR 
(NaCl): ν 3422 (C-H stretch), 1630 (aromatic C-C stretch), 1262 
(C-N stretch), 1222 (C-O stretch), 1177 (C-F stretch), 657 (C-Br 
stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 6.43 (d, J = 5.1 
Hz, 1H, CH-3), 7.19–7.24 (m, 1H, CH-14), 7.25 (d, J = 8.7 Hz, 
1H, CH-12), 7.44 (t, J = 7.4 Hz, 1H, CH-13), 7.54 (td, J = 8.7, 2.8 Hz, 1H, CH-8), 
7.73 (d, J = 9.9 Hz, 1H, CH-15), 8.02 (dd, 3J(H,F) = 9.3, 
4J(H,H) = 2.8 Hz, 1H, CH-6), 
8.12 (dd, 3J(H,H) = 9.2, 
4J(H,F) = 5.2 Hz, 1H, CH-9), 8.64 (d, J = 5.1 Hz, 1H, CH-2); 
13C-NMR (75 MHz, CDCl3) δ: 104.0 (CH-3), 105.7 (d, 2J(C,F) = 24 Hz, CH-6), 116.3 
(qC-16), 120.4 (d, 2J(C,F) = 26 Hz, CH-8), 121.7 (d, 
3J(C,F) = 10 Hz, qC-5), 123.3 
(CH-12), 127.5 (CH-14), 129.3 (CH-13), 131.7 (d, 3J(C,F) = 10 Hz, CH-9), 134.4 
(CH-15), 146.9 (qC-10), 150.3 (d, 6J(C,F) = 3 Hz, CH-2), 150.8 (qC-11), 160.3 (d, 
4J(C,F) 
= 5 Hz, qC-4), 160.4 (d, 1J(C,F) = 248 Hz, qC-7); 
19F-NMR (282 MHz, CDCl3) δ: -113 
(CF-7); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H10BrFNO: 317.9930; found: 
317.9917.  
4-(2-Bromophenoxy)-6,7-dimethoxyquinoline (111) 
Yellow solid; yield: 294 mg (91%); m.p. = 89–91 °C; IR 
(NaCl): ν 3373 (C-H stretch), 2932 (C-H stretch), 1572 
(aromatic C-C stretch), 1467 (aromatic C-C stretch), 1349 
(C-N stretch), 1250 (C-O stretch), 1225 (C-O stretch), 667 
(C-Br stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 4.07 (s, 
6H, CH3-17, CH3-18), 6.33 (d, J = 5.2 Hz, 1H, CH-3), 7.16–7.29 (m, 2H, CH-12, 
CH-14), 7.38–7.48 (m, 2H, CH-9, CH-13), 7.61 (s, 1H, CH-6), 7.73 (dd, J = 8.0, 1.5 
Hz, 1H, CH-15), 8.50 (d, J = 5.2 Hz, 1H, CH-2); 13C-NMR 75 MHz, CDCl3) δ: 56.2 
(CH3-17, CH3-18), 99.6 (CH-6), 103.0 (CH-3), 108.0 (CH-9), 115.8 (qC-5), 116.3 
(qC-16), 123.2 (CH-12), 127.1 (CH-14), 129.1 (CH-13), 134.3 (CH-15), 147.1 
(qC-10), 148.8 (CH-2), 149.7 (qC-7), 151.4 (qC-11), 152.9 (qC-8), 159.5 (qC-4); 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C17H15BrNO3: 360.0235; found: 360.0225.  
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4-(2-Bromophenoxy)-2-phenylquinoline (112) 
Pale yellow solid; yield: 185 mg (79%); m.p. = 112–113 °C; IR 
(NaCl): ν 3583 (C-H stretch), 3291 (C-H stretch), 1596 
(aromatic C-C stretch), 1470 (aromatic C-C stretch), 1353 (C-N 
stretch), 1225 (C-O stretch), 667 (C-Br stretch) cm-1; 1H-NMR 
(300 MHz, CDCl3) δ: 6.87 (s, 1H, CH-3), 7.15–7.31 (m, 2H, 
CH-12, CH-14), 7.35–7.51 (m, 4H, CH-13, CH-19, CH-20, CH-21), 7.58 (t, J = 7.5 
Hz, 1H, CH-7), 7.68–7.86 (m, 2H, CH-8, CH-15), 7.87–8.02 (m, 2H, CH-18, CH-22), 
8.18 (d, J = 8.4 Hz, 1H, CH-9), 8.39 (d, J = 8.1 Hz, 1H, CH-6); 13C-NMR (75 MHz, 
CDCl3) δ: 101.9 (CH-3), 116.3 (qC-16), 120.1 (qC-5), 121.8 (CH-6), 123.0 (CH-12), 
126.0 (CH-7), 127.2 (CH-14), 127.5 (CH-18,CH-22), 128.7 (CH-19,CH-21), 129.2 
(CH-13), 129.35 (CH-20), 129.41 (CH-9), 130.4 (CH-8), 134.4 (CH-15), 139.8 
(qC-17), 149.9 (qC-10), 151.4 (qC-11), 158.6 (qC-2), 161.3 (qC-4); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C21H15BrNO: 376.0337; found: 376.0323. 
4-((2-Bromophenyl)thio)quinoline (113) 
Off-white solid; yield: 226 mg (78%); m.p. = 72–73 °C; IR (NaCl): 
ν 3059 (C-H stretch), 1560, 1496 (aromatic C-C stretch), 831 (C-S 
stretch), 755 (C-Br stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 
6.83 (d, J = 4.7 Hz, 1H, CH-3), 7.27-7.32 (m, 1H, CH-14), 
7.32-7.38 (m, 1H, CH-13), 7.49 (dd, J = 7.2, 2.2 Hz, 1H, CH-12), 
7.60 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H, CH-7), 7.72-7.80 (m, 2H, CH-8, CH-15), 8.12 (dd, 
J = 8.5, 0.7 Hz, 1H, CH-9), 8.23 (dd, J = 8.4, 0.9 Hz, 1H, CH-6), 8.65 (d, J = 4.7 Hz, 
1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 119.4 (CH-3), 123.9 (CH-6), 126.4 (qC-5), 
126.8 (CH-7), 128.6 (CH-13), 129.0 (qC-16), 130.0 (CH-8), 130.1 (CH-9), 130.7 
(CH-14), 132.1 (qC-11), 134.1 (CH-15), 136.0 (CH-12), 145.6 (qC-4), 148.0 (qC-10), 
149.6 (CH-2); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H11BrNS: 315.9796; 
found: 315.9795.   
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3.16. General Procedure for Synthesis of 4-Phenoxy Quinoline Substrates – 
DMAP Method 
A mixture of 4-chloroquinoline (1 equiv.), the substituted 2-bromophenol (1.5 equiv.) 
and 4-dimethylaminopyridine (3 equiv.) in toluene (1.5 mL/mmol) was stirred at 130 
°C until the reaction was completed as evident by TLC (hexane/EtOAc 8:2). The 
cooled reaction mixture was diluted with 10% aq. NaOH (0.5 mL/mmol) and stirred 
at room temperature for 1 h. The aqueous phase was extracted with DCM (3 × 
1.5 mL/mmol). The combined organic layers were washed with 3M NaOH (3 × 
1 mL/mmol), 1M HCl (2 × 1 mL/mmol), water (1 mL/mmol) and brine (1 mL/mmol), 
dried over MgSO4, filtered and concentrated in vacuo. The crude mixture was purified 
by column chromatography over silica gel using hexane/EtOAc (8:2) as eluent. 
4-(2-Bromo-6-fluorophenoxy)quinoline (84) 
Pale yellow solid; yield: 318 mg (72%); m.p. = 118–119 °C; IR 
(NaCl): ν 3064 (C-H stretch), 1502 (aromatic C-C stretch), 1471 
(aromatic C-C stretch), 1305 (C-N stretch), 1271 (C-O stretch), 
1042 (C-F stretch), 665 (C-Br stretch) cm-1; 1H-NMR (300 MHz, 
CDCl3) δ: 6.39 (d, J = 5.1 Hz, 1H, CH-3), 7.15–7.30 (m, 2H, 
CH-13, CH-14), 7.47–7.54 (m, 1H, CH-15), 7.63 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H, CH-7), 
7.79 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H, CH-8), 8.13 (d, J = 8.5 Hz, 1H, CH-9), 8.46 (dd, J 
= 8.3, 1.1 Hz, 1H, CH-6), 8.69 (d, J = 5.0 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) 
δ: 102.5 (CH-3), 116.5 (d, 2J(C,F) = 19 Hz, CH-13), 118.3 (qC-16), 120.6 (qC-5), 121.9 
(CH-6), 126.4 (CH-7), 127.7 (d, 3J(C,F) = 8 Hz, CH-14), 129.1 (CH-9), 129.2 (CH-15), 
130.2 (CH-8), 139.3 (d, 2J(C,F) = 14 Hz, qC-11), 149.8 (qC-10), 150.9 (CH-2), 155.6 
(d, 1J(C,F) = 255 Hz, qC-12), 159.8 (qC-4); 
19F-NMR (282 MHz, CDCl3) δ: -124 
(CF-12); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H10BrFNO: 317.9930; found: 
317.9921.  
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4-(2-Bromo-5-chlorophenoxy)quinoline (85) 
White solid; yield: 290 mg (89%); m.p. = 79–81 °C; IR (NaCl): 
ν 3370 (C-H stretch), 1562 (aromatic C-C stretch), 1464 
(aromatic C-C stretch), 1305 (C-N stretch), 1252 (C-O stretch), 
765 (C-Cl stretch), 665 (C-Br stretch) cm-1; 1H-NMR (300 MHz, 
CDCl3) δ: 6.48 (d, J = 5.1 Hz, 1H, CH-3), 7.16–7.29 (m, 2H, 
CH-14, CH-16), 7.57–7.69 (m, 2H, CH-7, CH-13), 7.79 (ddd, J = 8.5, 6.9, 1.5 Hz, 1H, 
CH-8), 8.13 (d, J = 8.6 Hz, 1H, CH-9), 8.36 (dd, J = 8.4, 0.9 Hz, 1H, CH-6), 8.72 (d, 
J = 5.1 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 104.1 (CH-3), 114.4 (qC-12), 
120.9 (qC-5), 121.7 (CH-6), 123.3 (CH-16), 126.5 (CH-7), 127.4 (CH-14), 129.2 
(CH-9), 130.4 (CH-8), 134.5 (qC-15), 134.8 (CH-13), 149.9 (qC-10), 151.0 (CH-2), 
151.9 (qC-11), 160.1 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C15H10BrClNO: 333.9634; found: 333.9622.  
Methyl 4-bromo-3-(quinolin-4-yloxy)benzoate (86) 
Off white solid; yield: 258 mg (62%); m.p. = 87–89 °C; IR 
(NaCl): ν 3586 (C-H stretch), 2950 (C-H stretch), 1724 (ester 
C=O stretch), 1565 (aromatic C-C stretch), 1502 (aromatic 
C-C stretch), 1392 (C-N stretch), 1294 (C-O stretch), 1241 
(C-O stretch), 765 (C-Br stretch) cm-1; 1H-NMR (300 MHz, 
CDCl3) δ: 3.92 (s, 3H, CH3-18), 6.43 (d, J = 5.1 Hz, 1H, CH-3), 7.63 (ddd, J = 8.2, 
6.9, 1.1 Hz, 1H, CH-7), 7.76–7.90 (m, 4H, CH-8, CH-13, CH-14, CH-16), 8.13 (d, J 
= 8.5 Hz, 1H, CH-9), 8.40 (dd, J = 8.3, 0.9 Hz, 1H, CH-6), 8.70 (d, J = 5.1 Hz, 1H, 
CH-2); 13C-NMR (75 MHz, CDCl3) δ: 52.6 (CH3-18), 103.9 (CH-3), 121.0 (qC-5), 
121.7 (CH-6), 122.0 (qC-12), 123.9 (CH-16), 126.5 (CH-7), 128.0 (CH-14), 129.2 
(CH-9), 130.4 (CH-8), 131.6 (qC-15), 134.5 (CH-13), 149.9 (qC-10), 151.0 (CH-2), 
151.4 (qC-11), 160.3 (qC-4), 165.4 (qC-17); HRMS (ESI-TOF) m/z: [M+H]+ calcd. 
for C17H13BrNO3: 358.0079; found: 358.0089.  
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4-(2-Bromo-4-methoxyphenoxy)quinoline (87) 
Beige solid; yield: 304 mg (56%); m.p. = 184–185 °C; IR 
(NaCl): ν 3062 (C-H stretch), 2835 (C-H stretch), 1595 
(aromatic C-C stretch), 1487 (aromatic C-C stretch), 1392 
(C-N stretch), 1212 (C-O stretch), 765 (C-Br stretch) cm-1; 
1H-NMR (300 MHz, CDCl3) δ: 3.86 (s, 3H, CH3-17), 6.38 (d, 
J = 5.2 Hz, 1H, CH-3), 6.96 (dd, J = 8.9, 2.9 Hz, 1H, CH-13), 7.17 (d, J = 8.9 Hz, 1H, 
CH-12), 7.24 (d, J = 2.9 Hz, 1H, CH-15), 7.60 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H, CH-7), 
7.77 (ddd, J = 8.5, 6.9, 1.5 Hz, 1H, CH-8), 8.11 (d, J = 8.5 Hz, 1H, CH-9), 8.43 (dd, J 
= 8.3, 0.9 Hz, 1H, CH-6), 8.67 (d, J = 5.0 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) 
δ: 55.9 (CH3-17), 103.3 (CH-3), 114.9 (CH-13), 116.7 (qC-16), 118.9 (CH-15), 121.0 
(qC-5), 121.9 (CH-6), 123.7 (CH-12), 126.2 (CH-7), 129.0 (CH-9), 130.1 (CH-8), 
144.5 (qC-11), 149.7 (qC-10), 151.0 (CH-2), 157.9 (qC-14), 161.3 (qC-4); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C16H13BrNO2: 330.0130; found: 330.0125. 
4-((1-Bromonaphthalen-2-yl)oxy)quinoline (88) 
Off-white solid; yield: 318 mg (61%); m.p. = 197–200 °C; IR 
(NaCl): ν 3062 (C-H stretch), 1594 (aromatic C-C stretch), 
1568 (aromatic C-C stretch), 1499 (aromatic C-C stretch), 
1392 (C-N stretch), 1253 (C-O stretch), 764 (C-Br stretch) 
cm-1; 1H-NMR (300 MHz, CDCl3) δ: 6.42 (d, J = 5.1 Hz, 1H, 
CH-3), 7.36 (d, J = 8.8 Hz, 1H, CH-12), 7.55–7.72 (m, 3H, CH-7, CH-16, CH-17), 
7.80 (ddd, J = 8.5, 6.9, 1.5 Hz, 1H, CH-8), 7.92 (d, J = 8.1 Hz, 1H, CH-15), 7.93 (d, J 
= 8.8 Hz, 1H, CH-13), 8.14 (d, J = 8.5 Hz, 1H, CH-9), 8.33 (d, J = 8.5 Hz, 1H, CH-18), 
8.51 (dd, J = 8.3, 1.0 Hz, 1H, CH-6), 8.56 (d, J = 5.1 Hz, 1H, CH-2); 13C-NMR (75 
MHz, CDCl3) δ: 103.9 (CH-3), 115.2 (qC-20), 121.1 (qC-5), 121.3 (CH-12), 122.0 
(CH-6), 126.3 (CH-7), 126.6 (CH-16), 127.1 (CH-18), 128.2 (CH-17), 128.4 (CH-15), 
129.1 (CH-9), 129.8 (CH-13), 130.3 (CH-8), 132.4 (qC-14), 133.2 (qC-19), 149.0 
(qC-11), 149.8 (qC-10), 151.1 (CH-2), 160.8 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C19H13BrNO: 350.0181; found: 350.0178.  
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3-Bromo-4-(quinolin-4-yloxy)benzaldehyde (114) 
Pale yellow solid; yield: 215 mg (79%); m.p. = 139–141 °C; 
IR (NaCl): ν 3063, 2849 (C-H stretch), 1703 (aldehyde C=O 
stretch), 1566, 1503 (aromatic C-C stretch), 1392 (C-N 
stretch), 1257 (C-O stretch), 765 (C-Br stretch) cm-1; 1H-NMR 
(300 MHz, CDCl3) δ: 6.59 (d, J = 5.0 Hz, 1H, CH-3), 7.29 (d, 
J = 8.3 Hz, 1H, CH-12), 7.58-7.68 (m, 1H, CH-7), 7.81 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H, 
CH-8), 7.90 (dd, J = 8.3, 1.9 Hz, 1H, CH-13), 8.16 (d, J = 8.5 Hz, 1H, CH-9), 8.22-8.37 
(m, 2H, CH-6, CH-15), 8.76 (d, J = 4.9 Hz, 1H, CH-2), 9.99 (s, 1H, CH-17); 13C-NMR 
(75 MHz, CDCl3) δ: 105.4 (CH-3), 116.7 (qC-16), 121.1 (qC-5), 121.7 (CH-6), 122.2 
(CH-12), 126.8 (CH-7), 129.3 (CH-9), 130.53 (CH-13), 130.56 (CH-8), 134.7 
(qC-14), 135.6 (CH-15), 150.1 (qC-10), 151.0 (CH-2), 156.5 (qC-11), 159.5 (qC-4), 
189.4 (CH-17); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C16H11BrNO2: 327.9973; 
found: 327.9970.  
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3.17. General Procedure for Pd-Catalysed Intramolecular Direct Arylation 
A mixture of the 4-(2-bromophenoxy)quinoline substrate (1 equiv.), Pd(OAc)2 (2-5 
mol%), and anhydrous Cs2CO3 (2 equiv.) in anhydrous NMP (1.5 mL/mmol) was 
stirred at 135 °C in a sealed reaction tube. The reaction progress was monitored by 
periodically sampling the reaction mixture for 1H-NMR analysis in CDCl3. Once 
complete, the cooled reaction mixture was diluted with DCM, filtered through a short 
plug of Celite and concentrated in vacuo. The crude mixture was purified by column 
chromatography over silica gel using DCM/EtOAc (99:1–95:5) as eluent. 
Benzofuro[3,2-c]quinoline (70)[37]  
2 mol% Pd(OAc)2 used. White solid; yield: 68 mg (95%); m.p. = 
132–135 °C (lit. 135–138 °C); IR (NaCl): ν 3369 (C-H stretch), 
1566 (aromatic C-C stretch), 1510 (aromatic C-C stretch), 1399 
(C-N stretch), 1190 (C-O stretch) cm-1; 1H-NMR (300 MHz, 
CDCl3) δ: 7.44–7.58 (m, 2H, CH-13, CH-14), 7.65–7.83 (m, 3H, CH-7, CH-8, 
CH-12), 8.12 (dd, J = 7.2, 0.9 Hz, 1H, CH-15), 8.28 (d, J = 8.4 Hz, 1H, CH-9), 8.44 
(dd, J = 8.1, 1.0 Hz, 1H, CH-6), 9.51 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 
112.1 (CH-12), 116.3 (qC-3), 117.2 (qC-5), 120.6 (CH-15), 120.8 (CH-6), 122.7 
(qC-16), 124.1 (CH-14), 127.0 (CH-7), 127.2 (CH-13), 129.3 (CH-8), 129.9 (CH-9), 
144.4 (CH-2), 147.4 (qC-10), 156.0 (qC-11), 157.5 (qC-4); HRMS (ESI-TOF) m/z: 
[M+H]+ calcd. for C15H10NO: 220.0762; found: 220.0755. 
Spectral data were consistent with those reported in the literature. 
8-Fluorobenzofuro[3,2-c]quinoline (89)[37] 
2 mol% Pd(OAc)2 used. White solid; yield: 87 mg (91%); m.p. 
= 163–164 °C (lit. 162–163 °C); IR (NaCl): ν 3368 (C-H 
stretch), 1565 (aromatic C-C stretch), 1479 (aromatic C-C 
stretch), 1319 (C-N stretch), 1247 (C-O stretch), 1146 (C-F 
stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 7.21–7.33 (m, 1H, CH-13), 7.65–7.87 
(m, 4H, CH-7, CH-8, CH-12, CH-15), 8.28 (d, J = 8.4 Hz, 1H, CH-9), 8.41 (dd, J = 
8.1, 1.0 Hz, 1H, CH-6), 9.45 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 106.7 (d, 
2J(C,F) = 26 Hz, CH-15), 112.9 (d, 
3J(C,F) = 9 Hz, CH-12), 114.7 (d, 
2J(C,F) = 26 Hz, 
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CH-13), 116.1 (d, 4J(C,F) = 4 Hz, qC-3), 117.0 (qC-5), 120.8 (CH-6), 123.6 (d, 
3J(C,F) = 
11 Hz, qC-16), 127.2 (CH-7), 129.6 (CH-8), 129.9 (CH-9), 144.2 (CH-2), 147.5 
(qC-10), 151.9 (qC-11), 158.6 (qC-4), 159.7 (d, 1J(C,F) = 241 Hz, qC-14); 
19F-NMR 
(282 MHz, CDCl3) δ: -118 (CF-14); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C15H9FNO: 238.0668; found: 238.0659.  
Spectral data were consistent with those reported in the literature.  
9-Fluorobenzofuro[3,2-c]quinoline (90)[76] 
2 mol% Pd(OAc)2 used. White solid; yield: 64 mg (88%); m.p. = 
149–150 °C (lit. 148–150 °C); IR (NaCl): ν 3052 (C-H stretch), 
1564 (aromatic C-C stretch), 1512 (aromatic C-C stretch), 1396 
(C-N stretch), 1254 (C-O stretch), 1134 (C-F stretch) cm-1; 
1H-NMR (300 MHz, CDCl3) δ: 7.22 (ddd, 3J(H,F) = 8.9, 3J(H,H) = 6.9, 4J(H,H) = 2.2 Hz, 
1H, CH-14), 7.45 (dd, 3J(H,F) = 8.6, 
4J(H,H) = 2.2 Hz, 1H, CH-12), 7.63–7.85 (m, 2H, 
CH-7, CH-8), 8.00 (dd, 3J(H,H) = 8.6, 
4J(H,F) = 5.3 Hz, 1H, CH-15), 8.25 (d, J = 8.3 Hz, 
1H, CH-9), 8.36 (dd, J = 8.1, 1.1 Hz, 1H, CH-6), 9.43 (s, 1H, CH-2); 13C-NMR 
(75 MHz, CDCl3) δ: 100.3 (d, 2J(C,F) = 27 Hz, CH-12), 112.3 (d, 2J(C,F) = 24 Hz, 
CH-14), 115.8 (qC-3), 117.0 (qC-5), 118.9 (d, 4J(C,F) = 2 Hz, qC-16), 120.6 (CH-6), 
121.2 (d, 3J(C,F) = 10 Hz, CH-15), 127.2 (CH-7), 129.4 (CH-8), 129.8 (CH-9), 143.9 
(CH-2), 147.1 (qC-10), 156.1 (d, 3J(C,F) = 14 Hz, qC-11), 158.1 (d, 
5J(C,F) = 3 Hz, qC-4), 
162.2 (d, 1J(C,F) = 247 Hz, qC-13); 
19F-NMR (282 MHz, CDCl3) δ: -112 (CF-13); 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H9FNO: 238.0668; found: 238.0668.  
Spectral data were consistent with those reported in the literature.  
10-Fluorobenzofuro[3,2-c]quinoline (91)[37] 
2 mol% Pd(OAc)2 used. White solid; yield: 104 mg (93%); m.p. 
= 156–157 °C (lit. 157–158 °C); IR (NaCl): ν 3368 (C-H stretch), 
1564 (aromatic C-C stretch), 1496 (aromatic C-C stretch), 1347 
(C-N stretch), 1200 (C-O stretch), 1189 (C-F stretch) cm-1; 
1H-NMR (300 MHz, CDCl3) δ: 7.27–7.35 (m, 1H, CH-13), 7.42 (td, 3J(H,H) = 8.0, 4J(H,F) 
= 4.4 Hz, 1H, CH-14), 7.73 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H, CH-7), 7.79–7.92 (m, 2H, 
CH-8, CH-15), 8.29 (d, J = 8.2 Hz, 1H, CH-9), 8.49 (dd, J = 8.1, 0.9 Hz, 1H, CH-6), 
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9.50 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 113.7 (d, 2J(C,F) = 16 Hz, CH-13), 
116.0 (qC-3), 116.1 (d, 4J(C,F) = 4 Hz, CH-15), 117.0 (qC-5), 120.8 (CH-6), 124.8 (d, 
3J(C,F) = 6 Hz, CH-14), 126.2 (d, 
3J(C,F) = 3 Hz, qC-16), 127.3 (CH-7), 129.7 (CH-8), 
129.8 (CH-9), 142.7 (d, 2J(C,F) = 11 Hz, qC-11), 144.3 (CH-2), 147.7 (qC-10), 148.3 
(d, 1J(C,F) = 251 Hz, qC-12), 157.8 (qC-4); 
19F-NMR (282 MHz, CDCl3) δ: -135 
(CF-12); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H9FNO: 238.0668; found: 
238.0662.  
Spectral data were consistent with those reported in the literature.  
8-Chlorobenzofuro[3,2-c]quinoline (92)[37] 
2 mol% Pd(OAc)2 used. White solid; yield: 71 mg (93%); m.p. 
= 187–189 °C (lit. 189–190 °C); IR (NaCl): ν 2917 (C-H 
stretch), 1564 (C aromatic C-C stretch), 1511 (aromatic C-C 
stretch), 1395 (C-N stretch), 1194 (C-O stretch), 871 (C-Cl 
stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 7.51 (dd, J = 8.8, 2.2 Hz, 1H, CH-13), 
7.69 (dd, J = 8.8, 0.4 Hz, 1H, CH-12), 7.72 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H, CH-7), 7.82 
(ddd, J = 8.5, 7.0, 1.5 Hz, 1H, CH-8), 8.08 (dd, J = 2.2, 0.4 Hz, 1H, CH-15), 8.28 (d, 
J = 8.2 Hz, 1H, CH-9), 8.41 (dd, J = 8.2, 0.9 Hz, 1H, CH-6), 9.46 (s, 1H, CH-2); 
13C-NMR (100 MHz, CDCl3) δ: 113.1 (CH-12), 115.5 (qC-3), 117.0 (qC-5), 120.5 
(CH-15), 120.8 (CH-6), 124.1 (qC-16), 127.28 (CH-7), 127.34 (CH-13), 129.75 
(qC-14), 129.78 (CH-8), 130.0 (CH-9), 144.2 (CH-2), 147.6 (qC-10), 154.2 (qC-11), 
158.2 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H9ClNO: 254.0373; 
found: 254.0370. 
Spectral data were consistent with those reported in the literature. 
9-Chlorobenzofuro[3,2-c]quinoline (93) 
2 mol% Pd(OAc)2 used. White solid; yield: 86 mg (79%); m.p. = 
198–199 °C; IR (NaCl): ν 3047 (C-H stretch), 1562 (aromatic 
C-C stretch), 1508 (aromatic C-C stretch), 1338 (C-N stretch), 
1049 (C-O stretch), 755 (C-Cl stretch) cm-1; 1H-NMR (300 MHz, 
CDCl3) δ: 7.47 (dd, J = 8.3, 1.8 Hz, 1H, CH-14), 7.66–7.87 (m, 3H, CH-7, CH-8, 
CH-12), 8.00 (d, J = 8.3 Hz, 1H, CH-15), 8.27 (d, J = 8.4 Hz, 1H, CH-9), 8.40 (d, J 
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= 8.0 Hz, 1H, CH-6), 9.46 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 112.8 
(CH-12), 115.7 (qC-3), 117.0 (qC-5), 120.7 (CH-6), 121.1 (CH-15), 121.4 (qC-16), 
124.8 (CH-14), 127.2 (CH-7), 129.6 (CH-8), 129.9 (CH-9), 132.9 (qC-13), 144.1 
(CH-2), 147.5 (qC-10), 156.0 (qC-11), 157.8 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C15H9ClNO: 254.0373; found: 254.0363. 
8-Nitrobenzofuro[3,2-c]quinoline (94) 
2 mol% Pd(OAc)2 used. Orange solid; yield: 28 mg (46%); 
m.p. >250 °C; IR (NaCl): ν 3030 (C-H stretch), 1528 
(aromatic C-C stretch), 1397 (C-N stretch), 1344 (N-O 
stretch), 1200 (C-O stretch) cm-1; 1H-NMR (300 MHz, CDCl3) 
δ: 7.77 (ddd, J = 8.1, 7.2, 1.0 Hz, 1H, CH-7), 7.84–7.91 (m, 2H, CH-8, CH-12), 8.32 
(d, J = 8.5 Hz, 1H, CH-9), 8.41–8.52 (m, 2H, CH-6, CH-13), 9.02 (d, J = 2.3 Hz, 1H, 
CH-15), 9.56 (s, 1H, CH-2); 13C-NMR (100 MHz, CDCl3) δ: 112.6 (CH-12), 115.4 
(qC-3), 116.8 (qC-5), 117.1 (CH-15), 120.8 (CH-6), 123.0 (CH-13), 123.6 (qC-16), 
127.8 (CH-7), 130.1 (CH-9), 130.5 (CH-8), 144.1 (CH-2), 144.9 (qC-14), 148.1 
(qC-10), 158.6 (qC-11), 159.3 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C15H9N2O3: 265.0613; found: 265.0611.  
Methyl benzofuro[3,2-c]quinoline-9-carboxylate (95) 
2 mol% Pd(OAc)2 used. Beige solid; yield: 43 mg (56%); m.p. 
= 192–193 °C; IR (NaCl): ν 3402 (C-H stretch), 1717 (C=O 
stretch), 1565 (aromatic C-C stretch), 1434 (aromatic C-C 
stretch), 1397 (C-N stretch), 1281 (C-O stretch), 1234 (C-O 
stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 4.00 (s, 3H, 
CH3-18), 7.66–7.74 (m, 1H, CH-7), 7.81 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H, CH-8), 8.09 
(d, J = 7.8 Hz, 1H, CH-15), 8.16 (dd, J = 8.2, 1.3 Hz, 1H, CH-14), 8.26 (d, J = 8.4 Hz, 
1H, CH-9), 8.36–8.43 (m, 2H, CH-6, CH-12), 9.46 (s, 1H, CH-2); 13C-NMR (75 MHz, 
CDCl3) δ: 52.5 (CH3-18), 113.6 (CH-12), 115.5 (qC-3), 116.9 (qC-5), 120.2 (CH-15), 
121.0 (CH-6), 125.5 (CH-14), 126.8 (qC-16), 127.3 (CH-7), 129.0 (qC-13), 129.9 
(CH-9), 130.0 (CH-8), 144.5 (CH-2), 147.8 (qC-10), 155.4 (qC-11), 159.0 (qC-4), 
166.6 (qC-17); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C17H12NO3: 278.0817; 
found: 278.0811. 
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8-Methylbenzofuro[3,2-c]quinoline (96)[37] 
2 mol% Pd(OAc)2 used. White solid; yield: 62 mg (71%); m.p. 
= 145–148 °C (lit. 149–150 °C); IR (NaCl): ν 2917 (C-H 
stretch), 1564 (C aromatic C-C stretch), 1510 (C aromatic C-C 
stretch), 1321 (C-N stretch), 1192 (C-O stretch) cm-1; 1H-NMR 
(300 MHz, CDCl3) δ: 2.57 (s, 3H, CH3-17), 7.32–7.39 (ddd, J = 8.5, 1.8, 0.5 Hz, 1H, 
CH-13), 7.61–7.73 (m, 2H, CH-7, CH-12), 7.78 (ddd, J = 8.5, 6.9, 1.6 Hz, 1H, CH-8), 
7.89–7.92 (m, 1H, CH-15), 8.26 (d, J = 8.5 Hz, 1H, CH-9), 8.41 (dd, J = 8.1, 0.9 Hz, 
1H, CH-6), 9.47 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 21.4 (CH3-17), 111.5 
(CH-12), 116.2 (qC-3), 117.2 (qC-5), 120.5 (CH-15), 120.8 (CH-6), 122.6 (qC-16), 
126.8 (CH-7), 128.3 (CH-13), 129.1 (CH-8), 129.8 (CH-9), 133.7 (qC-14), 144.3 
(CH-2), 147.3 (qC-10), 154.3 (qC-11), 157.6 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C16H12NO: 234.0919; found: 234.0921. 
Spectral data were consistent with those reported in the literature. 
8-(tert-Butyl)benzofuro[3,2-c]quinoline (97)[37] 
2 mol% Pd(OAc)2 used. Pale yellow solid; yield: 25 mg 
(50%); m.p. = 97–100 °C (lit. 99–100 °C); IR (NaCl): ν 2962 
(C-H stretch), 1567 (aromatic C-C stretch), 1488 (aromatic 
C-C stretch), 1392 (C-N stretch), 1201 (C-O stretch) cm-1; 
1H-NMR (600 MHz, CDCl3) δ: 1.47 (s, 9H, CH3-18, CH3-19, CH3-20), 7.61 (dd, J = 
8.7, 2.0 Hz, 1H, CH-13), 7.67–7.72 (m, 2H, CH-7, CH-12), 7.79 (ddd, J = 8.4, 6.9, 1.5 
Hz, 1H, CH-8), 8.10 (d, J = 1.7 Hz, 1H, CH-15), 8.27 (d, J = 8.4 Hz, 1H, CH-9), 8.42 
(dd, J = 8.2, 1.0 Hz, 1H, CH-6), 9.52 (s, 1H, CH-2); 13C-NMR (150 MHz, CDCl3) δ: 
31.9 (CH3-18, CH3-19, CH3-20), 35.0 (qC-17), 111.4 (CH-12), 116.7 (qC-3), 116.9 
(CH-15), 117.3 (qC-5), 120.8 (CH-6), 122.3 (qC-16), 125.1 (CH-13), 126.9 (CH-7), 
129.2 (CH-8), 129.8 (CH-9), 144.4 (CH-2), 147.3 (qC-10), 147.4 (qC-14), 154.2 
(qC-11), 157.8 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C19H18NO: 
276.1388; found: 276.1377.  
Spectral data were consistent with those reported in the literature. 
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8-Methoxybenzofuro[3,2-c]quinoline (98)[38] 
2 mol% Pd(OAc)2 used. Off-white solid; yield: 32 mg (42%); 
m.p. = 165–167 °C (lit. 160–162 °C); IR (NaCl): ν 3350 (C-H 
stretch), 1570 (aromatic C-C stretch), 1486 (aromatic C-C 
stretch), 1330 (C-N stretch), 1186 (C-O stretch), 1164 (C-O 
stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 3.96 (s, 3H, CH3-17), 7.13 (dd, J = 9.0, 
2.6 Hz, 1H, CH-13), 7.54 (d, J = 2.6 Hz, 1H, CH-15), 7.59–7.85 (m, 3H, CH-7, CH-8, 
CH-12), 8.26 (d, J = 8.4 Hz, 1H, CH-9), 8.40 (dd, J = 8.1, 1.0 Hz, 1H, CH-6), 9.46 (s, 
1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 56.1 (CH3-17), 103.3 (CH-15), 112.6 
(CH-12), 115.5 (CH-13), 116.6 (qC-3), 117.3 (qC-5), 120.8 (CH-6), 123.3 (qC-16), 
127.0 (CH-7), 129.3 (CH-8), 129.8 (CH-9), 144.4 (CH-2), 147.3 (qC-10), 150.7 
(qC-11), 156.9 (qC-14), 158.1 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C16H12NO2: 250.0868; found: 250.0858.  
Spectral data were consistent with those reported in the literature. 
Naphtho[1',2':4,5]furo[3,2-c]quinoline (99) 
2 mol% Pd(OAc)2 used. Off-white solid; yield: 14 mg (17%); 
m.p. = 203–205 °C; IR (NaCl): ν 2919 (C-H stretch), 1562 
(aromatic C-C stretch), 1507 (aromatic C-C stretch), 1310 
(C-N stretch), 1223 (C-O stretch) cm-1; 1H-NMR (600 MHz, 
CDCl3) δ: 7.64 (ddd, J = 8.0, 6.9, 1.1 Hz, 1H, CH-16), 7.75 (ddd, J = 8.0, 6.9, 1.1 Hz, 
1H, CH-7), 7.79–7.85 (m, 2H, CH-8, CH-17), 7.94 (d, J = 8.9 Hz, 1H, CH-12), 8.02 
(d, J = 8.9 Hz, 1H, CH-13), 8.09 (d, J = 8.2 Hz, 1H, CH-15), 8.33 (d, J = 8.4 Hz, 1H, 
CH-9), 8.51 (dd, J = 8.4, 1.1 Hz, 1H, CH-6), 8.69 (d, J = 8.2 Hz, 1H, CH-18), 9.97 (s, 
1H, CH-2); 13C-NMR (150 MHz, CDCl3) δ: 112.7 (CH-12), 117.0 (qC-20), 117.3 
(qC-5), 117.7 (qC-3), 120.7 (CH-6), 124.2 (CH-18), 125.3 (CH-16), 127.2 (CH-7), 
127.7 (CH-17), 128.5 (qC-19), 128.8 (CH-13), 129.2 (CH-8), 129.4 (CH-15), 129.8 
(CH-9), 131.0 (qC-14), 145.1 (CH-2), 146.4 (qC-10), 154.1 (qC-11), 157.0 (qC-4); 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C19H12NO: 270.0919; found: 270.0916.  
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6-Methylbenzofuro[3,2-c]quinoline (100)[37] 
2 mol% Pd(OAc)2 used. Pale yellow solid; yield: 29 mg (78%); 
m.p. = 132–134 °C (lit. 132–133 °C); IR (NaCl): ν 3380 (C-H 
stretch), 1563 (aromatic C-C stretch), 1509 (aromatic C-C 
stretch), 1364 (C-N stretch), 1084 (C-O stretch) cm-1; 1H-NMR 
(300 MHz, CDCl3) δ: 3.16 (s, 3H, CH3-17), 7.41–7.69 (m, 3H, CH-7, CH-13, CH-14), 
7.72–7.79 (m, 2H, CH-8, CH-12), 8.10 (dd, J = 7.6, 2.1 Hz, 1H, CH-15), 8.18 (d, J = 
8.4 Hz, 1H, CH-9), 8.38 (dd, J = 8.1, 2.1 Hz, 1H, CH-6); 13C-NMR (75 MHz, CDCl3) 
δ: 24.3 (CH3-17), 112.1 (CH-12), 115.5 (qC-3), 116.2 (qC-5), 120.7 (CH-6), 121.8 
(CH-15), 123.5 (qC-16), 124.0 (CH-14), 126.1 (CH-7), 126.7 (CH-13), 128.9 (CH-9), 
129.4 (CH-8), 146.9 (qC-10), 154.8 (qC-2), 155.9 (qC-11), 157.5 (qC-4); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C16H12NO: 234.0919; found: 234.0915.  
Spectral data were consistent with those reported in the literature. 
6-Heptylbenzofuro[3,2-c]quinoline (101) 
2 mol% Pd(OAc)2 used. White solid; yield: 56 mg (70%); 
m.p. = 90–92 °C; IR (NaCl): ν 2917 (C-H stretch), 1559 
(aromatic C-C stretch), 1445 (aromatic C-C stretch), 
1363 (C-N stretch), 1202 (C-O stretch) cm-1; 1H-NMR 
(300 MHz, CDCl3) δ: 0.88 (t, J = 6.7 Hz, 3H, CH3-23), 1.22–1.64 (m, 8H, CH2-19, 
CH2-20, CH2-21, CH2-22), 1.95 (dt, J = 15.7, 7.7 Hz, 2H, CH2-18), 3.40 (t, J = 8.0 Hz, 
2H, CH2-17), 7.40–7.67 (m, 3H, CH-7, CH-13, CH-14), 7.69–7.79 (m, 2H, CH-8, 
CH-12), 8.00 (d, J = 7.3 Hz, 1H, CH-15), 8.19 (d, J = 8.4 Hz, 1H, CH-9), 8.35 (d, J = 
8.1 Hz, 1H, CH-6); 13C-NMR (75 MHz, CDCl3) δ: 14.1 (CH3-23), 22.7 (CH2-22), 28.6 
(CH2-18), 29.2 (CH2-20), 29.9 (CH2-19), 31.8 (CH2-21), 38.0 (CH2-17), 112.1 
(CH-12), 114.8 (qC-3), 116.2 (qC-5), 120.7 (CH-6), 121.8 (CH-15), 123.1 (qC-16), 
124.0 (CH-14), 126.0 (CH-7), 126.6 (CH-13), 129.1 (CH-9), 129.3 (CH-8), 146.9 
(qC-10), 155.9 (qC-11), 157.7 (qC-4), 159.0 (qC-2); HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C22H24NO: 318.1858; found: 318.1845.  
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2-Methoxybenzofuro[3,2-c]quinoline (102)[37] 
5 mol% Pd(OAc)2 used. Off-white solid; yield: 95 mg (84%); 
m.p. = 150–152 °C (lit. 150–153 °C); IR (NaCl): ν 2954 (C-H 
stretch), 1350 (C-H bend), 1514 (aromatic C-C stretch), 1468 
(aromatic C-C stretch), 1228 (C-N stretch), 1191 (C-O 
stretch), 1031 (C-O stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 3.96 (s, 3H, 
CH3-17), 7.28–7.53 (m, 4H, CH-6, CH-8, CH-13, CH-14), 7.64 (d, J = 8.1 Hz, 1H, 
CH-12), 7.97 (dd, J = 7.4, 0.8 Hz, 1H, CH-15), 8.08 (d, J = 9.2 Hz, 1H, CH-9), 9.23 
(s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 55.6 (CH3-17), 98.5 (CH-6), 111.9 
(CH-12), 116.4 (qC-3), 117.7 (qC-5), 120.6 (CH-15), 121.7 (CH-8), 122.8 (qC-16), 
123.9 (CH-14), 127.1 (CH-13), 131.3 (CH-9), 141.5 (CH-2), 143.3 (qC-10), 155.8 
(qC-11), 156.7 (qC-4), 158.2 (qC-7); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C16H12NO2: 250.0868; found: 250.0858.  
3-Methoxybenzofuro[3,2-c]quinoline (103) 
5 mol% Pd(OAc)2 used. Off-white solid; yield: 91 mg 
(81%); m.p. = 146–147 °C; IR (NaCl): ν 3022 (C-H 
stretch), 1345 (C-H bend), 1639 (aromatic C-C stretch), 
1452 (aromatic C-C stretch), 1324 (C-N stretch), 1242 
(C-O stretch), 1168 (C-O stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 3.97 (s, 3H, 
CH3-17), 7.31 (dd, J = 9.0, 2.3 Hz, 1H, CH-7), 7.36–7.54 (m, 2H, CH-13, CH-14), 
7.58 (d, J = 2.3 Hz, 1H, CH-9), 7.68 (d, J = 8.0 Hz, 1H, CH-12), 7.99 (d, J = 7.1 Hz, 
1H, CH-15), 8.25 (d, J = 9.0 Hz, 1H, CH-6), 9.37 (s, 1H, CH-2); 13C-NMR (75 MHz, 
CDCl3) δ: 55.5 (CH3-17), 108.4 (CH-9), 111.7 (qC-5), 112.0 (CH-12), 115.0 (qC-3), 
119.7 (CH-7), 120.3 (CH-15), 121.9 (CH-6), 122.8 (qC-16), 123.9 (CH-14), 126.7 
(CH-13), 144.6 (CH-2), 149.3 (qC-10), 155.8 (qC-11), 157.8 (qC-4), 160.7 (qC-8); 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C16H12NO2: 250.0868; found: 250.0865.  
2-(Trifluoromethyl)benzofuro[3,2-c]quinoline (104) 
2 mol% Pd(OAc)2 used. Yellow solid; yield: 49 mg (63%); 
m.p. = 141–143 °C; IR (NaCl): ν 2917 (C-H stretch), 1567 
(aromatic C-C stretch), 1443 (aromatic C-C stretch), 1348 
(C-N stretch), 1167 (C-O stretch), 1111 (C-F stretch) cm-1; 
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1H-NMR (300 MHz, CDCl3) δ: 7.43–7.67 (m, 2H, CH-13, CH-14), 7.80 (d, J = 8.2 
Hz, 1H, CH-12), 7.96 (dd, J = 9.0, 2.0 Hz, 1H, CH-8), 8.13 (d, J = 8.4 Hz, 1H, CH-15), 
8.38 (d, J = 8.9 Hz, 1H, CH-9), 8.75 (s, 1H, CH-6), 9.60 (s, 1H, CH-2); 13C-NMR 
(100 MHz, CDCl3) δ: 112.3 (CH-12), 116.3 (qC-5), 117.3 (qC-3), 119.1 (q, 3J(C,F) = 
5 Hz, CH-6), 120.8 (CH-15), 122.1 (qC-16), 124.3 (q, 1J(C,F) = 270 Hz, qC-17), 124.5 
(CH-14), 124.9 (q, 3J(C,F) = 3 Hz, CH-8), 127.9 (CH-13), 128.8 (q, 
2J(C,F) = 33 Hz, 
qC-7), 131.0 (CH-9), 146.4 (CH-2), 148.0 (qC-10), 156.1 (qC-11), 157.5 (qC-4); 
19F-NMR (282 MHz, CDCl3) δ: -62 (CF3-17); HRMS (ESI-TOF) m/z: [M+H]+ calcd. 
for C16H9F3NO: 288.0636; found: 288.0634.  
2-Fluorobenzofuro[3,2-c]quinoline (105)[76] 
2 mol% Pd(OAc)2 used. White solid; yield: 25 mg (67%); m.p. = 
146–148 °C (lit. 148–149 °C); IR (NaCl): ν 3399 (C-H stretch), 
1515 (aromatic C-C stretch), 1462 (aromatic C-C stretch), 1364 
(C-N stretch), 1195 (C-O stretch), 1175 (C-F stretch) cm-1; 
1H-NMR (300 MHz, CDCl3) δ: 7.45–7.61 (m, 3H, CH-8, CH-13, CH-14), 7.76 (d, J 
= 8.1 Hz, 1H, CH-12), 8.00 (dd, 3J(H,F) = 8.6, 
4J(H,H) = 2.8 Hz, 1H, CH-6), 8.10 (dd, J 
= 7.6, 0.8 Hz, 1H, CH-15), 8.26 (dd, 3J(H,H) = 9.3, 
4J(H,F) = 5.2 Hz, 1H, CH-9), 9.45 (s, 
1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 104.7 (d, 2J(C,F) = 24 Hz, CH-6), 112.2 
(CH-12), 116.8 (qC-3), 117.8 (d, 3J(C,F) = 11 Hz, qC-5), 119.3 (d, 
2J(C,F) = 26 Hz, 
CH-8), 120.8 (CH-15), 122.5 (qC-16), 124.2 (CH-14), 127.6 (CH-13), 132.5 (d, 3J(C,F) 
= 9 Hz, CH-9), 143.6 (d, 6J(C,F) = 3 Hz, CH-2), 144.4 (qC-10), 156.1 (qC-11), 157.1 
(d, 4J(C,F) = 5 Hz, qC-4), 160.8 (d, 
1J(C,F) = 249 Hz, qC-7); 
19F-NMR (282 MHz, CDCl3) 
δ: -111 (CF-7); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H9FNO: 238.0668; 
found: 238.0659.  
Spectral data were consistent with those reported in the literature.  
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3.18. Synthesis of Compound 106  
4-Bromoquinoline[80] (106)  
A mixture of 4-quinolinol (1 equiv.) and PBr3 (1.05 equiv.) in dry DMF 
(1.7 mL/mmol) was stirred at room temperature for 45 min under N2, until full 
consumption of the starting material was observed by TLC analysis of the reaction 
mixture (eluent DCM/MeOH 9:1). The cooled reaction mixture was slowly poured 
onto ice water (~8 mL/mmol) with stirring. Solid NaHCO3 was added portion-wise 
until the mixture reached pH 9–10. This aqueous mixture was transferred to a 
separating funnel and extracted with EtOAc (3 × 5 mL/mmol). The combined organic 
layers were washed with water (5 mL/mmol), brine (5 mL/mmol), dried over MgSO4, 
filtered and concentrated in vacuo to yield the crude product as an orange oil. 
Purification by column chromatography (DCM/MeOH 95:5) afforded the pure 
product 106 as a yellow solid (0.597 g, 83% yield). 
Yellow solid; yield: 597 mg (83%); m.p. = 28–30 °C (lit. 29–30 °C); 
IR (NaCl): ν 2549 (C-H stretch), 1492 (aromatic C-C stretch), 1377 
(C-N stretch), 651 (C-Cl stretch) cm-1; 1H-NMR (300 MHz, CDCl3 ) δ: 
7.62–7.82 (m, 3H, CH-3, CH-7, CH-8), 8.11 (d, J = 8.4 Hz, 1H, CH-9), 8.20 (dd, J = 
8.4, 0.9 Hz, 1H, CH-6), 8.68 (d, J = 4.7 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) 
δ: 125.1 (CH-3), 126.8 (CH-6), 127.88 (CH-7), 127.93 (qC-5), 129.9 (CH-9), 130.4 
(CH-8), 134.2 (qC-4), 149.0 (qC-10), 149.9 (CH-2); HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C9H7BrN: 207.9762; found: 207.9760.  
Spectral data were consistent with those reported in the literature. 
3.19. Synthesis of Compound 107 
N-(2-bromophenyl)quinolin-4-amine (107) 
To a degassed solution of Pd2(dba)3 (2 mol%) and XantPhos (4 mol%) in anhydrous 
1,4-dioxane (4 mL/mmol) were added Cs2CO3 (1.4 equiv.), 4-bromoquinoline (1 
equiv.) and 2-bromoaniline (1.1 equiv.) under a nitrogen atmosphere. The reaction 
mixture was stirred at 120 °C under N2 for 24 h. The cooled reaction mixture was 
diluted with DCM, filtered through Celite and concentrated in vacuo. The crude 
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mixture was purified by column chromatography over silica gel using DCM/EtOAc 
(3:1) as eluent to yield the product 107 as a yellow solid (0.322 g, 74%). 
Yellow/orange solid; yield: 322 mg (74%); m.p. = 238–241 °C; IR 
(NaCl): ν 3360 (N-H stretch), 3061 (C-H stretch), 1572 (aromatic 
C-C stretch), 1526 (aromatic C-C stretch), 1335 (C-N stretch), 747 
(C-Br stretch) cm1; 1H-NMR (300 MHz, CDCl3) δ: 6.88 (br s, 1H, 
NH), 7.02 (td, J = 8.0, 1.5 Hz, 1H, CH-14), 7.08 (d, J = 5.2 Hz, 1H, 
CH-3), 7.31–7.38 (m, 1H, CH-13), 7.51–7.61 (m, 2H, CH-7, CH-12), 7.65–7.78 (m, 
2H, CH-8, CH-15), 8.01 (d, J = 8.3 Hz, 1H, CH-6), 8.09 (d, J = 8.0 Hz, 1H, CH-9), 
8.66 (d, J = 5.2 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 103.4 (CH-3), 116.9 
(qC-16), 120.0 (CH-6), 120.3 (qC-5), 122.2 (CH-12), 125.0 (CH-14), 125.8 (CH-7), 
128.4 (CH-13), 129.6 (CH-8), 130.1 (CH-9), 133.5 (CH-15), 138.3 (qC-11), 146.2 
(qC-4), 149.2 (qC-10), 150.8 (CH-2); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C15H12BrN2: 299.0184; found: 299.0187.  
3.20. Synthesis of Compound 110 
tert-Butyl (2-bromophenyl)(quinolin-4-yl)carbamate (110) 
N-(2-Bromophenyl)quinolin-4-amine 107 (1 equiv.) and DMAP (0.2 equiv.) were 
added to a solution of (Boc)2O (1.2 equiv.) in dry THF (1 mL/mmol) and the mixture 
was stirred at 70 °C for 24 h. After cooling to room temperature, the reaction mixture 
was concentrated in vacuo. Purification by column chromatography (hexane/EtOAc 
8:2) afforded the product 110 as a yellow solid (0.09 g, 45 %). 
Yellow solid; yield: 90 mg (45%); m.p. = 165–167 °C; IR 
(NaCl): ν 3583 (C-H stretch), 2924 (C-H stretch), 1745 (ester 
C=O stretch), 1641 (aromatic C-C stretch), 1578 (aromatic C-C 
stretch), 1349 (C-N stretch), 12899 (C-O stretch), 734 (C-Br 
stretch) cm1; 1H-NMR (300 MHz, CDCl3) δ: 1.62 (s, 9H, 
CH3-19, CH3-20, CH3-21), 5.80 (d, J = 8.6 Hz, 1H, CH-3), 6.83–6.97 (m, 2H, CH-12, 
CH-14), 7.21–7.31 (m, 1H, CH-13), 7.39 (ddd, J = 8.1, 7.2, 1.1 Hz, 1H, CH-7), 7.50–
7.64 (m, 2H, CH-8, CH-15), 7.78 (d, J = 8.7 Hz, 1H, CH-2), 8.51 (dd, J = 8.8, 0.6 Hz, 
1H, CH-9), 8.61 (dd, J = 8.0, 1.7 Hz, 1H, CH-6); 13C-NMR (75 MHz, CDCl3) δ: 28.0 
(CH3-19, CH3-20, CH3-21), 85.3 (qC-18), 103.8 (CH-3), 115.9 (qC-16), 120.1 (CH-9), 
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121.9 (CH-12), 124.0 (CH-14), 125.2 (qC-5), 125.4 (CH-7), 125.9 (CH-6), 128.1 
(CH-13), 131.0 (CH-8), 133.1 (CH-15), 134.1 (CH-2), 137.1 (qC-10), 150.26 (qC-11), 
150.30 (qC-17), 154.3 (qC-4); HRMS (ESI-TOF) m/z: [M+H] calcd. for 
C16H11BrN2O2: 343.0077; found: 343.0074.  
3.21. Synthesis of Compound 108 
11H-Indolo[3,2-c]quinoline[88] (108) 
N-(2-bromophenyl)quinolin-4-amine 107 (1 equiv.), Pd(OAc)2 (5 mol%), PCy3·HBF4 
(10 mol%) and Cs2CO3 (2 equiv.) were added to degassed NMP (1.5 mL/mmol) in an 
inert Schlenk tube under a nitrogen atmosphere. The reaction mixture was stirred at 
150 °C (sand bath) for 3 h. The cooled reaction mixture was diluted with DCM and 
filtered through Celite. The mixture was washed with water (3 ×60 mL/mmol) and 
brine (90 mL/mmol), dried over MgSO4, filtered and concentrated in vacuo. The crude 
mixture was purified by column chromatography over silica gel using DCM/EtOAc 
(7:3) as eluent to yield the product 108 as an off-white solid (0.030 g, 83%). 
Off-white solid; yield: 30 mg (83%); m.p. >250 °C (lit. 340–341 
°C); IR (NaCl): ν 3355 (N-H stretch), 2916 (C-H stretch), 2849 
(C-H stretch), 1567 (aromatic C-C stretch), 1512 (aromatic C-C 
stretch), 1459 (C-N stretch), 1236 (C-N stretch) cm-1; 1H-NMR 
(300 MHz, DMSO-d6) δ: 7.35 (t, J = 7.5 Hz, 1H, CH-14), 7.51 (t, J = 7.6 Hz, 1H, CH-
13), 7.63–7.81 (m, 3H, CH-7, CH-8, CH-12), 8.15 (dd, J = 8.2, 1.3 Hz, 1H, CH-9), 
8.33 (d, J = 7.8 Hz, 1H, CH-15), 8.53 dd, J = 8.0, 1.4 Hz, 1H, CH-6), 9.60 (s, 1H, CH-
2), 12.72 (br s, 1H, N-H); 13C-NMR (75 MHz, DMSO-d6) δ: 112.3 (CH-12), 114.8 
(qC-3), 117.6 (qC-5), 120.6 (CH-15), 121.1 (CH-14), 122.4 (qC-16), 122.6 (CH-6), 
126.0 (CH-13), 126.1 (CH-7), 128.5 (CH-8), 130.0 (CH-9), 139.3 (qC-11), 140.2 (qC-
4), 145.3 (CH-2), 145.9 (qC-10); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H11N2: 
219.0922; found: 219.0911. 
Spectral data were consistent with those reported in the literature. 
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3.22. General Procedure for Synthesis of 4-Phenoxy Quinoline Substrates  
A mixture of the 6-bromo or 7-bromo-4-chloroquinoline substrate (1 equiv.), the 
2-bromophenol (5 equiv.) and NaOH (crushed pellets) (1.5 equiv.) was stirred at 
120 °C until reaction was completed (2–6 h) as evident by TLC (hexane/EtOAc 8:2). 
The cooled reaction mixture was diluted with 10% aq. NaOH (0.5 mL) and stirred at 
room temperature for 1 h. The aqueous phase was extracted with DCM (3 × 
1.5 mL/mmol). The combined organic layers were washed with 6M NaOH (3 × 
1 mL/mmol), water (1 mL/mmol) and brine (1 mL/mmol), dried over MgSO4, filtered 
and concentrated in vacuo. The crude mixture was purified by column 
chromatography over silica gel using hexane/EtOAc (8:2) as eluent. 
6-Bromo-4-(2-bromophenoxy)quinoline (115)  
Pale yellow solid; yield: 1.53 g (83%); m.p. = 97–98 °C; IR 
(NaCl): ν 3399 (C-H stretch), 1590 (aromatic C-C stretch), 1491 
(aromatic C-C stretch), 1350 (C-N stretch), 1221 (C-O stretch), 
665 (C-Br stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 6.41 (d, 
J = 5.2 Hz, 1H, CH-3), 7.19–7.28 (m, 2H, CH-12, CH-14), 7.39–
7.47 (m, 1H, CH-13), 7.73 (dd, J = 8.3, 1.5 Hz, 1H, CH-15), 7.84 (dd, J = 9.0, 2.2 Hz, 
1H CH-8), 7.98 (d, J = 9.0 Hz, 1H, CH-9), 8.58 (d, J = 2.2 Hz, 1H, CH-6), 8.67 (d, J 
= 5.2 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 104.2 (CH-3), 116.4 (qC-16), 
120.3 (qC-7), 122.2 (qC-5), 123.3 (CH-12), 124.3 (CH-6), 127.6 (CH-14), 129.3 
(CH-13), 130.9 (CH-9), 133.7 (CH-8), 134.4 (CH-15), 148.4 (qC-10), 150.8 (qC-11), 
151.4 (CH-2), 159.8 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H10Br2NO: 
377.9129; found: 377.9132. 
6-Bromo-4-phenoxyquinoline (118)  
Pale yellow solid; yield: 517 mg (83%); m.p. = 84–86 °C; IR 
(NaCl): ν 3401 (C-H stretch), 1561 (aromatic C-C stretch), 1487 
(aromatic C-C stretch), 1351 (C-N stretch), 1213 (C-O stretch), 
667 (C-Br stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 6.54 (d, 
J = 5.2 Hz, 1H, CH-3), 7.13–7.22 (m, 2H, CH-12, CH-16), 7.25–
7.36 (m, 1H, CH-14), 7.41–7.53 (m, 2H, CH-13, CH-15), 7.80 (dd, J = 9.0, 2.2 Hz, 
1H, CH-8), 7.95 (d, J = 9.0 Hz, 1H CH-9), 8.53 (d, J = 2.2 Hz, 1H CH-6), 8.65 (d, J = 
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5.2 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 104.7 (CH-3), 120.2 (qC-7), 121.1 
(CH-12, CH-16), 122.6 (qC-5), 124.3 (CH-6), 125.9 (CH-14), 130.4 (CH-13, CH-15), 
130.9 (CH-9), 133.6 (CH-8), 148.3 (qC-10), 151.5 (CH-2), 154.0 (qC-11), 161.0 
(qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H11BrNO: 300.0024; found: 
300.0013. 
7-Bromo-4-(2-bromophenoxy)quinoline (121)  
Pale yellow solid; yield: 409 mg (87%); m.p. = 73–74 °C; IR 
(NaCl): ν 3064 (C-H stretch), 1561 (aromatic C-C stretch), 1468 
(aromatic C-C stretch), 1301 (C-N stretch), 1220 (C-O stretch), 
657 (C-Br stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 6.41 (d, 
J = 5.2 Hz, 1H, CH-3), 7.19–7.30 (m, 2H, CH-12, CH-14), 7.39–
7.48 (m, 1H, CH-13), 7.66–7.76 (m, 2H, CH-7, CH-15), 8.25–8.33 (m, 2H, CH-6, 
CH-9), 8.66 (d, J = 5.2 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 103.9 (CH-3), 
116.3 (qC-16), 119.7 (qC-5), 123.3 (CH-12), 123.5 (CH-6), 124.6 (qC-8), 127.6 
(CH-14), 129.3 (CH-13), 129.8 (CH-7), 131.4 (CH-9), 134.4 (CH-15), 150.5 (qC-10), 
150.8 (qC-11), 152.1 (CH-2), 160.8 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C15H10Br2NO: 377.9129; found: 377.9119. 
4-(2,4-Dibromophenoxy)quinoline (123)  
Pale yellow solid; yield: 517 mg (85%); m.p. = 125–126 °C; IR 
(NaCl): ν 3394 (C-H stretch), 1596 (aromatic C-C stretch), 1464 
(aromatic C-C stretch), 1305 (C-N stretch), 1224 (C-O stretch), 
667 (C-Br stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 6.43 (d, 
J = 5.1 Hz, 1H, CH-3), 7.13 (d, J = 8.6 Hz, 1H, CH-12), 7.50–
7.68 (m, 2H, CH-7, CH-13), 7.79 (ddd, J = 8.5, 6.9, 1.4 Hz, 1H, CH-8), 7.88 (d, J = 
2.3 Hz, 1H CH-15), 8.12 (d, J = 8.4 Hz, 1H, CH-9), 8.38 (dd, J = 8.4, 0.9 Hz, 1H 
CH-6), 8.70 (d, J = 5.1 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 103.8 (CH-3), 
117.4 (qC-16), 119.3 (qC-14), 120.9 (qC-5), 121.8 (CH-6), 124.3 (CH-12), 126.5 
(CH-7), 129.2 (CH-9), 130.4 (CH-8), 132.3 (CH-13), 136.6 (CH-15), 149.8 (qC-10), 
150.5 (qC-11), 151.0 (CH-2), 160.3 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C15H10Br2NO: 377.9129; found: 377.9114. 
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6-Bromo-4-(2,4-dibromophenoxy)quinoline (125)  
Pale yellow solid; yield: 268 mg (57%); m.p. = 162–163 °C; IR 
(NaCl): ν 3370 (C-H stretch), 1590 (aromatic C-C stretch), 
1449 (aromatic C-C stretch), 1349 (C-N stretch), 1255 (C-O 
stretch), 665 (C-Br stretch) cm-1; 1H-NMR (300 MHz, CDCl3) 
δ: 6.42 (d, J = 5.1 Hz, 1H, CH-3), 7.12 (d, J = 8.6 Hz, 1H, 
CH-12), 7.56 (dd, J = 8.6, 2.3 Hz, 1H, CH-13), 7.80–7.91 (m, 2H, CH-8, CH-15), 7.98 
(d, J = 9.0 Hz, 1H, CH-9), 8.54 (d, J = 2.2 Hz, 1H CH-6), 8.68 (d, J = 5.1 Hz, 1H, 
CH-2); 13C-NMR (75 MHz, CDCl3) δ: 104.2 (CH-3), 117.4 (qC-16), 119.7 (qC-14), 
120.5 (qC-7), 122.0 (qC-5), 124.2 (CH-6), 124.4 (CH-12), 131.0 (CH-9), 132.4 
(CH-13), 133.9 (CH-8), 136.7 (CH-15), 148.4 (qC-10), 150.1 (qC-11), 151.3 (CH-2), 
159.4 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C15H9Br3NO: 455.8234; 
found: 455.8233. 
6-Bromo-4-(2-bromo-4-chlorophenoxy)quinoline (127)  
Pale pink solid; yield: 531 mg (77%); m.p. = 157–159 °C; IR 
(NaCl): ν 3392 (C-H stretch), 1590 (aromatic C-C stretch), 
1467 (aromatic C-C stretch), 1349 (C-N stretch), 1256 (C-O 
stretch), 729 (C-Cl stretch), 667 (C-Br stretch) cm-1; 1H-NMR 
(300 MHz, CDCl3) δ: 6.41 (d, J = 5.1 Hz, 1H, CH-3), 7.18 (d, 
J = 8.6 Hz, 1H, CH-12), 7.42 (dd, J = 8.6, 2.5 Hz, 1H, CH-13), 7.74 (d, J = 2.4 Hz, 
1H, CH-15), 7.84 (dd, J = 9.0, 2.2 Hz, 1H, CH-8), 7.98 (d, J = 9.0 Hz, 1H, CH-9), 
8.55 (d, J = 2.2 Hz, 1H CH-6), 8.68 (d, J = 5.1 Hz, 1H, CH-2); 13C-NMR (75 MHz, 
CDCl3) δ: 104.1 (CH-3), 117.0 (qC-16), 120.5 (qC-7), 122.0 (qC-5), 124.0 (CH-12), 
124.2 (CH-6), 129.4 (CH-13), 131.0 (CH-9), 132.4 (qC-14), 133.9 (CH-8), 134.0 
(CH-15), 148.4 (qC-10), 149.6 (qC-11), 151.3 (CH-2), 159.5 (qC-4); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C15H9Br2ClNO: 411.8739; found: 411.8730.  
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3.23. General Procedure for Pd-Catalysed One-Pot Tandem 
Suzuki-Miyaura/Direct Arylation Reactions 
A mixture of the 4-(2-bromophenoxy)quinoline substrate (1 equiv.), PhB(OH)2 
(1.1 equiv.), Pd(OAc)2 (2 mol%), and anhydrous K2CO3 (2 equiv.) in anhydrous NMP 
(1.5 mL/mmol) was stirred at 135 °C in a sealed reaction tube. The reaction progress 
was monitored by periodically sampling the reaction mixture for 1H-NMR analysis in 
CDCl3. Once complete, the cooled reaction mixture was diluted with DCM, filtered 
through a short plug of Celite and concentrated in vacuo. The crude mixture was 
purified by column chromatography over silica gel using DCM/EtOAc (99:1–95:5) as 
eluent. 
2-Phenylbenzofuro[3,2-c]quinoline (117)  
Pale yellow solid; yield: 63 mg (83%); m.p. = 169–171 
°C; IR (NaCl): ν 3450 (C-H stretch), 1559 (aromatic C-C 
stretch), 1460 (aromatic C-C stretch), 1359 (C-N stretch), 
1193 (C-O stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 
7.39–7.61 (m, 5H, CH-13, CH-14, CH-19, CH-20, CH-21), 7.74–7.87 (m, 3H, CH-12, 
CH-18, CH-22), 8.02–8.15 (m, 2H, CH-8, CH-15), 8.33 (d, J = 8.8 Hz, 1H, CH-9), 
8.62 (d, J = 1.7 Hz, 1H, CH-6), 9.49 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 
112.1 (CH-12), 116.6 (qC-3), 117.3 (qC-5), 118.4 (CH-6), 120.6 (CH-15), 122.7 
(qC-16), 124.1 (CH-14), 127.3 (CH-13), 127.5 (CH-18, CH-22), 127.9 (CH-20), 128.8 
(CH-8), 129.0 (CH-19, CH-21), 130.2 (CH-9), 139.7 (qC-7), 140.1 (qC-17), 144.2 
(CH-2), 146.7 (qC-10), 156.0 (qC-11), 157.6 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C21H14NO: 296.1075; found: 296.1062. 
4-Phenoxy-6-phenylquinoline (119)  
Pale yellow solid; yield: 168 mg (84%); m.p. = 78–80 °C; 
IR (NaCl): ν 3058 (C-H stretch), 1562 (aromatic C-C 
stretch), 1487 (aromatic C-C stretch), 1460 (aromatic C-C 
stretch), 1360 (C-N stretch), 1203 (C-O stretch) cm-1; 
1H-NMR (300 MHz, CDCl3) δ: 6.58 (d, J = 5.1 Hz, 1H, 
CH-3), 7.16–7.57 (m, 8H, CH-19, CH-20, CH-21, CH-12, CH-13, CH-14, CH-15, 
CH-16), 7.72–7.74 (m, 2H, CH-18, CH-22), 8.03 (dd, J = 8.8, 2.1 Hz, 1H, CH-8), 8.17 
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(d, J = 8.8 Hz, 1H, CH-9), 8.58 (d, J = 2.0 Hz, 1H, CH-6), 8.67 (d, J = 4.9 Hz, 1H, 
CH-2); 13C-NMR (75 MHz, CDCl3) δ: 104.6 (CH-3), 119.6 (CH-6), 121.2 (CH-12, 
CH-16), 121.7 (qC-5), 125.7 (CH-14), 127.5 (CH-18, CH-22), 127.7 (CH-20), 129.0 
(CH-19, CH-21), 129.6 (CH-9), 129.8 (CH-8), 130.3 (CH-13, CH-15), 139.0 (qC-7), 
140.5 (qC-17), 149.1 (qC-10), 151.1 (CH-2), 154.4 (qC-11), 162.1 (qC-4); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C21H16NO: 298.1226; found: 298.1228. 
4-(2-Bromophenoxy)-6-phenylquinoline (120)  
Pale yellow solid; yield: 73 mg (49%); m.p. = 85–87 °C; IR 
(NaCl): ν 3059 (C-H stretch), 1564 (aromatic C-C stretch), 
1460 (aromatic C-C stretch), 1361 (C-N stretch), 1222 (C-O 
stretch), 667 (C-Br stretch) cm-1; 1H-NMR (300 MHz, 
CDCl3) δ: 6.43 (d, J = 5.2 Hz, 1H, CH-3), 7.16–7.32 (m, 
2H, CH-12, CH-14), 7.34–7.57 (m, 4H, CH-13, CH-19, CH-20, CH-21), 7.70–7.84 
(m, 3H, CH-15, CH-18, CH-22), 8.05 (dd, J = 8.8, 2.1 Hz, 1H, CH-8), 8.20 (d, J = 8.7 
Hz, 1H, CH-9), 8.62 (d, J = 2.0 Hz, 1H, CH-6), 8.69 (d, J = 5.3 Hz, 1H, CH-2); 
13C-NMR (75 MHz, CDCl3) δ: 103.9 (CH-3), 116.4 (qC-16), 119.6 (CH-6), 121.3 
(qC-5), 123.3 (CH-12), 127.6 (CH-14, CH-18, CH-22), 127.9 (CH-20), 129.0 (CH-9, 
CH-19, CH-21), 129.3 (CH-13), 130.2 (CH-8), 134.4 (CH-15), 139.4 (qC-7), 140.3 
(qC-17), 148.2 (qC-10), 150.5 (CH-2), 151.0 (qC-11), 161.5 (qC-4); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C21H15BrNO: 376.0332; found: 376.0331. 
3-Phenylbenzofuro[3,2-c]quinoline (122)  
Pale yellow solid; yield: 146 mg (95%); m.p. = 172–173 
°C; IR (NaCl): ν 3275 (C-H stretch), 1559 (aromatic C-C 
stretch), 1452 (aromatic C-C stretch), 1379 (C-N stretch), 
1188 (C-O stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 
7.37–7.64 (m, 5H, CH-13, CH-14, CH-19, CH-20, 
CH-21), 7.72–7.88 (m, 3H, CH-12, CH-18, CH-22), 7.98 (dd, J = 8.5, 1.7 Hz, 1H, 
CH-7), 8.12 (dd, J = 7.5, 1.0 Hz, 1H, CH-15), 8.42–8.59 (m, 2H, CH-6, CH-9), 9.54 
(s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 112.2 (CH-12), 116.1 (qC-5), 116.4 
(qC-3), 120.6 (CH-15), 121.3 (CH-6), 122.8 (qC-16), 124.1 (CH-14), 126.6 (CH-7), 
127.3 (CH-13), 127.5 (CH-18, CH-22), 127.6 (CH-9), 128.0 (CH-20), 129.1 (CH-19, 
CH-21), 140.2 (qC-17), 142.2 (qC-8), 144.9 (CH-2), 147.8 (qC-10), 156.1 (qC-11), 
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157.5 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C21H14NO: 296.1070; found: 
296.1072. 
8-Phenylbenzofuro[3,2-c]quinoline (124)  
Yellow solid; yield: 103 mg (65%); m.p. = 153–155 °C; 
IR (NaCl): ν 2922 (C-H stretch), 1567 (aromatic C-C 
stretch), 1460 (aromatic C-C stretch), 1325 (C-N stretch), 
1202 (C-O stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 
7.36–7.45 (m, 1H, CH-20), 7.46–7.56 (m, 2H, CH-19, CH-21), 7.67–7.86 (m, 6H, 
CH-7, CH-8, CH-12, CH-13, CH-18, CH-22), 8.24–8.35 (m, 2H, CH-9, CH-15), 8.45 
(dd, J = 8.1, 1.6 Hz, 1H, CH-6), 9.55 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 
112.2 (CH-12), 116.4 (qC-3), 117.2 (qC-5), 119.1 (CH-15), 120.8 (CH-6), 123.3 
(qC-16), 126.7 (CH-13), 127.1 (CH-7), 127.4 (CH-20), 127.5 (CH-18, CH-22), 128.9 
(CH-19, CH-21), 129.4 (CH-8), 129.9 (CH-9), 137.9 (qC-14), 140.9 (qC-17), 144.4 
(CH-2), 147.5 (qC-10), 155.5 (qC-11), 158.0 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C21H14NO: 296.1070; found: 296.1072. 
2,8-Diphenylbenzofuro[3,2-c]quinoline (126)  
Pale yellow solid; yield: 129 mg (80%); m.p. = 
206–207 °C; IR (NaCl): ν 3054 (C-H stretch), 
2920 (C-H stretch), 1682 (aromatic C-C stretch), 
1560 (aromatic C-C stretch), 1460 (aromatic C-C 
stretch), 1358 (C-N stretch), 1200 (C-O stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 
7.37–7.60 (m, 6H, CH-19, CH-20, CH-21, CH-25, CH-26, CH-27), 7.68–7.88 (m, 6H, 
CH-12, CH-13, CH-18, CH-22, CH-24, CH-28), 8.07 (dd, J = 8.8, 2.1 Hz, 1H, CH-8), 
8.28–8.40 (m, 2H, CH-9, CH-15), 8.64 (d, J = 1.7 Hz, 1H CH-6), 9.54 (s, 1H, CH-2); 
13C-NMR (75 MHz, CDCl3) δ: 112.2 (CH-12), 116.6 (qC-3), 117.4 (qC-5), 118.4 
(CH-6), 119.1 (CH-15), 123.3 (qC-16), 126.8 (CH-13), 127.4 (CH-26), 127.50 
(CH-24, CH-28), 127.54 (CH-18, CH-22), 128.0 (CH-20), 128.9 (CH-8, CH-25, 
CH-27), 129.0 (CH-19, CH-21), 130.3 (CH-9), 137.9 (qC-14), 139.8 (qC-7), 140.1 
(qC-17), 140.9 (qC-23), 144.2 (CH-2), 146.8 (qC-10), 155.5 (qC-11), 158.1 (qC-4); 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C27H18NO: 372.1388; found: 372.1384. 
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8-Chloro-2-phenylbenzofuro[3,2-c]quinoline (128)  
Pale yellow solid; yield: 118 mg (60%); m.p. = 213–214 
°C; IR (NaCl): ν 3583 (C-H stretch), 1461 (aromatic 
C-C stretch), 1359 (C-N stretch), 1192 (C-O stretch), 
665 (C-Cl stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 
7.38–7.60 (m, 4H, CH-13, CH-19, CH-20, CH-21), 7.66 (d, J = 8.8 Hz, 1H, CH-12), 
7.75–7.87 (m, 2H, CH-18, CH-22), 7.99–8.12 (m, 2H, CH-8, CH-15), 8.31 (d, J = 8.8 
Hz, 1H CH-9), 8.55 (d, J = 1.8 Hz, 1H, CH-6), 9.41 (s, 1H, CH-2); 13C-NMR (75 
MHz, CDCl3) δ: 113.1 (CH-12), 115.8 (qC-3), 117.2 (qC-5), 118.4 (CH-6), 120.5 
(CH-15), 124.2 (qC-16), 127.4 (CH-13), 127.5 (CH-18, CH-22), 128.1 (CH-20), 129.1 
(CH-19, CH-21), 129.3 (CH-8), 129.9 (qC-14), 130.4 (CH-9), 140.0 (qC-17), 140.1 
(qC-7), 144.0 (CH-2), 147.0 (qC-10), 154.3 (qC-11), 158.4 (qC-4); HRMS (ESI-TOF) 
m/z: [M+H]+ calcd. for C21H13ClNO: 330.0681; found: 330.0684. 
2-(p-Tolyl)benzofuro[3,2-c]quinoline (129)  
White solid; yield: 89 mg (72%); m.p. = 183–185 °C; IR 
(NaCl): ν 3583 (C-H stretch), 3401 (C-H stretch), 1505 
(aromatic C-C stretch), 1460 (aromatic C-C stretch), 
1358 (C-N stretch), 1190 (C-O stretch) cm-1; 1H-NMR 
(300 MHz, CDCl3) δ: 2.45 (s, 3H, CH3-23), 7.35 (d, J = 7.9 Hz, 2H, CH-19, CH-21), 
7.44–7.62 (m, 2H, CH-13, CH-14), 7.69–7.82 (m, 3H, CH-12, CH-18, CH-22), 8.02–
8.16 (m, 2H, CH-8, CH-15), 8.33 (d, J = 8.8 Hz, 1H, CH-9), 8.61 (d, J = 1.9 Hz, 1H, 
CH-6), 9.49 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 21.2 (CH3-23), 112.1 
(CH-12), 116.5 (qC-3), 117.4 (qC-5), 118.0 (CH-6), 120.7 (CH-15), 122.7 (qC-16), 
124.1 (CH-14), 127.27 (CH-13), 127.34 (CH-18, CH-22), 128.8 (CH-8), 129.8 
(CH-19, CH-21), 130.2 (CH-9), 137.2 (qC-17), 137.9 (qC-20), 139.6 (qC-7), 144.0 
(CH-2), 146.6 (qC-10), 156.0 (qC-11), 157.6 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C22H16NO: 310.1232; found: 310.1222. 
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2-(4-Methoxyphenyl)benzofuro[3,2-c]quinoline (130)   
 White solid; yield: 84 mg (65%); m.p. = 189–191 °C; 
IR (NaCl): ν 3320 (C-H stretch), 1505 (aromatic C-C 
stretch), 1460 (aromatic C-C stretch), 1359 (C-N 
stretch), 1246 (C-O stretch), 1190 (C-O stretch) cm-1; 
1H-NMR (300 MHz, CDCl3) δ: 3.90 (s, 3H, CH3-23), 7.01–7.12 (m, 2H, CH-19, 
CH-21), 7.43–7.60 (m, 2H, CH-13, CH-14), 7.71–7.81 (m, 3H, CH-12, CH-18, 
CH-22), 8.01 (dd, J = 8.8, 2.1 Hz, 1H, CH-8), 8.10 (dd, J = 7.6, 0.9 Hz, 1H, CH-15), 
8.30 (d, J = 8.8 Hz, 1H, CH-9), 8.55 (d, J = 1.9 Hz, 1H, CH-6), 9.46 (s, 1H, CH-2); 
13C-NMR (75 MHz, CDCl3) δ: 55.4 (CH3-23), 112.1 (CH-12), 114.5 (CH-19, CH-21), 
116.5 (qC-3), 117.4 (qC-5), 117.5 (CH-6), 120.6 (CH-15), 122.7 (qC-16), 124.1 
(CH-14), 127.2 (CH-13), 128.56 (CH-18, CH-22), 128.61 (CH-8), 130.2 (CH-9), 
132.6 (qC-17), 139.3 (qC-7), 143.9 (CH-2), 146.4 (qC-10), 156.0 (qC-11), 157.5 
(qC-4), 159.7 (qC-20); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C22H16NO2: 
326.1181; found: 326.1185.  
2-(4-Chlorophenyl)benzofuro[3,2-c]quinoline (131)  
Pale yellow solid; yield: 106 mg (81%); m.p. = 191–192 
°C; IR (NaCl): ν 3389 (C-H stretch), 1556 (aromatic 
C-C stretch), 1458 (aromatic C-C stretch), 1356 (C-N 
stretch), 1191 (C-O stretch), 821 (C-Cl stretch) cm-1; 
1H-NMR (300 MHz, CDCl3) δ: 7.38–7.57 (m, 4H, CH-13, CH-14, CH-19, CH-21), 
7.61–7.75 (m, 3H, CH-12, CH-18, CH-22), 7.89 (dd, J = 8.8, 2.1 Hz, 1H, CH-8), 8.02 
(dd, J = 7.6, 0.8 Hz, 1H, CH-15), 8.24 (d, J = 8.8 Hz, 1H, CH-9), 8.43 (d, J = 2.0 Hz, 
1H, CH-6), 9.39 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 112.1 (CH-12), 116.7 
(qC-3), 117.3 (qC-5), 118.2 (CH-6), 120.7 (CH-15), 122.6 (qC-16), 124.1 (CH-14), 
127.3 (CH-13), 128.3 (CH-8), 128.6 (CH-18, CH-22), 129.1 (CH-19, CH-21), 130.4 
(CH-9), 134.1 (qC-20), 138.3 (qC-7), 138.5 (qC-17), 144.4 (CH-2), 146.7 (qC-10), 
155.9 (qC-11), 157.4 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C21H13ClNO: 
330.0680; found: 330.0676. 
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2-(4-Fluorophenyl)benzofuro[3,2-c]quinoline (132)  
Pale yellow solid; yield: 95 mg (77%); m.p. = 185–186 
°C; IR (NaCl): ν 3391 (C-H stretch), 1561 (aromatic C-C 
stretch), 1460 (aromatic C-C stretch), 1334 (C-N stretch), 
1192 (C-O stretch), 1123 (C-F stretch) cm-1; 1H-NMR 
(300 MHz, CDCl3) δ: 7.16–7.29 (m, 2H, CH-19, CH-21), 7.46–7.62 (m, 2H, CH-13, 
CH-14), 7.72–7.83 (m, 3H, CH-12, CH-18, CH-22), 8.00 (dd, J = 8.8, 2.1 Hz, 1H, 
CH-8), 8.13 (dd, J = 7.2, 1.3 Hz, 1H, CH-15), 8.33 (d, J = 8.8 Hz, 1H, CH-9), 8.57 (d, 
J = 2.0 Hz, 1H, CH-6), 9.50 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 112.1 
(CH-12), 115.9 (d, 2J(C,F) = 22 Hz, CH-19, CH-21), 116.7 (qC-3), 117.4 (qC-5), 118.2 
(CH-6), 120.7 (CH-15), 122.7 (qC-16), 124.1 (CH-14), 127.3 (CH-13), 128.6 (CH-8), 
129.1 (d, 3J(C,F) = 8 Hz, CH-18, CH-22), 130.4 (CH-9), 136.2 (qC-17), 138.7 (qC-7), 
144.3 (CH-2), 146.6 (qC-10), 156.0 (qC-11), 157.5 (qC-4), 162.9 (d, 1J(C,F) = 247 Hz, 
qC-20); 19F-NMR (282 MHz, CDCl3) δ: -115; HRMS (ESI-TOF) m/z: [M+H]+ calcd. 
for C21H13FNO: 314.0981; found: 314.0971. 
2-(4-(Trifluoromethyl)phenyl)benzofuro[3,2-c]quinoline (133)  
Pale yellow solid; yield: 114 mg (80%); m.p. = 194–
195 °C; IR (NaCl): ν 3384 (C-H stretch), 1614 
(aromatic C-C stretch), 1460 (aromatic C-C stretch), 
1331 (C-N stretch), 1189 (C-O stretch), 1116 (C-F 
stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 7.46–7.63 (m, 2H, CH-13, CH-14), 
7.74–7.85 (m, 3H, CH-12, CH-19, CH-21), 7.93 (d, J = 8.2 Hz, 2H, CH-18, CH-22), 
8.04 (dd, J = 8.8, 2.1 Hz, 1H, CH-8), 8.13 (d, J = 7.4 Hz, 1H, CH-15), 8.37 (d, J = 8.8 
Hz, 1H, CH-9), 8.65 (d, J = 1.9 Hz, 1H, CH-6), 9.53 (s, 1H, CH-2); 13C-NMR (75 
MHz, CDCl3) δ: 112.1 (CH-12), 116.8 (qC-3), 117.3 (qC-5), 119.0 (CH-6), 120.7 
(CH-15), 122.6 (qC-16), 124.22 (CH-14), 124.23 (q, 1J(C,F) = 270 Hz, qC-23), 125.9 
(q, 3J(C,F) = 4 Hz, CH-19, CH-21), 127.5 (CH-13), 127.7 (CH-18, CH-22), 128.4 
(CH-8), 130.0 (q, 2J(C,F) = 33 Hz, qC-20), 130.6 (CH-9), 138.1 (qC-7), 143.6 (qC-17), 
144.8 (CH-2), 146.9 (qC-10), 156.0 (qC-11), 157.5 (qC-4); 19F-NMR (282 MHz, 
CDCl3) δ: -62; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C22H13F3NO: 364.0949; 
found: 364.0938.  
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2-(3-(Trifluoromethyl)phenyl)benzofuro[3,2-c]quinoline (134)  
Pale yellow solid; yield: 104 mg (72%); m.p. = 171–
173 °C; IR (NaCl): ν 3391 (C-H stretch), 1561 
(aromatic C-C stretch), 1446 (aromatic C-C stretch), 
1334 (C-N stretch), 1166 (C-O stretch), 1123 (C-F 
stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 7.45–7.73 (m, 4H, CH-13, CH-14, 
CH-20, CH-21), 7.79 (d, J = 7.9 Hz, 1H, CH-12), 7.95–8.09 (m, 3H, CH-8, CH-18, 
CH-22), 8.13 (dd, J = 7.6, 0.8 Hz, 1H, CH-15), 8.37 (d, J = 8.8 Hz, 1H, CH-9), 8.63 
(d, J = 2.0 Hz, 1H, CH-6), 9.52 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 112.1 
(CH-12), 116.8 (qC-3), 117.3 (qC-5), 118.7 (CH-6), 120.7 (CH-15), 122.6 (qC-16), 
124.19 (CH-14), 124.20 (q, 1J(C,F) = 273 Hz, qC-23), 124.3 (q, 
3J(C,F) = 4 Hz, CH-18), 
124.6 (q, 3J(C,F) = 4 Hz, CH-20), 127.5 (CH-13), 128.4 (CH-8), 129.5 (CH-21), 130.6 
(CH-9), 130.7 (CH-22), 131.5 (q, 2J(C,F) = 32 Hz, qC-19), 138.1 (qC-7), 140.9 (qC-17), 
144.7 (CH-2), 146.8 (qC-10), 156.0 (qC-11), 157.5 (qC-4); 19F-NMR (282 MHz, 
CDCl3) δ: -62; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C22H13F3NO: 364.0944; 
found: 364.0947.  
2-(4-(Trifluoromethoxy)phenyl)benzofuro[3,2-c]quinoline (135)  
Yellow solid; yield: 105 mg (70%); m.p. = 148–150 
°C; IR (NaCl): ν 3583 (C-H stretch), 1504 (aromatic 
C-C stretch), 1459 (aromatic C-C stretch), 1283 (C-N 
stretch), 1210 (C-O stretch), 1191 (C-O stretch), 
1165 (C-F stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 7.37 (dd, J = 8.8, 0.9 Hz, 2H, 
CH-19, CH-21), 7.43–7.62 (m, 2H, CH-13, CH-14), 7.72–7.86 (m, 3H, CH-12, 
CH-18, CH-22), 7.97 (dd, J = 8.8, 2.1 Hz, 1H, CH-8), 8.09 (dd, J = 7.6, 0.8 Hz, 1H, 
CH-15), 8.31 (d, J = 8.8 Hz, 1H, CH-9), 8.54 (d, J = 2.0 Hz, 1H, CH-6), 9.47 (s, 1H, 
CH-2); 13C-NMR (75 MHz, CDCl3) δ: 112.1 (CH-12), 116.8 (qC-3), 117.4 (qC-5), 
118.6 (CH-6), 120.5 (q, 1J(C,F) = 257 Hz, qC-23), 120.7 (CH-15), 121.4 (CH-19, 
CH-21), 122.6 (qC-16), 124.2 (CH-14), 127.4 (CH-13), 128.5 (CH-8), 128.9 (CH-18, 
CH-22), 130.5 (CH-9), 138.3 (qC-7), 138.9 (qC-17), 144.5 (CH-2), 146.7 (qC-10), 
149.2 (q, 3J(C,F) = 2 Hz, qC-20), 156.0 (qC-11), 157.5 (qC-4); 
19F-NMR (282 MHz, 
CDCl3) δ: -58; HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C22H13F3NO2: 380.0898; 
found: 380.0889.  
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2-(3-Nitrophenyl)benzofuro[3,2-c]quinoline (136)  
Yellow solid; yield: 69 mg (51%); m.p. = 227–228 °C; 
IR (NaCl): ν 3392 (C-H stretch), 1529 (aromatic C-C 
stretch), 1460 (aromatic C-C stretch), 1348 (N-O 
stretch), 1321 (C-N stretch), 1191 (C-O stretch) cm-1; 
1H-NMR (300 MHz, CDCl3) δ: 7.47–7.64 (m, 2H, CH-13, CH-14), 7.72 (t, J = 8.0 Hz, 
1H, CH-21), 7.80 (d, J = 8.0 Hz, 1H, CH-12), 8.06 (dd, J = 8.8, 2.2 Hz, 1H, CH-8), 
8.10–8.19 (m, 2H, CH-15, CH-22), 8.30 (ddd, J = 8.2, 2.2, 1.0 Hz, 1H, CH-20), 8.40 
(d, J = 8.8 Hz, 1H, CH-9), 8.65–8.73 (m, 2H, CH-6, CH-18), 9.55 (s, 1H, CH-2); 
13C-NMR (75 MHz, CDCl3) δ: 112.2 (CH-12), 117.0 (qC-3), 117.4 (qC-5), 119.1 
(CH-6), 120.8 (CH-15), 122.3 (CH-18), 122.5 (qC-16), 122.6 (CH-20), 124.3 
(CH-14), 127.6 (CH-13), 128.2 (CH-8), 130.0 (CH-21), 131.0 (CH-9), 133.3 (CH-22), 
137.1 (qC-7), 141.9 (qC-17), 145.1 (CH-2), 147.0 (qC-10), 148.9 (qC-19), 156.1 
(qC-11), 157.5 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C21H13N2O3: 
341.0921; found: 341.0919.  
Ethyl 4-(benzofuro[3,2-c]quinolin-2-yl)benzoate (137)   
Beige solid; yield: 105 mg (72%); m.p. = 160–
161 °C; IR (NaCl): ν 2922 (C-H stretch), 1715 
(ester C=O stretch), 1607 (aromatic C-C stretch), 
1460 (aromatic C-C stretch), 1357 (C-N stretch), 
1278 (C-O stretch), 1190 (C-O stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 1.45 (t, 
J = 7.1 Hz, 3H, CH3-25), 4.44 (q, J = 7.1 Hz, 2H, CH2-24), 7.43–7.63 (m, 2H, CH-13, 
CH-14), 7.79 (d, J = 7.9 Hz, 1H, CH-12), 7.84–7.95 (m, 2H, CH-18, CH-22), 8.02–
8.28 (m, 4H, CH-8, CH-15, CH-19, CH-21), 8.36 (d, J = 8.8 Hz, 1H, CH-9), 8.67 (d, 
J = 1.7 Hz, 1H, CH-6), 9.52 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 14.4 
(CH3-25), 61.1 (CH2-24), 112.1 (CH-12), 116.7 (qC-3), 117.2 (qC-5), 118.8 (CH-6), 
120.7 (CH-15), 122.5 (qC-16), 124.1 (CH-14), 127.3 (CH-18, CH-22), 127.4 (CH-13), 
128.8 (CH-8), 129.8 (qC-20), 130.2 (CH-19, CH-21), 130.5 (CH-9), 138.3 (qC-7), 
144.2 (qC-17), 144.6 (CH-2), 146.9 (qC-10), 155.9 (qC-11), 157.4 (qC-4), 166.4 
(qC-23); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C24H18NO3: 368.1281; found: 
368.1282.  
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(4-(Benzofuro[3,2-c]quinolin-2-yl)phenyl)(phenyl)methanone (138)   
Pale yellow solid; yield: 94 mg (59%); m.p. = 
184–187 °C; IR (NaCl): ν 3401 (C-H stretch), 
1652 (C=O stretch), 1602 (aromatic C-C stretch), 
1460 (aromatic C-C stretch), 1357 (C-N stretch), 
1190 (C-O stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 7.46–7.70 (m, 5H, CH-13, 
CH-14, CH-26, CH-27, CH-28), 7.79 (d, J = 8.3 Hz, 1H, CH-12), 7.84–8.04 (m, 6H, 
CH-18, CH-19, CH-21, CH-22, CH-25, CH-29), 8.05–8.20 (m, 2H, CH-8, CH-15), 
8.38 (d, J = 8.8 Hz, 1H, CH-9), 8.71 (d, J = 1.9 Hz, 1H, CH-6), 9.53 (s, 1H, CH-2); 
13C-NMR (75 MHz, CDCl3) δ: 112.1 (CH-12), 116.8 (qC-3), 117.4 (qC-5), 119.0 
(CH-6), 120.7 (CH-15), 122.6 (qC-16), 124.2 (CH-14), 127.3 (CH-18, CH-22), 127.5 
(CH-13), 128.4 (CH-26, CH-28), 128.5 (CH-8), 130.0 (CH-25, CH-29), 130.6 (CH-9), 
130.9 (CH-19, CH-21), 132.5 (CH-27), 136.8 (qC-20), 137.6 (qC-24), 138.4 (qC-7), 
144.0 (qC-17), 144.7 (CH-2), 146.9 (qC-10), 156.0 (qC-11), 157.5 (qC-4), 196.2 
(qC-23); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C28H18NO2: 400.1332; found: 
400.1331.  
3-(p-Tolyl)benzofuro[3,2-c]quinoline (139)  
White solid; yield: 90 mg (74%); m.p. = 200–202 °C; IR 
(NaCl): ν 3150 (C-H stretch), 1554 (aromatic C-C 
stretch), 1450 (aromatic C-C stretch), 1379 (C-N 
stretch), 1190 (C-O stretch) cm-1; 1H-NMR (300 MHz, 
CDCl3) δ: 2.45 (s, 3H, CH3-23), 7.34 (d, J = 7.9 Hz, 2H, 
CH-19, CH-21), 7.44–7.60 (m, 2H, CH-13, CH-14), 7.66–7.81 (m, 3H, CH-12, 
CH-18, CH-22), 7.97 (dd, J = 8.5, 1.5 Hz, 1H, CH-7), 8.11 (dd, J = 7.6, 0.9 Hz, 1H, 
CH-15), 8.42–8.52 (m, 2H, CH-6, CH-9), 9.51 (s, 1H, CH-2); 13C-NMR (75 MHz, 
CDCl3) δ: 21.2 (CH3-23), 112.1 (CH-12), 115.9 (qC-5), 116.2 (qC-3), 120.5 (CH-15), 
121.1 (CH-6), 122.7 (qC-16), 124.0 (CH-14), 126.4 (CH-7), 127.1 (CH-13), 127.2 
(CH-9), 127.3 (CH-18, CH-22), 129.8 (CH-19, CH-21), 137.3 (qC-20), 137.9 (qC-17), 
142.0 (qC-8), 144.7 (CH-2), 147.9 (qC-10), 156.0 (qC-11), 157.4 (qC-4); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C22H16NO: 310.1232; found: 310.1244. 
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3-(4-Methoxyphenyl)benzofuro[3,2-c]quinoline (140)  
White solid; yield: 88 mg (70%); m.p. = 157–158 °C; 
IR (NaCl): ν 3369 (C-H stretch), 2998 (C-H stretch), 
1607 (aromatic C-C stretch), 1450 (aromatic C-C 
stretch), 1303 (C-N stretch), 1245 (C-O stretch), 1188 
(C-O stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 
3.88 (s, 3H, CH3-23), 6.99–7.10 (m, 2H, CH-19, CH-21), 7.41–7.57 (m, 2H, CH-13, 
CH-14), 7.68–7.77 (m, 3H, CH-12, CH-18, CH-22), 7.91 (dd, J = 8.6, 1.7 Hz, 1H, 
CH-7), 8.07 (dd, J = 7.5, 1.5 Hz, 1H, CH-15), 8.37–8.45 (m, 2H, CH-6, CH-9), 9.47 
(s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 55.4 (CH3-23), 112.1 (CH-12), 114.5 
(CH-19, CH-21), 115.7 (qC-5), 116.1 (qC-3), 120.5 (CH-15), 121.2 (CH-6), 122.8 
(qC-16), 124.1 (CH-14), 126.3 (CH-7), 126.8 (CH-9), 127.1 (CH-13), 128.5 (CH-18, 
CH-22), 132.7 (qC-17), 141.7 (qC-8), 144.8 (CH-2), 148.0 (qC-10), 156.0 (qC-11), 
157.5 (qC-4), 159.8 (qC-20); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C22H16NO2: 
326.1176; found: 326.1173. 
3-(4-(Trifluoromethyl)phenyl)benzofuro[3,2-c]quinoline (141)  
Yellow solid; yield: 114 mg (79%); m.p. = 205–208 °C; 
IR (NaCl): ν 3251 (C-H stretch), 1559 (aromatic C-C 
stretch), 1450 (aromatic C-C stretch), 1329 (C-N 
stretch), 1188 (C-O stretch), 1110 (C-F stretch) cm-1; 
1H-NMR (300 MHz, CDCl3) δ: 7.46–7.63 (m, 2H, 
CH-13, CH-14), 7.76–7.82 (m, 3H, CH-12, CH-19, CH-21), 7.86–8.02 (m, 3H, CH-7, 
CH-18, CH-22), 8.13 (dd, J = 7.6, 0.9 Hz, 1H, CH-15), 8.49–8.57 (m, 2H, CH-6, 
CH-9), 9.55 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 112.2 (CH-12), 116.7 
(qC-5, qC-3), 120.7 (CH-15), 121.6 (CH-6), 122.6 (qC-16), 124.21 (CH-14), 124.22 
(q, 1J(C,F) = 270 Hz, qC-23), 126.0 (q, 
3J(C,F) = 4 Hz, CH-19, CH-21), 126.2 (CH-7), 
127.5 (CH-13), 127.7 (CH-18, CH-22), 128.2 (CH-9), 129.9 (q, 2J(C,F) = 32 Hz, 
qC-20), 140.4 (qC-8), 143.7 (qC-17), 145.1 (CH-2), 147.6 (qC-10), 156.1 (qC-11), 
157.3 (qC-4); 19F-NMR (282 MHz, CDCl3) δ: -62; HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C22H13F3NO: 364.0949; found: 364.0951. 
Direct Arylation of Phenoxyquinolines  Experimental 
196 
 
4-(Benzofuro[3,2-c]quinolin-3-yl)benzonitrile (142)  
White solid; yield: 85 mg (67%); m.p. >250 °C; IR 
(NaCl): ν 3348 (C-H stretch), 2223 (C≡N stretch), 1553 
(aromatic C-C stretch), 1447 (aromatic C-C stretch), 
1344 (C-N stretch), 1184 (C-O stretch) cm-1; 1H-NMR 
(300 MHz, CDCl3) δ: 7.45–7.64 (m, 2H, CH-13, 
CH-14), 7.73–7.80 (m, 6H, CH-7, CH-12, CH-18, CH-19, CH-21, CH-22), 8.13 (dd, 
J = 7.6, 0.8 Hz, 1H, CH-15), 8.45–8.60 (m, 2H, CH-6, CH-9), 9.55 (s, 1H, CH-2); 
13C-NMR (75 MHz, CDCl3) δ: 111.7 (qC-20), 112.3 (CH-12), 116.9 (qC-5), 117.0 
(qC-3), 118.8 (qC-23), 120.8 (CH-15), 121.9 (CH-6), 122.6 (qC-16), 124.3 (CH-14), 
126.0 (CH-7), 127.6 (CH-13), 128.1 (CH-18, CH-22), 128.4 (CH-9), 132.9 (CH-19, 
CH-21), 139.9 (qC-8), 144.7 (qC-17), 145.3 (CH-2), 147.5 (qC-10), 156.2 (qC-11), 
157.2 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C22H13N2O: 321.1028; found: 
321.1033.  
3.24. General Procedure for Pd-Catalysed One-Pot Mizoroki-Heck and 
Intramolecular Direct Arylation Reactions 
A mixture of the 4-(2-bromophenoxy)quinoline substrate (1 equiv.), t-BuOAc 
(1.1 equiv.), Pd(OAc)2 (2 mol%), and anhydrous K2CO3 (2 equiv.) in anhydrous NMP 
(1.5 mL/mmol) was stirred at 135 °C in a sealed reaction tube. The reaction progress 
was monitored by periodically sampling the reaction mixture for 1H-NMR analysis in 
CDCl3. Once complete, the cooled reaction mixture was diluted with DCM, filtered 
through a short plug of Celite and concentrated in vacuo. The crude mixture was 
purified by column chromatography over silica gel using DCM/EtOAc (99:1–95:5) as 
eluent. 
tert-Butyl (E)-3-(benzofuro[3,2-c]quinolin-2-yl)acrylate (143)  
White solid; yield: 27 mg (60%); m.p. = 169–170 
°C; IR (NaCl): ν 3393 (C-H stretch), 2976 (C-H 
stretch), 1701 (ester C=O), 1560 (aromatic C-C 
stretch), 1460 (aromatic C-C stretch), 1366 (C-N 
stretch), 1238 (C-O stretch), 1151 (C-O stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 
1.58 (s, 9H, CH3-21, CH3-22, CH3-23), 6.60 (d, J = 16.0 Hz, 1H, CH-18), 7.44–7.65 
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(m, 2H, CH-13, CH-14), 7.73–7.89 (m, 2H, CH-12, CH-17), 7.94 (dd, J = 8.9, 2.0 Hz, 
1H, CH-8), 8.11 (dd, J = 7.6, 0.8 Hz, 1H, CH-15), 8.24 (d, J = 8.8 Hz, 1H, CH-9), 8.51 
(d, J = 1.9 Hz, 1H, CH-6), 9.49 (s, 1H, CH-2); 13C-NMR (100 MHz, CDCl3) δ: 28.2 
(CH3-21, CH3-22, CH3-23), 80.9 (qC-20), 112.3 (CH-12), 117.0 (qC-3), 117.3 (qC-5), 
120.8 (CH-15), 121.6 (CH-6), 122.0 (CH-18), 122.5 (qC-16), 124.3 (CH-14), 127.4 
(CH-8), 127.6 (CH-13), 130.5 (CH-9), 133.4 (qC-7), 142.5 (CH-17), 145.1 (CH-2), 
147.9 (qC-10), 156.1 (qC-11), 157.5 (qC-4), 166.1 (qC-19); HRMS (ESI-TOF) m/z: 
[M+H]+ calcd. for C22H20NO3: 346.1438; found: 346.1434. 
tert-Butyl (E)-3-(benzofuro[3,2-c]quinolin-3-yl)acrylate (144)  
Pale yellow solid; yield: 36 mg (80%); m.p. = 160–
162 °C; IR (NaCl): ν 3393 (C-H stretch), 2976 (C-H 
stretch), 1703 (ester C=O), 1560 (aromatic C-C 
stretch), 1452 (aromatic C-C stretch), 1366 (C-N 
stretch), 1285 (C-O stretch), 1149 (C-O stretch) 
cm-1; 1H-NMR (300 MHz, CDCl3) δ: 1.58 (s, 9H, CH3-21, CH3-22, CH3-23), 6.59 (d, 
J = 16.0 Hz, 1H, CH-18), 7.44–7.63 (m, 2H, CH-13, CH-14), 7.71–7.92 (m, 3H, CH-6, 
CH-7, CH-12), 8.11 (dd, J = 7.6, 0.8 Hz, 1H, CH-15), 8.30–8.46 (m, 2H, CH-9, 
CH-17), 9.51 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 28.2 (CH3-21, CH3-22, 
CH3-23), 80.8 (qC-20), 112.2 (CH-12), 117.1 (qC-3), 117.7 (qC-5), 120.8 (CH-15), 
121.4 (CH-6), 122.0 (CH-18), 122.5 (qC-16), 124.3 (CH-14), 125.1 (CH-7), 127.6 
(CH-13), 130.7 (CH-9), 135.6 (qC-8), 142.8 (CH-17), 145.2 (CH-2), 147.4 (qC-10), 
156.2 (qC-11), 157.1 (qC-4), 166.0 (qC-19); HRMS (ESI-TOF) m/z: [M+H]+ calcd. 
for C22H20NO3: 346.1438; found: 346.1432.  
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3.25. General Procedure for Synthesis of 4-Phenoxy Pyridine Substrates  
A mixture of the 4-chloropyridine (1 equiv.) and the 2-bromophenol (5 equiv.) was 
stirred at 130 °C until reaction was completed (18–24 h) as evident by 1H-NMR 
analysis. The cooled reaction mixture was diluted with 10% aq. NaOH (0.5 mL/mmol) 
and stirred at room temperature for 1 h. The aqueous phase was extracted with DCM 
(3 × 1.5 mL/mmol). The combined organic layers were washed with 6M NaOH (3 × 
1 mL/mmol), water (1 mL/mmol) and brine (1 mL/mmol), dried over MgSO4, filtered 
and concentrated in vacuo, yielding product which, if necessary, was recrystallised 
from cyclohexane. 
3-Bromo-4-(2-bromophenoxy)pyridine (145)  
Yellow solid; yield: 455 mg (88%); m.p. = 48–49 °C; IR (NaCl): ν 
3369 (C-H stretch), 1566 (aromatic C-C stretch), 1467 (aromatic C-C 
stretch), 1267 (C-N stretch), 1029 (C-O stretch), 657 (C-Br stretch) 
cm-1; 1H-NMR (300 MHz, CDCl3) δ: 6.45 (d, J = 5.6 Hz, 1H, CH-3), 
7.13-7.24 (m, 2H, CH-8, CH-10), 7.40 (td, J = 7.8, 1.5 Hz, 1H, 
CH-9), 7.70 (dd, J = 7.9, 1.4 Hz, 1H, CH-11), 8.31 (d, J = 5.5 Hz, 1H, CH-2), 8.72 (s, 
1H, CH-6); 13C-NMR (75 MHz, CDCl3) δ: 110.4 (qC-5), 110.9 (CH-3), 116.1 (qC-12), 
122.9 (CH-8), 127.6 (CH-10), 129.2 (CH-9), 134.4 (CH-11), 149.8 (CH-2), 150.6 
(qC-7), 153.4 (CH-6), 160.4 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C11H8Br2NO: 327.8973; found: 327.8963. 
4-(2-Bromophenoxy)pyridine[93] (147) 
Yellow solid; yield: 301 mg (68%); m.p. = 64–65 °C (lit. 64–66 °C); IR 
(NaCl): ν 3038 (C-H stretch), 1575, 1467 (aromatic C-C stretch), 1269 
(C-N stretch), 1047 (C-O stretch), 654 (C-Br stretch) cm-1; 1H-NMR 
(300 MHz, CDCl3) δ: 6.69 (d, J = 6.0 Hz, 2H, CH-3, CH-5), 7.11–7.24 
(m, 2H, CH-8, CH-10), 7.38 (td, J = 7.8, 1.5 Hz, 1H, CH-9), 7.38 (dd, 
J = 7.8, 1.2 Hz, 1H, CH-11), 8.48 (s, 2H, CH-2, CH-6); 13C-NMR (75 MHz, CDCl3) 
δ: 111.6 (CH-3, CH-5), 116.3 (qC-12), 123.1 (CH-8), 127.2 (CH-10), 129.2 (CH-9), 
134.2 (CH-11), 150.7 (qC-7), 151.5 (CH-2, CH-6), 163.9 (qC-4); HRMS (ESI-TOF) 
m/z: [M+H]+ calcd. for C11H9BrNO: 249.9862; found: 249.9862. 
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Spectral data were consistent with those reported in the literature. 
3-Bromo-4-phenoxypyridine (149)  
Yellow oil; yield: 345 mg (88%); IR (NaCl): ν 3046 (C-H stretch), 
1568 (aromatic C-C stretch), 1480 (aromatic C-C stretch), 1273 (C-N 
stretch), 1099 (C-O stretch), 689 (C-Br stretch) cm-1; 1H-NMR (300 
MHz, CDCl3) δ: 6.62 (d, J = 5.6 Hz, 1H, CH-3), 7.06–7.15 (m, 2H, 
CH-8, CH-12), 7.24–7.33 (m, 1H, CH-10), 7.40–7.50 (m, 2H, CH-9, 
CH-11), 8.30 (d, J = 5.6 Hz, 1H, CH-2), 8.70 (s, 1H, CH-6); 13C-NMR (75 MHz, 
CDCl3) δ: 110.9 (qC-5), 111.6 (CH-3), 120.7 (CH-8, CH-12), 125.8 (CH-10), 130.3 
(CH-9, CH-11), 149.8 (CH-2), 153.4 (CH-6), 153.8 (qC-7), 161.4 (qC-4); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C11H9BrNO: 249.9868; found: 249.9862. 
4-(2,4-Dibromophenoxy)pyridine (151)  
Yellow solid; yield: 381 mg (65%); m.p. = 43–45 °C; IR (NaCl): ν 
3393 (C-H stretch), 1593 (aromatic C-C stretch), 1465 (aromatic C-C 
stretch), 1263 (C-N stretch), 1046 (C-O stretch), 665 (C-Br stretch) 
cm-1; 1H-NMR (300 MHz, CDCl3) δ: 6.78 (dd, J = 4.8, 1.4 Hz, 2H, 
CH-3, CH-5), 7.03 (d, J = 8.6 Hz, 1H, CH-8), 7.50 (dd, J = 8.6, 2.3 Hz, 
1H, CH-9), 7.83 (d, J = 2.3 Hz, 1H, CH-11), 8.50 (d, J = 5.2 Hz, 2H, CH-2, CH-6); 
13C-NMR (75 MHz, CDCl3) δ: 111.6 (CH-3, CH-5), 117.3 (qC-12), 119.2 (qC-10), 
124.1 (CH-8), 132.2 (CH-9), 136.5 (CH-11), 150.1 (qC-7), 151.6 (CH-2, CH-6), 163.5 
(qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C11H8Br2NO: 327.8973; found: 
327.8971. 
4-(2,5-Dibromophenoxy)pyridine (152)  
Recrystallised from hot cyclohexane. Off-white solid; yield: 341 mg 
(65%); m.p. = 67–69 °C; IR (NaCl): ν 3035 (C-H stretch), 1565 
(aromatic C-C stretch), 1463 (aromatic C-C stretch), 1257 (C-N 
stretch), 1037 (C-O stretch), 665 (C-Br stretch) cm-1; 1H-NMR (300 
MHz, CDCl3) δ: 6.80 (dd, J = 4.7, 1.6 Hz, 2H, CH-3, CH-5), 7.27–7.35 
(m, 2H, CH-8, CH-10), 7.50–7.60 (m, 1H, CH-11), 8.52 (dd, J = 4.8, 1.5 Hz, 2H, 
CH-2, CH-6); 13C-NMR (75 MHz, CDCl3) δ: 111.7 (CH-3, CH-5), 115.1 (qC-12), 
121.8 (qC-9), 126.0 (CH-8), 130.2 (CH-10), 135.1 (CH-11), 151.6 (qC-7), 151.7 
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(CH-2, CH-6), 163.3 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C11H8Br2NO: 
327.8973; found: 327.8971. 
4-(2,6-Dibromophenoxy)pyridine (153)  
Recrystallised from hot cyclohexane. Off-white solid; yield: 365 mg 
(66%); m.p. = 91–93 °C; IR (NaCl): ν 3393 (C-H stretch), 1590 
(aromatic C-C stretch), 1434 (aromatic C-C stretch), 1261 (C-N 
stretch), 1200 (C-O stretch), 665 (C-Br stretch) cm-1; 1H-NMR (300 
MHz, CDCl3) δ: 6.75 (d, J = 5.0 Hz, 2H, CH-3, CH-5), 7.07 (t, J = 8.1 Hz, 1H, CH-10), 
7.63 (dd, J = 8.1, 1.9 Hz, 2H, CH-9, CH-11), 8.49 (d, J = 5.2 Hz, 2H, CH-2, CH-6); 
13C-NMR (75 MHz, CDCl3) δ: 110.8 (CH-3, CH-5), 118.3 (qC-8, qC-12), 128.3 
(CH-10), 133.1 (CH-9, CH-11), 147.7 (qC-7), 151.5 (CH-2, CH-6), 162.5 (qC-4); 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C11H8Br2NO: 327.8973; found: 327.8961. 
3.26. Synthesis of Compound 148  
Benzofuro[3,2-c]pyridine[37] (148)  
A mixture of 147 (1 equiv.), Pd(OAc)2 (2 mol%), and anhydrous Cs2CO3 (2 equiv.) in  
anhydrous NMP (1.5 mL/mmol) was stirred at 135 °C in a sealed reaction tube until 
the reaction was completed as evident by 1H-NMR analysis (20 h). The cooled reaction 
mixture was diluted with DCM, filtered through a short plug of Celite and 
concentrated in vacuo. The crude mixture was purified by column chromatography 
(DCM/EtOAc 95:5) to yield the product 148 as a yellow solid (0.026 g, 78%). 
Yellow solid; yield: 26 mg (78%); m.p. = 73–74 °C (lit. 74–76 °C); 
IR (NaCl): ν 3393 (C-H stretch), 2918 (C-H stretch), 1575 (aromatic 
C-C stretch), 1447 (aromatic C-C stretch), 1266 (C-N stretch), 1107 
(C-O stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 7.38–7.46 (m, 1H, 
CH-10), 7.49–7.59 (m, 2H, CH-5, CH-9), 7.63 (d, J = 8.1 Hz, 1H, CH-8), 8.04 (d, J = 
7.7 Hz, 1H, CH-11), 8.70 (d, J = 5.6 Hz, 1H, CH-6), 9.30 (s, 1H, CH-2); 13C-NMR 
(75 MHz, CDCl3) δ: 107.5 (CH-5), 112.0 (CH-8), 121.1 (CH-11), 121.7 (qC-3, 
qC-12), 123.9 (CH-10), 128.3 (CH-9), 143.5 (CH-2), 147.4 (CH-6), 155.9 (qC-7), 
161.0 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C11H8NO: 170.0600; found: 
170.0598. Spectral data were consistent with those reported in the literature. 
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3.27. Synthesis of Compound 150 
4-Phenoxy-3-phenylpyridine (150)  
A mixture of 149 (1 equiv.), PhB(OH)2 (1.1 equiv.), Pd(OAc)2 (5 mol%), and 
anhydrous K2CO3 (2 equiv.) in anhydrous NMP (1.5 mL/mmol) was stirred at 135 °C 
in a sealed reaction tube until the reaction was completed as evident by 1H-NMR 
analysis (18 h). The cooled reaction mixture was diluted with DCM, filtered through 
a short plug of Celite and concentrated in vacuo. The crude mixture was purified by 
column chromatography using DCM/EtOAc (99:1–95:5) as eluent to yield the product 
150 as a pale yellow solid (0.010g, 21%). Compound 148 was also obtained as a 
side-product in 37% yield. 
Yellow oil; yield: 10 mg (21%); IR (NaCl): ν 3374 (C-H 
stretch), 2923 (C-H stretch), 1575 (aromatic C-C stretch), 1447 
(aromatic C-C stretch), 1333 (C-N stretch), 1107 (C-O stretch), 
cm-1; 1H-NMR (300 MHz, CDCl3) δ: 6.73 (d, J = 3.5 Hz, 1H, 
CH-3), 7.05-7.10 (m, 2H, CH-8, CH-12), 7.18-7.25 (m, 1H, 
CH-10), 7.35-7.49 (m, 5H, CH-9, CH-11, CH-15, CH-16, CH-17), 7.60-7.66 (m, 2H, 
CH-14, CH-18), 8.42 (d,  J = 3.2 Hz, 1H, CH-2), 8.63 (s, 1H, CH-6); 13C-NMR (75 
MHz, CDCl3) δ: 111.3 (CH-3), 120.6 (CH-8, CH-12), 125.1 (CH-10), 127.5 (qC-5), 
128.0 (CH-16), 128.5 (CH-15, CH-17), 129.4 (CH-14, CH-18), 130.2 (CH-9, CH-11), 
134.3 (qC-13), 150.0 (CH-2), 151.8 (CH-6), 154.6 (qC-7), 161.6 (qC-4); HRMS 
(ESI-TOF) m/z: [M+H]+ calcd. for C17H14NO: 248.1070; found: 248.107. 
3.28. Synthesis of Compound 156 
6-Phenylbenzofuro[3,2-c]pyridine (156)  
A mixture of 153 (1 equiv.), PhB(OH)2 (1.1 equiv.), Pd(OAc)2 (2 mol%), and 
anhydrous K2CO3 (2 equiv.) in anhydrous NMP (1.5 mL/mmol) was stirred at 135 °C 
in a sealed reaction tube until the reaction was completed as evident by 1H-NMR 
analysis (18 h). The cooled reaction mixture was diluted with DCM, filtered through 
a short plug of Celite and concentrated in vacuo. The crude mixture was purified by 
column chromatography, first using DCM/EtOAc 99:1–95:5 as eluent, and then again 
using hexane/EtOAc (8:2–7:3), to yield the product 155 as a pale yellow solid (0.025g, 
22%). 
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Pale yellow solid; yield: 25 mg (22%); m.p. = 66–68 °C; IR (NaCl): 
ν 3402 (C-H stretch), 3032 (C-H stretch), 1577 (aromatic C-C 
stretch), 1450 (aromatic C-C stretch), 1332 (C-N stretch), 1168 (C-O 
stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 7.35–7.63 (m, 5H, 
CH-5, CH-10, CH-15, CH-16, CH-17), 7.67 (dd, J = 7.6, 1.3 Hz, 1H, 
CH-9), 7.83–7.92 (m, 2H, CH-14, CH-18), 8.01 (dd, J = 7.7, 1.3 Hz, 
1H, CH-11), 8.67 (d, J = 5.7 Hz, 1H, CH-6), 9.30 (s, 1H, CH-2); 13C-NMR (75 MHz, 
CDCl3) δ: 107.6 (CH-5), 120.1 (CH-11), 121.6 (qC-3), 122.4 (qC-12), 124.4 (CH-10), 
126.4 (qC-8), 128.07 (CH-9), 128.13 (CH-16), 128.77 (CH-15, CH-17), 128.80 
(CH-14, CH-18), 135.8 (qC-13), 143.7 (CH-2), 147.5 (CH-6), 153.1 (qC-7), 160.9 
(qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C17H12NO: 246.0913; found: 
246.0914. 
3.29. General Procedure for Synthesis of Iodinated 4-Chloroquinolines 
6-Bromo or 7-bromo-4-chloroquinoline (1 equiv.) was added to an inert Schlenk tube 
under a nitrogen atmosphere, along with anhydrous NaI (2 equiv.), CuI (5 mol%) and 
trans-N,Nʹ-dimethylcyclohexane-1,2-diamine (10 mol%). Anhydrous 1,4-dioxane 
(1 mL/mmol) was added and the reaction mixture was degassed with nitrogen for 10 
min. The resulting green/blue mixture was stirred at 110 °C for 24 h under a nitrogen 
atmosphere, until the reaction was determined to be complete by 1H-NMR analysis. 
The reaction mixture was cooled to room temperature and poured into ice water 
(15 mL/mmol) and extracted with DCM (3 × 25 mL/mmol). The combined organic 
extracts were washed with brine (25 mL/mmol), dried over MgSO4, filtered and 
concentrated in vacuo to yield the crude product as a grey solid, which was purified 
by column chromatography (DCM/EtOAc 95:5). 
4-Chloro-6-iodoquinoline[95] (159) 
Pale yellow solid; yield: 180 mg (75%); m.p. = 138–139 °C (lit. 138–
139 °C); IR (NaCl): ν 3382 (C-H stretch), 1549 (aromatic C-C stretch), 
1468 (aromatic C-C stretch), 1340 (C-N stretch), 825 (C-Cl stretch), 
570 (C-I stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 7.50 (d, J = 4.7 Hz, 1H, CH-3), 
7.84 (d, J = 8.9 Hz, 1H, CH-9), 8.02 (dd, J = 8.9, 1.9 Hz, 1H, CH-8), 8.63 (d, J = 1.9 
Hz, 1H, CH-6), 8.79 (d, J = 4.7 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 93.6 
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(qC-7), 121.8 (CH-3), 128.0 (qC-5), 131.4 (CH-9), 133.1 (CH-6), 139.3 (CH-8), 141.3 
(qC-4), 148.1 (qC-10), 150.4 (CH-2); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C9H6ClIN: 289.9234; found: 289.9232. 
Spectral data were consistent with those reported in the literature. 
4-Chloro-7-iodoquinoline[96] (160) 
Pale yellow solid; yield: 195 mg (81%); m.p. = 99–101 °C (lit. 101–
102 °C); IR (NaCl): ν 3399 (C-H stretch), 1576 (aromatic C-C stretch), 
1547 (aromatic C-C stretch), 1365 (C-N stretch), 824 (C-Cl stretch), 
576 (C-I stretch) cm-1; 1H-NMR (300 MHz, CDCl3) δ: 7.51 (d, J = 4.7 Hz, 1H, CH-3), 
7.88–7.99 (m, 2H, CH-6, CH-7), 8.56 (d, J = 1.1 Hz, 1H, CH-9), 8.77 (d, J = 4.7 Hz, 
1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 96.8 (qC-8), 121.7 (CH-3), 125.3 (CH-6), 
125.6 (qC-5), 136.3 (CH-7), 138.8 (CH-9), 142.8 (qC-4), 1497 (qC-10), 150.6 (CH-2); 
HRMS (ESI-TOF) m/z: [M+H]+ calcd. for C9H6ClIN: 289.9234; found: 289.9230. 
Spectral data were consistent with those reported in the literature. 
4-(2-Bromophenoxy)-6-iodoquinoline (161)  
Synthesised according to the same procedure as for the other 4-phenoxyquinoline 
substrates (page 187) using 6-iodo-4-chloroquinoline 159. 
Pale yellow solid; yield: 119 mg (78%); m.p. = 85–87 °C; IR 
(NaCl): ν 3392 (C-H stretch), 1585 (aromatic C-C stretch), 1468 
(aromatic C-C stretch), 1348 (C-N stretch), 1094 (C-O stretch), 
665 (C-Br stretch), 555 (C-I stretch) cm-1; 1H-NMR (300 MHz, 
CDCl3) δ: 6.39 (d, J = 5.2 Hz, 1H, CH-3), 7.18–7.28 (m, 2H, 
CH-12, CH-14), 7.39–7.49 (m, 1H, CH-13), 7.73 (dd, J = 8.3, 1.6 Hz, 1H, CH-15), 
7.83 (d, J = 8.9 Hz, 1H, CH-9), 8.01 (dd, J = 8.9, 2.0 Hz, 1H, CH-8), 8.66 (d, J = 4.9 
Hz, 1H, CH-2), 8.81 (d, J = 1.9 Hz, 1H, CH-6); 13C-NMR (75 MHz, CDCl3) δ: 91.8 
(qC-7), 104.1 (CH-3), 116.4 (qC-16), 122.6 (qC-5), 123.3 (CH-12), 127.6 (CH-14), 
129.3 (CH-13), 130.8 (CH-9), 130.9 (CH-6), 134.4 (CH-15), 139.0 (CH-8), 148.7 
(qC-10), 150.8 (qC-11), 151.5 (CH-2), 159.5 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C15H10BrINO: 425.8991; found: 425.9001. 
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4-(2-Bromophenoxy)-7-iodoquinoline (162)  
Synthesised according to the same procedure as for the other 4-phenoxyquinoline 
substrates (page 187) using 7-iodo-4-chloroquinoline 160. 
Pale yellow solid; yield: 134 mg (91%); m.p. = 113–115 °C; IR 
(NaCl): ν 3387 (C-H stretch), 1557 (aromatic C-C stretch), 1468 
(aromatic C-C stretch), 1299 (C-N stretch), 1219 (C-O stretch), 
665 (C-Br stretch), 575 (C-I stretch) cm-1; 1H-NMR (300 MHz, 
CDCl3) δ: 6.41 (d, J = 5.2 Hz, 1H, CH-3), 7.16–7.29 (m, 2H, 
CH-12, CH-14), 7.39–7.48 (m, 1H, CH-13), 7.73 (dd, J = 7.8, 1.4 Hz, 1H, CH-15), 
7.87 (dd, J = 8.8, 1.7 Hz, 1H, CH-7), 8.13 (d, J = 8.8 Hz, 1H, CH-6), 8.54 (d, J = 1.6 
Hz, 1H, CH-9), 8.64 (d, J = 5.2 Hz, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 96.7 
(qC-8), 104.1 (CH-3), 116.3 (qC-16), 120.2 (qC-5), 123.2 (CH-6), 123.3 (CH-12), 
127.5 (CH-14), 129.3 (CH-13), 134.4 (CH-15), 135.0 (CH-7), 138.1 (CH-9), 150.5 
(qC-10), 150.8 (qC-11), 151.8 (CH-2), 160.9 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ 
calcd. for C15H10BrINO: 425.8991; found: 425.8982.  
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3.30. Synthesis of Compound 163 
3-Bromobenzofuro[3,2-c]quinoline (163)  
A mixture of 121 (1 equiv.), Pd(QPhos)2 (5 mol%), QPhos (10 mol%) and PMP 
(2 equiv.) in anhydrous 1,4-dioxane (5 mL/mmol) was stirred at 125 °C in a sealed 
reaction tube under a nitrogen atmosphere. The reaction was periodically monitored 
by 1H-NMR analysis, and additional Pd(QPhos)2 and QPhos were added whenever the 
reaction seemed to stop progressing. Once the majority of the starting material was 
consumed and the cyclised product constituted the majority of the reaction mixture 
(72 h), the reaction was ceased. The cooled reaction mixture was diluted with DCM, 
filtered through a short plug of Celite and concentrated in vacuo. The crude mixture 
was purified by column chromatography (DCM/EtOAc 99:1–95:5) to yield the 
product 163 as a white solid (0.021 mg, 13%). 
White solid; yield: 21 mg (13%); m.p. = 166–167 °C; IR 
(NaCl): ν 2921 (C-H stretch), 1558 (aromatic C-C stretch), 
1449 (aromatic C-C stretch), 1369 (C-N stretch), 1186 (C-O 
stretch), 738 (C-Br stretch) cm-1; 1H-NMR (300 MHz, CDCl3) 
δ: 7.44–7.62 (m, 2H, CH-13, CH-14), 7.71–7.83 (m, 2H, CH-7, CH-12), 8.10 (dd, J = 
7.6, 0.8 Hz, 1H, CH-15), 8.29 (d, J = 8.8 Hz, 1H, CH-6), 8.46 (d, J = 1.8 Hz, 1H, 
CH-9), 9.49 (s, 1H, CH-2); 13C-NMR (75 MHz, CDCl3) δ: 112.2 (CH-12), 115.8 
(qC-5), 116.7 (qC-3), 120.7 (CH-15), 122.1 (CH-6), 122.4 (qC-16), 123.4 (qC-8), 
124.3 (CH-14), 127.6 (CH-13), 130.5 (CH-7), 132.3 (CH-9), 145.4 (CH-2), 148.0 
(qC-10), 156.0 (qC-11), 157.3 (qC-4); HRMS (ESI-TOF) m/z: [M+H]+ calcd. for 
C15H9BrNO: 297.9862; found: 297.9865. 
Direct Arylation of Phenoxyquinolines  References 
206 
 
3.31. Chapter 3 References 
1. Y. Nishihara Applied cross-coupling reactions, Vol. 80, Springer Science & 
Business Media, 2012. 
2. D. A. Horton, G. T. Bourne, M. L. Smythe, Chem. Rev. 2003, 103, 893-930. 
3. J. Stille, Angew. Chem. 1986, 98, 504-519. 
4. S. L. Buchwald, K. Fugami, T. Hiyama, M. Kosugi, M. Miura, N. Miyaura, A. 
Muci, M. Nomura, E. Shirakawa, K. Tamao Cross-coupling reactions: a 
practical guide, Vol. 219, Springer, 2003. 
5. T.-Y. Luh, M.-k. Leung, K.-T. Wong, Chem. Rev. 2000, 100, 3187-3204. 
6. J. Hassan, M. Sévignon, C. Gozzi, E. Schulz, M. Lemaire, Chem. Rev. 2002, 
102, 1359-1470. 
7. N. Miyaura, A. Suzuki, Chem. Rev. 1995, 95, 2457-2483. 
8. D. Milstein, J. Stille, J. Am. Chem. Soc. 1978, 100, 3636-3638. 
9. E.-I. Negishi, Acc. Chem. Res. 1982, 15, 340-348. 
10. D. Alberico, M. E. Scott, M. Lautens, Chem. Rev. 2007, 107, 174-238. 
11. G. P. McGlacken, L. M. Bateman, Chem. Soc. Rev. 2009, 38, 2447-2464. 
12. L. Ackermann, R. Vicente, A. R. Kapdi, Angew. Chem. Int. Ed. 2009, 48, 
9792-9826. 
13. D. J. C. Constable, P. J. Dunn, J. D. Hayler, G. R. Humphrey, J. J. L. Leazer, 
R. J. Linderman, K. Lorenz, J. Manley, B. A. Pearlman, A. Wells, A. Zaks, T. 
Y. Zhang, Green Chem. 2007, 9, 411-420. 
14. C. S. Yeung, V. M. Dong, Chem. Rev. 2011, 111, 1215-1292. 
15. B. Liégault, D. Lee, M. P. Huestis, D. R. Stuart, K. Fagnou, J. Org. Chem. 
2008, 73, 5022-5028. 
16. H. Li, R.-Y. Zhu, W.-J. Shi, K.-H. He, Z.-J. Shi, Org. Lett. 2012, 14, 4850-
4853. 
17. X.-S. Xue, P. Ji, B. Zhou, J.-P. Cheng, Chem. Rev. 2017, 117, 8622-8648. 
18. M. Kondrashov, D. Provost, O. F. Wendt, Dalton Trans. 2016, 45, 525-531. 
19. L.-C. Campeau, M. Parisien, A. Jean, K. Fagnou, J. Am. Chem. Soc. 2006, 128, 
581-590. 
20. M.-T. Nolan, L. M. Pardo, A. M. Prendergast, G. P. McGlacken, J. Org. Chem. 
2015, 80, 10904-10913. 
Direct Arylation of Phenoxyquinolines  References 
207 
 
21. L.-C. Campeau, M. Parisien, M. Leblanc, K. Fagnou, J. Am. Chem. Soc. 2004, 
126, 9186-9187. 
22. K. Mackey, L. M. Pardo, A. M. Prendergast, M.-T. Nolan, L. M. Bateman, G. 
P. McGlacken, Org. Lett. 2016, 18, 2540-2543. 
23. M.-T. Nolan, J. T. W. Bray, K. Eccles, M. S. Cheung, Z. Lin, S. E. Lawrence, 
A. C. Whitwood, I. J. S. Fairlamb, G. P. McGlacken, Tetrahedron 2014, 70, 
7120-7127. 
24. Y. Yang, J. Lan, J. You, Chem. Rev. 2017, 117, 8787-8863. 
25. R. Rossi, F. Bellina, M. Lessi, C. Manzini, Adv. Synth. Catal. 2014, 356, 17-
117. 
26. D. Ames, A. Opalko, Tetrahedron 1984, 40, 1919-1925. 
27. W. S. Yoon, S. J. Lee, S. K. Kang, D.-C. Ha, J. Du Ha, Tetrahedron Lett. 2009, 
50, 4492-4494. 
28. A. M. Prendergast, G. P. McGlacken, Eur. J. Org. Chem. 2018, 2018, 6068-
6082. 
29. A. M. Prendergast, Z. Zhang, Z. Lin, G. P. McGlacken, Dalton Trans. 2018, 
47, 6049-6053. 
30. J. P. Michael, Nat. Prod. Rep. 2008, 25, 166-187. 
31. R. D. Taylor, M. MacCoss, A. D. G. Lawson, J. Med. Chem. 2014, 57, 5845-
5859. 
32. G. Jones The Chemistry of Heterocyclic Compounds - Quinolines, Vol. 104, 
Wiley, 2009. 
33. T. Iwai, M. Sawamura, ACS Catal. 2015, 5, 5031-5040. 
34. Y.-L. Chen, C.-H. Chung, I. L. Chen, P.-H. Chen, H.-Y. Jeng, Bioorg. Med. 
Chem. 2002, 10, 2705-2712. 
35. Z. Xiao, N. C. Waters, C. L. Woodard, Z. Li, P.-K. Li, Bioorg. Med. Chem. 
Lett. 2001, 11, 2875-2878. 
36. M. Zhao, T. Kamada, A. Takeuchi, H. Nishioka, T. Kuroda, Y. Takeuchi, 
Bioorg. Med. Chem. Lett. 2015, 25, 5551-5554. 
37. F. Hong, Y. Chen, B. Lu, J. Cheng, Adv. Synth. Catal. 2016, 358, 353-357. 
38. M. K. Mehra, M. P. Tantak, I. Kumar, D. Kumar, Synlett 2016, 27, 604-610. 
39. M. Ye, G.-L. Gao, A. J. F. Edmunds, P. A. Worthington, J. A. Morris, J.-Q. 
Yu, J. Am. Chem. Soc. 2011, 133, 19090-19093. 
40. Y. Hayashi, Chem. Sci. 2016, 7, 866-880. 
Direct Arylation of Phenoxyquinolines  References 
208 
 
41. C. Vaxelaire, P. Winter, M. Christmann, Angew. Chem. Int. Ed. 2011, 50, 
3605-3607. 
42. R. Robinson, J. Chem. Soc., Trans. 1917, 111, 762-768. 
43. R. Willstätter, Ber. Dtsch. Chem. Ges. 1901, 34, 129-144. 
44. C. Grondal, M. Jeanty, D. Enders, Nat. Chem. 2010, 2, 167-178. 
45. T. Mukaiyama, H. Ishikawa, H. Koshino, Y. Hayashi, Chem. Eur. J. 2013, 19, 
17789-17800. 
46. Y. Hayashi, S. Ogasawara, Org. Lett. 2016, 18, 3426-3429. 
47. X. Ma, N. Gu, Y. Liu, P. Liu, J. Xie, B. Dai, Z. Liu, Appl. Organomet. Chem. 
2015, 29, 50-56. 
48. K. Matsumura, S. Yoshizaki, M. M. Maitani, Y. Wada, Y. Ogomi, S. Hayase, 
T. Kaiho, S. Fuse, H. Tanaka, T. Takahashi, Chem. Eur. J. 2015, 21, 9742-
9747. 
49. L. Ren, W. Chu, D. Guan, Y. Hou, M. Wang, X. Yuan, Z. Sun, Appl. 
Organomet. Chem. 2014, 28, 673-677. 
50. A. El Akkaoui, S. Berteina‐Raboin, A. Mouaddib, G. Guillaumet, Eur. J. Org. 
Chem. 2010, 2010, 862-871. 
51. J. Koubachi, S. El Kazzouli, S. Berteina-Raboin, A. Mouaddib, G. Guillaumet, 
J. Org. Chem. 2007, 72, 7650-7655. 
52. L. M. Geary, P. G. Hultin, Org. Lett. 2009, 11, 5478-5481. 
53. W.-Y. Wang, X. Feng, B.-L. Hu, C.-L. Deng, X.-G. Zhang, J. Org. Chem. 
2013, 78, 6025-6030. 
54. D. I. Chai, M. Lautens, J. Org. Chem. 2009, 74, 3054-3061. 
55. N. Nicolaus, P. T. Franke, M. Lautens, Org. Lett. 2011, 13, 4236-4239. 
56. P. Dobrounig, M. Trobe, R. Breinbauer, Monatsh. Chem. 2017, 148, 3-35. 
57. D. F. McMillen, D. M. Golden, Annu. Rev. Phys. Chem. 1982, 33, 493-532. 
58. M. Lautens, Y.-Q. Fang, Org. Lett. 2003, 5, 3679-3682. 
59. Y.-Q. Fang, M. Lautens, J. Org. Chem. 2008, 73, 538-549. 
60. T. Saget, D. Perez, N. Cramer, Org. Lett. 2013, 15, 1354-1357. 
61. S. G. Newman, M. Lautens, J. Am. Chem. Soc. 2010, 132, 11416-11417. 
62. A. H. Roy, J. F. Hartwig, J. Am. Chem. Soc. 2001, 123, 1232-1233. 
Direct Arylation of Phenoxyquinolines  References 
209 
 
63. A. H. Roy, J. F. Hartwig, J. Am. Chem. Soc. 2003, 125, 13944-13945. 
64. A. H. Roy, J. F. Hartwig, Organometallics 2004, 23, 1533-1541. 
65. S. G. Newman, M. Lautens, J. Am. Chem. Soc. 2011, 133, 1778-1780. 
66. Y. Lan, P. Liu, S. G. Newman, M. Lautens, K. Houk, Chem. Sci. 2012, 3, 1987-
1995. 
67. S. G. Newman, J. K. Howell, N. Nicolaus, M. Lautens, J. Am. Chem. Soc. 
2011, 133, 14916-14919. 
68. D. A. Petrone, M. Lischka, M. Lautens, Angew. Chem. Int. Ed. 2013, 52, 
10635-10638. 
69. X. Jia, D. A. Petrone, M. Lautens, Angew. Chem. Int. Ed. 2012, 51, 9870-9872. 
70. D. A. Petrone, H. A. Malik, A. Clemenceau, M. Lautens, Org. Lett. 2012, 14, 
4806-4809. 
71. N. I. Shank, H. H. Pham, A. S. Waggoner, B. A. Armitage, J. Am. Chem. Soc. 
2012, 135, 242-251. 
72. L. Shi, T.-T. Wu, Z. Wang, J.-Y. Xue, Y.-G. Xu, Eur. J. Med. Chem. 2014, 84, 
698-707. 
73. A. J. Pickard, F. Liu, T. F. Bartenstein, L. G. Haines, K. E. Levine, G. L. 
Kucera, U. Bierbach, Chem. Eur. J. 2014, 20, 16174-16187. 
74. C. H. Burgos, T. E. Barder, X. Huang, S. L. Buchwald, Angew. Chem. 2006, 
118, 4427-4432. 
75. H. Kaida, T. Goya, Y. Nishii, K. Hirano, T. Satoh, M. Miura, Org. Lett. 2017, 
19, 1236-1239. 
76. F. Ji, X. Li, W. Wu, H. Jiang, J. Org. Chem. 2014, 79, 11246-11253. 
77. L. R. Whittell, K. T. Batty, R. P. Wong, E. M. Bolitho, S. A. Fox, T. M. Davis, 
P. E. Murray, Bioorg. Med. Chem. 2011, 19, 7519-7525. 
78. N. Wang, M. Świtalska, M.-Y. Wu, K. Imai, T. A. Ngoc, C.-Q. Pang, L. Wang, 
J. Wietrzyk, T. Inokuchi, Eur. J. Med. Chem. 2014, 78, 314-323. 
79. B. J. Margolis, K. A. Long, D. L. Laird, J. C. Ruble, S. R. Pulley, J. Org. Chem. 
2007, 72, 2232-2235. 
80. T. Okamoto, H. Hayatsu, Y. Baba, Chem. Pharm. Bull. 1960, 8, 892-899. 
81. T. Zheng, H. Liao, J. Gao, L. Zhong, H. Gao, Q. Wu, Polymer Chemistry 2018, 
9, 3088-3097. 
82. T. Torigoe, T. Ohmura, M. Suginome, Angew. Chem. Int. Ed. 2017, 56, 14272-
14276. 
Direct Arylation of Phenoxyquinolines  References 
210 
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General Conclusions 
In Chapter 1, analogues of HHQ were synthesised with substitutions on the aryl ring, 
methylation at the nitrogen and oxygen atoms, a C-3 substituted quinazolinone 
analogue, and a HHQ analogue with a terminal alkene on the heptyl chain at C-2. An 
improved route to access 6-NO2 HHQ via regioselective nitration of HHQ was 
developed, and the secondary and tertiary methylated analogues of Hartmann’s 
antagonist were prepared. Through a collaboration with the BIOMERIT Research 
Centre at UCC, many of the HHQ analogues were shown to display antiswarming 
activity towards the soil bacterium B. atrophaeus, and antibiofilm activity towards 
pathogenic species of fungi (A. fumigatus) and yeast (C. albicans). A study involving 
the C-3 substituted 6-NO2 HHQ analogues elaborated on the role played by the C-3 
position of AHQs in suppression of PqsR activation. 
Chapter 2 described a new route towards the total synthesis of the nAChR agonist PHT 
which was developed during a placement project undertaken at Syngenta Crop 
Protection in Stein, Switzerland. After devising and pursuing two different 
retrosynthetic plans, the first six steps were optimised to produce good to excellent 
yields of the intermediate compounds. The key [3+2] cycloaddition step, which was 
required to access the bridged bicyclic framework of PHT, worked efficiently. 
Unfortunately, decarboxylation of the PHT substrate could not be achieved despite 
several attempts using various different approaches. A proof-of-concept debenzylation 
indicated that if the challenges of the decarboxylation step could be overcome, the 
target compound PHT would indeed be accessible using this novel synthetic route. 
The application of direct arylation methodology towards the synthesis of fused 
benzofuroquinoline products was demonstrated in Chapter 3. No added phosphine was 
required and the reactions were carried out in air. Using dibrominated substrates, a 
new one-pot tandem reaction was discovered, whereby a Suzuki-Miyaura coupling 
and direct arylation reaction occur on the same substrate, without requiring additional 
reagents or catalyst. Again, this tandem reaction occurs in the absence of added ligand 
and in air. Finally, reversible oxidative conditions allowed for the isolation of the C-7 
brominated product of the direct arylation reaction.
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A structure activity-relationship study of the
bacterial signal molecule HHQ reveals swarming
motility inhibition in Bacillus atrophaeus†
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Gerard P. McGlacken*b
The sharp rise in antimicrobial resistance has been matched by a decline in the identification and clinical
introduction of new classes of drugs to target microbial infections. Thus new approaches are being
sought to counter the pending threat of a post-antibiotic era. In that context, the use of non-growth
limiting small molecules, that target virulence behaviour in pathogens, has emerged as a solution with
real clinical potential. We have previously shown that two signal molecules (HHQ and PQS) from the
nosocomial pathogen Pseudomonas aeruginosa have modulatory activity towards other microorganisms.
This current study involves the synthesis and evaluation of analogues of HHQ towards swarming and
biofilm virulence behaviour in Bacillus atrophaeus, a soil bacterium and co-inhibitor with P. aeruginosa.
Compounds with altered C6–C8 positions on the anthranilate-derived ring of HHQ, display a surprising
degree of biological specificity, with certain candidates displaying complete motility inhibition. In contrast,
anti-biofilm activity of the parent molecule was completely lost upon alteration at any position indicating
a remarkable degree of specificity and delineation of phenotype.
Introduction
Quinolones are fused heterocyclic compounds that form the
active structure of a wide range of potent broad-spectrum anti-
microbial agents.1 In fact, fluoroquinolones are the most suc-
cessful non-natural product class of antibiotics.2 Another
important class of quinolones are the 2-alkyl-4-quinolones
(AHQs) which are used as quorum sensing (QS) signaling
molecules by pathogenic Gram-negative bacteria, including
Pseudomonas aeruginosa,3,4 and certain Burkholderia,5 and
Alteromonas6 strains. AHQ signaling pathways in these species
have been shown to control production of multiple virulence
determinants.7–9 This includes biofilm formation10,11 which is
a structured community of bacterial cells enclosed in a self-
produced polymeric matrix adhering to an inert or living
surface.12,13 This mode of growth is particularly resistant to
phagocytosis by white blood cells and to antibodies and anti-
biotics compared to planktonic cells.13 In multi-drug resistant
bacteria, biofilms play a key role in allowing the pathogen to
overcome host defences and contribute to its virulence. The
primary autoinducers of the P. aeruginosa AHQ signalling
pathway are 2-heptyl-4-quinolone (referred to as the Pseudomo-
nas quinolone signal, or PQS) and its biological precursor
2-heptyl-4-quinolone (HHQ) (Fig. 1)11 and PQS has been
shown to mediate biofilm formation in P. aeruginosa.7
Bacillus atrophaeus (also named B. globigii and previously
B. subtilis) is a Gram positive bacterium which co-inhabits the
soil environment with P. aeruginosa.14 It is indistinguishable
from the typed B. subtilis strain except for the production of
pigment, a feature that marks the organism as particularly
useful in the phenotypic analysis described here. Bacillus subti-
lis species are an excellent and well-utilised model system for
Gram positive bacteria, and a cross-species influence with
P. aeruginosa has been shown.15–17 In light of the co-existence
of both B. atrophaeus and P. aeruginosa in the soil, it is
perhaps unsurprising that communication mechanisms
Fig. 1 P. aeruginosa signalling molecules HHQ and PQS.
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between both organisms would exist and this type of commu-
nity dynamic and microbiome has received considerable atten-
tion.18 However, the extent of these networks and molecular
mechanisms remain to be ascertained. From a microbial
control point of view, suppression of key virulence phenotypes
in bacteria, independent of growth inhibition, should be less
susceptible to the build-up of resistance than with traditional
antibiotic treatment as metabolic processes and bacterial
growth are not directly targeted.
The SAR analysis presented in this study represents the pre-
liminary steps in delineating the action of AHQs towards Gram
positive bacteria, potentially providing a platform for future
therapeutic developments.
Results and discussion
In light of the important roles played by PQS and HHQ in viru-
lence, both molecules have been the subject of a number of
structure–activity relationship (SAR) analyses in recent
years.9,15,16,19 A study carried out by Hodgkinson’s group
showed evidence that the PQS regulator protein (PqsR), iron-
chelating ability (specifically PqsR-independent production of
pyoverdine) and membrane vesicle formation are altered upon
changes to the PQS framework.19 For example, shortening or
lengthening the C2 alkyl chain decreased activation of PqsR
and substitution of the anthranilate ring compromised either
the specific signalling, or membrane vesicle promotion. This
indicates that there are multiple signalling mechanisms by
which HHQ and PQS may possibly act. Antagonism of biofilm
formation or any cross-species effects were not reported.
A structure–activity investigation carried out by Reen et al.
focused on substitution of the C-3 position.16 HHQ was shown
to inhibit biofilm formation in species that inhabit the same
environment as P. aeruginosa whereas PQS and 3-halo-ana-
logues did not. Very recently Steinbach and Hartmann also
reported ‘blocking’ the C-3 position thus preventing hydroxy-
lation to a PQS analogue.20 Following on from their initial
investigations, a simple quinolone was elegantly designed to
target PqsR, and subsequently displayed antivirulence activity
in vivo.
In the current work, we generated a diverse range of novel
HHQ analogues by using derivatized anthranilates and, in
some cases, by extension of the alkyl chain at C-2 from seven
to nine carbons (Table 1). HHQ analogues were prepared using
a procedure similar to that described by Somanathan et al.,21
and us,22 involving a Conrad–Limpach type cyclisation. Thus
β-keto-esters were prepared by acylation of Meldrum’s acid
(2,2-dimethyl-1,3-dioxane-4,6-dione) with octanoyl chloride or
decanoyl chloride, followed by methanolysis (Scheme 1). Con-
densation with a variety of anilines in the presence of acid
using a Dean–Stark apparatus and subsequent cyclisation of
the enamine at reflux in diphenyl ether gave the corresponding
2-heptyl- (1–8) or 2-nonyl-4-quinolone (9–13). During the
course of this work, an alternative method for accessing the
enamine intermediate was also used.23 On occasion, this
method provided a more efficient route. As mentioned earlier,
B. atrophaeus was selected due to is co-existence with P. aerugi-
nosa in the soil. Additionally, the organism is widely used as
a surrogate for B. anthracis investigations in biodefense
research,24 as well as being used as a sterilisation control
strain in industry.25 B. atrophaeus also exhibits strong
swarming and biofilm phenotypes that are characteristic of the
multicellular behaviour underpinning virulence in many
Table 1 2-Alkyl-4-quinolones studied
Compound n R1 R2 R3 R4 Yield
a [%]
1 6 H Me H H 31
2 6 H n-Hex H H 35
3 6 H H –CH–CH–CH–CH– 46
4 6 H H H OMe 12
5 6 H H OMe H 33
6 6 H OMe H H 34
7 6 H Cl H H 21
8 6 H H H Cl 19
9 8 H H H H 23
10 8 H OMe H H 28
11 8 H F H H 16
12 8 H H –CH–CH–CH–CH– 51
13 8 H n-Hex H H 16
a% yields are isolated yields over two steps.
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pathogens.26 Firstly, growth of B. atrophaeus was investigated
in the presence of HHQ, PQS and the suite of analogues. Pre-
pared in honeycomb 100-well plates, in TSB supplemented
with 10 µM of compound or equivalent volume of methanol as
control, all readings were taken on a BioScreen Analyser.
Growth of B. atrophaeus was not significantly altered in the
presence of any of the modified analogues (SM Fig. 1) and
thus any virulence effects were likely to be growth indepen-
dent. Swarming motility is a key multicellular behaviour in
bacteria, considered a virulence phenotype in many organ-
isms27 and underpinned by both intra and intercellular signal-
ling. In the case of B. atrophaeus, swarming cells are joined in
chain formations and the phenotype is promoted by the
secretion of surfactant ahead of the swarm front.28,29 Pre-
viously, we showed that addition of PQS to swarm plates com-
pletely abolished swarming motility in B. atrophaeus, while
addition of HHQ led to little reduction in this key virulence
phenotype.15 However in the study reported herein, addition of
HHQ analogues (1–13) to swarming media led to a significant
alteration in activity compared to the parent compound HHQ.
Remarkably, some analogues exhibited PQS like inhibition,
while others had the effect of promoting swarming activity in
the model organism (Fig. 2). Of the compounds tested, com-
pounds 1, 3, 4, 6, 8, 12 and 14 led to a phenotype statistically
similar to that observed with the carrier control MeOH. Quino-
lones 2, 5, 9, 11 and 13 gave a moderate decrease in swarming,
whereas quinolones 7 and 10 completely abrogated swarming
activity in B. atrophaeus as shown in Fig. 2. Overall substitution
at the 6-position afforded the most response. In compounds
with a C-2 heptyl chain, an electron withdrawing group (7)
gave a dramatic decrease in swarming. Interestingly, this is
consistent with Hartmann’s observation, where a nitro group
at the 6-position gave antagonistic behaviour in P. aerugi-
nosa.20 When we prepared an analogue possessing an electron
releasing group (6) no decrease in swarming was observed.
Fig. 2 Swarming motility of B. atrophaeus is modulated by HHQ, PQS and their analogues on 0.3% agar (w/v) TSA plates. Measurements reflect the
total diameter of the swarm mass, and incorporates the point of inoculation which was performed by sterile toothpick. (A) is a visual representation
of swarming motility in the presence of each analogue while (B) is a graphical representation of the combined data. All experimental datapoints rep-
resent the mean of at least 5 independent biological replicates. Error is presented as standard error of the mean and statistical analysis was per-
formed using Student’s t-test and Bootsratio analysis (* p < 0.05, ** p < 0.005, *** p < 0.001).
Scheme 1 Synthesis of anthranilate-substituted 2-alkyl-4-quinolone.
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Remarkably, extension of the C-2 alkyl chain in the non-inhibi-
tory analogue, afforded a molecule (10) capable of returning
anti-motility behaviour.30
4-Quinolones such as HHQ exist as two interconverting tau-
tomeric forms (a 4-quinolone and a 4-hydroxyquinoline) and
equilibrium tends towards the quinolone form under physio-
logical conditions.31 We were intrigued to delineate these two
structural isomers and elucidate if either structural form main-
tained activity if ‘frozen out’ by methylation at oxygen or
nitrogen.
Preparation of the N- and O-methylated compounds was
carried out by reaction of quinolone substrate 10 with methyl
iodide in acetone and K2CO3. The resulting isomeric mixture
was purified by column chromatography to afford the desired
products 14 (quinolone) and 15 (quinoline) in 14 and 42%
respectively (Scheme 2). When tested on B. atrophaeus, both
compounds had lost anti-swarming activity (Fig. 2) relative to
the parent quinolone (10) but the quinoline form 15 did show
a slight enhancement of anti-swarming activity relative to qui-
nolone 14. We also chose to carry out a similar investigation
using quinolone 2, which displayed enhanced suppression of
swarming motility relative to MeOH (and HHQ itself ). In this
case the N–Me derivative 16 (isolated in 10%) again showed
little or no variation. However, addition of the O–Me variant 17
(isolated in 37%) led to significant enhancement of swarming
motility, in direct contrast to the parent molecule.
Having established the influence of the analogues on
swarming motility, it was expected that a similar profile would
emerge from an investigation of their impact on biofilm for-
mation. Swarming motility is associated with biofilm for-
mation in many pathogens, sometimes in what is an inverse
relationship. Therefore, each analogue was tested for its
impact on pellicle formation and attachment in B. atrophaeus.
Surprisingly, all analogues had lost their anti-pellicle and anti-
biofilm formation activity with respect to the parent molecule
HHQ. Modification of any part of the quinolone framework
led to loss of activity, even for those where suppression of
swarming motility was enhanced (Fig. 3).
Conclusions
In this study we prepared a number of analogues of known
P. aeruginosa signalling molecule HHQ, present in complex
multi-bacterial and multi-kingdom environments, and tested
them for anti-swarming and anti-biofilm activity towards
B. atrophaeus. Several of the novel analogues show potent sup-
pression of swarming motility, which suggests some degree of
freedom regarding the structural interaction between the qui-
nolone core molecule and the receiving organism. However,
the lack of anti-biofilm activity exhibited by all the analogues
would suggest that the anti-biofilm activity exhibited by HHQ
is highly sensitive to structural modification and may reflect a
highly specific protein–ligand interaction.
Previously, HHQ itself has shown very minor anti-swarming
activity in a range of organisms in contrast to PQS, which com-
pletely abolished swarming activity.15 Strikingly, modification
of the quinolone backbone structure described here, resulted
in quinolones possessing potent suppression of swarming,
similar to that with PQS. While there is no evidence of a pqsH
type-activity encoded in a genome outside of P. aeruginosa, and
thus no known mechanism for the hydroxylation of our HHQ
analogues to PQS analogues,15 other biosynthetic steps could
be at play and our investigations in this area will be published
in due course.
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Exploiting Interkingdom Interactions for Development of Small-
Molecule Inhibitors of Candida albicans Biofilm Formation
F. Jerry Reen,a John P. Phelan,a Lorna Gallagher,a David F. Woods,a Rachel M. Shanahan,b Rafael Cano,b Eoin Ó Muimhneacháin,b
Gerard P. McGlacken,b Fergal O’Garaa,c
Biomerit Research Centre, School of Microbiology, University College Cork—National University of Ireland, Cork, Irelanda; School of Chemistry and Analytical and
Biological Chemistry Research Facility (ABCRF), University College Cork—National University of Ireland, Cork, Irelandb; School of Biomedical Sciences, Curtin Health
Innovation Research Institute, Curtin University, Perth, Australiac
A rapid decline in the development of new antimicrobial therapeutics has coincided with the emergence of new andmore aggres-
sive multidrug-resistant pathogens. Pathogens are protected from antibiotic activity by their ability to enter an aggregative bio-
film state. Therefore, disrupting this process in pathogens is a key strategy for the development of next-generation antimicrobi-
als. Here, we present a suite of compounds, based on the Pseudomonas aeruginosa 2-heptyl-4(1H)-quinolone (HHQ) core
quinolone interkingdom signal structure, that exhibit noncytotoxic antibiofilm activity toward the fungal pathogen Candida
albicans. In addition to providing new insights into what is a clinically important bacterium-fungus interaction, the capacity to
modularize the functionality of the quinolone signals is an important advance in harnessing the therapeutic potential of signal-
ing molecules in general. This provides a platform for the development of potent next-generation small-molecule therapeutics
targeting clinically relevant fungal pathogens.
With the ever-increasing emergence of antibiotic-resistantpathogens and the lack of new antibiotics coming to market,
we are entering a “postantibiotic era” (1–3). This realization has
underpinned a global initiative to identify new and innovative
approaches to infection management. As such, targeting virulence
as a potential strategy for developing new antimicrobial drugs has
been the focus of several research initiatives (4–11). In principle,
suppressing virulence behavior and locking pathogens in a vege-
tative non-biofilm-forming lifestyle renders them less infective
and more susceptible to conventional antibiotics (4, 12). While
some success has been achieved against bacterial pathogens (6, 10,
13–19), less focus has been placed on fungal infections, which
nevertheless continue to cause serious complications and mortal-
ity in patients (8, 20–22). Indeed, despite the medical and eco-
nomic damage caused by fungal biofilms, there remains an urgent
and largely unmet need for the identification of compounds able
to specifically and selectively target and inhibit this mode of
growth in clinically relevant fungal pathogens (23).
The predominant nosocomial fungal pathogens, which in-
clude Candida spp., Aspergillus spp., and Fusarium spp., are diffi-
cult to diagnose and cause high morbidity and mortality, even
following antifungal therapy (21). Candida albicans causes a vari-
ety of complications ranging from mucosal disease to deep-seated
mycoses, particularly in immunocompromised individuals (21,
24). Along with other fungal and yeast pathogens, C. albicans is
known to form structured communities called biofilms on medi-
cal devices either pre- or postimplantation, leading to recurring
infections and in some cases death (25, 26). Once established in
the biofilm phase, C. albicans presents a significant clinical prob-
lem, with current treatment options severely limited by the intrin-
sic tolerance of fungal biofilms for antimycotics (20, 27, 28). Re-
cent combination therapies incorporating antibacterial and
antifungal agents have shown some success (29). However, as with
all antibiotic-based strategies, reports of resistance continue to
emerge (27), and biofilms themselves are considered a breeding
ground for the emergence of antibiotic-resistant strains, effec-
tively hastening the onset of the perfect storm where the rapid
decline in new antibiotic production has been met by an equally
rapid increase in multidrug-resistant organisms (1). Thus, there is
a need to consider new anti-infective strategies that do not target
essential processes in the target organism. While blocking biofilms
in these organisms remains a major clinical challenge (26, 30),
exploiting our increased understanding of microbial signaling
networks to control virulence and biofilm behavior is one inno-
vative approach with significant potential.
Many sites of infection are colonized by communities of mixed
fungal and bacterial organisms, and several layers of communica-
tion significantly impact the dynamics and flux of these popula-
tions (31, 32). For example, C. albicans is known to coexist with
Pseudomonas aeruginosa in the cystic fibrosis (CF) lung, and in-
terkingdom communication between the two organisms has pre-
viously been reported (16, 33). ThePseudomonas quinolone signal
(PQS), 2-heptyl-3-hydroxy-4-quinolone, and its biological pre-
cursor, 2-heptyl-4-quinolone (HHQ), are important virulence
factors produced by P. aeruginosa. Structurally, PQS and HHQ
differ by the presence of a hydrogen at C-3 in HHQ and a hydroxyl
group in PQS, giving rise to the increased interest in modulating
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this position to assign biological function to the structures of the
molecules (34–37). Previously, we have shown that HHQ, but not
PQS, suppresses biofilm formation by C. albicans (10). In re-
sponse, C. albicans produces farnesol, which has been shown to
modulate PQS production in P. aeruginosa (33). As both PQS and
HHQ promote virulence and pathogenicity of P. aeruginosa (38,
39), their utility as an anti-Candida treatment falls short of being a
viable antifungal treatment. However, the amenability of these
small molecules to chemical modification provides an opportu-
nity to develop compounds with specificity of function.
The transcriptional data and microscopic imaging described in
this study have implicated components of the cell wall as key fac-
tors in the response of C. albicans to P. aeruginosa alkylhydroxy-
quinolone (AHQ) signaling. Furthermore, the biological activity
of each class of analogue in bacterial, fungal, and host systems
provides new insight into the possible interkingdom role of
AHQs, particularly in a clinical setting such as the CF lung, where
all three systems coexist. From a translational perspective, lead
HHQ analogues with four key features were identified: (i) they
have potent antibiofilm activity toward C. albicans, (ii) they have
selective noncytotoxicity toward mammalian cell lines, (iii) they
are nonagonistic and (iv) they are potentially antagonistic to the
virulent pathogen P. aeruginosa. Several analogues retained the
significant potency of the parent HHQ molecule against C. albi-
cans biofilm formation while simultaneously becoming inactive in
P. aeruginosa quorum sensing. This suggests that these molecules
have the potential to be further optimized for use as anti-infectives
for Candida without the concomitant limitation of P. aeruginosa
virulence augmentation.
MATERIALS AND METHODS
C. albicans stock maintenance and culturing conditions. C. albicans
strain SC5314 was subcultured from 15% (vol/vol) glycerol stocks at
80°C onto yeast-peptone-dextrose (YPD) medium (1% [wt/vol] yeast
extract, 2% [wt/vol] peptone, and 2% [wt/vol] dextrose) and incubated at
30°C overnight.
P. aeruginosa stock maintenance and culturing conditions. P.
aeruginosa strains, PAO1 and a pqsA mutant, containing the chromo-
somally inserted pqsA-lacZ promoter fusion on plasmid pUC18-mini-
Tn7, were maintained on Luria-Bertani (LB) agar plates supplemented
with carbenicillin (200 g/ml) and 5-bromo-4-chloro-3-indolyl--D-ga-
lactopyranoside (X-Gal) (40 g/ml) and incubated at 37°C overnight.
Single colonies were inoculated into LB broth (20 ml) supplemented with
carbenicillin (200 g/ml) and incubated at 37°C with shaking at 180 rpm
overnight. For subsequent experiments, the optical density at 600 nm
(OD600) was recorded, and a starting OD600 of 0.02 was inoculated into
fresh LB broth supplemented with carbenicillin (200 g/ml) and incu-
bated at 37°C with shaking at 180 rpm.
Structural modification of HHQ. The synthesis of HHQ, PQS (40,
41), and other HHQ-based analogues (36, 37) was carried out via previ-
ously described methods. Novel compounds and compounds that re-
quired modified synthesis are described below and in the supplemental
material.
TLC analysis. Silica thin-layer chromatographic (TLC) plates, acti-
vated by soaking in 5% (wt/vol) K2HPO4 for 30 min, were placed in an
oven at 100°C for 1 h (42). Analogues (5l; 10 mM) were spotted approx-
imately 1 cm from the bottom. The spots were dried, and the plates were
placed in a mobile phase comprising dichloromethane-methanol (95:5).
The plate was viewed under UV light when the mobile phase had run 5 cm
below the top of the plate.
Biofilm formation, quantification, and visualization. C. albicans
biofilm formation was carried out in 96-well plates, as previously de-
scribed (43). Seeding densities for all subsequent experiments (n  3)
were an OD600 of 0.05. Biofilm formation was measured as previously
described, using a semiquantitative tetrazolium salt, 2,3-bis-(2-methoxy-
4-nitro-5-sulfophenyl)-2H tetrazolium-5-carboxanilide inner salt (XTT)
reduction assay (44). Experiments were repeated at least three times, with
at least eight technical replicates. Visualization of biofilm formation was
performed on glass coverslips in 6-well plates using confocal scanning
laser microscopy (CSLM). All images were captured using the Zeiss HBO-
100 microscope illuminating system, processed using the Zen AIM appli-
cation imaging program, and converted to JPGs using Axiovision 40 ver-
sion 4.6.3.0. A minimum of three independent biological repetitions were
carried out.
Viable-colony biofilm assay.C. albicans biofilms, supplemented with
analogues and parent compounds, were grown in 6-well plates and incu-
bated overnight at 37°C. Briefly, the OD600s of C. albicans yeast nitrogen
base (YNB) cultures were measured, and the cultures were diluted to an
OD600 of 0.05 in YNB-NP (see below), supplemented with analogues,
plated onto 6-well plates, and incubated for 1 h at 37°C. The medium was
removed, and the wells were washed twice with sterile phosphate-buffered
saline (PBS) and supplemented with fresh YNB-NP with analogues. The
plates were incubated overnight at 37°C, after which the medium was
removed and the wells were washed with sterile PBS. For serial dilutions,
biofilms were harvested by scraping adherent cells into 1 ml PBS, vor-
texed, and serially diluted in sterile PBS. The serial dilutions (100l) were
plated onto YPD agar and incubated overnight at 37°C. Colonies were
counted and recorded the next day.
C. albicans growth curves. Overnight C. albicans cultures grown in
YNB were diluted to an OD600 of 0.05 in YNB supplemented with ana-
logues. Cultures (200 l) were added to each well of a 100-well plate and
grown for 24-h period on a Bioscreen C spectrophotometer (Growth
Curves USA).
RNA isolation and qRT-PCR transcriptional analysis. Overnight C.
albicans cultures were diluted to an OD600 of 0.05 in either YNB or
YNB-NP (Difco). The YNB cultures were supplemented with methanol,
whereas YNB-NP cultures were supplemented with either 100 M HHQ
or the methanol volume equivalent. The cultures were grown at 37°C with
agitation (180 rpm) for 6 h, after which they were centrifuged at 4,000
rpm, the supernatants were discarded, and the pellets were frozen at
20°C until they were processed. RNA was isolated using the MasterPure
Yeast RNA purification kit (Cambio Ltd., Cambridge, United Kingdom)
according to the manufacturer’s specifications and quantified using an
ND-1000 spectrophotometer (NanoDrop Technologies, USA). Genomic
DNA was enzymatically removed using Turbo DNA-free DNase (Am-
bion), and samples were confirmed DNA free by PCR. RNA was con-
verted to cDNA using random primers and avian myeloblastosis virus
(AMV) reverse transcriptase (Promega) according to the manufacturer’s
instructions. Quantitative real-time (qRT)-PCR was carried out using the
Universal Probe Library (UPL) system (Roche) according to the manu-
facturer’s specifications, and samples were normalized toC. albicans actin
transcript expression (ACT1). A full list of primers and UPL probes used
in this study is provided in Table S1 in the supplemental material.
Phenazine extraction.P. aeruginosa strains were cultured as described
above for 24 h, with the addition of analogues (100 M), and pyocyanin
was extracted as described previously (45). The cultures were centrifuged
at 4,000 rpm for 10 min, and the cell-free supernatant (5 ml) was removed.
Chloroform (3 ml) was added and mixed by vortexing. After centrifuga-
tion at 4,000 rpm for 5 min, the lower aqueous phase was transferred to 0.2
M HCl (2 ml). Samples were mixed by vortexing and centrifuged at 4,000
rpm for 5 min to separate the phases. An aliquot of the top phase (1 ml)
was removed and spectrophotometrically analyzed at OD570. Phenazine
production was calculated using the following formula: OD570  2 
17.072, with the units expressed in micrograms per milliliter.
Promoter fusion-based expression analysis. Promoter fusion analy-
ses were performed in a 96-well format, with-galactosidase activity mea-
sured as described previously (46). Briefly, overnight cultures of wild-type
PAO1 pqsA-lacZ (pLP0996) and mutant strain PAO1 pqsA mutant pqsA-
Hydroxy Alkylquinolone Signals Target Candida Biofilm
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lacZ were diluted to an OD600 of 0.02 in LB broth. Analogues at 100 M
final concentration were added, mixed, aliquoted into 96-well plates, and
incubated overnight at 37°C with shaking. The next day, OD600 values
were recorded in a plate reader. Aliquots of cells (0.02 ml) were permeab-
ilized (100 mM dibasic sodium phosphate [Na2HPO4], 20 mM KCl, 2
mM MgSO4, 0.8 mg/ml CTAB [hexadecyltrimethylammonium bro-
mide], 0.4 mg/ml sodium deoxycholate, 5.4 l/ml -mercaptoethanol)
and added to substrate solution (60 mM Na2HPO4, 40 mM NaH2PO4, 1
mg/ml o-nitrophenyl--D-galactoside [ONPG], 2.7 l/ml -mercapto-
ethanol). The kinetics of color development was monitored, and the re-
actions were stopped using 1 M NaCO3. OD420 values were recorded as
described above. Miller units were calculated using the following equa-
tion; 1,000 [(OD420/OD600) 0.02 ml reaction time (min)].
Cytotoxicity assay. Lactate dehydrogenase (LDH) release from a
panel of mammalian cells was assayed as a measure of cytotoxicity using
an LDH colorimetric kit (Roche) according to the manufacturer’s instruc-
tions (36). Briefly, IB3-1 lung epithelial cells, A549 human lung adeno-
carcinoma epithelial cells, DU-145 human prostate cancer cells, and HeLa
cervical cancer cells were seeded onto 96-well plates and treated with
methanol (control) and analogues. Following 16 h of incubation at 37°C
and 5% CO2, the supernatants were removed and added to a catalyst
reaction mixture in a fresh plate and further incubated at 37°C and 5%
CO2 for 30 min to allow color development. After this period, the plate
was analyzed on an enzyme-linked immunosorbent assay (ELISA) plate
reader at OD490. Cytotoxicity was expressed as a percentage of that of cells
treated with 0.1% (vol/vol) Triton (100% cytotoxicity).
Statistical analysis. All graphs were compiled using GraphPad Prism
(version 5.01) unless otherwise stated. All data were analyzed using
built-in GraphPad Prism (version 5.01) functions as specified. The level of
significance was set at a P value of 0.05, and post hoc comparisons between
groups were performed using the Bonferroni multiple-comparison test.
RESULTS
Key modifications of the quinolone framework retain antibio-
film activity toward C. albicans. The HHQ molecule has previ-
ously been shown to suppress biofilm formation in C. albicans at
concentrations from 10 to 100 M (2.47 to 24.7 g/ml) indepen-
dent of any effects on the growth of planktonic cells (10). Previous
structure-function analysis of the activity of the quinolone frame-
work had implicated the C-3 position as a key component of in-
terspecies antibiofilm activity (36). We undertook further modi-
fication of the HHQ parent molecule with the aim of developing
viable antibiofilm compounds to target C. albicans. These com-
pounds were incorporated into a larger collection of alkylquin-
olone analogues, systematically modified at different positions on
the molecule, and classified on the basis of their substitutions rel-
ative to the parent framework HHQ (Table 1).
The suite of analogues was first tested to establish their potency
as antibiofilm compounds against C. albicans using an optimized
XTT assay, a commonly used quantitative method to assess Can-
dida biofilm mass and growth (47). As previously described (10),
HHQ significantly suppressed biofilm formation compared to un-
treated and methanol-treated cells, whereas PQS appeared to in-
duce biofilm formation (Fig. 1). When all the analogues were sim-
ilarly screened by XTT assay, several had antibiofilm activities
similar to that of HHQ (compounds 1 and 2 [class I; modified at
C-3]; 3, 4, 6, 7, and 9 [class II; modified anthranilate ring]; and 12
[class III; modified alkyl chain]) (Fig. 2a). These analogues were
diverse members of classes I, II, and III, suggesting that several
components of the HHQ framework contribute to the antibiofilm
activity of the parent compound. A number of substitutions led to
intermediate antibiofilm activity, including 5, 8, 10, and 11 (class
II; modified anthranilate ring) and 15 (class V; modified anthra-
nilate ring and alkyl chain length), while some analogues had
completely lost the ability to suppress C. albicans biofilm forma-
tion, e.g., 13 (class IV; modified C-4) and the class V compounds
14, 16, and 17 (Fig. 2a). While modification of the C-3 position to
produce PQS led to loss of antibiofilm activity (Fig. 1), incorpo-
ration of an -N-NH2 moiety (compound 2) at the 3 position or
substitution of C-3 with NH (1) did not affect the ability to sup-
press C. albicans biofilm formation (Fig. 2a). Addition of chlorine
(Cl) at the C-6 and C-8 positions of the anthranilate ring (com-
pounds 6 and 7) also did not lead to loss of antibiofilm activity. In
contrast, the introduction of considerable steric bulk with the ad-
dition of an n-hexyl alkyl chain at C-6 of the anthranilate ring
(compound 5) or elaboration of the aromatic group, as with the
naphthyl compound (compound 8), resulted in compounds with
significantly less potent antibiofilm activity than HHQ. These data
suggest an exquisite level of specificity for the interaction between
HHQ and the C. albicans biofilm intracellular machinery. Modi-
fication of the C-2 alkyl chain from n-heptyl (HHQ) to n-nonyl C9
(compound 12) did not affect antibiofilm activity, while parallel
modification of the anthranilate ring resulted in a complete loss, as
with the class V compound 16 or 17. After modifying the C-4
position (C  O to C  S) (compound 13), the quinolone thiol
exhibited an increase in XTT activity (P  0.05) relative to con-
trols (Fig. 2a), comparable to the increase observed in the presence
of PQS (Fig. 1). Previously, we have shown that HHQ elicits a
dose-dependent reduction in C. albicans biofilm formation (10).
In order to determine if this also applied to the analogues that
retain antibiofilm activity, dose-response analysis of selected com-
pounds, 1, 2, 4, 6, and 12 representing classes I, II, and IV, was
undertaken. This revealed compound-specific responses, with 10
M compounds 2, 4, and 12 being sufficient to elicit a statistically
significant reduction in biofilm formation (Fig. 2b). All five com-
pounds reduced biofilm formation when applied at 50 M and
100 M. To further confirm the antibiofilm activity of the lead
compounds, viable-colony counts were performed on selected an-
alogues using the maximum 100 M compound dose. This con-
firmed the outputs from the XTT assays; all the analogues, along
with HHQ, significantly reduced viable biofilm cells in compari-
son to the control (see Fig. S1a in the supplemental material).
Importantly, the antibiofilm activity was found to be independent
of planktonic growth, which was unaffected in the presence of
selected compounds (see Fig. S1b in the supplemental material).
Microscopic staining reveals structural changes in C. albi-
cans biofilms. The formation of biofilms in bacteria, yeasts, and
fungi is a highly ordered process involving multicellular behavior
and has been defined in several stages (22). Confocal microscopy
combined with intracellular staining was used to assess the struc-
tural integrity and cellular morphology of C. albicans incubated
on coverslips. Biofilms were individually stained with each of the
dyes, and multiple fields of view were visualized to accurately rep-
resent the effects of the analogues. The biofilms observed for
methanol-treated and untreated controls displayed all the charac-
teristics of a typical C. albicans biofilm and were classified as wild
type (Fig. 1). Calcofluor, concanavalin A, and FUN-1 staining
revealed uniform distribution of chitin/cellulose and cell wall
mannosyl/glucosyl residues indicative of viable wild-type mor-
phology (Fig. 1). The analogues identified by XTT assay as causing
impaired biofilm formation (1, 2, 3, 4, 6, 7, 9, 12, and 15) exhibited
markedly disrupted structures when grown on coverslips and
were classified as atypical morphologies (Fig. 3). Cells treated with
Reen et al.
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TABLE 1 Compound data
Compound Structure Yield (%)a MW Rf
b Classc
1 76 244.3 0.319 I
2d 3 259.3 0.907 I
3 34 273.4 0.252 II
4 31 257.4 0.286 II
5 35 327.5 0.504 II
6 21 277.8 0.403 II
7 19 277.8 0.630 II
8 46 293.4 0.294 II
9d 6 277.8 0.361 II
10 33 273.4 0.261 II
11 12 273.4 0.504 II
12 23 271.4 0.395 III
13d 48 259.4 1 IV
(Continued on following page)
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class I analogues were found to be largely compromised in their
biofilm-forming capabilities and were classified as morphologi-
cally atypical. Biofilms produced with both 1 and 2 were signifi-
cantly distorted, displaying a spindle-like phenotype. Hyphae
were short and predominantly displayed yeast cell types rather
than hyphal structures. Other structure-disrupting analogues
were from classes II, III, and V, suggesting that specific modifica-
tions on the anthranilate ring and alkyl chain variation do not
significantly affect the antibiofilm activity compared to the parent
compound (Fig. 3).
Some analogues, including those that exhibited intermediate
activity in the XTT assay, did not alter the biofilm structure, with
5, 11, 13, 14, and 16 all placed into the wild-type morphology
group. Biofilms formed in the presence of compound 13 showed
hyperproduction of short hyphae, creating a dense mycelial net-
work (see Fig. S2 in the supplemental material). The remaining
analogues from class II, 8 and 10 (see Fig. S1a in the supplemental
material), caused significant biofilm disruption, with fragmented
hyphae, stunted vegetative growth, and quite large cell debris
fields. Cells incubated with the class V molecule 17 induced a
severely compromised phenotype (see Fig. S2 in the supplemental
material) where debris fields comprising yeast cells and blasto-
spores characterized the structural phenotype.
Enhanced gene transcript expression ofHWP1, ECE1,ALS3,
IHD1, and the uncharacterized open reading frame (ORF)
orf19.2457provides amolecularmechanism for alkyl quinolone
activity towardC. albicans. In addition to providing new insights
into the interkingdom relationship between these important
TABLE 1 (Continued)
Compound Structure Yield (%)a MW Rf
b Classc
14 16 355.6 0.538 V
15 28 301.4 0.286 V
16 51 321.5 0.462 V
17 16 289.4 0.504 V
a Yields were isolated over all steps.
b TLC on silica plates with dichloromethane-MeOH (95:5) mobile phase.
c Class I, modified C-3; class II, modified anthranilate ring; class III, modified alkyl chain; class IV, modified C-4; class V, modified anthranilate ring and alkyl chain.
d New compounds synthesized in this study.
FIG 1 C. albicans biofilms are altered in the presence of HHQ. FilamentousC. albicans biofilms grown in the presence of PQS and HHQ (100M) were assessed
structurally by confocal microscopy and metabolically using the XTT biofilm assay. The data (means and standard errors of the mean [SEM]) are representative
of three independent biological experiments and are presented relative to the untreated control. A two-tailed paired Student t test was performed by comparison
of C. albicans in the presence of HHQ and PQS with C. albicans treated with methanol or ethanol (**, P 0.01; ***, P 0.001). ConA, concanavalin A.
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pathogens, strong emphasis has recently been placed on ligand-
receptor interactions and the need to provide molecular mecha-
nisms for the action of any potential therapeutic compound (48).
We previously implicated TUP1 in the HHQ-mediated suppres-
sion of biofilm formation in C. albicans, suggesting a role for the
cell wall in this interaction (10, 16). More recently, several reports
have shown changes in expression of cell wall-associated genes
linked to biofilm formation in the organism (16, 20, 28, 49–51).
They included a cohort of eight genes that are proposed to consti-
tute the core filamentous response network, namely, ALS3, ECE1,
HGT2, HWP1, IHD1, RBT1, DCK1, and the orf19.2457 gene with
unknown function (51). Therefore, transcript expression of a co-
hort of genes implicated in cell wall biogenesis, hyphal develop-
ment, biofilm formation, and other related functions that were
previously shown to be upregulated during the morphological
transition from yeast to filamentous growth was investigated (see
Table S1 in the supplemental material) (16, 51). The housekeep-
ing gene ACT1 was chosen for normalization based on previous
biofilm studies (52). We observed that several transcripts were
hyperexpressed in an HHQ-dependent manner, specifically,
HWP1, ECE1, ALS3, IDH1, and the as yet uncharacterized
orf19.2457 (Fig. 4). The remaining transcripts (CPH1, EFB1, ESS1,
RBT1, TUP1, BCR1, DCK1, and HGT2) yielded expression pat-
terns similar to those of control cells (see Fig. S3 in the supple-
mental material). It was perhaps somewhat surprising that,
while treatment of C. albicans with P. aeruginosa supernatants
has previously been shown to downregulate expression of the
RBT1, RBT5, and RBT8 genes (16), expression of RBT1 was
unaltered in the presence of HHQ (see Fig. S3 in the supple-
mental material). Taken together, these data suggest that HHQ
induces a specific subset of cell wall proteins in C. albicans.
Further work is needed to identify the upstream components of
this response, although in silico screening of C. albicans genome
sequences has ruled out the presence of an obvious PQS recep-
tor (unpublished data).
Lead compounds display reduced cytotoxic activity toward
specificmammalian cell lines. Evaluating the cytotoxicity of syn-
thetic compounds is crucial in the context of developing targeted
and highly optimized molecular therapeutics that are benign to
human cellular physiology and ideal for use in a clinical environ-
ment. In previous work, we showed that analogue 1 was signifi-
FIG 2 Decoration of HHQ exhibits variable biofilm activity against C. albi-
cans. (a) A panel of HHQ-derivatized analogues were incubated with filamen-
tous C. albicans and screened for biofilm formation using the metabolic XTT
biofilm assay. The data are presented as OD492 spectrophotometric output
normalized to the untreated control and are representative of at least three
independent biological replicates, with error bars representing SEM. (b) Dose-
dependent XTT analysis of selected antibiofilm compounds applied at 10, 50,
and 100 M. The data are the averages from at least two independent biolog-
ical replicates, each constituting eight technical replicates. Statistical analysis of
both data sets was performed by one-way analysis of variance (ANOVA) with
Bonferroni corrective testing, and the results are presented relative to the
MeOH control values; *, P 0.05; **, P 0.01; ***, P 0.001.
FIG 3 Microscopic analysis reveals altered biofilm structures. Analogues that
lead to reduced C. albicans biofilm formation in the XTT assay (1, 2, 3, 4, 6, 7,
9, 12, and 15) exhibit compromised biofilm structures. FilamentousC. albicans
biofilm in the presence of analogues (100 M) was stained for chitin and
cellulose (calcofluor; blue); lectins that bind to sugars, glycolipids, and glyco-
proteins (concanavalin A; green); and live/dead cells (FUN-1; red).
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cantly less cytotoxic than HHQ, with an 80% reduction in LDH
release relative to the parent compound (36). Therefore, the suite
of analogues was tested for in vitro cytotoxicity toward IB3-1 air-
way epithelial cells. Class I analogues exhibited reduced cytotox-
icity to IB3-1 cells, with compound 2 displaying approximately
34% toxicity (Fig. 5a). Several class II analogues (4, 6, and 9)
exhibited reduced cytotoxicity relative to IB3-1 cells treated with
HHQ, with 7 not reaching statistical significance. The class III
analogue 12 was comparable to HHQ. Of the analogues that did
not retain antibiofilm activity, 5, 8, 10, and 11 exhibited variable
cytotoxicity to IB3-1 cells, whereas 13 exhibited considerably re-
duced cytotoxicity to IB3-1 cells (see Fig. S4 in the supplemental
material). Finally, compound 16 exhibited very low levels of cyto-
toxicity, while 17 was reduced relative to HHQ-treated cells. Com-
pound 15 was the most toxic, killing approximately 91% of all cells
(Fig. 5a).
In order to achieve a more comprehensive understanding of
the selective toxicity of the lead compounds, several additional cell
lines were tested (Fig. 5b). LDH release assays were performed in
A549, DU145, and HeLa cell lines in the presence of 100M of the
lead compounds and revealed distinct cytotoxicity profiles, with 1
and 9 consistently proving the least cytotoxic of the compounds
tested. Compounds 4 and 6 exhibited reduced cytotoxicity in
DU145 cells (although not statistically significant) but were com-
parable to HHQ in both the A549 and HeLa cell lines, while com-
pound 2 exhibited increased cytotoxicity relative to HHQ in
DU145 cells (Table 2). These data suggest that cell-specific cyto-
toxicity analysis will need to be performed prior to the introduc-
tion of these compounds in an applied setting.
HHQ analogues display a spectrum of agonist activity to-
ward P. aeruginosa virulence. Taken together, compounds 1, 4,
6, and 9 pass both the first and second criteria described above, i.e.,
they retain antibiofilm activity towardC. albicanswhile exhibiting
reduced selective cytotoxicity toward specific host cell lines. How-
ever, both HHQ and PQS are coinducers of the virulence-associ-
ated LysR-type transcriptional regulator PqsR (41). The structural
moieties that underpin the interaction between HHQ/PQS and
PqsR remain to be fully characterized, although recent studies
have reported diverse classes of PqsR antagonists (53–55) and im-
plicated the hydrophobic pocket situated within the PqsR protein
(56). Therefore, in order to assess whether the lead compounds
could elicit a virulence response from P. aeruginosa, phenazine
production and pqsA promoter activity (57) were monitored in a
pqsA mutant where the capacity to produce native HHQ and PQS
had been lost.
Both HHQ and PQS restored phenazine production in the
pqsAmutant strain (Fig. 6a). In contrast, the majority of analogues
did not restore phenazine production in the strain, with the nota-
ble exception of compound 9. Several analogues from different
classes did partially restore phenazine production in the mutant
background, including compounds 10, 12, and 17 (Fig. 6; see Fig.
S5 in the supplemental material). None of the analogues inter-
fered with phenazine production in the wild-type PAO1 strain,
suggesting that they are ineffective as PQS antagonists (see Fig. S5
in the supplemental material).
Similarly, while some degree of PqsR agonist activity was ob-
served in the presence of compounds 6, 9, 10, 12, 13, and 17, only
HHQ and PQS significantly induced promoter activity. All the
FIG4 Hyphal pathway genes are hyperexpressed in response to HHQ. Transcript expression analysis (real-time RT-PCR) of a panel of biofilm genes was assessed
inC. albicans grown in YNB-NP (filament-inducing medium) in 100M HHQ for 6 h at 37°C. All the data were normalized to a housekeeping gene (ACT1). The
error bars represent standard deviations (SD) of three independent biological replicates. A two-tailed paired Student t test was performed by comparison of
HHQ-treated cells with methanol control in YNB-NP inducing medium (*, P 0.05).
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other analogues did not influence promoter activity in this system
(Fig. 6B; see Fig. S5 in the supplemental material). Somewhat sur-
prisingly, antagonistic activity toward pqsA promoter activity was
not observed, with almost all the analogues failing to significantly
suppress pqsA promoter activity in the wild-type strain (see Fig. S5
in the supplemental material). The relative ineffectiveness of these
analogues as PQS antagonists may in part be due to hydroxylation
of HHQ analogues (H at C-3) to PQS analogues (OH at C-3), thus
establishing the nonantagonistic behavior explained by a recent
report by Lu and colleagues, where the action of PqsH rendered
anti-PQS compounds ineffective through bioconversion (55).
DISCUSSION
Current antimicrobial therapies tend to be non-pathogen specific,
and there is evidence to suggest that the availability of relatively
nontoxic broad-spectrum therapies has contributed to the emer-
gence of resistance among both targeted and nontargeted mi-
crobes (58, 59). Consequently, there is an urgent need to create
innovative new options for the targeted prevention of microbial
infection while avoiding the inevitable emergence of resistance
that is the hallmark of broad-spectrum antibiotic therapies (59,
60). Increasingly, industry, academia, and regulatory bodies have
become interested in single-pathogen therapies to treat highly re-
sistant or totally resistant bacterial pathogens, rightly viewed as an
area of high unmet need (61–63). Exploiting interkingdom com-
FIG 5 Cytotoxicity toward specific mammalian cell lines is reduced in lead compounds. (a) Cytotoxicity, measured as a percentage of total LDH released from
IB3-1 cells treated with 0.1% Triton X-100 (100% cytotoxicity), was significantly reduced in the presence of several lead compounds. The data (means and SEM)
are representative of three independent biological experiments. (b) Selected lead compounds were tested against A549, DU145, and HeLa cell lines. The data
represent four independent biological replicates, and all the data points are normalized to Triton X-100 as described for panel a. One-way ANOVA was
performed, with Bonferroni corrective testing on all data sets, and comparison to an MeOH control is presented; *, P 0.05; **, P 0.01; ***, P 0.001.
TABLE 2 Selective toxicity indices of lead compounds
Compound
Selective toxicity index (% toxicity)
IB3-1 A549 DU145 HeLa
HHQ 26–50 51–75 26–50 76–100
PQS 0–25 26–50 0–25 0–25
1 0–25 0–25 0–25 0–25
2 26–50 76–100 76–100 76–100
4 0–25 76–100 26–50 76–100
6 26–50 51–75 0–25 76–100
9 0–25 26–50 0–25 26–50
12 26–50 51–75 26–50 76–100
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munication networks, and the mode of action of the chemical
messages or signals employed therein, offers us a powerful plat-
form from which to meet this need.
Previously, we showed that the HHQ interkingdom signal
molecule from P. aeruginosa could suppress biofilm formation
in C. albicans at concentrations ranging from 10 to 100 M
(2.47 to 24.7 g/ml) (10). This suppression occurred indepen-
dently of any growth limitation in planktonic cells, and mor-
phogenesis on spider medium was also found to be unaffected
(10). The design and subsequent analysis of a suite of analogues
based on the core HHQ quinolone framework has led to the
identification of several lead compounds that retain antibio-
film activity toward C. albicans but exhibit significantly reduced
cytotoxicity toward IB3-1 epithelial cells compared with the
parent HHQ molecule. The selective cytotoxicities of the lead
compounds, together with the dose-dependent antibiofilm ef-
fects, will be key considerations in determining the cell line-
specific therapeutic index of lead analogues as part of the on-
going development of these compounds. Furthermore, unlike
HHQ, these lead compounds are now inactive toward the P.
aeruginosa PqsR quorum-sensing system, a critical requirement
for their potential future development as antibiofilm therapeu-
tics. In addition, the ability to generate hydrochloride salts of
the compounds (reference 36 and data not shown) suggests
that the solubility of future therapeutics based on these scaf-
folds will not be a bottleneck. Several strategies have been pro-
posed for the implementation of antibiofilm compounds as
clinical therapeutics to target C. albicans biofilm infections
(64). As the HHQ analogues possess antibiofilm, but not anti-
Candida, activity, they would disrupt the formation of biofilms
but not likely remove the planktonic cells that remain at the site
of infection. Therefore, combination with conventional anti-
fungal compounds would be required for effective clearance.
Alternatively, where the potency of the antibiofilm activity can
be synthetically enhanced through further derivatization,
clearance by the immune system might also be realistic.
The molecular mechanisms through which AHQs and the
lead compounds identified in this study disrupt the formation
of biofilms by C. albicans remain to be fully elucidated. Previ-
ously, we have shown that HHQ does not affect adhesion, but
rather directly impacts the subsequent developmental stages in
a TUP1-dependent manner (10). In this study, we have shown
that the expression of several cell wall-associated genes is in-
creased in response to HHQ during the switch to hyphal
growth. These genes have previously been implicated in the
formation of C. albicans biofilms and have been shown to ex-
hibit increased levels of expression during the hyphal transi-
tion (50, 51, 65). Therefore, antibiofilm compounds might be
expected to suppress this induction rather than enhance it.
However, five of the target genes tested exhibited an increase in
expression relative to control cells under inducing conditions.
This may be a reflection of the previous observation that HHQ
interferes with the later stages of biofilm development (10).
Alternatively, this hyperexpression phenotype may affect the
capacity of the cell to engineer a community-based biofilm.
Future studies will focus on elucidating the pathways through
which C. albicans perceives and responds to challenge with
HHQ with the aim of identifying potential therapeutic targets.
Further work using defined in vivo models of biofilms and
infection will be required to further the development and evalua-
tion of these small molecules as antibiofilm compounds. Models
are now available for the investigation of infections involving
medical devices, such as vascular catheters, dentures, urinary
catheters, and subcutaneous implants, as well as mucosal biofilm
infections (66). The ongoing development of cell-based or animal
models to study in vivo infections (66–69), whether as single-
pathogen or coculture systems (70), has provided a well-equipped
tool kit for the preclinical assessment of these AHQ-based com-
pounds.
Conclusions. In this study, we have functionalized the impor-
tant microbial signaling molecules HHQ and PQS in order to
exploit their interkingdom roles in controlling biofilm formation
in C. albicans. In addition to deciphering further insights into the
molecular mechanism through which these chemical messages
elicit a biofilm-suppressive response from C. albicans, the bioac-
tivity of several lead compounds has provided a viable platform
for the development of next-generation therapeutics. Crucially,
some of these compounds are nontoxic to mammalian cells and
FIG 6 Influence of HHQ analogues on PQS-dependent virulence phenotypes in P. aeruginosa. Phenazine production (a) and pqsA-lacZ promoter activity (b)
were quantified in a PAO1 pqsA mutant in the presence of HHQ, PQS, and lead compounds. The data are presented as means and SEM and are representative
of at least three independent biological replicates. One-way ANOVA was performed, with Bonferroni corrective testing, and statistical significance relative to the
MeOH control is presented; **, P 0.01; ***, P 0.001.
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have been rendered incapable of activating P. aeruginosa virulence
systems, thus highlighting their potential utility as an effective
therapy combatting human infection.
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Faced with the continued emergence of antibiotic resistance to all known classes of
antibiotics, a paradigm shift in approaches toward antifungal therapeutics is required.
Well characterized in a broad spectrum of bacterial and fungal pathogens, biofilms are a
key factor in limiting the effectiveness of conventional antibiotics. Therefore, therapeutics
such as small molecules that prevent or disrupt biofilm formation would render
pathogens susceptible to clearance by existing drugs. This is the first report describing
the effect of the Pseudomonas aeruginosa alkylhydroxyquinolone interkingdom
signal molecules 2-heptyl-3-hydroxy-4-quinolone and 2-heptyl-4-quinolone on biofilm
formation in the important fungal pathogen Aspergillus fumigatus. Decoration of the
anthranilate ring on the quinolone framework resulted in significant changes in the
capacity of these chemical messages to suppress biofilm formation. Addition of methoxy
or methyl groups at the C5–C7 positions led to retention of anti-biofilm activity, in some
cases dependent on the alkyl chain length at position C2. In contrast, halogenation
at either the C3 or C6 positions led to loss of activity, with one notable exception.
Microscopic staining provided key insights into the structural impact of the parent and
modified molecules, identifying lead compounds for further development.
Keywords: biofilm, Aspergillus fumigatus, Pseudomonas aeruginosa, interkingdom interactions,
alkylhydroxyquinolone (AHQ), PQS, HHQ
INTRODUCTION
Aspergillus fumigatus is an opportunistic pathogenic fungus associated with hospital-acquired
infections. A. fumigatus infections contribute to morbidity and mortality in people with respiratory
diseases such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), as well
as infecting open skin wounds in burn patients and medical implants (Peleg et al., 2010; Speirs
et al., 2012). Indeed, there is a growing awareness of the importance of fungal pathogens in
the lung and other sites of infection through global microbiome analyses (Kolwijck and van de
Veerdonk, 2014; Kim et al., 2015). However, as with their bacterial counterparts, function and
effect in relation to their contribution to the pathophysiology of disease can be harder to define.
Aspergillus infection takes two principal forms; invasive pulmonary aspergillosis (IPA) and chronic
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necrotising pulmonary aspergillosis, with the latter being
characterized by the transformation of conidia to hyphae
(germination), which can subsequently invade the tissue (Kaur
and Singh, 2014; Kolwijck and van de Veerdonk, 2014).
Hyphal stage cells typically adopt a structured biofilm, either
as monospecies or multispecies, at which point the biofilm-
embedded cells become highly resistant to antimicrobial drug
therapy (Seidler et al., 2008; Manavathu et al., 2014). Several
reasons have been proposed to explain this increased tolerance,
such as biofilm specific upregulation of efflux proteins, the
presence of extracellular matrices, and persister cells that are
inherently drug resistant/tolerant due to their low metabolic rate
(Manavathu et al., 2014).
These inherently resistant biofilm characteristics of
A. fumigatus have led to conventional antifungal therapies
rapidly becoming redundant in the treatment of not only
nosocomial infections (e.g., hematologic disease) but also on
indwelling medical devices (IMDs) and implants (Ramage and
Williams, 2013). While both Candida and Aspergillus species are
causative agents in approximately 8% of all implant infections,
their potency and resistance to antifungals is increasing steadily
with survival rates for some implant patient groups as low as
50% (Lynch and Robertson, 2008; Ramage and Williams, 2013).
More recently, Aspergillus contamination of nebuliser devices
used by CF patients has been reported (Peckham et al., 2016).
The upward trend in Aspergillosis and other major fungal
infections poses a significant clinical, financial and health threat
and requires concerted and sustained efforts to identify and
characterize novel anti-fungal agents to tackle these preventable
diseases.
It is now becoming clear that the co-existence and mutual
interaction of bacteria and fungi at the site of infection
contributes to the pathogenesis of disease. In the case of
CF, A. fumigatus has been isolated in up to 60% of patients
with Pseudomonas aeruginosa infection, suggesting a close
relationship between established colonization by P. aeruginosa
and superinfection by A. fumigatus (Paugam et al., 2010; Briard
et al., 2015). Interkingdom interactions between A. fumigatus
and bacterial competitors has been described previously, with
significant attention focused on the interaction with P. aeruginosa
(McAlester et al., 2008; Mowat et al., 2010; Briard et al., 2015;
Ferreira et al., 2015; Zheng et al., 2015). Perhaps somewhat
surprisingly, given their co-occurrence, many of these studies
describe an antagonistic influence of P. aeruginosa secreted
factors on A. fumigatus biofilm formation. Mowat et al. (2010)
ascribed the competitive inhibition of filamentous A. fumigatus
growth by P. aeruginosa to the effects of small diffusible and
heat-stable molecules. Interestingly, anti-biofilm activity in the
supernatants of P. aeruginosa lasR and lasI quorum sensing
mutants was reduced but not lost entirely, suggesting the factors
responsible are not entirely under Acyl Homoserine Lactone
(AHL) control. Several studies have described the impact of
redox active metabolites produced by P. aeruginosa on biofilm
formation and hyphal development in A. fumigatus (Briard et al.,
2015; Zheng et al., 2015), effects that are likely to be strain and
condition specific (Ferreira et al., 2015). More recently, Briard
et al. (2016) demonstrated stimulation of A. fumigatus growth
by volatile compounds produced by P. aeruginosa. Moreover,
strain specificity was also highlighted in a recent study by
Shirazi et al. (2016) where biofilm filtrates of P. aeruginosa
strains isolated from CF patients were shown to inhibit pre-
formed A. fumigatus biofilms through apoptosis. Therefore,
it is clear that the factors that govern the dynamics of the
P. aeruginosa – A. fumigatus interaction in vivo remain to be fully
understood. From a clinical perspective, a strategy that targets
biofilm inhibition should be less susceptible than conventional
antibiotic treatment to the emergence of resistance in pathogens,
particularly as metabolic processes and bacterial growth are not
directly targeted.
In this study, we investigated the anti-biofilm activity
of P. aeruginosa alkylhydroxyquinolone (AHQ) autoinducers
against A. fumigatus. Growth was unaffected, while biofilm
biomass and structure was significantly altered in the presence
of both 2-heptyl-4-quinolone (HHQ) and 2-heptyl-3-hydroxy-
4-quinolone (PQS). Having established the activity of the
parent molecules, a suite of analogs was tested for anti-
biofilm activity and lead compounds were identified that
retained activity against A. fumigatus. The synthesis of new
compounds incorporating decorations on the anthranilate ring
identified further lead compounds with activity comparable to
the parent HHQ molecule, providing important insights into the
structure function relationship underpinning the suppression of
fungal biofilms. Importantly, anti-biofilm activity was retained
against clinical isolates from a pediatric cohort, providing a
framework for further functionalization and future clinical
implementation.
MATERIALS AND METHODS
Fungal and Bacterial Culture Conditions
Aspergillus fumigatus Af293 was routinely grown on Sabouraud
dextrose agar (SDA) in 100 ml cell culture flasks at 37◦C
for 3–4 days. Sputum samples from a pediatric CF cohort
(Cork University Hospital) were cultured on SDA plates
and incubated for 4–7 days at 37◦C. Conidia were collected
by scraping in PBS with 0.025% (v/v) Tween 20, and the
Internal Transcribed Spacer (ITS) region was amplified by
PCR using ITS4 (5′-TCCTCCGCTTATTGATATGC-3′) and
ITS5 (5′-GGAAGTAAAAGTCGTAACAAGG-3′) for taxonomic
identification. PCR reaction conditions were as follows: 30 cycles
of alternating denaturation (94◦C for 45 s), annealing (58◦C for
45 s), and extension (72◦C for 2 min). Yeast cultures of Candida
albicans were routinely grown on yeast peptone dextrose (YPD)
agar and were cultured at 30◦C overnight. Bacterial cultures of
P. aeruginosa containing the pLP0996 pqsA-lacZ promoter fusion
were maintained on Luria Bertani (LB) plates supplemented with
carbenicillin (200 µg/ml), and routinely grown at 37◦C.
Spore Capture and Biofilm Assay
Conidia were harvested by flooding the surface of the agar
plates with 5 ml PBS (Oxoid) containing 0.025% (v/v) Tween
20 and gently moving the liquid over the surface of the fungal
lawn. The conidial suspension was transferred into a 25 ml
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sterile container and conidia were counted using a Neubauer
haemocytometer and light microscope. Conidia were adjusted to
the required concentration in RPMI 1640 (Sigma) buffered to pH
7.0 with 0.165 M MOPS immediately prior to biofilm formation
analysis.
To assess biofilm formation, counted A. fumigatus spores
(1 × 105) in MOPS buffered RPMI 1640 were inoculated into
24- and 96-well plates and grown overnight in the presence
of 100 µM HHQ, PQS and the compound collection. After
24 h, the media was removed and the biofilm washed twice
with distilled water after which 0.1 % crystal violet (CV) was
added to each well and allowed to stand for 1 h at room
temperature. The CV was removed and all wells washed in a water
bath by inversion. Ethanol was added to each well to solubilize
biofilms after which samples were read on a spectrophotometer
at OD595nm.
Analysis of preformed biofilms (24 h) was carried out
by allowing biofilms to establish in buffered RPMI, or
compound/carrier treated RPMI as described above. Disks were
removed and washed gently in PBS to remove unattached cells.
Disks from the buffered RPMI wells were transferred into 1 ml
of buffered RMPI with 100 µM HHQ, 1, or methanol control.
In tandem, disks from pre-treated wells were also transferred
and treated again with their respective compound or methanol
control. All plates were incubated for 24 h at 37◦C and biofilm
quantified as before.
Staining and Microscopy
Aspergillus fumigatus spores (1 × 105) were inoculated onto
plastic coverslips in 24 well plates and grown in the presence
of analogs overnight at 37◦C in RPMI buffered with MOPS
pH 7.0. After 24 h, plastic coverslips were washed once in PBS
and stained. Calcofluor (1 mg/ml) and 10% (w/v) potassium
hydroxide were added drop-wise to coverslips, washed in PBS,
mounted, and viewed. Concanavalin A (Con A) and FUN-1
were added at 50 µg/ml in 1 ml PBS and incubated at 37◦C for
30 min. All imaging was carried out on a Zeiss LSM5 confocal
microscope. Confocal images were recorded under a bright field
lens using ×20 objective magnification. Filter cubes facilitating
fluorescent imaging were used to record images for Calcofluor
at Abs405nm, Con A at Abs488nm and FUN-1 at Abs543nm. All
images were captured using the Zeiss HBO-100 microscope
illuminating system, processed using the Zen AIM application
imaging program and converted to JPG using Axiovision 40 Ver.
4.6.3.0.
Growth Assays
Aspergillus fumigatus Af293 was grown in RPMI buffered media
or YPD to assess sensitivity to HHQ, PQS, and lead analogs. Spore
suspensions were collected from SDA plates in PBS Tween 20
(0.025%), counted using a haemocytometer, and inoculated into
fresh YPD to a cell count of 1× 105 spores/ml. Spore suspensions,
either treated with lead compounds, carrier solvent, or untreated,
were then added in quadruplicate to 96-well plates and incubated
with gentle agitation for 24 h. The OD405nm was determined
spectrophotometrically.
Promoter Fusion Analysis
Alkylhydroxyquinolone signaling was monitored using the pqsA-
lacZ promoter fusion pLP0996 in both the wild-type PAO1
strain and its isogenic pqsA− mutant (McGrath et al., 2004).
Cells from overnight cultures were transferred to fresh LB media
(carbenicillin 200 µg/ml) to a starting OD600 nm 0.02 in the
presence of compounds 20–24 (100 µM) or equivalent volumes
of DMSO. Samples were taken at late log phase growth and
β-galactosidase activity was measured as before (Reen et al.,
2016).
Cytotoxicity Assays
Lactate dehydrogenase (LDH) release from HeLa (cervical
epithelial adenocarcinoma) cells was assayed as a measure of
cytotoxicity using an LDH colorimetric kit (Roche) according
to manufacturers’ instructions. HeLa cells were seeded into 96
well plates and treated with methanol (control) and analogs.
Following a 16 h incubation at 37◦C and 5% CO2, supernatants
were removed and added to catalyst reaction mixture in a fresh
plate and further incubated at 37◦C and 5% CO2 for 30 min
to allow for color development. After this period, the plate
was analyzed by measuring the absorbance on a microplate
spectrophotometer at OD490nm.
XTT Biofilm Assays
The C. albicans biofilm response to analogs was assessed
using the XTT [2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-
Tetrazolium-5-Carboxanilide] assay in 96 well plates at 37◦C.
After overnight growth in the presence of methanol (control)
and analogs, C. albicans biofilms were treated with 100 µl
freshly prepared XTT (Sigma) and menadione (Sigma). After
a 2 h incubation at 37◦C, biofilm formation was determined
by measuring the absorbance at OD492nm on a microplate
spectrophotometer.
Statistical Analysis
Data presentation and statistical analysis was performed using
the GraphPad Prism v5.03 software package or the Bootstratio
algorithm (Cleries et al., 2012).
Compound Synthesis
The synthesis of HHQ, PQS (Pesci et al., 1999; McGlacken et al.,
2010) and other HHQ-based analogs (Reen et al., 2012, 2015,
2016) was carried out via previously described methods. Novel
compounds and compounds which required modified syntheses
are described vide infra and in the Supplementary Data Sheet.
Ethics Statement
Sputum samples were collected from pediatric patients attending
the CF clinic at Cork University Hospital, Ireland. This study
was carried out in accordance with the recommendations
of the Clinical Research Ethics Committee of the Cork
Teaching Hospitals (CREC), with written informed consent
from all subjects. All subjects gave written informed consent
in accordance with the Declaration of Helsinki. The protocol
was approved by the CREC and all samples were handled in
accordance with the approved guidelines.
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RESULTS
P. aeruginosa Signal Molecules Interfere
with Biofilm Formation in A. fumigatus
The P. aeruginosa signaling molecules HHQ and PQS have
previously been shown to possess interkingdom activity,
influencing the phenotypic and transcriptional behavior of both
microbes and higher order organisms (Reen et al., 2011; Tashiro
et al., 2013; Trejo-Hernandez et al., 2014), including mammalian
cells (Kim et al., 2010). While the P. aeruginosa secretome
has previously been shown to suppress biofilm formation in
A. fumigatus (Mowat et al., 2010), the extent of the active
components remained to be defined. Our previous finding that
HHQ suppressed biofilm formation in the pathogenic yeast,
C. albicans (Reen et al., 2011), led us to investigate the anti-
biofilm activity of these signals against A. fumigatus. Addition of
either HHQ or PQS to the model strain A. fumigatus Af293 led to
a significant reduction in attachment to the wells of polystyrene
plates (Figure 1A). As expected, loss of the alkyl chain led to a
significant reduction in the potency of this anti-biofilm activity,
consistent with the functional requirement for this feature in
AHQ signaling.
In order to visualize the biofilm structures, attached cells were
treated with specific intracellular stains to assess impact on key
cellular components. These included cellulose and chitin with
Calcofluor; live cellular vacuolar stain FUN-1 which functions
as a live/dead stain; and lectin (carbohydrate) structures with
Concanavalin A. Confocal microscopic analysis confirmed the
effect of HHQ and PQS on formation of biofilm mass and
revealed a significant reduction and disruption of hyphal
development (Figure 1B). Cells treated with either HHQ or PQS
appeared locked in a spore form, with minimal evidence for
formation of hyphal structures, and the absence of the interwoven
network characteristic of A. fumigatus.
Structurally Modified AHQ Analogs
Retain Anti-biofilm Activity
Having established that both HHQ and PQS interfered with
biofilm formation, a suite of 4-quinolone analogs, bearing diverse
structural features (Supplementary Figure S1), were tested for
anti-biofilm activity toward A. fumigatus. Analogs included
modifications at the C3 and C4 positions, on the anthranilate
ring, and of the alkyl chain length, while substitutions were
predominantly with halogen, n-hexyl, methyl or methoxy groups.
The results of this analysis revealed that an exquisite degree
of structural conservation is required for AHQ inter-kingdom
activity (Figure 2A). Of these, compound 5 (n-hexyl at C6) and
compound 12 (methoxy at C7) gave the greatest reduction in
biofilm formation. Compound 14, in which the alkyl chain length
was extended relative to the parent molecule HHQ, retained its
anti-biofilm activity, while addition of halogen groups at C3 led
to loss of anti-biofilm activity. Addition of a methoxy (3) or
methyl (4) group to the C6 position of HHQ with a seven carbon
alkyl chain led to loss of anti-biofilm activity (Figure 2B), while
activity was retained in methoxy (11) and halogen (17) modified
equivalents upon extension of the alkyl chain to nine carbons.
Isolation of quinolones with substituents at C5 is difficult,
as the corresponding regioisomer (at C7) is also formed in
the Conrad-Limpach cyclisation step. Thus we chose to focus
on symmetrical aniline precursors, which allowed for further
elaboration at the 6-position. Compounds were synthesized with
Br (20), CO2C2H5 (21), an electron withdrawing F (22), and
an electron donating bulky C–C3H9 (23) at the C6 position
(Figure 3). Use of the 3,5-dimethyl aniline precursor gave a
C5–C7 substituted CH3 (24). All analogs were assessed for
antagonism of biofilm formation in A. fumigatus Af293. While
two of the substituted analogs, 20 and 23, had lost their anti-
biofilm activity, compounds 21, 22, and 24 retained activity
against the fungus, suppressing biofilm formation to the same
degree as lead compounds (Figure 4). It is clear that the structural
organization of the anthranilate ring components is of critical
importance to the anti-biofilm activity. The retention of anti-
biofilm formation by analogs functionalized at the C6 and C8
positions was particularly interesting given that halogenation
of these positions had previously been shown to enhance
antagonism of PQS signaling in P. aeruginosa (Ilangovan et al.,
2013).
Microscopic analysis of biofilms formed on plastic coverslips
in the presence of selected compounds confirmed the disruption
of hyphal structures in Af293 (Figure 5). Staining with Calcofluor
revealed the absence of intact hyphal networks in samples
treated with compounds 1, 12, 21, and 24 while inactive
compounds 3 and 15 did not affect this phenotype. This anti-
biofilm activity was shown to be independent of any impact
on growth of Af293, with the exception of compound 2 which
reduced the final OD600 nm reached by 0.1 unit (Supplementary
Figure S2).
Having determined that the alkylhydroxyquinolone derivative
compounds could suppress biofilm formation in A. fumigatus,
the next stage was to assess whether or not they could affect
pre-formed A. fumigatus biofilms. The addition of HHQ or 1 to
preformed biofilms on plastic disks led to a reduction relative
to the methanol control, although only 1 reached statistical
significance (Figure 6). Pre-treatment from the outset with either
HHQ or 1 led to a marked reduction in biofilm formation on
disks when compared with the control sample, further evidence
that both attachment and the development of hyphal biofilms
may be key targets for the lead compounds.
C6-Modified Analogs Exhibit
Non-cytotoxic A. fumigatus Specific
Activity
Any assessment of the utility of these compounds as anti-biofilm
agents must consider the origin of the parent molecules HHQ and
PQS as co-inducers of AHQ mediated virulence in P. aeruginosa.
Both HHQ and PQS control multiple virulence phenotypes
through activation of the PqsR transcriptional regulator (Xiao
et al., 2006). Previously, we have shown that several of the lead
analogs described here e.g., 1 and 2 are non-agonists of the
AHQ signaling system in P. aeruginosa, are selectively non-
cytotoxic, and are also effective biofilm blockers in C. albicans
(Supplementary Table S1) (Reen et al., 2016). Therefore, this
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FIGURE 1 | Suppression of A. fumigatus biofilm formation in response to HHQ and PQS. (A) Biofilm assays using crystal violet (CV) staining. mPQS and
mHHQ refer to the parent compounds with the C7 alkyl chain removed. RPMI constitutes the untreated sample whereby no compound or carrier has been added.
Data is presented as mean fold change (+/− SEM) of Abs595nm relative to untreated cells. Data is representative of five independent biological replicates. Statistical
significance using methanol treated cells as reference is represented by one way ANOVA with post hoc Bonferroni correction (∗p < 0.05, ∗∗p < 0.005;
∗∗∗P < 0.001). (B) Confocal microscopic analysis (×20) of biofilm formation on plastic coverslips. Staining was performed using Calcofluor-1 (cellulose and chitin),
Concanavalin A (live cellular vacuoles), and FUN-1 (lectins/carbohydrates).
analysis was extended to the newly synthesized compounds 20–
24 to provide a comprehensive profile of all the compounds
described in this study. Addition of compounds 21, 23, and 24
did not lead to increased pqsA promoter activity in a PAO1
pqsA− mutant strain indicating that they are non-agonists of the
PqsR virulence system (Figure 7A). In contrast, compounds 20
and 22 significantly increased expression relative to the control,
suggesting that further modification would be required to silence
this activity. In spite of being ineffective PqsR ligands, none of the
five analogs were capable of interfering with AHQ signaling in the
wild-type PAO1 strain, as seen with the comparable activity of the
pqsA promoter in both treated and untreated cells (Figure 7B).
In order to determine whether or not the anti-biofilm activity
extends to other fungal pathogens, C. albicans was tested for
biofilm formation in the presence and absence of compounds
20–24 (Figure 7C). None of the compounds were found to be
active against C. albicans biofilm formation, in contrast to some
of the other lead compounds identified in this study, such as
1 and 2 (Reen et al., 2016). Further extending the profile and
characterization of these compounds, cytotoxicity was measured
in a host cell line (Figure 7D). Only compound 24 elicited any
measurable degree of cytotoxicity, and this was to a lesser extent
than the parent molecule HHQ. The other four analogs were
comparable to the methanol control.
AHQ Analogs Block Biofilm in Clinical
A. fumigatus Isolates
There is a growing realization that the genomes of clinical isolates
can vary markedly from typed environmental strains, with
niche-specific selective pressures manifesting in considerable
heterogeneity, even within species. This led us to investigate
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FIGURE 2 | Biofilm formation in A. fumigatus cells following incubation with (A) active and (B) inactive AHQ analogs. CV stained multi-well biofilm assays.
Data is presented as mean fold change (+/− SEM) in Abs595nm relative to untreated treated cells and includes at least five independent biological replicates.
Statistical significance using methanol treated cells as reference is represented by one way ANOVA with post hoc Bonferroni correction (∗∗∗P < 0.001).
FIGURE 3 | Synthesis pipeline for anthranilate ring analogs 20–24.
the effectiveness of the lead compounds against clinical isolates
from a pediatric CF cohort, each of which exhibited significant
wrinkling of the mycelial mat compared to the smoothness
of Af293 (Figure 8). Both HHQ and PQS were capable of
suppressing biofilm formation in each of the clinical isolates. It
was notable, however, that the suppression of biofilm formation
was not to same extent as that seen against the lab strain
Af293, suggesting some degree of tolerance or adaptation in
the clinical isolates (Figure 8). Lead compounds were also
found to be effective against biofilm formation in clinical
strains, underpinning their suitability for further therapeutic
development (Figure 9).
The structural impact of lead compounds on biofilm
formation in both Af293 and the clinical isolates was assessed
using confocal microscopy of calcofluor stained cells. As
expected, anti-biofilm compounds disrupted the formation of
hyphal structures, while inactive compounds (e.g., 23) did not
markedly affect this phenotype. In general, active compounds
(e.g., 2 and 24) appeared to lock the fungal cells in the spore state,
with little or no evidence for hyphal development (Figure 10).
Although present in some of the clinical isolates (e.g., CFBRC2
and CFBRC3, 24), hyphal structures were weak and sparse,
indicating that a key mode of action of these compounds is the
prevention of the hyphal switch.
DISCUSSION
Exposure of immunocompromised individuals to A. fumigatus
can result in significant morbidity and even mortality in severe
cases. The incidence is on the rise owing largely to the
increased prevalence of respiratory conditions such as asthma,
increased frequency of lung transplantation, and the ongoing
use of immunosuppressive therapies. In many of these cases,
A. fumigatus adopts a biofilm lifestyle, enhancing its persistence
and contributing directly to morbidity and mortality associated
with these infections. A. fumigatus has recently been associated
with medical device infections (Ramage et al., 2012; Ramage
and Williams, 2013; Nett and Andes, 2015). Cases of serious
biomaterial-related infections of joint replacements, catheters,
heart valves, cardiac pace makers, and breast augmentation
implants have been reported. Often, high risk invasive surgical
procedures are used to treat these A. fumigatus infections, as
the formation of biofilm structures and the associated increased
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FIGURE 4 | Anti-biofilm activity of anthranilate ring substituted
compounds. Data is presented as mean fold change (+/− SEM) of Abs595nm
relative to untreated cells and includes five independent biological replicates.
Statistical significance relative to methanol treated cells is represented by one
way ANOVA with post hoc Bonferroni correction (∗p < 0.05; ∗∗p < 0.005;
∗∗∗P < 0.001).
FIGURE 5 | Microscopic analysis of Af293 biofilm formation on plastic
coverslips in the presence of selected active and inactive AHQ
analogs.
rate of antifungal resistance renders conventional treatment
ineffectual (Desai et al., 2014; Nett and Andes, 2015). Antifungal
tolerance in fungal infections has been attributed to the secretion
of an extracellular polymeric matrix and increased activity of
efflux pumps (Mowat et al., 2008; Rajendran et al., 2013).
Therefore, therapies that combat biofilms directly are likely to
enhance the survival and life expectancy of infected individuals.
In this study we have shown that two signal molecules
secreted by the nosocomial pathogen P. aeruginosa can
suppress biofilm formation in A. fumigatus. This may be a
consequence of the proximity in which these organisms co-
exist in clinical and environmental niches, including the lungs
of immunocompromised patients and the plant ecosystem.
Interactions between co-existing organisms have been widely
reported, with signaling molecules showing activity ranging from
inter-species to inter-kingdom (Reen et al., 2011; Chen et al.,
2014; Michelsen et al., 2014; Kendall and Sperandio, 2016). Both
FIGURE 6 | Anti-biofilm activity of lead compounds on preformed
A. fumigatus Af293 biofilms on plastic disks. Data presented is the mean
(+/− SEM) of six independent biological replicates. Statistical analysis is
performed by one way ANOVA with post hoc Bonferronic correction
(∗p < 0.05; ∗∗∗p < 0.001).
HHQ and PQS were capable of interfering with the formation
of A. fumigatus biofilms, leading to reduced biomass and the
absence of intact hyphal structures in treated cells. Derivatization
of the quinolone framework at the C6 and C8 positions
revealed the anthranilate ring to be particularly important in
the anti-biofilm activity. Several of these compounds have no
agonistic activity toward P. aeruginosa virulence, unlike the
parent molecules HHQ and PQS, thus presenting a viable
framework for therapeutic development against medical device
fungal pathogens [Figure 7 and (Reen et al., 2016)]. Furthermore,
they are selectively non-cytotoxic to host cell lines, further
supporting their development as viable molecular therapeutics.
The next stage in the development of these lead compounds will
be the characterization of the molecular mechanism(s) through
which they elicit their anti-biofilm activity. One approach
will be to investigate the possibility of fungal sensory and
signal transduction systems that may be involved in perception
of alkylhydroxyquinolones and transduction of that response
to exist in a non-hyphal growth state. Alternatively, alkyl-
quinolones, and PQS in particular, have also been reported
previously to possess both pro- and anti-oxidant activity, while
interaction with lipopolysaccharide, cellular membranes, and
membrane vesicles has also been reported in several bacterial
species (Haussler and Becker, 2008; Mashburn-Warren et al.,
2009).
The modulation of A. fumigatus biofilm by HHQ and
PQS adds another layer of complexity to the interkingdom
interactions that are characteristic of mixed P. aeruginosa fungal
communities. Phenazines, a redox active toxin controlled by
PQS and secreted by P. aeruginosa reportedly undergo chemical
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FIGURE 7 | Profiling the spectrum of activity of compounds 20–24. Promoter fusion analysis of the pqsA-lacZ pLP0996 plasmid in (A) a PAO1 pqsA− mutant,
and (B) PAO1 wild-type strain, (C) XTT biofilm analysis of C. albicans and (D) LDH release cytotoxicity assays using HeLa cell lines. Data in all experiments is the
mean (+/− SEM) of at least three independent biological replicates. Statistical analysis was performed by one-way ANOVA with post hoc Bonferroni correction
(∗∗∗p ≤ 0.001).
transformation by A. fumigatus and C. albicans (Moree et al.,
2012; Chen et al., 2014). The AHL class of quorum sensing
signal has also been shown to play a role in modulating biofilm
formation in these fungal pathogens (McAlester et al., 2008;
Mowat et al., 2010), while HHQ and PQS have previously been
shown to modulate biofilm formation in C. albicans (Reen et al.,
2011, 2016). Apart from signal mediated interactions, there is
recent evidence to suggest that interspecies and interkingdom
interactions can foster mutability in co-existing organisms
(Michelsen et al., 2014; Trejo-Hernandez et al., 2014). It must
also be considered that microbial signals are just one factor in
the process of fungal biofilm formation in the host. Other factors
such as the availability of nutrients, host related factors such
as the immune system and the surface upon which the biofilm
will form, mechanical factors such as flow rate within the niche,
and the presence of dispersion agents can have a significant
influence on fungal biofilm formation. Notwithstanding this,
deciphering the chemical messages used by microbes themselves
to control the behavior of pathogenic species, without disrupting
the growth of the microbiome as a whole, remains a key goal in
the age of molecular based therapeutics (Figure 11). As a greater
understanding of the connection between microbiome dysbiosis
and disease status continues to emerge, the critical need for
therapeutics that retain the functionality of the core microbiome
becomes ever more relevant.
CONCLUSION
Microbial communities are founded on intricate and long-
evolved communication systems that determine the flux and
dynamics of particular species in response to local and
environmental cues. Therefore, deciphering these chemical
messages has the potential to deliver on the new and innovative
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FIGURE 8 | AHQs suppress biofilm formation in clinical isolates. (A) Morphological analysis of clinical A. fumigatus isolates. (B) Biofilm formation in
A. fumigatus treated cells following incubation with AHQ signals HHQ and PQS. Data is presented as mean fold change (+/− SEM) in OD595nm relative to methanol
treated cells and includes five independent biological replicates. Statistical significance is represented by Bootstratio analysis (∗p < 0.05; ∗∗p < 0.005; ∗∗∗P < 0.001).
FIGURE 9 | Biofilm formation in A. fumigatus clinical isolates following incubation with AHQ analogs. Data is presented as mean fold change (+/− SEM)
in OD595nm relative to methanol treated cells and includes at least three independent biological replicates. Statistical significance is represented by Bootstratio
analysis (∗p < 0.05; ∗∗p < 0.005; ∗∗∗P < 0.001).
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FIGURE 10 | CLSM analysis of biofilm formation in Af293 and clinical isolates in the presence of lead compounds 2 and 24. All data presented is
representative of three independent biological replicates.
FIGURE 11 | The lead compounds identified in this study address a key clinical need for alternatives to broad spectrum antifungals. Challenge: While
still the lead option for the management of microbial infections, broad spectrum growth limiting antifungals are increasingly being challenged by limiting factors
including antifungal resistance, the aggressive persistence of known pathogens in a biofilm lifestyle, and the collateral damage caused to the host microbiome
leading to dysbiosis, Solution: Exploiting new knowledge of cell–cell communication systems and utilizing synthetic chemistry approaches to generate suites of
derivatized compounds, has made possible the development of anti-biofilm small molecules that are selectively non-toxic in mammalian cell lines. These have the
potential to lock yeast and fungal pathogens such as A. fumigatus in the non-hyphal state, potentially rendering them more susceptible to immune challenge, and
enhancing the effectiveness of conventional antifungal compounds.
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alternatives being sought to conventional growth limiting
antibiotics. This is an attractive route to therapy due to the
chemical tractability of these signals, opening up avenues for
functionalization to improve activity and drug-ability of lead
compounds. The work described here is highly significant and
potentially relevant to several sectors within the clinical and
medical device arena where the occurrence of in vivo and
nosocomial Aspergillus infections is destructive from both a
human and financial perspective.
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The requirements at the C-3 position of
alkylquinolones for signalling in Pseudomonas
aeruginosa†
Rachel Shanahan,‡a F. Jerry Reen,‡b Rafael Cano,a Fergal O’Gara*b,c and
Gerard P. McGlacken*a
The ‘perfect storm’ of increasing bacterial antibiotic resistance and
a decline in the discovery of new antibiotics, has made it necessary
to search for new and innovative strategies to treat bacterial infec-
tions. Interruption of bacterial cell-to-cell communication signal-
ling (Quorum Sensing), thus neutralizing virulence in pathogenic
bacteria, is a growing area. 2-Alkyl-4-quinolones, HHQ and PQS,
play a key role in the quorum sensing circuitry of P. aeruginosa. We
report a new set of isosteres of 2-heptyl-6-nitroquinolin-4-one,
with alterations at C-3, and evaluate the key structural require-
ments for agonistic and antagonistic activity in Pseudomonas
aeruginosa.
Introduction
The dramatic increase in drug-resistant bacterial strains, along
with a decrease in antibiotic research investment by pharma-
ceutical companies, is a serious cause of concern.1,2 It is now
clear that new strategies3 must be developed to target bacterial
infection. Non-biocidal approaches, which do not place an
evolutionary stress on bacteria, could also avoid the acqui-
sition of bacterial resistance.4
One of these strategies is based on the inhibition of the
bacterial cell-to-cell communication system, known as
Quorum-sensing (QS).5,6 QS uses extracellular signal molecules
to coordinate cellular behaviour, motility, virulence and the
formation of protective biofilms.7 Recently, efforts have been
focused on the design of new molecules that could interfere
with QS systems.8–10 Much work has focused on the important
nosocomial pathogen Pseudomonas aeruginosa, in which multi-
drug resistance continues to emerge.11,12
P. aeruginosa13,14 is a highly adaptable Gram-negative bac-
terium, capable of colonizing a wide variety of environments
including burn wounds and the lungs, primarily in immuno-
compromised or hospitalized patients. It is also the primary
cause of morbidity and mortality in patients with cystic fibro-
sis (CF)15 and is one of six multi-drug resistant bacteria high-
lighted by the Centers for Disease Control and Prevention
(CDC) as ‘the most urgent and serious’ threat to healthcare
patients.16 Once P. aeruginosa has established itself in the
lungs of immunocompromised patients, it adopts a chronic
persistent lifestyle that is almost impossible to eradicate.
2-Alkyl-4-quinolones (AHQs) are used as QS signalling
molecules by P. aeruginosa to control production of multiple
virulence determinants,17–19 including biofilm formation.20
The primary autoinducers of the P. aeruginosa AHQ signalling
pathway are 2-heptyl-3-hydroxy-4-quinolone (Pseudomonas
quinolone signal, or PQS) and its biological precursor 2-heptyl-
4-quinolone (HHQ) (Fig. 1).21,22 HHQ is converted by the
monooxygenase PqsH to PQS in P. aeruginosa. The action of
PQS and HHQ on P. aeruginosa is complex.23,24 It is known to
be dependent on the pqsABCDE biosynthetic operon which is
positively regulated by the transcriptional regulator PqsR.25,26
PQS and HHQ activate PqsR, and thus enhance the expression
of this operon and the subsequent virulence factors. Therefore
PqsR is a key target in the search for a P. aeruginosa QS
inhibitor.
Modifying the structural properties of HHQ and PQS in an
effort to interfere with normal binding at PqsR, has recently
been reported.27–30 Alterations to the alkyl chain11 and the aro-
matic backbone30 have given an insight into the structure–
activity relationships of these molecules. What is clearly
Fig. 1 Structure of the P. aeruginosa signalling molecules.
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c6ob01930g
‡Both authors contributed equally.
aDepartment of Chemistry and Analytical & Biological Chemistry Research Facility
(ABCRF), University College Cork, Ireland. E-mail: g.mcglacken@ucc.ie;
Fax: +353 21 4274097
bBIOMERIT Research Centre, Department of Microbiology, University College Cork,
Ireland. E-mail: f.ogara@ucc.ie; Fax: +353 21 4903101
cSchool of Biomedical Sciences, CHIRI, Curtin University, Perth WA 6845, Australia
306 | Org. Biomol. Chem., 2017, 15, 306–310 This journal is © The Royal Society of Chemistry 2017
Pu
bl
ish
ed
 o
n 
30
 N
ov
em
be
r 2
01
6.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 C
ol
le
ge
 C
or
k 
on
 3
1/
08
/2
01
7 
09
:1
9:
16
. 
View Article Online
View Journal  | View Issue
evident, is the exquisite structural specificity required for
activity. A particularly interesting case has been recently
reported by the Hartmann group.31,32 This study reported a
potent PqsR antagonist could be accessed by placing a nitro
group at the C-6 position of HHQ (Fig. 2, Compound A).
However, when tested in vivo on P. aeruginosa (and Escherichia
coli), the new compound displayed agonistic behaviour, remi-
niscent of PQS. Clever experiments and interpretation allowed
for the discovery that the supposed antagonist was being
hydroxylated by PqsH in P. aeruginosa into the corresponding
PQS-like analogue (Fig. 2, Compound B), which was a strong
PqsR agonist. In order to suppress this functional inversion,
the Authors ‘blocked’ the C-3 position, leading to the develop-
ment of a highly active antagonist (Fig. 2, Compound C).
Results and discussion
Prior to the Hartmann reports, we had previously shown the
implications of altering the C-3 position of HHQ on phenazine
production in P. aeruginosa and also on biofilm formation in
Bacillus subtilis.28 Since then, two important observations by
Hartmann31 necessitate further investigation of the role played
by the 3-position of alkylquinolones. Firstly, the insertion of
the NO2 group at C-6 in HHQ, greatly improves the antagonistic
effects in P. aeruginosa. Thus moving forward, this group
should remain a key factor in designing antagonists. Secondly,
insertion of a C-3 blocking group prevents hydroxylation by
P. aeruginosa, and thus the in situ formation of agonists. Thus,
evaluation of the blocking group is crucial. For example, do
the installed C-3 groups merely block the hydroxylation site?
Or do they bestow additionally biological properties? In this
report, we address these issues.
We suspected that addition of the amide group in com-
pound C (Fig. 2) offered additional properties to the molecule,
such as H-donor/acceptor capabilities as well as a new site for
hydrophilic interaction. We were confident that the C-3 group
did not purely act to prevent hydroxylation. Thus we set about
preparing a number of analogues of HHQ,33 all possessing the
key 6-NO2 group but with different groups at C-3. In this way
we hoped to shed some light on the requirement at C-3 for
antagonistic properties. Moreover, recent work on the structure
of the PqsR active site,34 would allow for a better interpretation
of our results.
We started by developing a new route to 6-nitro-HHQ.
Hartmann found that the final step en route to this molecule
was low yielding (1%)27 which probably reflects the lower
nucleophilicity of the nitro aniline in the Conrad–Limpach
cyclisation steps. Instead we transformed HHQ itself into the
nitro analogue in one step via electrophilic aromatic substi-
tution in 67% yield (Scheme 1). Next, we installed a number of
C-3 blocking groups. We began with a small non-polar methyl
group, followed by nitration at C-6 (Scheme 1).
Using nitroquinolone 2, we then introduced Br, Cl and
I-groups to give 4, 5 and 6 using Br2, NaDCC (sodium dichloro-
isocyanurate) and NIS (N-iodosuccinimide) respectively
(Scheme 2). Introduction of a fluorine group required extensive
optimisation. However fluoroquinolone 7 could be isolated,
pure, in 4% yield.
Lastly, an interesting deuterium-containing35 compound 8
was prepared by a deuteriodehalogenation protocol (Scheme 3).
Next we sought to alter the H-donor/acceptor properties of
the amide group at C-3 by preparing the corresponding sec-
ondary and tertiary amide. This was achieved by following
Hartmann’s synthesis of the carboxylic acid precursor followed
by an amide coupling reaction using 1,1-carbonyldiimidazole
(Scheme 4).
Fig. 2 Structure of the P. aeruginosa signalling molecules containing
the nitro group at C-6 position. Scheme 1 Synthesis of 2-heptyl-6-nitroquinolin-4(1H)-one.
Scheme 2 Synthesis of 3-halo-2-heptyl-6-nitroquinolin-4(1H)-ones.
Scheme 3 Synthesis of 3-deutero-2-heptyl-6-nitroquinolin-4(1H)-one.
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Biological results
As previously stated, the QS system (and HHQ/PQS production)
is known to be dependent on the pqsABCDE biosynthetic
operon, which is positively regulated by the transcriptional regu-
lator PqsR.36,37 As PqsR controls the expression of pqsA, the
monitoring of pqsA promoter activity can be used to determine
PqsR agonism and antagonism.
Two genotypes of P. aeruginosa were chosen to be tested with
the prepared molecules. Firstly a wild-type P. aeruginosa (PAO1)
which would appropriately reflect the natural biochemistry of
P. aeruginosa and secondly, an isogenic pqsAmutant (PAO1pqs−)
in which the ability to produce endogenous HHQ and PQS has
been abolished. HHQ and PQS are co-inducers of PqsR signal-
ling,36 thus it is crucial to test our compounds on this genotype,
to appropriately assess the actions of analogues, without inter-
ference from the naturally occurring activator, PQS. Thus all
compounds (2–12) were tested using promotor fusion analysis
of the PqsR-regulated pqsA–E operon in P. aeruginosa wild-type
PAO1 and its isogenic pqsAmutant (Fig. 3).
Firstly, the deactivating effect of the 6-NO2 group (on the
anthranilate ring) towards PqsR was confirmed, as almost all
of the compounds showed some decrease in PqsR activity
(Fig. 3a and b). Compounds 4 and 9 exhibited a statistically
significant antagonistic activity in the mutant strain, with
compound 9 eliciting the greatest reduction. Compound 8 also
elicited a reduction in pqsA activation, although this did not
reach statistical significance. When tested in the wild-type
strain where pqsA activation occurs through endogenous PQS,
compounds 2, 3, 8, and 9 were statistically active, with 9 being
the most potent antagonist. Based on structural data related to
the binding pocket of PqsR reported by Williams et al.34 it is
possible that the 6-NO2 group interacts with an isoleucine
residue (Ile-149) within the pocket, decreasing activation of the
receptor. However, as might be expected, the level of de-
activation was influenced by other parts of the molecule.
Compounds with a Cl, Br or I group at C-3 (4–6) showed
activity similar to the unsubstituted analogue 2. Compound 8
(with deuterium at C-3 position) behaved similarly to the
hydrogen analogue.
A very interesting case is the 3-F analogue (Compound 7).
We predicted that this analogue would possess three key struc-
tural elements for antagonistic activity. 1: A nitro group at C6,
as determined by Hartmann, 2: A robust blocking group at C3
to prevent hydroxylation and 3: A direct isosteric replacement
at C3 (F for H) to minimise supplementary interactions. But in
fact, 7 showed very little loss in activity relative to PQS. We sus-
pected at this stage that the alteration at C3 had, in fact,
negated the antagonist effects of the 6-nitro group. To probe
this idea, we then decided to prepare a 3-F analogue, this time
without the nitro-group. This should give a compound with
enhanced agonistic effects. 3-Fluoro-2-heptylquinolin-4(1H)-
one (Fig. 4, compound 12) was thus prepared (see ESI†).
Gratifyingly, when tested, quinolone 12 displayed remarkable
activation of the receptor, even stronger than PQS.
This suggests that there is a strong interaction between the
fluorine atom and the PqsR binding pocket. It is well known
that F can act as an isostere of the OH group,38,39 as it has a
similar size (van der Waals radii: 1.47 Å for F; 1.53 Å for OH).40
But the suspected key agonistic role of the –OH group in PQS
(as a H-donor/acceptor) is now less certain.
Compounds 10 and 11, tested on the mutant strain, showed
minimal inhibition and were less potent than compound 9.
Inhibitory effects decreased with increasing substitution of the
amide indicating that the amide group is not acting solely as a
blocking group, suggesting that the H-bond donor capability
of the nitrogen is important. The extensive study on AHQ-
receptor interactions by Williams et al.34 has also highlighted
the requirement for an –NH2 group at the C-3 position for
competitive antagonism. They suggest that strengthened
electrostatic interactions between the 3-NH2 group and carbo-
nyl groups in the Leu207 backbone within the pocket results
in stronger binding than native ligands. Finally, analogues
9–11 were also tested with the wild type PAO1 strain. With this
strain, the differences between the amides were more obvious
and neither the secondary nor the tertiary amide showed com-
parable activity to the primary amide.
Fig. 4 Structure of compound 12, a very strong activator.
Scheme 4 Synthesis of 3-amido-2-heptyl-6-nitroquinolin-4(1H)-ones.
Fig. 3 Promoter fusion analysis (pqsA-lacZ pLP0996) of AHQ analogue
treated PAO1 pqsA− and PAO1 strains. Where indicated, mutant cells
were supplemented with 50 nM PQS upon inoculation. Data are normal-
ized to the carrier control. All datapoints are the mean of at least three
biological replicates. Statistical analysis was performed by Bootstratio
(*p ≤ 0.5, **p ≤ 0.005, ***p ≤ 0.001). MeOH and DMSO were used as
solvents depending on solubility. Where compounds were soluble in
both, negligible activity differences were observed.
Communication Organic & Biomolecular Chemistry
308 | Org. Biomol. Chem., 2017, 15, 306–310 This journal is © The Royal Society of Chemistry 2017
Pu
bl
ish
ed
 o
n 
30
 N
ov
em
be
r 2
01
6.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 C
ol
le
ge
 C
or
k 
on
 3
1/
08
/2
01
7 
09
:1
9:
16
. 
View Article Online
Heretofore, all analysis was performed using a single con-
centration (10 µM) of compound. Therefore, we undertook a
concentration dependent investigation of lead compounds,
selecting 4, 8 and 9. Concentrations of 100 nM, 1 µM and
10 µM were tested against the PAO1 pqsA− mutant strain sup-
plemented with 50 nM PQS. Samples were taken during mid-
logarithmic (ML) and early stationary (ES) phase growth for
comparison. As expected, the control test involving addition of
PQS, led to enhanced promoter activity at all concentrations,
with the most significant increases occurring upon addition of
1 µM and 10 µM PQS (Fig. 5). In contrast, addition of all three
analogues led to a concentration-dependent reduction in pqsA
promoter activity. Compounds 4 and 9 displayed antagonistic
activity at both time points and at all three concentrations
tested. Compound 8 activity was less potent at 100 nM in mid-
log phase samples and at early stationary phase growth, poss-
ibly owing to PqsH-mediated conversion to the parent mole-
cule PQS.
Finally and importantly, growth curve analysis ruled out
any growth limiting effects from these compounds (ESI,
Fig. S1†).
Conclusions
The preparation of a variety of 6-nitro-quinolones, isosteric at
C-3 are reported. We have shown that the group at C-3 has
further roles beyond acting as a blocking group to prevent
hydroxylation by PqsH. It appears that a primary amide is
needed to achieve optimised antagonistic activity. This is con-
sistent with an interaction with the PqsR pocket, via establish-
ing H bonds with the Leu207 carbonyl group, as postulated in
previous studies. Finally, enhanced agonistic activity towards
the PqsR receptor was observed with a novel 3-F quinolone.
Importantly, the structural elements which lead to strong
agonistic activity, can also be helpful in the pursuit of antagon-
ists.41,42 Overall, it appears that while antagonistic behaviour
seems to be strongly dependent on the ability of the molecule
to engage in hydrogen-bonding interactions at the C-3 posi-
tion, agonistic behaviour does not, and may be ruled by more
polar dipole interactions.
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Direct Arylation
Synthesis of Benzofuroquinolines via Phosphine-Free Direct
Arylation of 4-Phenoxyquinolines in Air
Rachel M. Shanahan,[a] Aobha Hickey,[a] F. Jerry Reen,[b] Fergal O'Gara,[c,d] and
Gerard P. McGlacken*[a]
Abstract: A palladium-catalysed, phosphine-free, direct aryl-
ation of 4-phenoxyquinolines, in air is described. Using an intra-
molecular approach, the ring-closed products are formed in
Introduction
The quinoline nucleus occurs in many natural and synthetic
pharmacologically active compounds,[1] and is ranked 22nd in
the top 100 most frequently used ring systems present in FDA
approved drugs.[2] Thus, the quinoline motif is considered a
privileged biological scaffold, utilised by synthetic chemists to
build molecular complexity, and ultimately improve biological
activity. As a versatile heterocycle, it displays reactivity similar
to that of other aromatic (pyridine/benzene) analogues, and
thus can undergo a wide range of synthetic transformations.[3,4]
One of the most important transformations in organic syn-
thesis remains the linking of two (hetero)aryl groups via a new
carbon–carbon bond.[5] Traditionally, the most reliable class of
C–C bond forming reactions involves the palladium-catalysed
coupling of an aryl or vinyl halide with an organometallic rea-
gent.[6–9] Examples include the Suzuki–Miyaura coupling,[10]
Stille coupling,[11] and Negishi coupling.[12] An alternative
is the use of direct arylation protocols, which are less reliant on
the installation of a reactive functionality prior to cross-cou-
pling.[13–15]
Direct arylation of simple arenes has been increasingly util-
ised in organic synthesis to access complex polycyclic ring sys-
tems.[16–20] By comparison, similar reactions involving hetero-
cycles tend to require specialised catalyst/ligand systems and
are therefore less prevalent in the literature.[21] One of the earli-
est relevant examples of an intramolecular direct arylation of a
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yields of up to 95 %. This approach allows access to a range of
benzofuroquinolines. An array of functional groups on both the
quinoline and phenoxy rings are tolerated.
heteroarene was reported in 1984 by Ames and Opalko.[22] As
a recent example, Ha et al. reported a palladium-catalysed syn-
thesis of benzofuropyridines in moderate to excellent yields.[23]
Herein we report a palladium-catalysed direct arylation of
4-phenoxyquinolines as a route to benzofuro[3,2-c]quinolines
(Figure 1). Access to these products will aid exploration of their
untapped biological potential, given that similar quinoline-
based compounds exhibit anticancer,[24] antimalarial[25] and
antibacterial[26] effects.
Figure 1. Intramolecular direct arylation of 4-phenoxyquinolines.
Previous syntheses of some of these substrates via direct
arylation have relied upon positioning the activated carbon-
halide on the C-3 position of the quinoline coupling part-
ner[27,28] which limits the accessibility and versatility of products
Figure 2. Palladium-catalysed direct arylation at the C-3 position of quinol-
ines.
Full Paper
formed. The first example of non-directed direct arylation/C–H
activation of the C-3 position of pyridines and quinolines was
reported by Yu and co-workers (Figure 2(i)), using phenanthrol-
ine ligands under inert reaction conditions.[29] This method also
relies upon the use of a large excess of the quinoline or pyridine
substrate, which is only applicable to an intermolecular system.
Herein we describe a system that requires no added ligand for
arylation of the C-3 position of the quinoline ring, via intra-
molecular direct arylation, in air [Figure 2 (ii)].
Results and Discussion
Initially, 4-(2-bromophenoxy)quinoline 1a was chosen as a
model substrate, which was readily accessible from reaction of
4-chloroquinoline and 2-bromophenol. Our initial coupling con-
ditions allowed formation of the fused product 2a in 57 % iso-
lated yield in air (Table 1 entry 1). Next, a variety of reaction
parameters were assessed (Table 1). A solvent screen indicated
that high-boiling point amide solvents were necessary for good
conversion (entries 1–3). Other organic solvents gave little or
no conversion to product (entries 4–8). Changing the base from
Na2CO3 to K2CO3 or Cs2CO3 allowed the reaction to reach 100 %
conversion (entry 9 and 10), while use of a stronger butoxide
base resulted in partial decomposition of the starting material
(entry 11). A further reduction in catalyst loading to 2 mol-%
was also achieved (entry 12), at which point the desired product
2a could be obtained in 95 % isolated yield under the opti-
mised conditions.
Table 1. Optimisation of reaction conditions.
Entry Base Solvent Yield by NMR [%][a] Isolated Yield [%]
1 Na2CO3 DMA – 57
2 Na2CO3 DMF 67 –
3 Na2CO3 NMP 70 72
4 Na2CO3 DMSO 0 –
5[b] Na2CO3 1,4-dioxane 0 –
6[b] Na2CO3 EtOH 0 –
7[b] Na2CO3 1,2-DCE 0 –
8[b] Na2CO3 MeCN 0 –
9 K2CO3 NMP 72 –
10 Cs2CO3 NMP 83 –
11 NaOtBu NMP 39[c] –
12[d] Cs2CO3 NMP 99 95
13[e] Cs2CO3 NMP 33 –
[a] Yields determined by 1H NMR analysis of the crude reaction mixture using
1,3,5-trimethoxybenzene as internal standard. [b] Reaction carried out at the
reflux temperature of solvent. [c] Decomposition of starting material ob-
served. [d] 2 mol-% Pd(OAc)2 used. [e] 1 mol-% Pd(OAc)2 used.
With optimised conditions in hand, the substrate scope of
the reaction was evaluated (Figure 3). Overall, it was observed
that the reaction could tolerate a variety of functional groups
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on both the phenoxy and quinoline coupling partners. Sub-
strates bearing weakly electron-withdrawing substituents (2b–
f ) on the phenoxy ring were well tolerated. Additionally, the
chlorides in 2e and 2f were retained as a synthetic handle for
further cross-coupling. The more strongly electron-withdrawing
substituents on 2g and 2h led to cyclisation in excellent yields
of 88 % and 90 %, respectively. Moderate yields were observed
in the case of the nitro (2i) and ester (2j) analogues.
Figure 3. Substrate scope. All yields are isolated yields. [a] The yield of this
product could be improved to 60 % when using the following conditions:
5 mol-% Pd(OAc)2, 10 mol-% PCy3·HBF4, 2 equiv. Cs2CO3 under N2 at 135 °C
for 18 h. [b] The yield of this product could be improved to 66 % when using
the same conditions described in [a]. [c] 5 mol-% Pd(OAc)2 used.
Longer reaction times were required in the case of electron-
rich phenoxy substrates (2k–m). In the case of the naphthyl
analogue 2n, the desired product could only be obtained in
17 % isolated yield, with the majority of the remaining material
attributed to unreacted starting material. This may be due to
the steric bulk of the naphthyl group hindering access to the
coupling site. Pleasingly, compound 2o bearing a pyridine moi-
ety instead of an aryl was obtained in an excellent yield of 81 %.
The scope of the reaction with respect to the quinoline was
also examined. A methyl group at the C-2 position was well
tolerated (2p). On the aryl backbone, both electron donating
-OMe substituents (2q and 2r) and electron withdrawing -CF3,
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-F and -Cl substituents (2s–v) also led to very good yields of
product. The reaction conditions were also applicable to a 4-
phenoxy pyridine substrate.[30] A few quinoline analogues (p-
pyridinyl, aldehydic, and those with an S-linker) failed to cyclise
under these conditions.[31]
Compounds containing fused indolquinoline rings are
known to possess antimalarial,[32] antiproliferative and antican-
cer activity.[33] Thus, we hoped to access similar compounds by
including this functionality in our substrate scope. A Hartwig–
Buchwald coupling gave the precursor 3 in 74 % isolated yield
(Scheme 1). However, when this compound was subjected to
the previously optimised direct arylation conditions given
above, no product was observed. Even when using the pro-
tected (N-Boc) substrate, coupling could not be achieved under
these conditions.[34] We reasoned at this point that inhibitive
N-ligation to palladium could be avoided by the addition of
competitive phosphine ligands.[35] Indeed, when a new catalytic
system of 5 mol-% Pd(OAc)2 and 10 mol-% PCy3·HBF4 was em-
ployed, the fused product could be obtained in 83 % isolated
yield after 3 h. An inert atmosphere was required (Scheme 1).[36]
Scheme 1. Synthesis and direct arylation of 4-anilinoquinoline substrate.
The mechanism probably proceeds via an initial oxidative
addition followed by a rate-determining C–H activation via a
concerted metalation deprotonation (CMD).[29,37–40] A CMD
mechanism is often characterised by the acidity of the key
C–H bond. To probe this, a number of competition experiments
were carried out using a basic quinoline substrate 1a and those
substituted with an electron-withdrawing (1s) and an electron-
donating (1q) group (Figure 4 and SI). In all cases the experi-
ment revealed that the electron-poor substrate outpaced the
electron-rich substrate.
Figure 4. Competition experiment between 1s and 1q.
We then wished to apply the methodology to a more chal-
lenging quinoline of potential biological importance. Many spe-
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cies of bacteria use a sophisticated communication system
termed “quorum sensing” (QS).[41] This coordinated behaviour
allows for the construction of protective biofilms and the pro-
duction of virulence factors, ultimately for the benefit of the
entire colony. In contrast to antibiotic treatment, disrupting QS,
termed “quorum quenching”, is non-biocidal and thus as a
strategy, is less likely to promote bacterial resistance by reduc-
ing the level of mutant dominance.[42] Pseudomonas aeruginosa
uses quinolones such as 4-hydroxy-2-heptylquinoline (HHQ)
and its 3-OH analogue Pseudomonas quinolone signal (PQS) to
modulate quorum sensing (Figure 5). Thus analogues of these
molecules could be used as competitive binders, disrupting nu-
merous downstream processes.
Figure 5. HHQ-like substrate blocked at C-3.
Following on from our continuing investigation of quinolone
and quinoline analogues of HHQ and PQS,[43–49] using mol-
ecules which are “blocked” at the C-3 position, we chose to
apply our intramolecular arylation methodology to a HHQ/PQS
analogue (Figure 5). Substitution of C-3 is often crucial as it
prevents hydroxylation of HHQ at this position by PqsH. Ana-
logues with a hydroxyl group at C-3 can lead to unwanted ago-
nistic behaviour.[50,51]
Thus HHQ was converted into the phenoxy precursor, which
cyclised well, considering the steric encumbrance of the heptyl
chain (the heptyl chain is critical for most biological activity).
The impact of compound 2w on quinolone signalling (more
specifically PqsR signalling) was then investigated. HHQ (and
PQS) are known to act as co-inducer signals of the PqsR LysR-
type transcriptional regulator, leading to transcriptional activa-
tion of the pqsA promoter. Thus, the pqsA promoter itself acts as
a proxy for activation of PqsR signalling. A pqsA fusion plasmid
reporter (pLP0996) contains the pqsA promoter sequence up-
stream of the lacZ encoding gene and thus was ultimately used
as indicator.[52] Wild-type P. aeruginosa produces endogenous
HHQ, and thus any interference with activation of the plasmid
encoded pqsA-promoter would likely infer antagonism of natu-
ral co-inducer binding. However, no such interference was ob-
served and levels of pqsA transcriptional activation were com-
parable in carrier and cells treated with cyclised quinoline 2w
(Figure 6). Activation of the pLP0996 encoded pqsA promoter
in a pqsA mutant lacking endogenous HHQ and PQS can only
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occur upon addition of exogenous signal. In this case, while
HHQ activated promoter activity, addition of quinoline 2w had
no effect beyond baseline. Thus quinoline 2w displayed neither
agonist nor antagonist behaviour with respect to PqsR signal-
ling. This was further evident from the lack of inhibition of pyo-
cyanin production in a wild-type strain and the lack of pyo-
cyanin restoration in the pqsA mutant.
Figure 6. (A) Transcriptional activation of the pqsA promoter was unaffected
in wild-type (PAO1 pMP0996) and mutant (PAO1 pqsA– pLP0996) cells upon
addition of 2w. This suggests that the compound is neither an antagonist
nor an agonist of PqsR signalling under conditions tested. (B) Pyocyanin pro-
duction followed a similar pattern, i.e. unaffected in the presence of 2w in
either the wild-type or mutant cells. All data presented is the mean (+/– SEM)
of three independent biological replicates. Statistical analysis was performed
by Students t-test and one way ANOVA with Bonferroni post-hoc testing
(*** p < 0.001).
The production of HHQ-like compounds which do not and
cannot be hydroxylated in vivo at C-3[51] and thus do not ex-
hibit any strong agonistic or antagonist behaviour, make for
an excellent molecular framework for further modification and
structure-activity studies. Further details of the biological activ-
ity will be published in due course.
Conclusions
In summary, the application of direct arylation methodology
towards the synthesis of fused benzofuroquinoline products
has been demonstrated. Placement of the halide on the phen-
oxy component of the coupling precursor allows for easy access
to cyclised products. No added phosphine is required and the
reactions can be carried out in air. Modification of the method-
ology allows for the inclusion of 4-anilinoquinoline substrates,
without the requirement for N-protection. Finally, electron-poor
quinolines appear to work best as evidenced by competition
experiments. Application to a sterically hindered (C-2 = n-hept-
yl) HHQ mimic proceeds well.
Experimental Section
General Methods: Solvents and reagents were used as obtained
from commercial sources and without purification. Melting points
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were measured in a Thomas Hoover Capillary Melting Point appara-
tus. Infrared spectra were measured on a Perkin–Elmer FT-IR spec-
trometer. Nuclear Magnetic Resonance (NMR) samples were run in
deuterated chloroform (CDCl3) or deuterated dimethylsulfoxide
([D6]DMSO) as specified. 1H NMR (600 MHz), 1H NMR (500 MHz),
1H NMR (400 MHz), and 1H NMR (300 MHz) spectra were recorded
on Bruker Avance 600, Bruker Avance 500, Bruker Avance 400 and
Bruker Avance 300 NMR spectrometers, respectively, in proton cou-
pled mode using tetramethysilane (TMS) as the internal standard.
13C NMR (150 MHz), 13C NMR (125 MHz), 13C NMR (100 MHz), and
13C NMR (75 MHz) spectra were recorded on Bruker Avance 600,
Bruker Avance 500, Bruker Avance 400 and Bruker Avance 300 NMR
spectrometers, respectively, in proton decoupled mode at 20 °C
using tetramethysilane (TMS) as the internal standard. 19F NMR
(282 MHz) spectra were recorded on a Bruker Avance 300 NMR
spectrometer in proton decoupled mode at 20 °C. All spectra were
run at University College Cork. Chemical shifts (δ) are expressed as
parts per million (ppm), positive shift being downfield from TMS;
coupling constants (J) are expressed in Hertz [Hz]. Splitting patterns
in 1H NMR spectra are designated as: s (singlet), bs (broad singlet),
d (doublet), dd (doublet of doublets), ddd (doublet of doublets of
doublets), t (triplet), td (triplet of doublets),
q (quartet), quin (quintet) and m (multiplet). High resolution precise
mass spectra (HRMS) were recorded on a Waters LCT Premier Tof
LC-MS instrument in electrospray ionisation (ESI) mode using 50 %
acetonitrile/water containing 0.1 % formic acid as eluent; samples
were made up in acetonitrile at a concentration of ca. 1 mg/mL.
Column chromatography was carried out using 60 Å (35–70 μm)
silica. TLC was carried out on pre-coated silica gel plates (Merck 60
PF254). The developed plates were visualized under UV light.
Palladium-catalysed intramolecular direct arylation reactions were
carried out in sealed reaction tubes which were placed in a solid
multi-reaction heating plate.
General Procedures for Synthesis of 4-(2-Bromophenoxy)quin-
oline Substrates 1a–1w
Method (a): Compounds 1a–1c, 1f, 1i, 1k, 1l, 1o–1w: A mixture
of the 4-chloroquinoline substrate (1 equiv.), the substituted 2-
bromophenol (5 equiv.) and sodium hydroxide (crushed pellets)
(1.5 equiv.) was stirred at 120 °C until reaction was completed (2–
6 h) as evident by thin layer chromatography (hexane/ethyl acetate,
8:2). The cooled reaction mixture was diluted with 10 % aq. NaOH
(5 mL) and stirred at room temperature for 1 h. The aqueous phase
was extracted with DCM (3 × 20 mL). The combined organic layers
were washed with 6 M NaOH (3 × 10 mL), water (10 mL) and brine
(10 mL), dried with MgSO4, filtered and concentrated in vacuo. The
crude mixture was purified by column chromatography over silica
gel using hexane/ethyl acetate (8:2) as eluent.
Method (b): Compounds 1d, 1e, 1g, 1h, 1j, 1m, 1n: A mixture of
4-chloroquinoline (1 equiv.), the substituted 2-bromophenol
(1.5 equiv.) and 4-dimethylaminopyridine (3 equiv.) in toluene
(1.5 mL/mmol) was stirred at 130 °C until the reaction was com-
pleted as evident by thin layer chromatography (hexane/ethyl acet-
ate, 8:2). The cooled reaction mixture was diluted with 10 % aq.
NaOH (5 mL) and stirred at room temperature for 1 h. The aqueous
phase was extracted with DCM (3 × 20 mL). The combined organic
layers were washed with 3 M NaOH (3 × 10 mL), 1 M HCl (2 × 10 mL),
water (10 mL) and brine (10 mL), dried with MgSO4, filtered and
concentrated in vacuo. The crude mixture was purified by column
chromatography over silica gel using hexane/ethyl acetate (8:2) as
eluent.
4-(2-Bromophenoxy)quinoline (1a): Method (a) – white solid
(2.89 g, 78 %); m.p. 62–64 °C. IR (film): ν˜max = 3434, 1596, 1305,
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1223, 659 cm–1. 1H NMR (300 MHz, CDCl3): δ = 6.41 (d, J = 5.1 Hz,
1 H), 7.18–7.27 (m, 2 H), 7.43 (ddd, J = 8.1, 7.3, 1.6 Hz, 1 H), 7.61
(ddd, J = 8.2, 6.9, 1.1 Hz, 1 H), 7.70–7.82 (m, 2 H), 8.12 (d, J = 8.2 Hz,
1 H), 8.42 (dd, J = 8.3, 0.9 Hz, 1 H), 8.68 (d, J = 5.1 Hz, 1 H) ppm.
13C NMR (75 MHz, CDCl3): δ = 103.7, 116.4, 121.1, 121.9, 123.2, 126.3,
127.3, 129.1, 129.2, 130.2, 134.3, 149.8, 151.0, 151.2, 160.7 ppm.
HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C15H11BrNO: 300.0024,
found 300.0016.
4-(2-Bromo-5-fluorophenoxy)quinoline (1b): Method (a) – pale
yellow solid (0.891 g, 91 %); m.p. 77–78 °C. IR (film): ν˜max = 3066,
1476, 1305, 1252, 1159, 601 cm–1. 1H NMR (300 MHz, CDCl3): δ =
6.49 (d, J = 5.1 Hz, 1 H), 6.94–7.01 (m, 1 H), 6.99 (d, J = 8.1 Hz, 1 H),
7.57–7.74 (m, 2 H), 7.80 (ddd, J = 8.4, 6.9, 1.4 Hz, 1 H), 8.13 (d, J =
8.5 Hz, 1 H), 8.37 (dd, J = 8.4, 1.0 Hz, 1 H), 8.73 (d, J = 5.1 Hz, 1 H)
ppm. 13C NMR (75 MHz, CDCl3): δ = 104.1, 110.7, 110.9 [d, 2J(C,F) =
25 Hz], 114.5 [d, 2J(C,F) = 22 Hz], 120.9, 121.7, 126.5, 129.2, 130.4,
134.7 [d, 3J(C,F) = 9 Hz], 149.9, 151.0, 152.0 [d, 3J(C,F) = 11 Hz],
160.1, 162.4 [d, 1J(C,F) = 250 Hz] ppm. 19F NMR (282 MHz, CDCl3):
δ = –111 ppm. HRMS (ESI-TOF)m/z: [M + H]+ calcd. for C15H10BrFNO:
317.9930, found 317.9936.
4-(2-Bromo-4-fluorophenoxy)quinoline (1c): Method (a) – pale
yellow solid (0.188 g, 38 %); m.p. 100–103 °C. IR (film): ν˜max = 3065,
1480, 1305, 1248, 1183, 765 cm–1. 1H NMR (300 MHz, CDCl3): δ =
6.39 (d, J = 5.1 Hz, 1 H), 7.10–7.29 (m, 2 H), 7.48 (dd, J = 7.7, 2.8 Hz,
1 H), 7.62 (ddd, J = 8.2, 5.5, 1.2 Hz, 1 H), 7.79 (ddd, J = 8.5, 6.9,
1.5 Hz, 1 H), 8.12 (d, J = 8.5 Hz, 1 H), 8.40 (dd, J = 8.3, 0.9 Hz, 1 H),
8.69 (d, J = 5.1 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 103.4,
116.1 [d, 2J(C,F) = 23 Hz], 116.9 [d, 3J(C,F) = 10 Hz], 120.9, 121.3 [d,
2J(C,F) = 26 Hz], 121.8, 124.3 [d, 3J(C,F) = 9 Hz], 126.4, 129.2, 130.3,
147.4, 149.8, 151.0, 159.9 [d, 1J(C,F) = 250 Hz], 160.7 ppm. 19F NMR
(282 MHz, CDCl3): δ = –114 ppm. HRMS (ESI-TOF) m/z: [M + H]+
calcd. for C15H10BrFNO: 317.9930, found 317.9935.
4-(2-Bromo-6-fluorophenoxy)quinoline (1d): Method (b) – pale
yellow solid (0.318 g, 72 %); m.p. 118–119 °C. IR (film): ν˜max = 3064,
1502, 1471, 1305, 1271, 1042, 665 cm–1. 1H NMR (300 MHz, CDCl3):
δ = 6.39 (d, J = 5.1 Hz, 1 H), 7.15–7.30 (m, 2 H), 7.47–7.54 (m, 1 H),
7.63 (ddd, J = 8.1, 7.0, 1.1 Hz, 1 H), 7.79 (ddd, J = 8.4, 6.9, 1.5 Hz, 1
H), 8.13 (d, J = 8.5 Hz, 1 H), 8.46 (dd, J = 8.3, 1.1 Hz, 1 H), 8.69 (d,
J = 5.0 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 102.5, 116.5 [d,
2J(C,F) = 19 Hz], 118.3, 120.6, 121.9, 126.4, 127.7 [d, 3J(C,F) = 8 Hz],
129.10, 129.16, 130.2, 139.3 [d, 2J(C,F) = 14 Hz], 149.8, 150.9, 155.6
[d, 1J(C,F) = 255 Hz], 159.8 ppm. 19F NMR (282 MHz, CDCl3): δ =
–124 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C15H10BrFNO:
317.9930, found 317.9921.
4-(2-Bromo-5-chlorophenoxy)quinoline (1e): Method (b) – white
solid (0.290 g, 89 %); m.p. 79–81 °C. IR (film): ν˜max = 3370, 1562,
1464, 1305, 1252, 765, 665 cm–1. 1H NMR (300 MHz, CDCl3): δ =
6.48 (d, J = 5.1 Hz, 1 H), 7.16–7.29 (m, 2 H), 7.57–7.69 (m, 2 H), 7.79
(ddd, J = 8.5, 6.9, 1.5 Hz, 1 H), 8.13 (d, J = 8.6 Hz, 1 H), 8.36 (dd, J =
8.4, 0.9 Hz, 1 H), 8.72 (d, J = 5.1 Hz, 1 H) ppm. 13C NMR (75 MHz,
CDCl3): δ = 104.1, 114.4, 120.9, 121.7, 123.3, 126.5, 127.4, 129.2,
130.4, 134.5, 134.8, 149.9, 151.0, 151.9, 160.1 ppm. HRMS (ESI-TOF)
m/z: [M + H]+ calcd. for C15H10BrClNO: 333.9634, found 333.9622.
4-(2-Bromo-4-chlorophenoxy)quinoline (1f): Method (a) – off-
white solid (1.97 g, 96 %); m.p. 112–115 °C. IR (film): ν˜max = 3403,
1596, 1465, 1392, 1257, 824, 765 cm–1. 1H NMR (300 MHz, CDCl3):
δ = 6.42 (d, J = 5.1 Hz, 1 H), 7.17 (d, J = 8.6 Hz, 1 H), 7.40 (dd, J =
8.7, 2.5 Hz, 1 H), 7.61 (ddd, J = 8.2, 6.9, 1.2 Hz, 1 H), 7.70–7.84 (m,
2 H), 8.12 (d, J = 8.5 Hz, 1 H), 8.38 (dd, J = 8.4, 0.9 Hz, 1 H), 8.70 (d,
J = 5.1 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 103.7, 117.0,
120.9, 121.7, 123.8, 126.4, 129.2, 129.3, 130.3, 132.0, 133.9, 149.9,
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150.0, 151.0, 160.4 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for
C15H10BrClNO: 333.9634, found 333.9629.
4-[2-Bromo-4-(trifluoromethyl)phenoxy]quinoline (1g): Method
(b) – sticky colourless oil (0.0731 g, 20 %). IR (film): ν˜max = 1623,
1569, 1320, 1263, 1231, 1130, 588 cm–1. 1H NMR (300 MHz, CDCl3):
δ = 6.50 (d, J = 5.1 Hz, 1 H), 7.28 (d, J = 8.5 Hz, 1 H), 7.54–7.70 (m,
2 H), 7.79 (ddd, J = 8.4, 6.9, 1.4 Hz, 1 H), 8.00 (d, J = 1.7 Hz, 1 H),
8.14 (d, J = 8.5 Hz, 1 H), 8.34 (dd, J = 8.4, 0.9 Hz, 1 H), 8.73 (d, J =
4.9 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 104.7, 116.5, 121.0,
121.7, 122.6, 122.9 [q, 1J(C,F) = 272 Hz], 126.4 [q, 3J(C,F) = 4 Hz],
126.7, 129.2 [q, 2J(C,F) = 34 Hz], 129.3, 130.5, 131.7 [q, 3J(C,F) =
4 Hz], 150.0, 150.9, 154.4, 159.8 ppm. 19F NMR (282 MHz, CDCl3):
δ = –62 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C16H10BrF3NO:
367.9898, found 367.9886.
4-[2-Bromo-4-(trifluoromethoxy)phenoxy]quinoline (1h):
Method (b) – pale yellow solid (0.3015 g, 78 %); m.p. 50–52 °C. IR
(film): ν˜max = 1640, 1597, 1306, 1253, 1218, 1187, 567 cm–1. 1H NMR
(300 MHz, CDCl3): δ = 6.44 (d, J = 5.1 Hz, 1 H), 7.22–7.35 (m, 2 H),
7.55–7.69 (m, 2 H), 7.79 (ddd, J = 8.5, 6.9, 1.5 Hz, 1 H), 8.13 (d, J =
8.4 Hz, 1 H), 8.38 (dd, J = 8.4, 0.9 Hz, 1 H), 8.71 (d, J = 5.1 Hz, 1 H)
ppm. 13C NMR (75 MHz, CDCl3): δ = 103.8, 116.9, 120.4 [q, 1J(C,F) =
259 Hz], 120.9, 121.7, 121.8, 123.7, 126.5, 127.0, 129.2, 130.4, 146.6,
149.9, 150.0, 151.0, 160.3 ppm. 19F NMR (282 MHz, CDCl3): δ =
–58 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C16H10BrF3NO2:
383.9847, found 383.9843.
4-(2-Bromo-4-nitrophenoxy)quinoline (1i): Method (a) – pale yel-
low solid (0.192 g, 80 %); m.p. 151–152 °C. IR (film): ν˜max = 3376,
1523, 1346, 1305, 1257, 665 cm–1. 1H NMR (300 MHz, CDCl3): δ =
6.65 (d, J = 5.0 Hz, 1 H), 7.23 (d, J = 8.9 Hz, 1 H), 7.64 (ddd, J = 8.1,
7.1, 0.7 Hz, 1 H), 7.83 (ddd, J = 8.4, 7.0, 1.3 Hz, 1 H), 8.17 (d, J =
8.5 Hz, 1 H), 8.25 (d, J = 8.8 Hz, 1 H), 8.27 (dd, J = 8.9, 2.7 Hz, 1 H),
8.65 (d, J = 2.6 Hz, 1 H), 8.80 (d, J = 5.0 Hz, 1 H) ppm. 13C NMR
(75 MHz, CDCl3): δ = 106.0, 115.9, 121.1, 121.2, 121.5, 124.6, 127.1,
129.5, 129.9, 130.7, 144.9, 150.2, 151.0, 157.2, 159.1 ppm. HRMS
(ESI-TOF) m/z: [M + H]+ calcd. for C15H10BrN2O3: 344.9875, found
344.9865.
Methyl 4-Bromo-3-(quinolin-4-yloxy)benzoate (1j): Method (b) –
off white solid (0.258 g, 62 %); m.p. 87–89 °C. IR (film): ν˜max = 3586,
2950, 1724, 1565, 1502, 1392, 1294, 1241, 765 cm–1. 1H NMR
(300 MHz, CDCl3): δ = 3.92 (s, 3 H), 6.43 (d, J = 5.1 Hz, 1 H), 7.63
(ddd, J = 8.2, 6.9, 1.1 Hz, 1 H), 7.76–7.90 (m, 4 H), 8.13 (d, J = 8.5 Hz,
1 H), 8.40 (dd, J = 8.3, 0.9 Hz, 1 H), 8.70 (d, J = 5.1 Hz, 1 H) ppm.
13C NMR (75 MHz, CDCl3): δ = 52.6, 103.9, 121.0, 121.7, 122.0, 123.9,
126.5, 128.0, 129.2, 130.4, 131.6, 134.5, 149.9, 151.0, 151.4, 160.3,
165.4 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C17H13BrNO3:
358.0079, found 358.0089.
4-(2-Bromo-4-methylphenoxy)quinoline (1k): Method (a) – or-
ange solid (0.242 g, 84 %); m.p. 122–125 °C. IR (film): ν˜max = 3064,
1568, 1485, 1392, 1255, 765 cm–1. 1H NMR (300 MHz, CDCl3): δ =
2.41 (s, 3 H), 6.40 (d, J = 5.2 Hz, 1 H), 7.13 (d, J = 8.2 Hz, 1 H), 7.22
(dd, J = 8.2, 1.5 Hz, 1 H), 7.54 (d, J = 1.4 Hz, 1 H), 7.61 (ddd, J = 8.1,
6.9, 1.1 Hz, 1 H), 7.78 (ddd, J = 8.4, 6.9, 1.4 Hz, 1 H), 8.11 (d, J =
8.5 Hz, 1 H), 8.43 (dd, J = 8.3, 1.0 Hz, 1 H), 8.67 (d, J = 5.1 Hz, 1 H)
ppm. 13C NMR (75 MHz, CDCl3): δ = 20.7, 103.5, 115.9, 121.1, 121.9,
122.9, 126.2, 129.1, 129.8, 130.1, 134.5, 137.5, 148.8, 149.8, 151.0,
161.0 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C16H13Br NO:
314.0181, found 314.0169.
4-[2-Bromo-4-(tert-butyl)phenoxy]quinoline (1l): Method (a) –
pale yellow solid (0.073 g, 56 %); m.p. 68–70 °C. IR (film): ν˜max =
2963, 1568, 1488, 1391, 1306, 1263, 766 cm–1. 1H NMR (300 MHz,
CDCl3): δ = 1.36 (s, 9 H), 6.43 (d, J = 5.1 Hz, 1 H), 7.16 (d, J = 8.5 Hz,
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1 H), 7.41 (dd, J = 8.5, 2.2 Hz, 1 H), 7.60 (t, J = 7.6 Hz, 1 H), 7.65–
7.83 (m, 2 H), 8.11 (d, J = 8.5 Hz, 1 H), 8.42 (d, J = 8.3 Hz, 1 H), 8.67
(d, J = 5.0 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 31.3, 34.7,
103.6, 115.8, 121.1, 121.9, 122.6, 126.2, 126.3, 129.0, 130.2, 131.2,
148.5, 149.7, 150.9, 151.1, 160.9 ppm. HRMS (ESI-TOF) m/z: [M + H]+
calcd. for C19H19BrNO: 356.0650, found 356.0642.
4-(2-Bromo-4-methoxyphenoxy)quinoline (1m): Method (b) –
beige solid (0.304 g, 56 %); m.p. 184–185 °C. IR (film): ν˜max = 3062,
2835, 1595, 1487, 1392, 1212, 765 cm–1. 1H NMR (300 MHz, CDCl3):
δ = 3.86 (s, 3 H), 6.38 (d, J = 5.2 Hz, 1 H), 6.96 (dd, J = 8.9, 2.9 Hz,
1 H), 7.17 (d, J = 8.9 Hz, 1 H), 7.24 (d, J = 2.9 Hz, 1 H), 7.60 (ddd,
J = 8.1, 6.9, 1.1 Hz, 1 H), 7.77 (ddd, J = 8.5, 6.9, 1.5 Hz, 1 H), 8.11 (d,
J = 8.5 Hz, 1 H), 8.43 (dd, J = 8.3, 0.9 Hz, 1 H), 8.67 (d, J = 5.0 Hz, 1
H) ppm. 13C NMR (75 MHz, CDCl3): δ = 55.9, 103.3, 114.9, 116.7,
118.9, 121.0, 121.9, 123.7, 126.2, 129.0, 130.1, 144.5, 149.7, 151.0,
157.9, 161.3 ppm. HRMS (ESI-TOF) m/z : [M + H]+ calcd. for
C16H13BrNO2: 330.0130, found 330.0125.
4-[(1-Bromonaphthalen-2-yl)oxy]quinoline (1n): Method (a)
– off-white solid (0.318 g, 61 %); m.p. 197–200 °C. IR (film): ν˜max =
3062, 1594, 1568, 1499, 1392, 1253, 764 cm–1. 1H NMR (300 MHz,
CDCl3): δ = 6.42 (d, J = 5.1 Hz, 1 H), 7.36 (d, J = 8.8 Hz, 1 H), 7.55–
7.72 (m, 3 H), 7.80 (ddd, J = 8.5, 6.9, 1.5 Hz, 1 H), 7.92 (d, J = 8.1 Hz,
1 H), 7.93 (d, J = 8.8 Hz, 1 H), 8.14 (d, J = 8.5 Hz, 1 H), 8.33 (d, J =
8.5 Hz, 1 H), 8.51 (dd, J = 8.3, 1.0 Hz, 1 H), 8.56 (d, J = 5.1 Hz, 1 H)
ppm. 13C NMR (75 MHz, CDCl3): δ = 103.9, 115.2, 121.1, 121.3, 122.0,
126.3, 126.6, 127.1, 128.2, 128.4, 129.1, 129.8, 130.3, 132.4, 133.2,
149.0, 149.8, 151.1, 160.8 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd.
for C19H13BrNO: 350.0181, found 350.0178.
4-[(2-Bromopyridin-3-yl)oxy]quinoline (1o): Method (a) – pale
pink solid (0.2378 g, 79 %); m.p. 170–173 °C. IR (film): ν˜max = 1639,
1503, 1305, 1268, 666 cm–1. 1H NMR (300 MHz, CDCl3): δ = 6.45 (d,
J = 5.1 Hz, 1 H), 7.38 (dd, J = 8.0, 4.6 Hz, 1 H), 7.47–7.70 (m, 2 H),
7.79 (ddd, J = 8.4, 7.0, 1.4 Hz, 1 H), 8.13 (d, J = 8.5 Hz, 1 H), 8.28–
8.47 (m, 2 H), 8.72 (d, J = 5.1 Hz, 1 H) ppm. 13C NMR (75 MHz,
CDCl3): δ = 104.1, 121.0, 121.7, 124.0, 126.7, 129.2, 130.5, 130.5,
136.6, 147.0, 148.7, 149.9, 150.8, 159.9 ppm. HRMS (ESI-TOF) m/z: [M
+ H]+ calcd. for C14H10BrN2O: 300.9976, found 300.9986.
4-(2-Bromophenoxy)-2-methylquinoline (1p): Method (a) – pale
pink solid (0.331 g, 93 %); m.p. 98–101 °C. IR (film): ν˜max = 2923,
1599, 1470, 1342, 1235, 754 cm–1. 1H NMR (300 MHz, CDCl3): δ =
2.60 (s, 3 H), 6.29 (s, 1 H), 7.15–7.29 (m, 2 H), 7.42 (ddd, J = 8.6, 7.3,
1.6 Hz, 1 H), 7.54 (ddd, J = 8.2, 6.9, 1.2 Hz, 1 H), 7.68–7.79 (m, 2 H),
8.02 (d, J = 8.4 Hz, 1 H), 8.35 (dd, J = 8.4, 1.0 Hz, 1 H) ppm. 13C NMR
(75 MHz, CDCl3): δ = 25.8, 104.2, 116.3, 119.5, 121.7, 123.2, 125.4,
127.1, 128.3, 129.1, 130.2, 134.3, 149.4, 151.3, 159.9, 160.8 ppm.
HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C16H13BrNO: 314.0181,
found 314.0179.
4-(2-Bromophenoxy)-6-methoxyquinoline (1q): Method (a) – yel-
low sticky oil (0.599 g, 70 %). IR (film): ν˜max = 3392, 1596, 1467,
1365, 1262, 1223, 778 cm–1. 1H NMR (300 MHz, CDCl3): δ = 3.98 (s,
3 H), 6.40 (d, J = 5.1 Hz, 1 H), 7.16–7.29 (m, 2 H), 7.37–7.47 (m, 2 H),
7.64 (d, J = 2.8 Hz, 1 H), 7.73 (dd, J = 8.0, 1.5 Hz, 1 H), 8.01 (d, J =
9.2 Hz, 1 H), 8.54 (d, J = 5.1 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3):
δ = 55.7, 99.4, 104.2, 116.4, 121.8, 122.9, 123.2, 127.2, 129.2, 130.7,
134.3, 145.9, 148.4, 151.3, 157.8, 159.7 ppm. HRMS (ESI-TOF) m/z:
[M + H]+ calcd. for C16H13BrNO2: 330.0130, found 330.0130.
4-(2-Bromophenoxy)-7-methoxyquinoline (1r): Method (a) – pale
yellow solid (0.380 g, 74 %); m.p. 99–100 °C. IR (film): ν˜max = 3388,
1622, 1428, 1315, 1227, 665 cm–1. 1H NMR (300 MHz, CDCl3): δ =
3.98 (s, 3 H), 6.30 (d, J = 5.2 Hz, 1 H), 7.15–7.29 (m, 3 H), 7.36–7.47
(m, 2 H), 7.72 (dd, J = 7.9, 1.5 Hz, 1 H), 8.29 (d, J = 9.2 Hz, 1 H), 8.59
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(d, J = 5.2 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 55.5, 102.4,
107.3, 115.8, 116.3, 119.2, 123.1, 123.2, 127.1, 129.1, 134.2, 151.2,
151.5, 151.8, 160.7, 161.3 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd.
for C16H12BrNO2: 330.0130, found 330.0128.
4-(2-Bromophenoxy)-6-(trifluoromethyl)quinoline (1s): Method
(a) – off-white solid (0.254 g, 80 %); m.p. 67–69 °C. IR (film): ν˜max =
3069, 1570, 1467, 1316, 1224, 1126, 739 cm–1. 1H NMR (300 MHz,
CDCl3): δ = 6.47 (d, J = 5.2 Hz, 1 H), 7.21–7.32 (m, 2 H), 7.46 (ddd,
J = 8.1, 7.3, 1.6 Hz, 1 H), 7.75 (dd, J = 7.9, 1.3 Hz, 1 H), 7.95 (dd, J =
8.9, 2.1 Hz, 1 H), 8.22 (d, J = 8.9 Hz, 1 H), 8.76 (s, 1 H), 8.77 (d, J =
5.2 Hz, 1 H) ppm. 13C NMR (125 MHz, CDCl3): δ = 104.4, 116.4, 120.2,
120.3 [q, 3J(C,F) = 5 Hz], 123.4, 124.1 [q, 1J(C,F) = 272 Hz], 126.0 [q,
3J(C,F) = 3 Hz], 127.8, 128.2 [q, 2J(C,F) = 33 Hz], 129.4, 130.3, 134.5,
150.6, 150.7, 153.2, 161.3 ppm. 19F NMR (282 MHz, CDCl3): δ =
–62 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C16H10BrF3NO:
367.9898, found 367.9894.
4-(2-Bromophenoxy)-6-fluoroquinoline (1t): Method (a) – pale
yellow solid (0.344 g, 65 %); m.p. 75–79 °C. IR (film): ν˜max = 3422,
1630, 1262, 1222, 1177, 657 cm–1. 1H NMR (300 MHz, CDCl3): δ =
6.43 (d, J = 5.1 Hz, 1 H), 7.19–7.24 (m, 1 H), 7.25 (d, J = 8.7 Hz, 1 H),
7.44 (t, J = 7.4 Hz, 1 H), 7.54 (td, J = 8.7, 2.8 Hz, 1 H), 7.73 (d, J =
9.9 Hz, 1 H), 8.02 (dd, J = 9.3, 2.8 Hz, 1 H), 8.12 (dd, J = 9.2, 5.2 Hz,
1 H), 8.64 (d, J = 5.1 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ =
104.0, 105.7 [d, 2J(C,F) = 24 Hz], 116.3, 120.4 [d, 2J(C,F) = 26 Hz],
121.7 [d, 3J(C,F) = 10 Hz], 123.3, 127.5, 129.3, 131.7 [d, 3J(C,F) =
10 Hz], 134.4, 146.9, 150.3 [d, 6J(C,F) = 3 Hz], 150.8, 160.3 [d, 4J(C,F) =
5 Hz], 160.4 [d, 1J(C,F) = 248 Hz] ppm. 19F NMR (282 MHz, CDCl3):
δ = –113 ppm. HRMS (ESI-TOF)m/z: [M + H]+ calcd. for C15H10BrFNO:
317.9930, found 317.9917.
4-(2-Bromophenoxy)-8-fluoroquinoline (1u): Method (a) – pale
yellow crystalline solid (0.2519 g, 53 %); m.p. 87–90 °C. IR (film):
ν˜max = 1631, 1597, 1264, 1224, 949, 612 cm–1. 1H NMR (300 MHz,
CDCl3): δ = 6.45 (d, J = 5.1 Hz, 1 H), 7.12–7.29 (m, 2 H), 7.34–7.58
(m, 3 H), 7.70 (dd, J = 8.0, 1.4 Hz, 1 H), 8.19 (d, J = 8.0 Hz, 1 H), 8.71
(d, J = 5.1 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 104.4, 114.3
[d, 4J(C,F) = 19 Hz], 116.2, 117.7 [d, 4J(C,F) = 5 Hz], 122.7 [d, 3J(C,F) =
3 Hz], 123.2, 126.0 [d, 3J(C,F) = 8 Hz], 127.55, 129.3, 134.3, 140.0 [d,
2J(C,F) = 13 Hz], 150.7, 151.2, 157.9 [d, 1J(C,F) = 256 Hz], 160.6 [d,
4J(C,F) = 4 Hz] ppm. 19F NMR (282 MHz, CDCl3): δ = –125 ppm.
HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C15H10BrFNO: 317.9930,
found 317.9918.
4-(2-Bromophenoxy)-6-chloroquinoline (1v): Method (a) – off-
white solid (0.4525 g, 90 %); m.p. 89–90 °C. IR (film): ν˜max = 1642,
1563, 1262, 1222, 666, 643 cm–1. 1H NMR (300 MHz, CDCl3): δ =
6.41 (d, J = 5.2 Hz, 1 H), 7.17–7.30 (m, 2 H), 7.44 (ddd, J = 8.2, 7.3,
1.6 Hz, 1 H), 7.65–7.69 (m, 2 H), 8.04 (d, J = 9.0 Hz, 1 H), 8.40 (d, J =
2.3 Hz, 1 H), 8.66 (d, J = 5.2 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3):
δ = 104.2, 116.3, 121.0, 121.6, 123.2, 127.5, 129.3, 130.8, 131.1, 132.2,
134.3, 148.1, 150.7, 151.2, 160.0 ppm. HRMS (ESI-TOF) m/z: [M + H]+
calcd. for C15H10BrClNO: 333.9634, found 333.9628.
4-(2-Bromophenoxy)-2-heptylquinoline (1w): Method (a) – off-
white solid (0.205 g, 90 %); m.p. 75–77 °C. IR (film): ν˜max = 2926,
2855, 1600, 1470, 1359, 1234, 763 cm–1. 1H NMR (300 MHz, CDCl3):
δ = 0.85 (t, J = 6.7 Hz, 3 H), 1.14–1.42 (m, 8 H), 1.68 (m, 2 H), 2.80
(t, J = 8.1 Hz, 2 H), 6.30 (s, 1 H), 7.17–7.25 (m, 2 H), 7.42 (ddd, J =
8.5, 7.2, 1.5 Hz, 1 H), 7.53 (ddd, J = 8.1, 7.0, 1.1 Hz, 1 H), 7.63–7.81
(m, 2 H), 8.05 (d, J = 8.4 Hz, 1 H), 8.34 (dd, J = 8.3, 0.9 Hz, 1 H) ppm.
13C NMR (75 MHz, CDCl3): δ = 14.1, 22.6, 29.2, 29.4, 30.0, 31.8, 39.7,
103.8, 116.3, 119.7, 121.7, 123.1, 125.4, 127.1, 128.5, 129.2, 130.1,
134.3, 149.5, 151.4, 160.7, 164.2 ppm. HRMS (ESI-TOF) m/z: [M + H]+
calcd. for C22H25BrNO: 398.1120, found 398.1135.
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General Procedure for Palladium-Catalysed Intramolecular Di-
rect Arylation Reactions for the Preparation of Compounds 2a–
2w: A mixture of the 4-(2-bromophenoxy)quinoline substrate 1
(1 equiv.), Pd(OAc)2 (2–5 mol-%), and anhydrous caesium carbonate
(2 equiv.) in anhydrous N-methylpyrrolidone (1.5 mL/mmol) was
stirred at 135 °C in a sealed reaction tube until the reaction was
completed as evident by 1H NMR analysis. The cooled reaction mix-
ture was diluted with DCM, filtered through a short plug of Celite
and concentrated in vacuo. The crude mixture was purified by col-
umn chromatography over silica gel using DCM/EtOAc (99:1–95:5)
as eluent.
Benzofuro[3,2-c]quinoline (2a):[27] White solid (0.068 g, 95 %);
m.p. 132–135 °C (lit.[27] 135–138 °C). IR (film): ν˜max = 3369, 1566,
1510, 1399, 1190 cm–1. 1H NMR (300 MHz, CDCl3): δ = 7.44–7.58 (m,
2 H), 7.65–7.83 (m, 3 H), 8.12 (dd, J = 7.2, 0.9 Hz, 1 H), 8.28 (d, J =
8.4 Hz, 1 H), 8.44 (dd, J = 8.1, 1.0 Hz, 1 H), 9.51 (s, 1 H) ppm. 13C
NMR (75 MHz, CDCl3): δ = 112.1, 116.3, 117.2, 120.6, 120.8, 122.7,
124.1, 127.0, 127.2, 129.3, 129.9, 144.4, 147.4, 156.0, 157.5 ppm.
HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C15H10NO: 220.0762, found
220.0755.
9-Fluorobenzofuro[3,2-c]quinoline (2b):[53] White solid (0.064 g,
88 %); m.p. 149–150 °C (lit.[53] 148–150 °C). IR (film): ν˜max = 3052,
1564, 1512, 1396, 1254, 1134 cm–1. 1H NMR (300 MHz, CDCl3): δ =
7.22 (ddd, J = 8.9, 6.9, 2.2 Hz, 1 H), 7.45 (dd, J = 8.6, 2.2 Hz, 1 H),
7.63–7.85 (m, 2 H), 8.00 (dd, J = 8.6, 5.3 Hz, 1 H), 8.25 (d, J = 8.3 Hz,
1 H), 8.36 (dd, J = 8.1, 1.1 Hz, 1 H), 9.43 (s, 1 H) ppm. 13C NMR
(75 MHz, CDCl3): δ = 100.3 [d, 2J(C,F) = 27 Hz], 112.3 [d, 2J(C,F) =
24 Hz], 115.8, 117.0, 118.9 [d, 4J(C,F) = 2 Hz], 120.6, 121.2 [d, 3J(C,F) =
10 Hz], 127.2, 129.4, 129.8, 143.9, 147.1, 156.1 [d, 3J(C,F) = 14 Hz],
158.1 [d, 5J(C,F) = 3 Hz], 162.2 [d, 1J(C,F) = 247 Hz] ppm. 19F NMR
(282 MHz, CDCl3): δ = –112 ppm. HRMS (ESI-TOF) m/z: [M + H]+
calcd. for C15H9FNO: 238.0668, found 238.0668.
8-Fluorobenzofuro[3,2-c]quinoline (2c):[27] White solid (0.087 g,
91 %); m.p. 163–164 °C (lit.[27] 162–163 °C). IR (film): ν˜max = 3368,
1565, 1479, 1319, 1247, 1146 cm–1. 1H NMR (300 MHz, CDCl3): δ =
7.21–7.33 (m, 1 H), 7.65–7.87 (m, 4 H), 8.28 (d, J = 8.4 Hz, 1 H), 8.41
(dd, J = 8.1, 1.0 Hz, 1 H), 9.45 (s, 1 H) ppm. 13C NMR (75 MHz, CDCl3):
δ = 106.7 [d, 2J(C,F) = 26 Hz], 112.9 [d, 3J(C,F) = 9 Hz], 114.7 [d,
2J(C,F) = 26 Hz], 116.1 [d, 4J(C,F) = 4 Hz], 117.0, 120.8, 123.6 [d,
3J(C,F) = 11 Hz], 127.2, 129.6, 129.9, 144.2, 147.5, 151.9, 158.6, 159.7
[d, 1J(C,F) = 241 Hz] ppm. 19F NMR (282 MHz, CDCl3): δ = –118 ppm.
HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C15H9FNO: 238.0668, found
238.0659.
10-Fluorobenzofuro[3,2-c]quinoline (2d):[27] White solid (0.104 g,
93 %); m.p. 156–157 °C (lit.[27] 157–158 °C). IR (film): ν˜max = 3368,
1564, 1496, 1347, 1200, 1189 cm–1. 1H NMR (300 MHz, CDCl3): δ =
7.27–7.35 (m, 1 H), 7.42 (td, J = 8.0, 4.4 Hz, 1 H), 7.73 (ddd, J = 8.1,
7.0, 1.2 Hz, 1 H), 7.79–7.92 (m, 2 H), 8.29 (d, J = 8.2 Hz, 1 H), 8.49
(dd, J = 8.1, 0.9 Hz, 1 H), 9.50 (s, 1 H) ppm. 13C NMR (75 MHz, CDCl3):
δ = 113.7 [d, 2J(C,F) = 16 Hz], 116.0, 116.1 [d, 4J(C,F) = 4 Hz], 117.0,
120.8, 124.8 [d, 3J(C,F) = 6 Hz], 126.2 [d, 3J(C,F) = 3 Hz], 127.3, 129.7,
129.8, 142.7 [d, 2J(C,F) = 11 Hz], 144.3, 147.7, 148.3 [d, 1J(C,F) =
251 Hz], 157.8 ppm. 19F NMR (282 MHz, CDCl3): δ = –135 ppm.
HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C15H9FNO: 238.0668, found
238.0662.
9-Chlorobenzofuro[3,2-c]quinoline (2e): White solid (0.086 g,
79 %); m.p. 198–199 °C. IR (film): ν˜max = 3047, 1562, 1508, 1338,
1049, 755 cm–1. 1H NMR (300 MHz, CDCl3): δ = 7.47 (dd, J = 8.3,
1.8 Hz, 1 H), 7.66–7.87 (m, 3 H), 8.00 (d, J = 8.3 Hz, 1 H), 8.27 (d, J =
8.4 Hz, 1 H), 8.40 (d, J = 8.0 Hz, 1 H), 9.46 (s, 1 H) ppm. 13C NMR
(75 MHz, CDCl3): δ = 112.8, 115.7, 117.0, 120.7, 121.1, 121.4, 124.8,
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127.2, 129.6, 129.9, 132.9, 144.1, 147.5, 156.0, 157.8 ppm. HRMS (ESI-
TOF) m/z: [M + H]+ calcd. for C15H9ClNO: 254.0373, found 254.0363.
8-Chlorobenzofuro[3,2-c]quinoline (2f):[27] White solid (0.071 g,
93 %); m.p. 187–189 °C (lit.[27] 189–190 °C). IR (film): ν˜max = 2917,
1564, 1511, 1395, 1194, 871 cm–1. 1H NMR (300 MHz, CDCl3): δ =
7.51 (dd, J = 8.8, 2.2 Hz, 1 H), 7.69 (dd, J = 8.8, 0.4 Hz, 1 H), 7.72
(ddd, J = 8.1, 7.0, 1.2 Hz, 1 H), 7.82 (ddd, J = 8.5, 7.0, 1.5 Hz, 1 H),
8.08 (dd, J = 2.2, 0.4 Hz, 1 H), 8.28 (d, J = 8.2 Hz, 1 H), 8.41 (dd, J =
8.2, 0.9 Hz, 1 H), 9.46 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ =
113.1, 115.5, 117.0, 120.5, 120.8, 124.1, 127.28, 127.34, 129.75,
129.78, 130.0, 144.2, 147.6, 154.2, 158.2 ppm. HRMS (ESI-TOF) m/z:
[M + H]+ calcd. for C15H9ClNO: 254.0373, found 254.0370.
8-(Trifluoromethyl)benzofuro[3,2-c]quinoline (2g): White crystal-
line solid (0.0533 g, 88 %); m.p. 170–173 °C. IR (film): ν˜max = 1627,
1567, 1333, 1310, 1151, 1110 cm–1. 1H NMR (400 MHz, CDCl3): δ =
7.65–7.91 (m, 4 H), 8.29 (d, J = 8.5 Hz, 1 H), 8.35–8.48 (m, 2 H), 9.52
(s, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 112.5, 115.4, 116.8,
118.3 [q, 3J(C,F) = 4 Hz], 120.7, 123.0, 124.3 [q, 3J(C,F) = 4 Hz], 124.3
[q, 1J(C,F) = 272 Hz], 126.8 [q, 2J(C,F) = 33 Hz], 127.4, 129.9, 130.0,
144.1, 147.8, 157.2, 158.4 ppm. 19F NMR (282 MHz, CDCl3): δ =
–61 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C16H9F3NO:
288.0636, found 288.0629.
8-(Trifluoromethoxy)benzofuro[3,2-c]quinoline (2h): White crys-
talline solid (0.1367 g, 90 %); m.p. 124–126 °C. IR (film): ν˜max = 1641,
1512, 1280, 1247, 1206, 1141, 1156 cm–1. 1H NMR (300 MHz, CDCl3):
δ = 7.41 (ddd, J = 8.9, 2.4, 0.8 Hz, 1 H), 7.64–7.88 (m, 3 H), 7.95 (d,
J = 1.1 Hz, 1 H), 8.28 (d, J = 8.4 Hz, 1 H), 8.41 (dd, J = 8.1, 1.0 Hz, 1
H), 9.47 (s, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 113.0, 113.6,
115.9, 117.0, 120.6 [q, 1J(C,F) = 257 Hz], 120.7, 120.8, 123.8, 127.4,
129.9, 130.0, 144.2, 145.8, 147.8, 153.9, 158.7 ppm. 19F NMR
(282 MHz, CDCl3): δ = –58 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd.
for C16H9F3NO2: 304.0585, found 304.0574.
8-Nitrobenzofuro[3,2-c]quinoline (2i): Orange solid (0.028 g,
46 %); m.p. > 250 °C. IR (film): ν˜max = 3030, 1528, 1397, 1344,
1200 cm–1. 1H NMR (300 MHz, CDCl3): δ = 7.77 (ddd, J = 8.1, 7.2,
1.0 Hz, 1 H), 7.84–7.91 (m, 2 H), 8.32 (d, J = 8.5 Hz, 1 H), 8.41–8.52
(m, 2 H), 9.02 (d, J = 2.3 Hz, 1 H), 9.56 (s, 1 H) ppm. 13C NMR
(100 MHz, CDCl3): δ = 112.6, 115.4, 116.8, 117.1, 120.8, 123.0, 123.6,
127.8, 130.1, 130.5, 144.1, 144.9, 148.1, 158.6, 159.3 ppm. HRMS (ESI-
TOF) m/z: [M + H]+ calcd. for C15H9N2O3: 265.0613, found 265.0611.
Methyl Benzofuro[3,2-c]quinoline-9-carboxylate (2j): Beige solid
(0.043 g, 56 %); m.p. 192–193 °C. IR (film): ν˜max = 3402, 1717, 1565,
1434, 1397, 1281, 1234 cm–1. 1H NMR (300 MHz, CDCl3): δ = 4.00 (s,
3 H), 7.70 (m, 1 H), 7.81 (ddd, J = 8.5, 7.0, 1.5 Hz, 1 H), 8.09 (d, J =
7.8 Hz, 1 H), 8.16 (dd, J = 8.2, 1.3 Hz, 1 H), 8.26 (d, J = 8.4 Hz, 1 H),
8.36–8.43 (m, 2 H), 9.46 (s, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ =
52.5, 113.6, 115.5, 116.9, 120.2, 121.0, 125.5, 126.8, 127.3, 129.0,
129.9, 130.0, 144.5, 147.8, 155.4, 159.0, 166.6 ppm. HRMS (ESI-TOF)
m/z: [M + H]+ calcd. for C17H12NO3: 278.0817, found 278.0811.
8-Methylbenzofuro[3,2-c]quinoline (2k):[27] White solid (0.062 g,
71 %); m.p. 145–148 °C (lit.[27] 149–150 °C). IR (film): ν˜max = 2917,
1564, 1510, 1321, 1192 cm–1. 1H NMR (300 MHz, CDCl3): δ = 2.57 (s,
3 H), 7.35 (ddd, J = 8.5, 1.8, 0.5 Hz, 1 H), 7.61–7.73 (m, 2 H), 7.78
(ddd, J = 8.5, 6.9, 1.6 Hz, 1 H), 7.89–7.92 (m, 1 H), 8.26 (d, J = 8.5 Hz,
1 H), 8.41 (dd, J = 8.1, 0.9 Hz, 1 H), 9.47 (s, 1 H) ppm. 13C NMR
(75 MHz, CDCl3): δ = 21.4, 111.5, 116.2, 117.2, 120.5, 120.8, 122.6,
126.8, 128.3, 129.1, 129.8, 133.7, 144.3, 147.3, 154.3, 157.6 ppm.
HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C16H12NO: 234.0919, found
234.0921.
8-(tert-Butyl)benzofuro[3,2-c]quinoline (2l):[27] Pale yellow solid
(0.025 g, 50 %); m.p. 97–100 °C (lit.[27] 99–100 °C). IR (film): ν˜max =
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2962, 1567, 1488, 1392, 1201 cm–1. 1H NMR (600 MHz, CDCl3): δ =
1.47 (s, 9 H), 7.61 (dd, J = 8.7, 2.0 Hz, 1 H), 7.67–7.72 (m, 2 H), 7.79
(ddd, J = 8.4, 6.9, 1.5 Hz, 1 H), 8.10 (d, J = 1.7 Hz, 1 H), 8.27 (d, J =
8.4 Hz, 1 H), 8.42 (dd, J = 8.2, 1.0 Hz, 1 H), 9.52 (s, 1 H) ppm. 13C
NMR (150 MHz, CDCl3): δ = 31.9, 35.0, 111.4, 116.7, 116.9, 117.3,
120.8, 122.3, 125.1, 126.9, 129.2, 129.8, 144.4, 147.3, 147.4, 154.2,
157.8 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C19H18NO:
276.1388, found 276.1377.
8-Methoxybenzofuro[3,2-c]quinoline (2m):[28] Off-white solid
(0.032 g, 42 %); m.p. 165–167 °C (lit.[28] 160–162 °C). IR (film): ν˜max =
3350, 1570, 1486, 1330, 1186, 1164 cm–1. 1H NMR (300 MHz, CDCl3):
δ = 3.96 (s, 3 H), 7.13 (dd, J = 9.0, 2.6 Hz, 1 H), 7.54 (d, J = 2.6 Hz,
1 H), 7.59–7.85 (m, 3 H), 8.26 (d, J = 8.4 Hz, 1 H), 8.40 (dd, J = 8.1,
1.0 Hz, 1 H), 9.46 (s, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 56.1,
103.3, 112.6, 115.5, 116.6, 117.3, 120.8, 123.3, 127.0, 129.3, 129.8,
144.4, 147.3, 150.7, 156.9, 158.1 ppm. HRMS (ESI-TOF) m/z: [M + H]+
calcd. for C16H12NO2: 250.0868, found 250.0858.
Naphtho[1′,2′:4,5]furo[3,2-c]quinoline (2n): Off-white solid
(0.014 g, 17 %); m.p. 203–205 °C. IR (film): ν˜max = 2919, 1562, 1507,
1310, 1223 cm–1. 1H NMR (600 MHz, CDCl3): δ = 7.64 (ddd, J = 8.0,
6.9, 1.1 Hz, 1 H), 7.75 (ddd, J = 8.0, 6.9, 1.1 Hz, 1 H), 7.79–7.85 (m,
2 H), 7.94 (d, J = 8.9 Hz, 1 H), 8.02 (d, J = 8.9 Hz, 1 H), 8.09 (d, J =
8.2 Hz, 1 H), 8.33 (d, J = 8.4 Hz, 1 H), 8.51 (dd, J = 8.4, 1.1 Hz, 1 H),
8.69 (d, J = 8.2 Hz, 1 H), 9.97 (s, 1 H) ppm. 13C NMR (150 MHz,
CDCl3): δ = 112.7, 117.0, 117.3, 117.7, 120.7, 124.2, 125.3, 127.2,
127.7, 128.5, 128.8, 129.2, 129.4, 129.8, 131.0, 145.1, 146.4, 154.1,
157.0 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C19H12NO:
270.0919, found 270.0916.
Pyrido[2′,3′:4,5]furo[3,2-c]quinoline (2o): Pale yellow solid
(0.0896 g, 81 %); m.p. 174–175 °C. IR (film): ν˜max = 1637, 1570, 1306,
1264 cm–1. 1H NMR (300 MHz, CDCl3): δ = 7.42 (dd, J = 8.4, 4.8 Hz,
1 H), 7.60–7.86 (m, 2 H), 7.96 (dd, J = 8.4, 1.3 Hz, 1 H), 8.17–8.43 (m,
2 H), 8.71 (dd, J = 4.8, 1.2 Hz, 1 H), 9.66 (s, 1 H) ppm. 13C NMR
(75 MHz, CDCl3): δ = 115.3, 116.9, 119.0, 120.6, 121.3, 127.3, 130.0,
130.2, 142.8, 144.4, 146.6, 148.2, 149.2, 159.1 ppm. HRMS (ESI-TOF)
m/z: [M + H]+ calcd. for C14H9N2O: 221.0715, found 221.0710.
6-Methylbenzofuro[3,2-c]quinoline (2p):[27] Pale yellow solid
(0.029 g, 78 %); m.p. 132–134 °C (lit.[27] 132–133 °C). IR (film): ν˜max =
3380, 1563, 1509, 1364, 1084 cm–1. 1H NMR (300 MHz, CDCl3): δ =
3.16 (s, 3 H), 7.41–7.69 (m, 3 H), 7.72–7.79 (m, 2 H), 8.10 (dd, J = 7.6,
2.1 Hz, 1 H), 8.18 (d, J = 8.4 Hz, 1 H), 8.38 (dd, J = 8.1, 2.1 Hz, 1 H)
ppm. 13C NMR (75 MHz, CDCl3): δ = 24.3, 112.1, 115.5, 116.2, 120.7,
121.8, 123.5, 124.0, 126.1, 126.7, 128.9, 129.4, 146.9, 154.8, 155.9,
157.5 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C16H12NO:
234.0919, found 234.0915.
2-Methoxybenzofuro[3,2-c]quinoline (2q):[27] Off-white solid
(0.095 g, 84 %); m.p. 150–152 °C (lit.[27] 150–153 °C). IR (film): ν˜max =
2954, 1350, 1514, 1468, 1228, 1191, 1031 cm–1. 1H NMR (300 MHz,
CDCl3): δ = 3.96 (s, 3 H), 7.28–7.53 (m, 4 H), 7.64 (d, J = 8.1 Hz, 1
H), 7.97 (dd, J = 7.4, 0.8 Hz, 1 H), 8.08 (d, J = 9.2 Hz, 1 H), 9.23 (s, 1
H) ppm. 13C NMR (75 MHz, CDCl3): δ = 55.6, 98.5, 111.9, 116.4, 117.7,
120.6, 121.7, 122.8, 123.9, 127.1, 131.3, 141.5, 143.3, 155.8, 156.7,
158.2 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C16H12NO2:
250.0868, found 250.0858.
3-Methoxybenzofuro[3,2-c]quinoline (2r): Off-white solid
(0.091 g, 81 %); m.p. 146–147 °C. IR (film): ν˜max = 3022, 1639, 1452,
1345, 1324, 1242, 1168 cm–1. 1H NMR (300 MHz, CDCl3): δ = 3.97 (s,
3 H), 7.31 (dd, J = 9.0, 2.3 Hz, 1 H), 7.36–7.54 (m, 2 H), 7.58 (d, J =
2.3 Hz, 1 H), 7.68 (d, J = 8.0 Hz, 1 H), 7.99 (d, J = 7.1 Hz, 1 H), 8.25
(d, J = 9.0 Hz, 1 H), 9.37 (s, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ =
55.5, 108.4, 111.7, 112.0, 115.0, 119.7, 120.3, 121.9, 122.8, 123.9,
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126.7, 144.6, 149.3, 155.8, 157.8, 160.7 ppm. HRMS (ESI-TOF) m/z:
[M + H]+ calcd. for C16H12NO2: 250.0868, found 250.0865.
2-(Trifluoromethyl)benzofuro[3,2-c]quinoline (2s): Yellow solid
(0.049 g, 63 %); m.p. 141–143 °C. IR (film): ν˜max = 2917, 1567, 1443,
1348, 1167, 1111 cm–1. 1H NMR (300 MHz, CDCl3): δ = 7.43–7.67 (m,
2 H), 7.80 (d, J = 8.2 Hz, 1 H), 7.96 (dd, J = 9.0, 2.0 Hz, 1 H), 8.13 (d,
J = 8.4 Hz, 1 H), 8.38 (d, J = 8.9 Hz, 1 H), 8.75 (s, 1 H), 9.60 (s, 1 H)
ppm. 13C NMR (100 MHz, CDCl3): δ = 112.3, 116.3, 117.3, 119.1 [q,
3J(C,F) = 5 Hz], 120.8, 122.1, 124.3 [q, 1J(C,F) = 270 Hz], 124.5, 124.9
[q, 3J(C,F) = 3 Hz], 127.9, 128.8 [q, 2J(C,F) = 33 Hz], 131.0, 146.4,
148.0, 156.1, 157.5 ppm. 19F NMR (282 MHz, CDCl3): δ = –62 ppm.
HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C16H9F3NO: 288.0636, found
288.0634.
2-Fluorobenzofuro[3,2-c]quinoline (2t):[53] White solid (0.025 g,
67 %); m.p. 146–148 °C (lit.[53] 148–149 °C). IR (film): ν˜max = 3399,
1515, 1462, 1364, 1195, 1175 cm–1. 1H NMR (300 MHz, CDCl3): δ =
7.45–7.61 (m, 3 H), 7.76 (d, J = 8.1 Hz, 1 H), 8.00 (dd, J = 8.6, 2.8 Hz,
1 H), 8.10 (dd, J = 7.6, 0.8 Hz, 1 H), 8.26 (dd, J = 9.3, 5.2 Hz, 1 H),
9.45 (s, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 104.7 [d, 2J(C,F) =
24 Hz], 112.2, 116.8, 117.8 [d, 3J(C,F) = 11 Hz], 119.3 [d, 2J(C,F) =
26 Hz], 120.8, 122.5, 124.2, 127.6, 132.5 [d, 3J(C,F) = 9 Hz], 143.6 [d,
6J(C,F) = 3 Hz], 144.4, 156.1, 157.1 [d, 4J(C,F) = 5 Hz], 160.8 [d,
1J(C,F) = 249 Hz] ppm. 19F NMR (282 MHz, CDCl3): δ = –111 ppm.
HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C15H9FNO: 238.0668, found
238.0659.
4-Fluorobenzofuro[3,2-c]quinoline (2u): White crystalline solid
(0.0405 g, 49 %); m.p. 153–155 °C. IR (film): ν˜max = 1640, 1596, 1300,
1249, 949 cm–1. 1H NMR (300 MHz, CDCl3): δ = 7.40–7.68 (m, 4 H),
7.75 (d, J = 8.1 Hz, 1 H), 7.99–8.27 (m, 2 H), 9.53 (s, 1 H) ppm. 13C
NMR (100 MHz, CDCl3): δ = 112.2, 113.7 [d, 2J(C,F) = 19 Hz], 116.6
[d, 2J(C,F) = 19 Hz], 117.3, 118.9 [d, 3J(C,F) = 3 Hz], 120.9, 122.4,
124.3, 127.1 [d, 3J(C,F) = 8 Hz], 127.7, 137.3 [d, 2J(C,F) = 12 Hz],
144.6, 156.0, 157.0 [d, 4J(C,F) = 5 Hz], 158.6 [d, 1J(C,F) = 257 Hz]
ppm. 19F NMR (282 MHz, CDCl3): δ = –122 ppm. HRMS (ESI-TOF)
m/z: [M + H]+ calcd. For C15H9FNO: 238.0668, found 238.0661.
2-Chlorobenzofuro[3,2-c]quinoline (2v):[53] White crystalline solid
(0.0865 g, 68 %); m.p. 141–142 °C (lit.[53] 139–141 °C). 1H NMR
(300 MHz, CDCl3): δ = 7.38–7.58 (m, 2 H), 7.59–7.76 (m, 2 H), 8.02
(dd, J = 7.6, 0.6 Hz, 1 H), 8.12 (d, J = 9.0 Hz, 1 H), 8.27 (d, J = 2.3 Hz,
1 H), 9.38 (s, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 112.2 116.9,
117.7, 119.8, 120.7, 122.3, 124.2, 127.6, 130.0, 131.4, 132.9, 144.4,
145.5, 156.0, 156.3 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for
C15H9ClNO: 254.0373, found 254.0368.
6-Heptylbenzofuro[3,2-c]quinoline (2w): White solid (0.056 g,
70 %); m.p. 90–92 °C. IR (film): ν˜max = 2917, 1559, 1445, 1363,
1202 cm–1. 1H NMR (300 MHz, CDCl3): δ = 0.88 (t, J = 6.7 Hz, 3 H),
1.22–1.64 (m, 8 H), 1.95 (dt, J = 15.7, 7.7 Hz, 2 H), 3.40 (t, J = 8.0 Hz,
2 H), 7.40–7.67 (m, 3 H), 7.69–7.79 (m, 2 H), 8.00 (d, J = 7.3 Hz, 1 H),
8.19 (d, J = 8.4 Hz, 1 H), 8.35 (d, J = 8.1 Hz, 1 H) ppm. 13C NMR
(75 MHz, CDCl3): δ = 14.1, 22.7, 28.6, 29.2, 29.9, 31.8, 38.0, 112.1,
114.8, 116.2, 120.7, 121.8, 123.1, 124.0, 126.0, 126.6, 129.1, 129.3,
146.9, 155.9, 157.7, 159.0 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd.
for C22H24NO: 318.1858, found 318.1845.
Synthesis of N-(2-Bromophenyl)quinolin-4-amine (3): To a de-
gassed solution of Pd2(dba)3 (2 mol-%) and XantPhos (4 mol-%) in
anhydrous 1,4-dioxane (4 mL/mmol) were added caesium carb-
onate (1.4 equiv.), 4-bromoquinoline (1 equiv.) and 2-bromoaniline
(1.1 equiv.) under a nitrogen atmosphere. The reaction mixture was
stirred at 120 °C under nitrogen for 24 h. The cooled reaction mix-
ture was diluted with DCM, filtered through Celite and concentrated
in vacuo. The crude mixture was purified by column chromatogra-
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phy over silica gel using DCM/EtOAc (3:1) as eluent to yield the
product as a yellow solid (0.322 g, 74 %); m.p. 238–241 °C. IR (film):
ν˜max = 3360, 3061, 1572, 1526, 1335, 747 cm1 cm–1. 1H NMR
(300 MHz, CDCl3): δ = 6.88 (br. s, 1 H), 7.02 (td, J = 8.0, 1.5 Hz, 1 H),
7.08 (d, J = 5.2 Hz, 1 H), 7.31–7.38 (m, 1 H), 7.51–7.61 (m, 2 H), 7.65–
7.78 (m, 2 H), 8.01 (d, J = 8.3 Hz, 1 H), 8.09 (d, J = 8.0 Hz, 1 H), 8.66
(d, J = 5.2 Hz, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 103.4, 116.9,
120.0, 120.3, 122.2, 125.0, 125.8, 128.4, 129.6, 130.1, 133.5, 138.3,
146.2, 149.2, 150.8 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for
C15H12BrN2: 299.0184, found 299.0187.
Synthesis of 11H-Indolo[3,2-c]quinoline (4):[54] N-(2-bromo-
phenyl)quinolin-4-amine 3 (1 equiv.), Pd(OAc)2 (5 mol-%), PCy3·HBF4
(10 mol-%) and caesium carbonate (2 equiv.) were added to de-
gassed N-methylpyrrolidone (1.5 mL/mmol) under Schlenk condi-
tions under a nitrogen atmosphere. The reaction mixture was stirred
at 150 °C (sand bath) for 3 h. The cooled reaction mixture was
diluted with DCM and filtered through Celite. The mixture was
washed with water (3 × 10 mL) and brine (15 mL), dried with
MgSO4, filtered and concentrated in vacuo. The crude mixture was
purified by column chromatography over silica gel using DCM/
EtOAc (7:3) as eluent to yield the product as an off-white solid
(0.030 g, 83 %); m.p. > 250 °C (lit.[54] 340–341 °C). IR (film): ν˜max =
3355, 2916, 2849, 1567, 1512, 1459, 1236 cm–1. 1H NMR (300 MHz,
[D6]DMSO): δ = 7.35 (t, J = 7.5 Hz, 1 H), 7.51 (t, J = 7.6 Hz, 1 H),
7.63–7.81 (m, 3 H), 8.15 (dd, J = 8.2, 1.3 Hz, 1 H), 8.33 (d, J = 7.8 Hz,
1 H), 8.53 (dd, J = 8.0, 1.4 Hz, 1 H), 9.60 (s, 1 H), 12.72 (s, 1 H) ppm.
13C NMR (75 MHz, [D6]DMSO): δ = 112.3, 114.8, 117.6, 120.6, 121.1,
122.4, 122.6, 126.0, 126.1, 128.5, 130.0, 139.3, 140.2, 145.3,
145.9 ppm. HRMS (ESI-TOF) m/z: [M + H]+ calcd. for C15H11N2:
219.0922, found 219.0911.
Supporting Information (see footnote on the first page of this
article): Additional competition experiments, as well as 1H, 13C and
19F NMR spectra of all new compounds, key intermediates and final
products.
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ABSTRACT: Herein, we report a one-pot process that marries mechanistically
distinct, traditional cross-coupling reactions with C−H functionalization using the
same precatalyst. The reactions proceed in yields of up to 95%, in air, and require
no extraneous ligand. The reactions are thought to be facilitated by harnessing the
substrate quinoline as an N-ligand, and evidence of the palladium−quinoline
interaction is provided by 1H-15N HMBC NMR spectroscopy and X-ray
crystallographic structures. Application of the methodology is demonstrated by
the quick formation of fluorescent, π-extended frameworks.
■ INTRODUCTION
The formation of multiple carbon−carbon bonds in a
telescoped, one-pot procedure is an efficient and environ-
mentally friendly approach to the construction of new chemical
entities.1 However, carrying out two or more chemical
reactions in a single vessel places significant demands on the
methodologies involved, specifically in terms of reagent,
catalyst, and substrate compatibility.2 Additionally, avoiding
secondary manipulation during a reaction is highly preferable if
the procedures are to be applied industrially.
Pyridine, quinoline, and furan moieties are prominent in
synthetic and naturally occurring pharmacologically active
compounds.3 In drugs, they represent the 2nd, 22nd, and 25th
most common ring systems, respectively.4 We recently
reported a palladium-catalyzed intramolecular direct arylation
(DA) protocol that gives a variety of benzofuro[3,2-
c]quinolines 2 from 4-(2-bromophenoxy)quinolines 1 in
excellent yields (Scheme 1).5
Chemoselectivity and regioselectivity proved to be very
predictable in these mono-halogenated systems. Conversely,
cross-coupling reactions involving substrates bearing more
than one halogen are far less predictable.2,6 The selective
functionalization of substrates with two different halogens
usually relies upon the marked difference in the rates of
oxidative addition (OA) at the C−X bonds. Using halogens of
the same type is considerably more difficult as significant rate
differences in the oxidation step (I vs Br or Br vs Cl) are not
easily harnessed.7 A limited number of one-pot reactions
combining C−H functionalization with a Suzuki−Miyaura
reaction have been reported.8 However, we are aware of very
few protocols that do not require perturbation of the reaction
setup by the addition of secondary reactants, reagents, or
catalysts subsequent to reaction initiation.9 In all cases, added
phosphine ligand is required. The use of phosphine ligands
adds significantly to the cost of any catalytic process; in fact,
they are often the most expensive component of a catalytic
system.10
This report describes a selection of one-pot tandem Suzuki−
Miyaura/direct arylation (SM/DA) and Mizoroki−Heck/
direct arylation (MH/DA) reactions with di- and tribromo-
quinolines. Once the reaction is initiated, no further
manipulation is required, and no subsequent addition of
solvents, reagents, reactants, or catalysts is needed. Overall, the
reaction proceeds using 2 mol % Pd(OAc)2, in air, and without
recourse to extraneous ligands. Through further development
to a one-pot Mizoroki−Heck/direct arylation protocol, π-
extended quinolines, with structural features of interest to
Received: December 10, 2019
Published: January 23, 2020
Scheme 1. Intramolecular Direct Arylation of 1
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medicinal11 and materials12 chemists, were prepared. These
entities are challenging to synthesize by traditional, stepwise
cross-coupling techniques.13 We provide structural character-
ization of initially formed palladium−quinoline (Pd−Q)
complexes using cystallography, mass spectrometry, and
heteronuclear multiple bond correlation (HMBC) NMR
spectroscopy.
■ RESULTS AND DISCUSSION
Our initial aim was to test the chemoselectivity of 3a and
perhaps exploit entropic factors to carry out the intramolecular
DA reaction while leaving the bromide on the quinoline
backbone untouched. Using the reaction conditions that had
so efficiently furnished 2 from 1, no DA was observed (Scheme
2). We doubted that the bromine on the quinoline ring would
affect the electronics of the C-3 position to such an extent that
C−H functionalization would be prevented. Thus, we
rationalized that OA at the quinoline-Br was favored over
the phenoxy-Br. In the absence of a suitable coupling partner,
the OA product 3a′ was a catalytic dead end, with the
palladium trapped at a nonproductive site.
In an effort to liberate the palladium, phenylboronic acid was
introduced into the reaction mixture. Indeed, after optimiza-
tion, the Suzuki−Miyaura reaction occurred, along with the
direct arylation, giving 2-phenyl-benzofuro[3,2-c]quinoline 4a
in 83% isolated yield (Table 1).
A broad range of substituted phenylboronic acids underwent
one-pot tandem SM/DA coupling, allowing access to novel
benzofuroquinolines in good to excellent yields. Both electron-
releasing (4b and 4c) and electron-withdrawing (4d−4k)
groups were well tolerated. The chloride on 4f and 4l was
retained as a synthetic handle. Considering the prevalence of
the pyridine moiety in biologically active compounds,14 we
also applied the SM/DA reaction conditions to this substrate
and were pleased to furnish the benzofuropyridine 4m in good
yield. The Suzuki−Miyaura coupling was also conducive to
positioning the bromine at C-7 (4n−4r) (Figure 1a).
We were then keen to expand the scope of our one-pot
process to include Mizoroki−Heck transformations. Using
either tert-butyl acrylate or styrene derivatives, the one-pot
tandem MH/DA products were obtained in very good yields
(5a−5h) (Figure 1b). Both transformations also worked
efficiently when the second bromine was placed on the
phenoxy ring (6a−6c) (Figure 1c). Given the apparent
versatility of our methodology, a three-component tandem
process was devised using tribrominated substrates and two
equivalents of either coupling partner (7a−7c) (Figure 1d).
The structures of 4a, 4n, and 5b were confirmed by X-ray
diffraction analysis of single crystals (Figure 2 and see
Supporting Information S3−S6).
Incorporating heteroatomic substrates in cross-coupling
reactions usually necessitates the employment of an added
ligand and inert atmosphere,15 and in the reported C−H
functionalization of pyridines and quinolines,16 ancillary
ligands are also required. Considering that pyridines,17 and
indeed quinolines,18 possess the propensity to act as ligands for
palladium, we suspected that our methodology might be
underpinned by Pd−Q coordination. In order to determine
any Pd−Q interaction, we undertook 1H-15N HMBC NMR
spectroscopy. Inherent in this powerful technique are gradient-
enhanced pulse sequences, which allow for suppression of t1
noise facilitating the observation of the relatively weak long-
range 1H-15N correlations.19 Overall, the low natural
abundance and low gyromagnetic ratio are overcome. Using
this technique, structures 8a and 8b were elucidated. Initially,
0.5 equiv of Pd(OAc)2 was added to 1 and 3b in CDCl3
(Scheme 3), and the 1H, 13C, and 1H-15N HMBC NMR
spectra were recorded (see Supporting Information S14).
Complete consumption of both substrates was observed,
accompanied by upfield shifts in the 1H signals of the C-2, C-3,
and C-8 protons and a dramatic upfield shift in the 15N nucleus
resonance (for example, from 291.7 ppm 1 to 196.7 ppm 8a)
in the respective 1H-15N HMBC spectra (Figure 3 and
Supporting Information S14−S25). The significant shielding of
the nitrogen atom and the considerable accompanying shift in
both the C-2 and C-8 protons are indicative of direct Pd−N
coordination.20 Upon addition of Pd(OAc)2 to 3h,
1H and 13C
NMR shifts analogous to those in 8a and 8b were observed.
Similar downfield shifts were also discerned in the 1H NMR
spectra of 8a in dioxane-d8 and ACN-d3 (Supporting
Information S16 and S20). Crystal structures for complexes
8a and 8c were obtained (Figure 4), and the compositions of
8a−8c were also verified by HRMS data (Supporting
Information S8−S13).
Scheme 2. Failed Intramolecular DA of Dibromoquinoline
3a
Table 1. Solvent and Base Screen for Tandem SM/DA
Reaction of 3a
entry base solvent conv. (%) yielda (%)
1 Cs2CO3 NMP 100 73 (75)
2b Cs2CO3 1,4-dioxane 90 68
3c Cs2CO3 toluene 25
4c Cs2CO3 xylene 16
5c Cs2CO3 cyclohexanone 85 61
6c Cs2CO3 i-PrOAc 25
7c Cs2CO3 n-BuOAc 20
8 Na2CO3 NMP 100 80
9 K2CO3 NMP 100 86 (83)
10 KOH NMP 30 20
11 NaOH NMP 65 44
12 NaOt-Bu NMP 0d
aYields determined by 1H NMR analysis of the crude reaction mixture
using 1,3,5-trimethoxybenzene as an internal standard; values in
parentheses represent isolated yields. bReaction carried out at 125 °C.
cReaction carried out at 110 °C. dComplete decomposition of 3a was
observed.
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We consider the Suzuki−Miyaura reaction to be the initial
transformation in the sequence (Supporting Information
Schemes S1 and S2), progressing via the typical Pd(II)/
Pd(0) mechanistic cycle. For the DA step, we postulate two
plausible mechanisms: first, OA at C−Br followed by C−H
activation via, for example, concerted metalation−deprotona-
Figure 1. One-pot tandem SM/DA and MH/DA substrate scope. All
yields are isolated. a2.2 equiv. of coupling partner employed in the
synthesis of 7a−7c. b5 mol % Pd(OAc)2 used for all styrene-based
derivatives.
Figure 2. Crystal structures of 4a, 4n, and 5b drawn at the 50%
probability level. Second molecule in the asymmetric unit of 4a
omitted for clarity (see Supporting Information S4 for further
information).
Scheme 3. Precatalyst Formation and Structure
Figure 3. 1H-15N HMBC NMR spectrum of 8a in CDCl3 at 300 K as
recorded at 600 MHz (1H) and 60 MHz (15N). All chemical shifts δ
reported in ppm.
Figure 4. Crystal structures of 8a and 8c drawn at the 50% probability
level. Disordered solvent (methanol) treated using solvent masking
techniques for structure 8c (see Supporting Information S4−S7 for
further information).
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tion (CMD),21 and second, a Pd(II)/Pd(IV) route is also
plausible, as proposed by Yu and Morokuma.16a,22
Albeit undefined at this stage, we envisage these complexes
playing an important role as precatalysts, with the quinoline
aiding precatalyst-to-catalyst transformation, although it is
difficult to rule out an additional role of the quinoline in
preventing catalyst decomposition.23 Importantly, 8c was
deemed a competent precatalyst for the SM/DA reaction
(Scheme 4a). A further experiment using mono-bromo-Pd
complex 8a as the sole catalytic-source for the SM/DA
reaction yielded both 2 and 4a, proving that the Pd−Q
interaction is fluxional and ruling out a spectator-only role for
the quinoline ligands (analogous to phosphine ligands for
example) in the initially formed complexes 8a and 8b (Scheme
4b).24
Many small, conjugated organic molecules have the ability to
emit fluorescent light and can be exploited for a variety of
applications, such as in selective probes for ion detection12,25
and optoelectronic devices26 and as dyes or tags in
bioimaging.27 We were intrigued to investigate if our π-
extended MH/DA products displayed any useful photophysical
characteristics. Thus, UV−Visible absorption data for the
styrene-functionalized compounds 2, 5c−5h, 6c, and 7c was
obtained, and their fluorescent properties were investigated.
The standard benzofuro[3,2-c]quinoline framework 2 is given
for comparison (Table 2).
All compounds exhibit their maximum absorption band
(λmax) in the UV or near-UV region and yield large molar
absorption coefficients (ε) in the range of 104 dm3 mol−1 cm−1.
The addition of further auxochromes to the substituted
frameworks resulted in notable shifts in λmax. For example,
the introduction of an electron releasing methoxy group (5d
and 5g) induced a hypsochromic shift relative to the parent
styrene compounds 5c and 5f. In contrast, the more
electronically poor quinoline frameworks (5e and 5h) were
blueshifted by a single nanometer. A significant bathochromic
shift and increased intensity are displayed in the emission
spectra for all compounds with respect to 2. The addition of
electron-poor/rich groups to our molecular framework gives
rise to tunable differences in emission intensity and wave-
length.
In summary, we report the occurrence of two mechanisti-
cally distinct reactions in one pot using the same precatalyst
and without a requisite for an added ligand. The reactions
work well in air, furnishing substituted benzofuroquinolines,
which represent an interesting molecular framework for
biological investigations. Direct evidence that the substrate
quinoline forms a precatalytic species with palladium is
provided, and excellent characterization data is furnished.
The π-extended products also display interesting and
potentially useful florescence properties.
■ EXPERIMENTAL SECTION
Materials and Methods. Solvents and reagents were used as
obtained from commercial sources and without purification.
Melting points were measured in a Thomas Hoover Capillary
Melting Point apparatus.
Infrared spectra were measured on a Perkin-Elmer FT-IR
spectrometer as thin films in dichloromethane (DCM).
Column chromatography was carried out using 60 Å (35−70 μm)
silica. Thin-layer chromatography (TLC) was carried out on
precoated silica gel plates (Merck 60 PF254). The developed plates
were visualized under UV light.
High-resolution precise mass spectra (HRMS) were recorded on a
Waters LCT Premier Tof LC-MS instrument in University College
Cork. Samples were run in electrospray ionization (ESI) mode using
50% acetonitrile/water containing 0.1% formic acid as an eluent;
samples were made up at a concentration of ca. 1 mg mL−1. HRMS of
metal-containing complexes were recorded on a Bruker compact
TOF-MS in the University of York. Samples were run in electrospray
ionization (ESI) mode using 50% MeOH/water as eluent; samples
were made up at a concentration of ca. 1 mg mL−1. Acquisitions were
internally calibrated using sodium formate clusters.
Nuclear magnetic resonance (NMR) samples were run in
deuterated chloroform (CDCl3), deuterated dimethyl sulfoxide
((CD3)2SO), deuterated dioxane (C4D8O2), or deuterated acetoni-
trile (C2D3N) as specified.
1H NMR (600 MHz) and 1H NMR (300
MHz) spectra were recorded on Bruker Avance III 600 and Bruker
Avance III 300 NMR spectrometers, respectively, in proton-coupled
mode using tetramethysilane (TMS) as the internal standard. 13C
NMR (150 MHz), 13C NMR (100 MHz), and 13C NMR (75 MHz)
spectra were recorded on Bruker Avance III 600, Bruker Avance 400,
and Bruker Avance III 300 NMR spectrometers, respectively, in
Scheme 4. Preformed 8c/8a as Competent Precatalysts for the SM/DA Reaction
Table 2. UV−Vis Data, Fluorescence Emission (em.) Data,
and Molar Absorption Coefficients (ε) for Compounds 2,
5c−5h, 6c, and 7c (See Supporting Information S125−S133
for More Information)
compd abs. λmax (nm) em. λem (nm) ε
a (dm3 mol−1 cm−1)
2 257 353 63,300
5c 301 389 45,188
5d 259 416 38,338
5e 300 388 42,000
5f 337 387 38,500
5g 260 421 31,700
5h 336 386 43,638
6c 258 382 36,538
7c 342 346 51,438
aε calculated at 8 × 10−6 mol dm−3.
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proton-decoupled mode at 300 K using TMS as the internal standard.
19F NMR (282 MHz) spectra were recorded on a Bruker Avance III
300 NMR spectrometer in proton-decoupled mode at 300 K. 1H-15N
HMBC spectra were recorded on a Bruker Avance III 600 NMR
spectrometer [600 MHz (1H) and 60 MHz (15N)] equipped with
Bruker BBFO cryoprobe. All spectra recorded at 300 K and
referenced externally to nitromethane at 380.2 ppm, and the value
of which was uncorrected. 1H-15N HMBC spectra were acquired using
the Bruker HMBC pulse program (2D H-1/X correlation via
heteronuclear zero and double quantum coherence optimized on
long-range couplings) with four scans and a spectral width of 600−
650 ppm. All spectra were run at University College Cork. Chemical
shifts (δ) are expressed as parts per million (ppm), positive shift being
downfield from TMS; coupling constants (J) are expressed in hertz
(Hz). Splitting patterns in 1H NMR spectra are designated as follows:
s (singlet), bs (broad singlet), d (doublet), dd (doublet of doublets),
ddd (doublet of doublets of doublets), t (triplet), td (triplet of
doublets), q (quartet), quin (quintet), and m (multiplet).
Single-crystal X-ray analysis was performed on a Rigaku AFC12
FRE-HF diffractometer equipped with an Oxford Cryosystems low-
temperature device. The crystals were kept at a steady T = 100(2) K
during data collection. The structures were solved with the ShelXT28
structure solution program using the Intrinsic Phasing solution
method and by using Olex229 as the graphical interface. The models
were refined with version 2016/6 of ShelXL28 using least-squares
minimization. Cell parameters were retrieved and refined using the
CrysAlisPro (Rigaku, V1.171.40.37a, 2019). All nonhydrogen atoms
were refined anisotropically. Hydrogen atom positions were calculated
geometrically and refined using the riding model. Further information
is available in the Supporting Information.
UV−Visible absorption was measured on a Thermo Scientific
Evolution 60S UV−Visible spectrophotometer. All solutions were
made up in DCM, and measurements were performed in high-
precision quartz cells of 10 mm in path length. A baseline in DCM
was recorded by an internal reference detector. Molar absorption
values were calculated using Beer’s law at a concentration of 8 × 10−6
mol dm−3. Fluorescence intensities were measured on a PerkinElmer
Fluorescence Spectrometer LS 55. All solutions were made up in
DCM, and measurements were performed in high-precision quartz
cells of 10 × 10 mm in path length. Spectra were recorded in the
range of 200−700 nm, and compounds were excited at 257 nm.
General Procedure for the Synthesis of 4-Phenoxyquino-
line Substrates. A mixture of the 4-chloroquinoline substrate (1
equiv), the phenol (5 equiv), and NaOH (crushed pellets) (1.5 equiv)
was stirred at 120 °C in an aluminum heating mantle until the
reaction was complete (2−6 h) as evidenced by TLC (Hex/EtOAc
8:2). The cooled reaction mixture was diluted with 10% aqueous
NaOH (5 mL) and stirred at room temperature for 1 h. The aqueous
phase was extracted with DCM (3 × 20 mL). The combined organic
layers were washed with 6 M NaOH (3 × 10 mL), water (10 mL),
and brine (10 mL), dried over MgSO4, filtered, and concentrated in
vacuo. The crude mixture was purified by column chromatography
over silica gel using Hex/EtOAc (8:2) as an eluent unless otherwise
specified.
6-Bromo-4-(2-bromophenoxy)quinoline (3a). 6-Bromo-4-chloro-
quinoline (0.970 g, 4.0 mmol), 2-bromophenol (2.32 mL, 20 mmol),
and NaOH (0.240 g, 6.0 mmol) were reacted according to the general
procedure for the synthesis of 4-phenoxyquinolines above to give the
title product as a pale yellow solid; yield: 1.406 g (93%); m.p. 97−98
°C; IR (NaCl): ν 3399, 1590, 1491, 1350, 1221, 665 cm−1; 1H NMR
(300 MHz, CDCl3) δ: 6.41 (d, J = 5.2 Hz, 1H), 7.19−7.28 (m, 2H),
7.39−7.47 (m, 1H), 7.73 (dd, J = 8.3, 1.5 Hz, 1H), 7.84 (dd, J = 9.0,
2.2 Hz, 1H), 7.98 (d, J = 9.0 Hz, 1H), 8.58 (d, J = 2.2 Hz, 1H), 8.67
(d, J = 5.2 Hz, 1H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ: 104.2,
116.4, 120.3, 122.2, 123.3, 124.3, 127.6, 129.3, 130.9, 133.7, 134.4,
148.4, 150.8, 151.4, 159.8 ppm; HRMS (ESI-TOF) m/z: [M + H]+
calcd for C15H10Br2NO 377.9129; found: 377.9132.
7-Bromo-4-(2-bromophenoxy)quinoline (3b). 7-Bromo-4-chloro-
quinoline (0.970 g, 4.0 mmol), 2-bromophenol (2.32 mL, 20.0
mmol), and NaOH (0.240 g, 6.0 mmol) were reacted according to the
general procedure for the synthesis of 4-phenoxyquinolines above to
give the title product as a pale yellow solid; yield: 1.397 g (92%); m.p.
73−74 °C; IR (NaCl): ν 3064, 1561, 1468, 1301, 1220, 657 cm−1; 1H
NMR (300 MHz, CDCl3) δ: 6.41 (d, J = 5.2 Hz, 1H), 7.19−7.30 (m,
2H), 7.39−7.48 (m, 1H), 7.66−7.76 (m, 2H), 8.25−8.33 (m, 2H),
8.66 (d, J = 5.2 Hz, 1H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ:
103.9, 116.3, 119.7, 123.3, 123.5, 124.6, 127.6, 129.3, 129.8, 131.4,
134.4, 150.5, 150.8, 152.1, 160.8 ppm; HRMS (ESI-TOF) m/z: [M +
H]+ calcd for C15H10Br2NO 377.9129; found: 377.9119.
6-Bromo-4-(2-bromo-4-chlorophenoxy)quinoline (3c). 6-Bromo-
4-chloroquinoline (0.500 g, 2.06 mmol), 2-bromo-4-chlorophenol
(2.140 g, 10.31 mmol), and NaOH (0.126 g, 3.14 mmol) were
reacted according to the general procedure for the synthesis of 4-
phenoxyquinolines above to give the title product as a pale pink solid;
yield: 531 mg (77%); m.p. 157−159 °C; IR (NaCl): ν 3392, 1590,
1467, 1349, 1256, 729, 667 cm−1; 1H NMR (300 MHz, CDCl3) δ:
6.41 (d, J = 5.1 Hz, 1H), 7.18 (d, J = 8.6 Hz, 1H), 7.42 (dd, J = 8.6,
2.5 Hz, 1H), 7.74 (d, J = 2.4 Hz, 1H), 7.84 (dd, J = 9.0, 2.2 Hz, 1H),
7.98 (d, J = 9.0 Hz, 1H), 8.55 (d, J = 2.2 Hz, 1H), 8.68 (d, J = 5.1 Hz,
1H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ: 104.1, 117.0, 120.5,
122.0, 124.0, 124.2, 129.4, 131.0, 132.4, 133.9, 134.0, 148.4, 149.6,
151.3, 159.5 ppm; HRMS (ESI-TOF) m/z: [M + H]+ calcd for
C15H9Br2ClNO 411.8739; found: 411.8730.
4-(2,6-Dibromophenoxy)pyridine (3d). A neat mixture of 4-
chloropyridine (0.250 g, 1.66 mmol) and 2,6-dibromophenol (0.630
g, 2.50 mmol) was stirred at 120 °C in an aluminum heating mantle
until the reaction was complete (16 h) as evidenced by TLC (Hex/
EtOAc 8:2). The cooled reaction mixture was diluted with 10%
aqueous NaOH (5 mL) and stirred at room temperature for 1 h. The
aqueous phase was extracted with DCM (3 × 20 mL). The combined
organic layers were washed with 6 M NaOH (3 × 10 mL), water (10
mL), and brine (10 mL), dried over MgSO4, filtered, and
concentrated in vacuo. The crude mixture was purified by
recrystallization from cyclohexane to give the title product as an off-
white solid; yield: 365 mg (66%); m.p. 91−93 °C; IR (NaCl): ν 3393,
1590, 1434, 1261, 1200, 665 cm−1; 1H NMR (300 MHz, CDCl3) δ:
6.75 (d, J = 5.0 Hz, 2H), 7.07 (t, J = 8.1 Hz, 1H), 7.63 (dd, J = 8.1,
1.9 Hz, 2H), 8.49 (d, J = 5.2 Hz, 2H) ppm; 13C{1H} NMR (75 MHz,
CDCl3) δ: 110.8, 118.3, 128.3, 133.1, 147.7, 151.5, 162.5 ppm;
HRMS (ESI-TOF) m/z: [M + H]+ calcd for C11H8Br2NO 327.8973;
found: 327.8961.
4-(2,4-Dibromophenoxy)quinoline (3e). 4-Chloroquinoline
(0.260 g, 1.60 mmol), 2,4-dibromophenol (2.00 g, 7.90 mmol), and
NaOH (0.095 g, 2.40 mmol) were reacted according to the general
procedure for the synthesis of 4-phenoxyquinolines above to give the
title product as a pale yellow solid; yield: 517 mg (85%); m.p. 125−
126 °C; IR (NaCl): ν 3394, 1596, 1464, 1305, 1224, 667 cm−1; 1H
NMR (300 MHz, CDCl3) δ: 6.43 (d, J = 5.1 Hz, 1H), 7.13 (d, J = 8.6
Hz, 1H), 7.50−7.68 (m, 2H), 7.79 (ddd, J = 8.5, 6.9, 1.4 Hz, 1H),
7.88 (d, J = 2.3 Hz, 1H), 8.12 (d, J = 8.4 Hz, 1H), 8.38 (dd, J = 8.4,
0.9 Hz, 1H), 8.70 (d, J = 5.1 Hz, 1H) ppm; 13C{1H} NMR (75 MHz,
CDCl3) δ: 103.8, 117.4, 119.3, 120.9, 121.8, 124.3, 126.5, 129.2,
130.4, 132.3, 136.6, 149.8, 150.5, 151.0, 160.3 ppm; HRMS (ESI-
TOF) m/z: [M + H]+ calcd for C15H10Br2NO 377.9129; found:
377.9114.
6-Bromo-4-(2,4-dibromophenoxy)quinoline (3f). 6-Bromo-4-
chloroquinoline (0.240 g, 0.99 mmol), 2,4-dibromophenol (1.247 g,
4.95 mmol), and NaOH (0.059 g, 1.5 mmol) were reacted according
to the general procedure for the synthesis of 4-phenoxyquinolines
above to give the title product as a pale yellow solid; yield: 268 mg
(59%); m.p. 162−163 °C; IR (NaCl): ν 3370, 1590, 1449, 1349,
1255, 665 cm−1; 1H NMR (300 MHz, CDCl3) δ: 6.42 (d, J = 5.1 Hz,
1H), 7.12 (d, J = 8.6 Hz, 1H), 7.56 (dd, J = 8.6, 2.3 Hz, 1H), 7.80−
7.91 (m, 2H), 7.98 (d, J = 9.0 Hz, 1H), 8.54 (d, J = 2.2 Hz, 1H), 8.68
(d, J = 5.1 Hz, 1H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ: 104.2,
117.4, 119.7, 120.5, 122.0, 124.2, 124.4, 131.0, 132.4, 133.9, 136.7,
148.4, 150.1, 151.3, 159.4 ppm; HRMS (ESI-TOF) m/z: [M + H]+
calcd for C15H9Br3NO 455.8234; found: 455.8233.
7-Bromo-4-(2,4-dibromophenoxy)quinoline (3g). 7-Bromo-4-
chloroquinoline (0.243 g, 1.0 mmol), 2,4-dibromophenol (1.26 g,
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5.0 mmol), and NaOH (0.06 g, 1.5 mmol) were reacted according to
the general procedure for the synthesis of 4-phenoxyquinolines above
to give the title product as a white solid; yield: 398 mg (87%); m.p.
140−142 °C; IR (NaCl) ν 3583, 1615, 1559, 1302, 1096, 666 cm−1;
1H NMR (300 MHz, CDCl3) δ: 6.42 (d, J = 5.2 Hz, 1H), 7.13 (d, J =
8.6 Hz, 1H), 7.56 (dd, J = 8.6, 2.3 Hz, 1H), 7.70 (dd, J = 8.9, 1.9 Hz,
1H), 7.88 (d, J = 2.3 Hz, 1H), 8.18−8.36 (m, 2H), 8.68 (d, J = 5.2
Hz, 1H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ: 103.9, 117.4,
119.6, 119.7, 123.3, 124.4, 124.7, 130.0, 131.5, 132.4, 136.7, 150.2,
150.5, 152.1, 160.5 ppm; HRMS (ESI-TOF) m/z: [M + H]+ calcd for
C15H9Br3NO 455.8229; found: 455.8233.
4-Phenoxyquinoline (3h).30 4-Chloroquinoline (0.164 g, 1.0
mmol), phenol (0.471 g, 5.0 mmol), and NaOH (0.06 g, 1.5
mmol) were reacted according to the general procedure for the
synthesis of 4-phenoxyquinolines above to give the title product as a
yellow oil; yield: 192 mg (87%); 1H NMR (300 MHz, CDCl3) δ: 6.54
(d, J = 5.2 Hz, 1H), 7.13−7.22 (m, 2H), 7.23−7.33 (m, 1H), 7.39−
7.50 (m, 2H), 7.56 (ddd, J = 8.2, 6.9, 1.1 Hz, 1H), 7.74 (ddd, J = 8.5,
6.9, 1.5 Hz, 1H), 8.10 (d, J = 8.3 Hz, 1H), 8.36 (dd, J = 8.4, 1.1 Hz,
1H), 8.66 (d, J = 5.1 Hz, 1H) ppm; 13C{1H} NMR (75 MHz, CDCl3)
δ: 104.4, 121.1, 121.5, 121.8, 125.6, 126.1, 129.1, 130.1, 130.3, 149.8,
151.1, 154.4, 161.9 ppm; HRMS (ESI-TOF) m/z: [M + H]+ calcd for
C15H12NO 222.0913; found: 222.0913.
6-Bromo-4-phenoxyquinoline (3i). 6-Bromo-4-chloroquinoline
(0.500 g, 2.1 mmol), phenol (0.970 g, 10.31 mmol), and NaOH
(0.126 g, 3.14 mmol) were reacted according to the general procedure
for the synthesis of 4-phenoxyquinolines above to give the title
product as a pale yellow solid; yield: 517 mg (83%); m.p. 84−86 °C;
IR (NaCl): ν 3401, 1561, 1487, 1351, 1213, 667 cm−1; 1H NMR (300
MHz, CDCl3) δ: 6.54 (d, J = 5.2 Hz, 1H), 7.13−7.22 (m, 2H), 7.25−
7.36 (m, 1H), 7.41−7.53 (m, 2H), 7.80 (dd, J = 9.0, 2.2 Hz, 1H), 7.95
(d, J = 9.0 Hz, 1H), 8.53 (d, J = 2.2 Hz, 1H), 8.65 (d, J = 5.2 Hz, 1H)
ppm; 13C{1H} NMR (75 MHz, CDCl3) δ: 104.7, 120.2, 121.1, 122.6,
124.3, 125.9, 130.4, 130.9, 133.6, 148.3, 151.5, 154.0, 161.0 ppm;
HRMS (ESI-TOF) m/z: [M + H]+ calcd for C15H11BrNO 300.0024;
found: 300.0013.
General Procedure for Palladium-Catalyzed One-Pot Suzu-
ki−Miyaura and Intramolecular Direct Arylation Reactions. A
mixture of the 4-(2-bromophenoxy)quinoline substrate (1 equiv),
PhB(OH)2 (1.1 equiv), Pd(OAc)2 (2 mol %), and anhydrous K2CO3
(2 equiv) in anhydrous NMP (1.5 mL mmol−1) was stirred at 135 °C
in a sealed reaction tube in an aluminum multireaction heating mantle
until the reaction was complete as evidenced by 1H NMR analysis.
The cooled reaction mixture was diluted with DCM, filtered through
a short plug of Celite, and concentrated in vacuo. The crude mixture
was purified by column chromatography over silica gel using DCM/
EtOAc (99:1−95:5) as an eluent unless otherwise specified.
2-Phenylbenzofuro[3,2-c]quinoline (4a). A mixture of substrate
3a (0.100 g, 0.26 mmol), phenylboronic acid (0.035 g, 0.29 mmol),
Pd(OAc)2 (1.2 mg, 2 mol %), and anhydrous K2CO3 (0.073 g, 0.53
mmol) in anhydrous NMP (0.4 mL, 1.5 mL mmol−1) was reacted
according to the general one-pot SM/DA procedure above to give the
title product as a pale yellow solid; X-ray quality crystals were
obtained via vapor diffusion from a saturated solution of toluene in
hexane, the CCDC number is 1967876; yield: 63 mg (83%); m.p.
169−171 °C; IR (NaCl): ν 3450, 1559, 1460, 1359, 1193 cm−1; 1H
NMR (300 MHz, CDCl3) δ: 7.39−7.61 (m, 5H), 7.74−7.87 (m, 3H),
8.02−8.15 (m, 2H), 8.33 (d, J = 8.8 Hz, 1H), 8.62 (d, J = 1.7 Hz,
1H), 9.49 (s, 1H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ: 112.1,
116.6, 117.3, 118.4, 120.6, 122.7, 124.1, 127.3, 127.5, 127.9, 128.8,
129.0, 130.2, 139.7, 140.1, 144.2, 146.7, 156.0, 157.6 ppm; HRMS
(ESI-TOF) m/z: [M + H]+ calcd for C21H14NO 296.1075; found:
296.1062.
2-(p-Tolyl)benzofuro[3,2-c]quinoline (4b). A mixture of substrate
3a (0.150 g, 0.396 mmol), o-tolylboronic acid (0.059 g, 0.435 mmol),
Pd(OAc)2 (1.8 mg, 2 mol %), and anhydrous K2CO3 (0.109 g, 0.79
mmol) in anhydrous NMP (0.6 mL, 1.5 mL mmol−1) was reacted
according to the general one-pot SM/DA procedure above to give the
title product as a white solid; yield: 89 mg (72%); m.p. 183−185 °C;
IR (NaCl): ν 3583, 3401, 1505, 1460, 1358, 1190 cm−1; 1H NMR
(300 MHz, CDCl3) δ: 2.45 (s, 3H), 7.35 (d, J = 7.9 Hz, 2H), 7.44−
7.62 (m, 2H), 7.69−7.82 (m, 3H), 8.02−8.16 (m, 2H), 8.33 (d, J =
8.8 Hz, 1H), 8.61 (d, J = 1.9 Hz, 1H), 9.49 (s, 1H) ppm; 13C{1H}
NMR (75 MHz, CDCl3) δ: 21.2, 112.1, 116.5, 117.4, 118.0, 120.7,
122.7, 124.1, 127.27, 127.34, 128.8, 129.8, 130.2, 137.2, 137.9, 139.6,
144.0, 146.6, 156.0, 157.6 ppm; HRMS (ESI-TOF) m/z: [M + H]+
calcd for C22H16NO 310.1232; found: 310.1222.
2-(4-Methoxyphenyl)benzofuro[3,2-c]quinoline (4c). A mixture
of substrate 3a (0.150 g, 0.396 mmol), 4-methoxyphenylboronic acid
(0.066 g, 0.435 mmol), Pd(OAc)2 (4.5 mg, 5 mol %), and anhydrous
K2CO3 (0.109 g, 0.79 mmol) in anhydrous NMP (0.6 mL, 1.5 mL
mmol−1) was reacted according to the general one-pot SM/DA
procedure above to give the title product as a white solid; yield: 84 mg
(65%); m.p. 189−191 °C; IR (NaCl): ν 3320, 1505, 1460, 1359,
1246, 1190 cm−1; 1H NMR (300 MHz, CDCl3) δ: 3.90 (s, 3H),
7.01−7.12 (m, 2H), 7.43−7.60 (m, 2H), 7.71−7.81 (m, 3H), 8.01
(dd, J = 8.8, 2.1 Hz, 1H), 8.10 (dd, J = 7.6, 0.9 Hz, 1H), 8.30 (d, J =
8.8 Hz, 1H), 8.55 (d, J = 1.9 Hz, 1H), 9.46 (s, 1H) ppm; 13C{1H}
NMR (75 MHz, CDCl3) δ: 55.4, 112.1, 114.5, 116.5, 117.4, 117.5,
120.6, 122.7, 124.1, 127.2, 128.56, 128.61, 130.2, 132.6, 139.3, 143.9,
146.4, 156.0, 157.5, 159.7 ppm; HRMS (ESI-TOF) m/z: [M + H]+
calcd for C22H16NO2 326.1181; found: 326.1185.
2-(4-(Trifluoromethoxy)phenyl)benzofuro[3,2-c]quinoline (4d). A
mixture of substrate 3a (0.150 g, 0.396 mmol), (4-(trifluoromethoxy)-
phenyl)boronic acid (0.090 g, 0.435 mmol), Pd(OAc)2 (1.8 mg, 2
mol %), and anhydrous K2CO3 (0.109 g, 0.79 mmol) in anhydrous
NMP (0.6 mL, 1.5 mL mmol−1) was reacted according to the general
one-pot SM/DA procedure above to give the title product as a yellow
solid; yield: 105 mg (70%); m.p. 148−150 °C; IR (NaCl): ν 3583,
1504, 1459, 1283, 1210, 1191, 1165 cm−1; 1H NMR (300 MHz,
CDCl3) δ: 7.37 (dd, J = 8.8, 0.9 Hz, 2H), 7.43−7.62 (m, 2H), 7.72−
7.86 (m, 3H), 7.97 (dd, J = 8.8, 2.1 Hz, 1H), 8.09 (dd, J = 7.6, 0.8 Hz,
1H), 8.31 (d, J = 8.8 Hz, 1H), 8.54 (d, J = 2.0 Hz, 1H), 9.47 (s, 1H)
ppm; 13C{1H} NMR (75 MHz, CDCl3) δ: 112.1, 116.8, 117.4, 118.6,
120.5 (q, 1J(C,F) = 257 Hz), 120.7, 121.4, 122.6, 124.2, 127.4, 128.5,
128.9, 130.5, 138.3, 138.9, 144.5, 146.7, 149.2 (q, 3J(C,F) = 2 Hz),
156.0, 157.5 ppm; 19F{1H} NMR (282 MHz, CDCl3) δ: −58 ppm;
HRMS (ESI-TOF) m/z: [M + H]+ calcd for C22H13F3NO2 380.0898;
found: 380.0889.
2-(4-Fluorophenyl)benzofuro[3,2-c]quinoline (4e). A mixture of
substrate 3a (0.150 g, 0.396 mmol), 4-fluorophenylboronic acid
(0.061 g, 0.435 mmol), Pd(OAc)2 (1.8 mg, 2 mol %), and anhydrous
K2CO3 (0.109 g, 0.79 mmol) in anhydrous NMP (0.6 mL, 1.5 mL
mmol−1) was reacted according to the general one-pot SM/DA
procedure above to give the title product as a pale yellow solid; yield:
95 mg (77%); m.p. 185−186 °C; IR (NaCl): ν 3391, 1561, 1460,
1334, 1192, 1123 cm−1; 1H NMR (300 MHz, CDCl3) δ: 7.16−7.29
(m, 2H), 7.46−7.62 (m, 2H), 7.72−7.83 (m, 3H), 8.00 (dd, J = 8.8,
2.1 Hz, 1H), 8.13 (dd, J = 7.2, 1.3 Hz, 1H), 8.33 (d, J = 8.8 Hz, 1H),
8.57 (d, J = 2.0 Hz, 1H), 9.50 (s, 1H) ppm; 13C{1H} NMR (75 MHz,
CDCl3) δ: 112.1, 115.9 (d,
2J(C,F) = 22 Hz), 116.7, 117.4, 118.2,
120.7, 122.7, 124.1, 127.3, 128.6, 129.1 (d, 3J(C,F) = 8 Hz), 130.4,
136.2, 138.7, 144.3, 146.6, 156.0, 157.5, 162.9 (d, 1J(C,F) = 247 Hz)
ppm; 19F{1H} NMR (282 MHz, CDCl3) δ: −115 ppm; HRMS (ESI-
TOF) m/z: [M + H]+ calcd for C21H13FNO 314.0981; found:
314.0971.
2-(4-Chlorophenyl)benzofuro[3,2-c]quinoline (4f). A mixture of
substrate 3a (0.150 g, 0.396 mmol), 4-chlorophenylboronic acid
(0.068 g, 0.435 mmol), Pd(OAc)2 (1.8 mg, 2 mol %), and anhydrous
K2CO3 (0.109 g, 0.79 mmol) in anhydrous NMP (0.6 mL, 1.5 mL
mmol−1) was reacted according to the general one-pot SM/DA
procedure above to give the title product as a pale yellow solid; yield:
106 mg (81%); m.p. 191−192 °C; IR (NaCl): ν 3389, 1556, 1458,
1356, 1191, 821 cm−1; 1H NMR (300 MHz, CDCl3) δ: 7.38−7.57
(m, 4H), 7.61−7.75 (m, 3H), 7.89 (dd, J = 8.8, 2.1 Hz, 1H), 8.02 (dd,
J = 7.6, 0.8 Hz, 1H), 8.24 (d, J = 8.8 Hz, 1H), 8.43 (d, J = 2.0 Hz,
1H), 9.39 (s, 1H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ: 112.1,
116.7, 117.3, 118.2, 120.7, 122.6, 124.1, 127.3, 128.3, 128.6, 129.1,
130.4, 134.1, 138.3, 138.5, 144.4, 146.7, 155.9, 157.4 ppm; HRMS
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(ESI-TOF) m/z: [M + H]+ calcd for C21H13ClNO 330.0680; found:
330.0676.
2-(4-(Trifluoromethyl)phenyl)benzofuro[3,2-c]quinoline (4g). A
mixture of substrate 3a (0.150 g, 0.396 mmol), (4-(trifluoromethyl)-
phenyl)boronic acid (0.083 g, 0.435 mmol), Pd(OAc)2 (1.8 mg, 2
mol %), and anhydrous K2CO3 (0.109 g, 0.79 mmol) in anhydrous
NMP (0.6 mL, 1.5 mL mmol−1) was reacted according to the general
one-pot SM/DA procedure above to give the title product as a pale
yellow solid; yield: 114 mg (80%); m.p. 194−195 °C; IR (NaCl): ν
3384, 1614, 1460, 1331, 1189, 1116 cm−1; 1H NMR (300 MHz,
CDCl3) δ: 7.46−7.63 (m, 2H), 7.74−7.85 (m, 3H), 7.93 (d, J = 8.2
Hz, 2H), 8.04 (dd, J = 8.8, 2.1 Hz, 1H), 8.13 (d, J = 7.4 Hz, 1H), 8.37
(d, J = 8.8 Hz, 1H), 8.65 (d, J = 1.9 Hz, 1H), 9.53 (s, 1H) ppm;
13C{1H} NMR (75 MHz, CDCl3) δ: 112.1, 116.8, 117.3, 119.0, 120.7,
122.6, 124.22, 124.23 (q, 1J(C,F) = 270 Hz), 125.9 (q,
3J(C,F) = 4 Hz),
127.5, 127.7, 128.4, 130.0 (q, 2J(C,F) = 33 Hz), 130.6, 138.1, 143.6,
144.8, 146.9, 156.0, 157.5 ppm; 19F{1H} NMR (282 MHz, CDCl3) δ:
−62 ppm; HRMS (ESI-TOF) m/z: [M + H]+ calcd for C22H13F3NO
364.0949; found: 364.0938.
2-(3-(Trifluoromethyl)phenyl)benzofuro[3,2-c]quinoline (4h). A
mixture of substrate 3a (0.150 g, 0.396 mmol), (3-(trifluoromethyl)-
phenyl)boronic acid (0.083 g, 0.435 mmol), Pd(OAc)2 (1.8 mg, 2
mol %), and anhydrous K2CO3 (0.109 g, 0.79 mmol) in anhydrous
NMP (0.6 mL, 1.5 mL mmol−1) was reacted according to the general
one-pot SM/DA procedure above to give the title product as a pale
yellow solid; yield: 104 mg (72%); m.p. 171−173 °C; IR (NaCl): ν
3391, 1561, 1446, 1334, 1166, 1123 cm−1; 1H NMR (300 MHz,
CDCl3) δ: 7.45−7.73 (m, 4H), 7.79 (d, J = 7.9 Hz, 1H), 7.95−8.09
(m, 3H), 8.13 (dd, J = 7.6, 0.8 Hz, 1H), 8.37 (d, J = 8.8 Hz, 1H), 8.63
(d, J = 2.0 Hz, 1H), 9.52 (s, 1H) ppm; 13C{1H} NMR (75 MHz,
CDCl3) δ: 112.1, 116.8, 117.3, 118.7, 120.7, 122.6, 124.19, 124.20 (q,
1J(C,F) = 273 Hz), 124.3 (q,
3J(C,F) = 4 Hz), 124.6 (q,
3J(C,F) = 4 Hz),
127.5, 128.4, 129.5, 130.6, 130.7, 131.5 (q, 2J(C,F) = 32 Hz), 138.1,
140.9, 144.7, 146.8, 156.0, 157.5 ppm; 19F{1H} NMR (282 MHz,
CDCl3) δ: −62 ppm; HRMS (ESI-TOF) m/z: [M + H]+ calcd for
C22H13F3NO 364.0944; found: 364.0947.
Ethyl 4-(Benzofuro[3,2-c]quinolin-2-yl)benzoate (4i). A mixture
of substrate 3a (0.150 g, 0.396 mmol), 4-ethoxycarbonylphenylbor-
onic acid (0.084 g, 0.435 mmol), Pd(OAc)2 (1.8 mg, 2 mol %), and
anhydrous K2CO3 (0.109 g, 0.79 mmol) in anhydrous NMP (0.6 mL,
1.5 mL mmol−1) was reacted according to the general one-pot SM/
DA procedure above to give the title product as a beige solid; yield:
105 mg (70%); m.p. 160−161 °C; IR (NaCl): ν 2922, 1715, 1607,
1460, 1357, 1278, 1190 cm−1; 1H NMR (300 MHz, CDCl3) δ: 1.45
(t, J = 7.1 Hz, 3H), 4.44 (q, J = 7.1 Hz, 2H), 7.43−7.63 (m, 2H), 7.79
(d, J = 7.9 Hz, 1H), 7.84−7.95 (m, 2H), 8.02−8.28 (m, 4H), 8.36 (d,
J = 8.8 Hz, 1H), 8.67 (d, J = 1.7 Hz, 1H), 9.52 (s, 1H) ppm; 13C{1H}
NMR (75 MHz, CDCl3) δ: 14.4, 61.1, 112.1, 116.7, 117.2, 118.8,
120.7, 122.5, 124.1, 127.3, 127.4, 128.8, 129.8, 130.2, 130.5, 138.3,
144.2, 144.6, 146.9, 155.9, 157.4, 166.4 ppm; HRMS (ESI-TOF) m/
z: [M + H]+ calcd for C24H18NO3: 368.1281; found: 368.1282.
(4-(Benzofuro[3,2-c]quinolin-2-yl)phenyl)(phenyl)methanone
(4j). A mixture of substrate 3a (0.150 g, 0.396 mmol), (4-
benzoylphenyl)boronic acid (0.098 g, 0.435 mmol), Pd(OAc)2 (1.8
mg, 2 mol %), and anhydrous K2CO3 (0.109 g, 0.79 mmol) in
anhydrous NMP (0.6 mL, 1.5 mL mmol−1) was reacted according to
the general one-pot SM/DA procedure above to give the title product
as a pale yellow solid; yield: 94 mg (59%); m.p. 184−187 °C; IR
(NaCl): ν 3401, 1652, 1602, 1460, 1357, 1190 cm−1; 1H NMR (300
MHz, CDCl3) δ: 7.46−7.70 (m, 5H), 7.79 (d, J = 8.3 Hz, 1H), 7.84−
8.04 (m, 6H), 8.05−8.20 (m, 2H), 8.38 (d, J = 8.8 Hz, 1H), 8.71 (d, J
= 1.9 Hz, 1H), 9.53 (s, 1H) ppm; 13C{1H} NMR (75 MHz, CDCl3)
δ: 112.1, 116.8, 117.4, 119.0, 120.7, 122.6, 124.2, 127.3, 127.5, 128.4,
128.5, 130.0, 130.6, 130.9, 132.5, 136.8, 137.6, 138.4, 144.0, 144.7,
146.9, 156.0, 157.5, 196.2 ppm; HRMS (ESI-TOF) m/z: [M + H]+
calcd for C28H18NO2 400.1332; found: 400.1331.
2-(3-Nitrophenyl)benzofuro[3,2-c]quinoline (4k). A mixture of
substrate 3a (0.150 g, 0.396 mmol), 3-nitrophenylboronic acid (0.072
g, 0.435 mmol), Pd(OAc)2 (1.8 mg, 2 mol %), and anhydrous K2CO3
(0.109 g, 0.79 mmol) in anhydrous NMP (0.6 mL, 1.5 mL mmol−1)
was reacted according to the general one-pot SM/DA procedure
above to give the title product as a yellow solid; yield: 69 mg (51%);
m.p. 227−228 °C; IR (NaCl): ν 3392, 1529, 1460, 1348, 1321, 1191
cm−1; 1H NMR (300 MHz, CDCl3) δ: 7.47−7.64 (m, 2H), 7.72 (t, J
= 8.0 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 8.06 (dd, J = 8.8, 2.2 Hz,
1H), 8.10−8.19 (m, 2H), 8.30 (ddd, J = 8.2, 2.2, 1.0 Hz, 1H), 8.40 (d,
J = 8.8 Hz, 1H), 8.65−8.73 (m, 2H), 9.55 (s, 1H) ppm; 13C{1H}
NMR (75 MHz, CDCl3) δ: 112.2, 117.0, 117.4, 119.1, 120.8, 122.3,
122.5, 122.6, 124.3, 127.6, 128.2, 130.0, 131.0, 133.3, 137.1, 141.9,
145.1, 147.0, 148.9, 156.1, 157.5 ppm; HRMS (ESI-TOF) m/z: [M +
H]+ calcd for C21H13N2O3: 341.0921; found: 341.0919.
8-Chloro-2-phenylbenzofuro[3,2-c]quinoline (4l). A mixture of
substrate 3c (0.200 g, 0.60 mmol), phenylboronic acid (0.080 g, 0.658
mmol), Pd(OAc)2 (2.7 mg, 2 mol %), and anhydrous K2CO3 (0.165
g, 1.20 mmol) in anhydrous NMP (0.9 mL, 1.5 mL mmol−1) was
reacted according to the general one-pot SM/DA procedure above to
give the title product as a pale yellow solid; yield: 118 mg (60%); m.p.
213−214 °C; IR (NaCl): ν 3583, 1461, 1359, 1192, 665 cm−1; 1H
NMR (300 MHz, CDCl3) δ: 7.38−7.60 (m, 4H), 7.66 (d, J = 8.8 Hz,
1H), 7.75−7.87 (m, 2H), 7.99−8.12 (m, 2H), 8.31 (d, J = 8.8 Hz,
1H), 8.55 (d, J = 1.8 Hz, 1H), 9.41 (s, 1H) ppm; 13C{1H} NMR (75
MHz, CDCl3) δ: 113.1, 115.8, 117.2, 118.4, 120.5, 124.2, 127.4,
127.5, 128.1, 129.1, 129.3, 129.9, 130.4, 140.0, 140.1, 144.0, 147.0,
154.3, 158.4 ppm; HRMS (ESI-TOF) m/z: [M + H]+ calcd for
C21H13ClNO 330.0681; found: 330.0684.
6-Phenylbenzofuro[3,2-c]pyridine (4m). A mixture of substrate 3d
(0.150 g, 0.456 mmol), phenylboronic acid (0.061 g, 0.50 mmol),
Pd(OAc)2 (2.0 mg, 2 mol %), and anhydrous K2CO3 (0.126 g, 0.912
mmol) in anhydrous NMP (0.7 mL, 1.5 mL mmol−1) was reacted
according to the general one-pot SM/DA procedure above and
purified via column chromatography using 100% Et2O as an eluent to
give the title product as a pale yellow solid; yield: 77 mg (69%); m.p.
66−68 °C; IR (NaCl): ν 3402, 3032, 1577, 1450, 1332, 1168 cm−1;
1H NMR (300 MHz, CDCl3) δ: 7.35−7.63 (m, 5H), 7.67 (dd, J = 7.6,
1.3 Hz, 1H), 7.83−7.92 (m, 2H), 8.01 (dd, J = 7.7, 1.3 Hz, 1H), 8.67
(d, J = 5.7 Hz, 1H), 9.30 (s, 1H) ppm; 13C{1H} NMR (75 MHz,
CDCl3) δ: 107.6, 120.1, 121.6, 122.4, 124.4, 126.4, 128.07, 128.13,
128.77, 128.80, 135.8, 143.7, 147.5, 153.1, 160.9 ppm; HRMS (ESI-
TOF) m/z: [M + H]+ calcd for C17H12NO 246.0913; found:
246.0914. Note: Here, a second Suzuki−Miyaura reaction occurred in
competition with the direct arylation. These products were separable
by careful column chromatography.
3-Phenylbenzofuro[3,2-c]quinoline (4n). A mixture of substrate
3b (0.200 g, 0.528 mmol), phenylboronic acid (0.071 g, 0.58 mmol),
Pd(OAc)2 (2.4 mg, 2 mol %), and anhydrous K2CO3 (0.146 g, 1.06
mmol) in anhydrous NMP (0.8 mL, 1.5 mL mmol−1) was reacted
according to the general one-pot SM/DA procedure above to give the
title product as a pale yellow solid; X-ray quality crystals were
obtained via vapor diffusion from a saturated solution of toluene in
hexane, the CCDC number is 1967484; yield: 146 mg (95%); m.p.
172−173 °C; IR (NaCl): ν 3275, 1559, 1452, 1379, 1188 cm−1; 1H
NMR (300 MHz, CDCl3) δ: 7.37−7.64 (m, 5H), 7.72−7.88 (m, 3H),
7.98 (dd, J = 8.5, 1.7 Hz, 1H), 8.12 (dd, J = 7.5, 1.0 Hz, 1H), 8.42−
8.59 (m, 2H), 9.54 (s, 1H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ:
112.2, 116.1, 116.4, 120.6, 121.3, 122.8, 124.1, 126.6, 127.3, 127.5,
127.6, 128.0, 129.1, 140.2, 142.2, 144.9, 147.8, 156.1, 157.5 ppm;
HRMS (ESI-TOF) m/z: [M + H]+ calcd for C21H14NO 296.1070;
found: 296.1072.
3-(p-Tolyl)benzofuro[3,2-c]quinoline (4o). A mixture of substrate
3b (0.150 g, 0.396 mmol), o-tolylboronic acid (0.059 g, 0.435 mmol),
Pd(OAc)2 (1.8 mg, 2 mol %), and anhydrous K2CO3 (0.109 g, 0.79
mmol) in anhydrous NMP (0.6 mL, 1.5 mL mmol−1) was reacted
according to the general one-pot SM/DA procedure above to give the
title product as a white solid; yield: 90 mg (74%); m.p. 200−202 °C;
IR (NaCl): ν 3150, 1554, 1450, 1379, 1190 cm−1; 1H NMR (300
MHz, CDCl3) δ: 2.45 (s, 3H), 7.34 (d, J = 7.9 Hz, 2H), 7.44−7.60
(m, 2H), 7.66−7.81 (m, 3H), 7.97 (dd, J = 8.5, 1.5 Hz, 1H), 8.11 (dd,
J = 7.6, 0.9 Hz, 1H), 8.42−8.52 (m, 2H), 9.51 (s, 1H) ppm; 13C{1H}
NMR (75 MHz, CDCl3) δ: 21.2, 112.1, 115.9, 116.2, 120.5, 121.1,
122.7, 124.0, 126.4, 127.1, 127.2, 127.3, 129.8, 137.3, 137.9, 142.0,
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144.7, 147.9, 156.0, 157.4 ppm; HRMS (ESI-TOF) m/z: [M + H]+
calcd for C22H16NO 310.1232; found: 310.1244.
3-(4-(Trifluoromethyl)phenyl)benzofuro[3,2-c]quinoline (4p). A
mixture of substrate 3b (0.150 g, 0.396 mmol), (4-(trifluoromethyl)-
phenyl)boronic acid (0.083 g, 0.435 mmol), Pd(OAc)2 (1.8 mg, 2
mol %), and anhydrous K2CO3 (0.109 g, 0.79 mmol) in anhydrous
NMP (0.6 mL, 1.5 mL mmol−1) was reacted according to the general
one-pot SM/DA procedure above to give the title product as a yellow
solid; yield: 114 mg (79%); m.p. 205−208 °C; IR (NaCl): ν 3251,
1559, 1450, 1329, 1188, 1110 cm−1; 1H NMR (300 MHz, CDCl3) δ:
7.46−7.63 (m, 2H), 7.76−7.82 (m, 3H), 7.86−8.02 (m, 3H), 8.13
(dd, J = 7.6, 0.9 Hz, 1H), 8.49−8.57 (m, 2H), 9.55 (s, 1H) ppm;
13C{1H} NMR (75 MHz, CDCl3) δ: 112.2, 116.7, 120.7, 121.6, 122.6,
124.21, 124.22 (q, 1J(C,F) = 270 Hz), 126.0 (q,
3J(C,F) = 4 Hz), 126.2,
127.5, 127.7, 128.2, 129.9 (q, 2J(C,F) = 32 Hz), 140.4, 143.7, 145.1,
147.6, 156.1, 157.3 ppm; 19F{1H} NMR (282 MHz, CDCl3) δ: −62
ppm; HRMS (ESI-TOF) m/z: [M + H]+ calcd for C22H13F3NO
364.0949; found: 364.0951. Note: 13C NMR shift at 116.7 ppm
represents two individual carbon signals as confirmed by 2D NMR
experiments.
4-(Benzofuro[3,2-c]quinolin-3-yl)benzonitrile (4q). A mixture of
substrate 3b (0.150 g, 0.396 mmol), 4-cyanophenylboronic acid
(0.065 g, 0.435 mmol), Pd(OAc)2 (4.4 mg, 5 mol %), and anhydrous
K2CO3 (0.109 g, 0.79 mmol) in anhydrous NMP (0.6 mL, 1.5 mL
mmol−1) was reacted according to the general one-pot SM/DA
procedure above to give the title product as a white solid; yield: 85 mg
(67%); m.p. >250 °C; IR (NaCl): ν 3348, 2223, 1553, 1447, 1344,
1184 cm−1; 1H NMR (300 MHz, CDCl3) δ: 7.45−7.64 (m, 2H),
7.73−7.80 (m, 6H), 8.13 (dd, J = 7.6, 0.8 Hz, 1H), 8.45−8.60 (m,
2H), 9.55 (s, 1H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ: 111.7,
112.3, 116.9, 117.0, 118.8, 120.8, 121.9, 122.6, 124.3, 126.0, 127.6,
128.1, 128.4, 132.9, 139.9, 144.7, 145.3, 147.5, 156.2, 157.2 ppm;
HRMS (ESI-TOF) m/z: [M + H]+ calcd for C22H13N2O: 321.1028;
found: 321.1033.
3-(4-Methoxyphenyl)benzofuro[3,2-c]quinoline (4r). A mixture of
substrate 3b (0.150 g, 0.396 mmol), 4-methoxyphenylboronic acid
(0.066 g, 0.435 mmol), Pd(OAc)2 (1.8 mg, 2 mol %), and anhydrous
K2CO3 (0.109 g, 0.79 mmol) in anhydrous NMP (0.6 mL, 1.5 mL
mmol−1) was reacted according to the general one-pot SM/DA
procedure above to give the title product as a white solid; yield: 88 mg
(70%); m.p. 157−158 °C; IR (NaCl): ν 3369, 2998, 1607, 1450,
1303, 1245, 1188 cm−1; 1H NMR (300 MHz, CDCl3) δ: 3.88 (s, 3H),
6.99−7.10 (m, 2H), 7.41−7.57 (m, 2H), 7.68−7.77 (m, 3H), 7.91
(dd, J = 8.6, 1.7 Hz, 1H), 8.07 (dd, J = 7.5, 1.5 Hz, 1H), 8.37−8.45
(m, 2H), 9.47 (s, 1H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ:
55.4, 112.1, 114.5, 115.7, 116.1, 120.5, 121.2, 122.8, 124.1, 126.3,
126.8, 127.1, 128.5, 132.7, 141.7, 144.8, 148.0, 156.0, 157.5, 159.8
ppm; HRMS (ESI-TOF) m/z: [M + H]+ calcd for C22H16NO2
326.1176; found: 326.1173.
General Procedure for Palladium-Catalyzed One-Pot Miz-
oroki−Heck and Intramolecular Direct Arylation Reactions. A
mixture of the 4-(2-bromophenoxy)quinoline substrate (1 equiv),
Heck coupling partner (1.1 equiv), Pd(OAc)2 (2 mol % for tert-butyl
acrylate or 5 mol % for styrene derivatives), and anhydrous K2CO3 (2
equiv) in anhydrous NMP (1.5 mL mmol−1) was stirred at 135 °C in
a sealed reaction tube in an aluminum multireaction heating mantle
until the reaction was completed as evidenced by 1H NMR analysis
(18−24 h). The cooled reaction mixture was diluted with DCM,
filtered through a short plug of Celite, and concentrated in vacuo. The
crude mixture was purified by column chromatography over silica gel
using DCM/EtOAc (99:1−95:5) as an eluent.
tert-Butyl (E)-3-(Benzofuro[3,2-c]quinolin-2-yl)acrylate (5a). A
mixture of substrate 3a (0.050 g, 0.132 mmol), tert-butyl acrylate (21
μL, 0.145 mmol), Pd(OAc)2 (0.6 mg, 2 mol %), and anhydrous
K2CO3 (0.036 g, 0.264 mmol) in anhydrous NMP (0.2 mL, 1.5 mL
mmol−1) was reacted according to the general one-pot MH/DA
procedure above to give the title product as a white solid; yield: 27 mg
(60%); m.p. 169−170 °C; IR (NaCl): ν 3393, 2976, 1701, 1560,
1460, 1366, 1238, 1151 cm−1; 1H NMR (300 MHz, CDCl3) δ: 1.58
(s, 9H), 6.60 (d, J = 16.0 Hz, 1H), 7.44−7.65 (m, 2H), 7.73−7.89
(m, 2H), 7.94 (dd, J = 8.9, 2.0 Hz, 1H), 8.11 (dd, J = 7.6, 0.8 Hz,
1H), 8.24 (d, J = 8.8 Hz, 1H), 8.51 (d, J = 1.9 Hz, 1H), 9.49 (s, 1H)
ppm; 13C{1H} NMR (100 MHz, CDCl3) δ: 28.2, 80.9, 112.3, 117.0,
117.3, 120.8, 121.6, 122.0, 122.5, 124.3, 127.4, 127.6, 130.5, 133.4,
142.5, 145.1, 147.9, 156.1, 157.5, 166.1 ppm; HRMS (ESI-TOF) m/
z: [M + H]+ calcd for C22H20NO3: 346.1438; found: 346.1434.
tert-Butyl (E)-3-(Benzofuro[3,2-c]quinolin-3-yl)acrylate (5b). A
mixture of substrate 3b (0.050 g, 0.132 mmol), tert-butyl acrylate (21
μL, 0.145 mmol), Pd(OAc)2 (0.6 mg, 2 mol %), and anhydrous
K2CO3 (0.036 g, 0.264 mmol) in anhydrous NMP (0.2 mL, 1.5 mL
mmol−1) was reacted according to the general one-pot MH/DA
procedure above to give the title product as a pale yellow solid; X-ray
quality crystals were obtained via vapor diffusion from a saturated
solution of toluene in hexane, the CCDC number is 1967537; yield:
36 mg (80%); m.p. 160−162 °C; IR (NaCl): ν 3393, 2976, 1703,
1560, 1452, 1366, 1285, 1149 cm−1; 1H NMR (300 MHz, CDCl3) δ:
1.58 (s, 9H), 6.59 (d, J = 16.0 Hz, 1H), 7.44−7.63 (m, 2H), 7.71−
7.92 (m, 3H), 8.11 (dd, J = 7.6, 0.8 Hz, 1H), 8.30−8.46 (m, 2H), 9.51
(s, 1H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ: 28.2, 80.8, 112.2,
117.1, 117.7, 120.8, 121.4, 122.0, 122.5, 124.3, 125.1, 127.6, 130.7,
135.6, 142.8, 145.2, 147.4, 156.2, 157.1, 166.0 ppm; HRMS (ESI-
TOF) m/z: [M + H]+ calcd for C22H20NO3: 346.1438; found:
346.1432.
(E)-2-Styrylbenzofuro[3,2-c]quinoline (5c). A mixture of substrate
3a (0.114 g, 0.30 mmol), styrene (38 μL, 0.33 mmol), Pd(OAc)2 (3.4
mg, 5 mol %), and anhydrous K2CO3 (0.083 g, 0.60 mmol) in
anhydrous NMP (0.5 mL, 1.5 mL mmol−1) was reacted according to
the general one-pot MH/DA procedure above to give the title
product as a white solid; yield: 70 mg (73%); m.p. 201−202 °C; IR
(NaCl) ν 3379, 1662, 1561, 1377, 1188 cm−1; 1H NMR (300 MHz,
CDCl3) δ: 7.22−7.66 (m, 9H), 7.76 (d, J = 8.1 Hz, 1H), 7.98 (dd, J =
8.9, 2.0 Hz, 1H), 8.07 (dd, J = 7.6, 0.8 Hz, 1H), 8.22 (d, J = 8.9 Hz,
1H), 8.39 (d, J = 1.8 Hz, 1H), 9.41 (s, 1H) ppm; 13C{1H} NMR (75
MHz, CDCl3) δ: 112.1, 116.7, 117.4, 118.6, 120.7, 122.7, 124.1,
126.8, 127.2, 127.3, 127.8, 128.1, 128.8, 130.1, 130.6, 136.1, 137.0,
143.9, 147.0, 156.0, 157.4 ppm; HRMS (ESI-TOF) m/z: [M + H]+
calcd for C23H16NO 322.1226; found: 322.1223.
(E)-2-(4-Methoxystyryl)benzofuro[3,2-c]quinoline (5d). A mixture
of substrate 3a (0.114 g, 0.30 mmol), 4-methoxystyrene (44 μL, 0.33
mmol), Pd(OAc)2 (3.4 mg, 5 mol %), and anhydrous K2CO3 (0.083
g, 0.60 mmol) in anhydrous NMP (0.5 mL, 1.5 mL mmol−1) was
reacted according to the general one-pot MH/DA procedure above to
give the title product as a white solid; yield: 86 mg (82%); m.p. 190−
192 °C; IR (NaCl) ν 3388, 1656, 1602, 1562, 1346, 1250, 1110 cm−1;
1H NMR (300 MHz, CDCl3) δ: 3.86 (s, 3H), 6.84−7.04 (m, 2H),
7.12−7.38 (m, 2H), 7.40−7.65 (m, 4H), 7.76 (d, J = 8.1 Hz, 1H),
7.97 (dd, J = 8.9, 1.8 Hz, 1H), 8.09 (d, J = 7.4 Hz, 1H), 8.21 (d, J =
8.9 Hz, 1H), 8.38 (d, J = 1.7 Hz, 1H), 9.41 (s, 1H) ppm; 13C{1H}
NMR (75 MHz, CDCl3) δ: 55.4, 112.1, 114.3, 116.7, 117.5, 118.1,
120.7, 122.8, 124.1, 125.7, 127.2, 127.3, 128.0, 129.8, 130.1, 130.2,
136.5, 143.7, 146.9, 156.0, 157.4, 159.7 ppm; HRMS (ESI-TOF) m/
z: [M + H]+ calcd for C24H18NO2 352.1332; found: 352.1328.
(E)-2-(4-Fluorostyryl)benzofuro[3,2-c]quinoline (5e). A mixture of
substrate 3a (0.114 g, 0.30 mmol), 4-fluorostyrene (39 μL, 0.33
mmol), Pd(OAc)2 (3.4 mg, 5 mol %), and anhydrous K2CO3 (0.083
g, 0.60 mmol) in anhydrous NMP (0.5 mL, 1.5 mL mmol−1) was
reacted according to the general one-pot MH/DA procedure above to
give the title product as a yellow solid; yield: 82 mg (80%); m.p. 189−
191 °C; IR (NaCl) ν 3404, 1676, 1598, 1559, 1346, 1234, 1096 cm−1;
1H NMR (300 MHz, CDCl3) δ: 7.00−7.15 (m, 2H), 7.17−7.34 (m,
2H), 7.41−7.63 (m, 4H), 7.75 (d, J = 8.1 Hz, 1H), 7.95 (dd, J = 8.9,
2.0 Hz, 1H), 8.07 (d, J = 7.5 Hz, 1H), 8.21 (d, J = 8.9 Hz, 1H), 8.37
(d, J = 1.8 Hz, 1H), 9.41 (s, 1H) ppm; 13C{1H} NMR (75 MHz,
CDCl3) δ: 112.1, 115.8 (d,
2J(C,F) = 22 Hz), 116.7, 117.4, 118.6,
120.7, 122.7, 124.1, 127.1, 127.3, 127.6 (d, 6J(C,F) = 2 Hz), 128.3 (d,
3J(C,F) = 8 Hz), 129.4, 130.2, 133.2 (d,
4J(C,F) = 3 Hz), 135.9, 144.0,
147.0, 156.0, 157.4, 162.6 (d, 1J(C,F) = 248 Hz) ppm;
19F{1H} NMR
(282 MHz, CDCl3) δ: −113 ppm; HRMS (ESI-TOF) m/z: [M + H]+
calcd for C23H15FNO 340.1132; found: 340.1135.
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(E)-3-Styrylbenzofuro[3,2-c]quinoline (5f). A mixture of substrate
3b (0.114 g, 0.30 mmol), styrene (38 μL, 0.33 mmol), Pd(OAc)2 (3.4
mg, 5 mol %), and anhydrous K2CO3 (0.083 g, 0.60 mmol) in
anhydrous NMP (0.5 mL, 1.5 mL mmol−1) was reacted according to
the general one-pot MH/DA procedure above to give the title
product as a yellow solid; yield: 72 mg (75%); m.p. 179−182 °C; IR
(NaCl) ν 3583, 1656, 1632, 1561, 1348, 1190 cm−1; 1H NMR (300
MHz, CDCl3) δ: 7.20−7.65 (m, 9H), 7.74 (d, J = 7.9 Hz, 1H), 7.91
(dd, J = 8.6, 1.5 Hz, 1H), 8.07 (dd, J = 7.5, 0.9 Hz, 1H), 8.27 (d, J =
1.3 Hz, 1H), 8.36 (d, J = 8.6 Hz, 1H), 9.46 (s, 1H) ppm; 13C{1H}
NMR (75 MHz, CDCl3) δ: 112.1, 116.3, 120.6, 121.1, 122.7, 124.1,
124.9, 126.8, 127.2, 128.0, 128.1, 128.8, 130.7, 137.0, 138.5, 144.8,
147.9, 156.1, 157.4 ppm; HRMS (ESI-TOF) m/z: [M + H]+ calcd for
C23H16NO 322.1226; found: 322.1227. Note:
13C NMR shifts at
116.3 and 128.1 ppm represent two individual carbon signals as
confirmed by 2D NMR experiments.
(E)-3-(4-Methoxystyryl)benzofuro[3,2-c]quinoline (5g). A mixture
of substrate 3b (0.114 g, 0.30 mmol), 4-methoxystyrene (44 μL, 0.33
mmol), Pd(OAc)2 (3.4 mg, 5 mol %), and anhydrous K2CO3 (0.083
g, 0.60 mmol) in anhydrous NMP (0.5 mL, 1.5 mL mmol−1) was
reacted according to the general one-pot MH/DA procedure above to
give the title product as a yellow solid; yield: 84 mg (80%); m.p. 168−
170 °C; IR (NaCl) ν 3379, 1687, 1603, 1560, 1347, 1176, 1033 cm−1;
1H NMR (300 MHz, CDCl3) δ: 3.86 (s, 3H), 6.89−7.00 (m, 2H),
7.13−7.39 (m, 2H), 7.42−7.65 (m, 4H), 7.75 (d, J = 7.8 Hz, 1H),
7.92 (dd, J = 8.6, 1.5 Hz, 1H), 8.09 (dd, J = 7.2, 1.3 Hz, 1H), 8.27 (d,
J = 1.2 Hz, 1H), 8.38 (d, J = 8.6 Hz, 1H), 9.47 (s, 1H) ppm; 13C{1H}
NMR (75 MHz, CDCl3) δ: 55.4, 112.1, 114.3, 116.0, 116.2, 120.5,
121.0, 122.8, 124.1, 124.8, 126.0, 127.1, 127.5, 128.1, 129.8, 130.3,
138.9, 144.7, 148.0, 156.0, 157.4, 159.7 ppm; HRMS (ESI-TOF) m/
z: [M + H]+ calcd for C24H18NO2 352.1332; found: 352.1333.
(E)-3-(4-Fluorostyryl)benzofuro[3,2-c]quinoline (5h). A mixture of
substrate 3b (0.114 g, 0.30 mmol), 4-fluorostyrene (39 μL, 0.33
mmol), Pd(OAc)2 (3.4 mg, 5 mol %), and anhydrous K2CO3 (0.083
g, 0.60 mmol) in anhydrous NMP (0.5 mL, 1.5 mL mmol−1) was
reacted according to the general one-pot MH/DA procedure above to
give the title product as a yellow solid; yield: 63 mg (62%); m.p. 209−
211 °C; IR (NaCl) ν 3049, 1682, 1637, 1508, 1347, 1228, 1012 cm−1;
1H NMR (300 MHz, CDCl3) δ: 7.02−7.16 (m, 2H), 7.20−7.38 (m,
2H), 7.42−7.64 (m, 4H), 7.76 (dd, J = 7.6, 0.7 Hz, 1H), 7.91 (dd, J =
8.6, 1.6 Hz, 1H), 8.04−8.15 (m, 1H), 8.28 (d, J = 1.4 Hz, 1H), 8.39
(d, J = 8.6 Hz, 1H), 9.48 (s, 1H), ppm; 13C{1H} NMR (75 MHz,
CDCl3) δ: 112.1, 115.8 (d,
2J(C,F) = 22 Hz), 116.31, 116.34, 120.6,
121.1, 122.7, 124.1, 124.8, 127.3, 127.86, 127.89, 128.3 (d, 3J(C,F) = 8
Hz), 129.4, 133.2 (d, 4J(C,F) = 3 Hz), 138.3, 144.8, 147.9, 156.0, 157.4,
162.6 (d, 1J(C,F) = 248 Hz) ppm;
19F{1H} NMR (282 MHz, CDCl3)
δ: −113 ppm; HRMS (ESI-TOF) m/z: [M + H]+ calcd for
C23H15FNO 340.1132; found: 340.1135.
General Procedure for the Synthesis of Phenoxy-Substi-
tuted SM/DA and MH/DA Products. The same procedures and
purification methods outlined for the SM/DA and MH/DA reactions
were employed here using 4-(2,4-dibromphenoxy)quinoline 3e (1
equiv) as the substrate.
8-Phenylbenzofuro[3,2-c]quinoline (6a). A mixture of substrate
3e (0.200 g, 0.528 mmol), phenylboronic acid (0.071 g, 0.58 mmol),
Pd(OAc)2 (2.4 mg, 2 mol %), and anhydrous K2CO3 (0.146 g, 1.06
mmol) in anhydrous NMP (0.8 mL, 1.5 mL mmol−1) was reacted
according to the general one-pot SM/DA procedure above to give the
title product as a yellow solid; yield: 103 mg (65%); m.p. 153−155
°C; IR (NaCl): ν 2922, 1567, 1460, 1325, 1202 cm−1; 1H NMR (300
MHz, CDCl3) δ: 7.36−7.45 (m, 1H), 7.46−7.56 (m, 2H), 7.67−7.86
(m, 6H), 8.24−8.35 (m, 2H), 8.45 (dd, J = 8.1, 1.6 Hz, 1H), 9.55 (s,
1H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ: 112.2, 116.4, 117.2,
119.1, 120.8, 123.3, 126.7, 127.1, 127.4, 127.5, 128.9, 129.4, 129.9,
137.9, 140.9, 144.4, 147.5, 155.5, 158.0 ppm; HRMS (ESI-TOF) m/
z: [M + H]+ calcd for C21H14NO 296.1070; found: 296.1072.
tert-Butyl (E)-3-(Benzofuro[3,2-c]quinolin-8-yl)acrylate (6b). A
mixture of substrate 3e (0.076 g, 0.20 mmol), tert-butyl acrylate (32
μL, 0.22 mmol), Pd(OAc)2 (0.9 mg, 2 mol %), and anhydrous K2CO3
(0.055 g, 0.40 mmol) in anhydrous NMP (0.3 mL, 1.5 mL mmol−1)
was reacted according to the general one-pot MH/DA procedure
above to give the title product as a white solid; yield: 50 mg (73%);
m.p. 157−158 °C; IR (NaCl) ν 3434, 1703, 1638, 1594, 1566, 1367,
1203, 1151 cm−1; 1H NMR (300 MHz, CDCl3) δ: 1.58 (s, 9H), 6.47
(d, J = 15.9 Hz, 1H), 7.50−7.89 (m, 5H), 8.09−8.30 (m, 2H), 8.36
(dd, J = 8.1, 1.1 Hz, 1H), 9.45 (s, 1H) ppm; 13C{1H} NMR (75 MHz,
CDCl3) δ: 28.3, 80.7, 112.5, 115.9, 117.1, 120.2, 120.4, 120.8, 123.5,
127.22, 127.24, 129.6, 130.0, 131.2, 143.0, 144.3, 147.7, 156.7, 158.2,
166.2 ppm; HRMS (ESI-TOF) m/z: [M + H]+ C22H20NO3:
346.1438; found: 346.1430.
(E)-8-Styrylbenzofuro[3,2-c]quinoline (6c). A mixture of substrate
3e (0.076 g, 0.20 mmol), styrene (25 μL, 0.22 mmol), Pd(OAc)2 (2.5
mg, 5 mol %), and anhydrous K2CO3 (0.055 g, 0.40 mmol) in
anhydrous NMP (0.3 mL, 1.5 mL mmol−1) was reacted according to
the general one-pot MH/DA procedure above to give the title
product as a yellow solid; yield: 25 mg (40%); m.p. 200−203 °C; IR
(NaCl) ν 3583, 1650, 1598, 1567, 1324, 1195 cm−1; 1H NMR (300
MHz, CDCl3) δ: 7.11−7.47 (m, 5H), 7.55−7.61 (m, 2H), 7.63−7.87
(m, 4H), 8.11−8.32 (m, 2H), 8.39 (dd, J = 8.1, 1.3 Hz, 1H), 9.50 (s,
1H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ: 112.2, 116.2, 117.2,
118.2, 120.8, 123.3, 126.0, 126.5, 127.1, 127.8, 128.1, 128.8, 128.9,
129.4, 129.9, 133.9, 137.2, 144.4, 147.5, 155.6, 158.0 ppm; HRMS
(ESI-TOF) m/z: [M + H]+ calcd for C23H16NO 322.1226; found:
322.1223.
General Procedure for the Synthesis of Three-Component
SM/DA and MH/DA Products. The same procedures and
purification methods outlined for the SM/DA and MH/DA reactions
were employed here using bromo-4-(2,4-dibromphenoxy)quinoline
(1 equiv) as the substrate and double the equivalent of coupling
partner (2.2 equiv).
2,8-Diphenylbenzofuro[3,2-c]quinoline (7a). A mixture of sub-
strate 3f (0.200 g, 0.437 mmol), phenylboronic acid (0.117 g, 0.96
mmol), Pd(OAc)2 (2.0 mg, 2 mol %), and anhydrous K2CO3 (0.121
g, 0.873 mmol) in anhydrous NMP (0.7 mL, 1.5 mL mmol−1) was
reacted according to the general one-pot SM/DA procedure above to
give the title product as a pale yellow solid; yield: 129 mg (80%); m.p.
206−207 °C; IR (NaCl): ν 3054, 2920, 1682, 1560, 1460, 1358, 1200
cm−1; 1H NMR (300 MHz, CDCl3) δ: 7.37−7.60 (m, 6H), 7.68−
7.88 (m, 6H), 8.07 (dd, J = 8.8, 2.1 Hz, 1H), 8.28−8.40 (m, 2H), 8.64
(d, J = 1.7 Hz, 1H), 9.54 (s, 1H) ppm; 13C{1H} NMR (75 MHz,
CDCl3) δ: 112.2, 116.6, 117.4, 118.4, 119.1, 123.3, 126.8, 127.4,
127.50, 127.54, 128.0, 128.9, 129.0, 130.3, 137.9, 139.8, 140.1, 140.9,
144.2, 146.8, 155.5, 158.1 ppm; HRMS (ESI-TOF) m/z: [M + H]+
calcd for C27H18NO 372.1388; found: 372.1384. Note:
13C NMR
shift at 128.9 ppm represents two individual carbon signals as
confirmed by 2D NMR experiments.
Di-tert-butyl 3,3′-(Benzofuro[3,2-c]quinoline-3,8-diyl)(2E,2′E)-di-
acrylate (7b). A mixture of substrate 3g (0.050 g, 0.11 mmol), tert-
butyl acrylate (35 μL, 0.242 mmol), Pd(OAc)2 (0.5 mg, 2 mol %),
and anhydrous K2CO3 (0.030 g, 0.22 mmol) in anhydrous NMP (0.3
mL, 1.5 mL mmol−1) was reacted according to the general one-pot
MH/DA procedure above to give the title product as a white solid;
yield: 23 mg (43%); m.p. 217−219 °C; IR (NaCl) ν 3402, 1703,
1638, 1559, 1512, 1368, 1201, 1148 cm−1; 1H NMR (300 MHz,
CDCl3) δ: 1.50−1.61 (m, 18H), 6.40−6.67 (m, 2H), 7.66−7.94 (m,
5H), 8.23 (d, J = 0.8 Hz, 1H), 8.29−8.44 (m, 2H), 9.49 (s, 1H) ppm;
13C{1H} NMR (75 MHz, CDCl3) δ: 28.22, 28.24, 80.7, 80.9, 112.6,
116.6, 117.6, 120.3, 120.5, 121.4, 122.3, 123.3, 125.3, 127.5, 130.7,
131.4, 136.0, 142.7, 142.8, 145.0, 147.7, 156.9, 157.8, 166.0, 166.1
ppm; HRMS (ESI-TOF) m/z: [M + H]+ calcd for C29H30NO5:
472.2118; found: 472.2117.
3,8-Di((E)-styryl)benzofuro[3,2-c]quinoline (7c). A mixture of
substrate 3g (0.115 g, 0.25 mmol), styrene (63 μL, 0.55 mmol),
Pd(OAc)2 (2.8 mg, 5 mol %), and anhydrous K2CO3 (0.069 g, 0.50
mmol) in anhydrous NMP (0.4 mL, 1.5 mL mmol−1) was reacted
according to the general one-pot MH/DA procedure above to give
the title product as a white solid; yield: 76 mg (36%); m.p. >250 °C;
IR (NaCl) ν 3387, 1691, 1594, 1560, 1326, 1044 cm−1; 1H NMR
(600 MHz, (CD3)2SO) δ: 7.20−7.54 (m, 9H), 7.59 (app. s, 2H),
7.63−7.75 (m, 4H), 7.87 (dd, J = 8.6, 1.6 Hz, 1H), 7.94 (d, J = 8.5
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Hz, 1H), 8.17 (dd, J = 8.7, 1.4 Hz, 1H), 8.35 (d, J = 1.3 Hz, 1H), 8.41
(d, J = 8.5 Hz, 1H), 8.61 (d, J = 1.5 Hz, 1H), 9.69 (s, 1H) ppm;
13C{1H} NMR (150 MHz, (CD3)2SO) δ: 112.8, 115.9, 116.4, 119.1,
121.4, 123.2, 127.0, 127.2, 127.3, 128.29, 128.33, 128.6, 129.0, 129.3,
131.2, 134.3, 137.3, 137.5, 139.0, 146.0, 148.1, 155.5, 157.4 ppm;
HRMS (ESI-TOF) m/z: [M + H]+ calcd for C31H22NO 424.1696;
found: 424.1690. Note: This compound was highly insoluble, spectra
were acquired on <3 mg of this compound after heating in (CD3)2SO,
and it was difficult to directly assign. As with other compounds, some
13C shifts from this spectrum represent more than one signal as
confirmed by 2D NMR experiments.
Isolation of Suzuki−Miyaura Only Products. To further probe
the hypothesis that the Suzuki−Miyaura reaction was occurring at the
C-6 position before direct arylation at the C-3 position, substrate 3i
was synthesized. This substrate could only undergo the Suzuki−
Miyaura reaction and proceeded as anticipated (Supporting
Information Scheme S1).
4-Phenoxy-6-phenylquinoline (4s). A mixture of substrate 3i
(0.200 g, 0.666 mmol, 1 equiv), phenylboronic acid (0.081 g, 0.666
mmol, 1 equiv), Pd(OAc)2 (3.0 mg, 2 mol %), and anhydrous K2CO3
(0.184 g, 1.333 mmol, 2 equiv) in anhydrous NMP (1.0 mL, 1.5 mL
mmol−1) was stirred at 135 °C in a sealed reaction tube in an
aluminum multireaction heating mantle until the reaction was
completed as evidenced by 1H NMR analysis (4 h). The cooled
reaction mixture was diluted with DCM, filtered through a short plug
of Celite, and concentrated in vacuo. The crude mixture was purified
by column chromatography over silica gel using Hex/EtOAc (7:3−
6:4) as an eluent to give the title product as a pale yellow solid; yield:
168 mg (84%); m.p. 78−80 °C; IR (NaCl): ν 3058, 1562, 1487,
1460, 1360, 1203 cm−1; 1H NMR (300 MHz, CDCl3) δ: 6.58 (d, J =
5.1 Hz, 1H), 7.16−7.57 (m, 8H), 7.72−7.74 (m, 2H), 8.03 (dd, J =
8.8, 2.1 Hz, 1H), 8.17 (d, J = 8.8 Hz, 1H), 8.58 (d, J = 2.0 Hz, 1H),
8.67 (d, J = 4.9 Hz, 1H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ:
104.6, 119.6, 121.2, 121.7, 125.7, 127.5, 127.7, 129.0, 129.6, 129.8,
130.3, 139.0, 140.5, 149.1, 151.1, 154.4, 162.1 ppm; HRMS (ESI-
TOF) m/z: [M + H]+ calcd for C21H16NO 298.1226; found:
298.1228.
The tandem reaction was carried out on 3a at a lower temperature
to see if the Suzuki−Miyaura only product could be isolated and
prove that it was happening prior to the direct arylation reaction. At
this temperature, the major product was the uncyclized Suzuki−
Miyaura product 4t, although some of the tandem product 4a and
starting material 3a were also isolated (Supporting Information
Scheme S2).
4-(2-Bromophenoxy)-6-phenylquinoline (4t). A mixture of
substrate 3a (0.150 g, 0.396 mmol), phenylboronic acid (0.048 g,
0.396 mmol), Pd(OAc)2 (1.8 mg, 2 mol %), and anhydrous K2CO3
(0.109 g, 0.79 mmol) in anhydrous NMP (0.6 mL, 1.5 mL mmol−1)
was stirred at 100 °C in a sealed reaction tube in an aluminum
multireaction heating mantle for 24 h. The cooled reaction mixture
was diluted with DCM, filtered through a short plug of Celite, and
concentrated in vacuo. The crude mixture was purified by column
chromatography over silica gel using Hex/EtOAc (8:2−7:3) as an
eluent to give the title product as a pale yellow solid; yield: 73 mg
(49%); m.p. 85−87 °C; IR (NaCl): ν 3059, 1564, 1460, 1361, 1222,
667 cm−1; 1H NMR (300 MHz, CDCl3) δ: 6.43 (d, J = 5.2 Hz, 1H),
7.16−7.32 (m, 2H), 7.34−7.57 (m, 4H), 7.70−7.84 (m, 3H), 8.05
(dd, J = 8.8, 2.1 Hz, 1H), 8.20 (d, J = 8.7 Hz, 1H), 8.62 (d, J = 2.0 Hz,
1H), 8.69 (d, J = 5.3 Hz, 1H) ppm; 13C{1H} NMR (75 MHz, CDCl3)
δ: 103.9, 116.4, 119.6, 121.3, 123.3, 127.6, 127.9, 129.0, 129.3, 130.2,
134.4, 139.4, 140.3, 148.2, 150.5, 151.0, 161.5 ppm; HRMS (ESI-
TOF) m/z: [M + H]+ calcd for C21H15BrNO 376.0332; found:
376.0331. Note: 13C NMR shifts at 127.6 and 129.0 ppm each
represent two individual carbon signals as confirmed by 2D NMR
experiments.
The Synthesis of Palladium−Quinoline Complexes. 4-(2-
Bromophenoxy)quinoline Palladium Diacetate Dimer (8a). To an
NMR tube were added 1 (61.5 mg, 0.204 mmol, 1.0 equiv),
Pd(OAc)2 (22.9 mg, 0.102 mmol, 0.5 equiv), and CDCl3 (0.6 mL);
X-ray quality crystals were obtained via vapor diffusion from a
saturated solution of toluene/methanol in hexane, the CCDC number
is 1970630; decomposition >150 °C; IR (NaCl) ν 3436, 1615, 1589,
1573, 1303, 1217, 1075, 695 cm−1; 1H NMR (300 MHz, CDCl3) δ:
1.53 (s, 6H), 6.47 (d, J = 6.2 Hz, 2H), 7.11−7.34 (m, 4H), 7.37−7.54
(m, 2H), 7.59−7.84 (m, 4H), 8.08 (ddd, J = 8.6, 7.0, 1.4 Hz, 2H),
8.41 (dd, J = 8.1, 0.9 Hz, 2H), 9.46 (d, J = 6.2 Hz, 2H), 10.20 (d, J =
8.6 Hz, 2H) ppm; 13C{1H} NMR (150 MHz, CDCl3) δ: 22.6, 103.9,
116.2, 121.3, 122.0, 123.4, 127.4, 128.1, 129.0, 129.4, 132.1, 134.5,
147.9, 150.2, 156.1, 162.6, 178.3 ppm; HRMS (ESI-TOF) m/z: [M −
OAc]+ calcd for C32H23Br2N2O4Pd 762.9054; found: 762.9081.
7-Bromo-4-(2-bromophenoxy)quinoline Palladium Diacetate
Dimer (8b). To an NMR tube were added 3b (60.8 mg, 0.160
mmol, 1.0 equiv), Pd(OAc)2 (18.0 mg, 0.080 mmol, 0.5 equiv), and
CDCl3 (0.6 mL). Decomposition >190 °C; IR (NaCl) ν 3419, 1623,
1590, 1511, 1306, 1219, 1063, 733, 693 cm−1; 1H NMR (600 MHz,
CDCl3) δ: 1.59 (s, 6H), 6.46 (d, J = 6.2 Hz, 2H), 7.16−7.37 (m, 4H),
7.41−7.57 (m, 2H), 7.66−7.93 (m, 4H), 8.29 (d, J = 8.8 Hz, 2H),
9.43 (d, J = 6.2 Hz, 2H), 10.36 (d, J = 1.7 Hz, 2H) ppm; 13C{1H}
NMR (150 MHz, CDCl3) δ: 22.7, 104.2, 116.1, 120.1, 123.3, 123.5,
127.0, 128.4, 129.6, 131.2, 134.6, 148.4, 149.9, 157.4, 162.8, 178.4
ppm; HRMS (ESI-TOF) m/z: [M − OAc]+ calcd for
C32H21Br4N2O4Pd 918.7264; found: 918.7284. Note:
13C NMR
shift at 131.2 ppm represents two individual carbon signals as
confirmed by 2D NMR experiments.
4-Phenoxyquinoline Palladium Diacetate Dimer (8c). To 25 mL
of RBF were added 3h (55.0 mg, 0.249 mmol, 1.0 equiv), Pd(OAc)2
(27.9 mg, 0.124 mmol, 0.5 equiv), and CDCl3 (2 mL); X-ray quality
crystals were obtained via vapor diffusion from a saturated solution of
toluene/methanol in hexane, the CCDC number is 1970507;
decomposition >150 °C; IR (NaCl) ν 3413, 1621, 1595, 1305,
1512, 1203, 1063 cm−1; 1H NMR (300 MHz, CDCl3) δ: 1.53 (s, 6H),
6.50 (d, J = 6.2 Hz, 2H), 7.03−7.21 (m, 4H), 7.23−7.51 (m, 6H),
7.61 (ddd, J = 8.2, 7.0, 1.0 Hz, 2H), 7.99 (ddd, J = 8.6, 7.0, 1.4 Hz,
2H), 8.28 (dd, J = 8.4, 1.0 Hz, 2H), 9.34 (d, J = 6.2 Hz, 2H), 10.08
(d, J = 8.6 Hz, 2H) ppm; 13C{1H} NMR (75 MHz, CDCl3) δ: 22.7,
104.3, 121.4, 121.8, 122.0, 126.7, 127.3, 129.1, 130.7, 132.0, 148.0,
153.4, 156.1, 163.9, 178.3 ppm; HRMS (ESI-TOF) m/z: [M −
OAc]+ calcd for C32H25N2O4Pd 607.0844; found: 607.0849.
Experiments To Prove Viability of Palladium−Quinoline
Complexes. 1. A 0.062 M stock solution of 8c in CDCl3 was
prepared, and 0.1 mL (4.1 mg, 2 mol %) was transferred to a reaction
tube and concentrated in vacuo to give a yellow residue. To the tube
containing this residue were added substrate 3a (0.118 g, 0.310 mmol,
1 equiv), phenylboronic acid (0.042 g, 0.341 mmol, 1.1 equiv),
anhydrous K2CO3 (0.086 g, 0.62 mmol), and NMP (0.5 mL, 1.5 mL
mmol−1). The resulting mixture was stirred at 135 °C in the sealed
reaction tube in an aluminum multireaction heating mantle until the
reaction was complete as evidenced by 1H NMR analysis (20 h). The
cooled reaction mixture was diluted with DCM, filtered through a
short plug of Celite, and concentrated in vacuo. A yield of 81% 4a was
determined by 1H NMR analysis of the crude reaction mixture using
1,3,5-trimethoxybenzene as an internal standard (Scheme 4a).
2. A 0.062 M stock solution of 8c in CDCl3 was prepared, and 0.1
mL (4.1 mg, 2 mol %) was transferred to a reaction tube and
concentrated in vacuo to give a yellow residue. To the tube containing
this residue were added substrate 1 (0.093 g, 0.310 mmol, 1 equiv),
anhydrous K2CO3 (0.086 g, 0.62 mmol), and NMP (0.5 mL, 1.5 mL
mmol−1). The resulting mixture was stirred at 135 °C in the sealed
reaction tube in an aluminum multireaction heating mantle until the
reaction was complete as evidenced by 1H NMR analysis (20 h). The
cooled reaction mixture was diluted with DCM, filtered through a
short plug of Celite, and concentrated in vacuo. A 99% yield of 2 was
determined by 1H NMR analysis of the crude reaction mixture using
1,3,5-trimethoxybenzene as an internal standard (Supporting
Information Scheme S3).
3. A 0.10 M stock solution of 8a in CHCl3 was prepared, and 0.2
mL (16.5 mg, 10 mol %) was transferred to a reaction tube and
concentrated in vacuo to give a yellow residue. To the tube containing
this residue were added substrate 3a (0.076 g, 0.20 mmol, 1 equiv),
phenylboronic acid (0.027 g, 0.22 mmol, 1.1 equiv), anhydrous
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K2CO3 (0.055 g, 0.40 mmol), and NMP (0.3 mL, 1.5 mL mmol
−1).
The resulting mixture was stirred at 135 °C in the sealed reaction tube
in an aluminum multi-reaction heating mantle until the reaction was
complete as evidenced by 1H NMR analysis (18 h). The cooled
reaction mixture was diluted with DCM, filtered through a short plug
of Celite, and concentrated in vacuo. Upon analysis of the crude
reaction mixture, no starting material remained, and the peaks for
both products 4a and 2 were present. The signals for 4a and 2 were
too close to obtain accurate NMR yields and were nonseparable by
column chromatography (Scheme 4b).
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